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Abstract	  	  The	  non-­‐invasive	  detection	  of	  neuronal	   transmission	   is	  of	  prime	   importance	   in	  order	  to	  understand	  brain	   function	  better.	  This	  will	  aid	  cognitive	  neuroscience,	  as	   well	   as	   medical	   science,	   in	   the	   early	   detection	   of	   diseased	   states.	   Herein,	  approaches	   to	  molecular	   imaging	  of	   the	  NMDA	  receptor,	   a	   receptor	   subtype	  of	  the	  excitatory	  neurotransmitter	  glutamate,	  through	  the	  use	  of	  targeted	  contrast	  agents,	  is	  described.	  Initially,	  a	  series	  of	  NMDA	  receptor-­‐targeted	  MRI	  contrast	  agents	  was	  developed	  based	  upon	  a	  known	  competitive	  NMDA	  receptor	  antagonist,	  appended	  to	  an	  N-­‐linked	   ‘Gd-­‐DOTA’	   core	   that	   possesses	   a	   fast-­‐exchanging	   water	  molecule.	   Their	  use	  as	  responsive	  MR	  imaging	  probes	  was	  evaluated	  in	  vitro	  using	  a	  neuronal	  cell	  line	   model,	   and	   three	   contrast	   agents	   showed	   large	   enhancements	   in	   cellular	  relaxation	  rates.	  In	   order	   to	   confirm	   NMDA	   receptor	   localisation,	   derivatives	   of	   the	   lead	  compounds	   were	   also	   prepared.	   The	   derivatives	   contained	   a	   biotin	   moiety,	  which	  allowed	  direct	  visualisation	  of	  the	  cell-­‐surface	  receptors,	  after	  addition	  of	  an	  AvidinAlexaFluor®-­‐488	  conjugate.	  Using	  these	  derivatives,	  the	  specificity	  and	  reversibility	  (in	  the	  presence	  of	  glutamate)	  of	  binding	  at	  the	  NMDA	  receptor	  was	  demonstrated	  in	  living	  cells	  using	  laser	  scanning	  confocal	  microscopy.	  In	   an	   attempt	   to	   generate	   a	   single-­‐component	  NMDA	   receptor-­‐targeted	   optical	  imaging	   agent,	   a	   very	   bright	   europium	   complex	   conjugated	   to	   an	   NMDA	  receptor-­‐binding	  moiety	  was	  synthesised.	  Unfortunately,	  upon	  incubation	  with	  a	  neuronal	   cell	   line	   model,	   complex	   localisation	   appeared	   to	   be	   dictated	   by	   the	  ligand	  structure	  and	  not	  by	  the	  receptor-­‐binding	  moiety.	  One	  emerging	  imaging	  technique	  with	  potential	  applications	  in	  neuronal	  imaging	  is	   photoacoustic	   imaging.	   Two	  NMDA	   receptor-­‐targeted	   photoacoustic	   imaging	  agents	  were	   synthesised	   and	   their	   ability	   to	   label	  NMDA	   receptors	   assessed	   in	  
vitro.	  Finally,	  preliminary	  in	  vivo	  evaluation	  of	  the	  most	  promising	  photoacoustic	  imaging	  agent	  is	  described.	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Figure	  1.	  Key	  preclinical	  and	  clinical	  molecular	  imaging	  modalities.1	  	  Historically,	   these	  methods	  were	  developed	  to	   image	  non-­‐specific	  physiological	  changes.	  However,	  over	  the	  past	  twenty	  years,	  efforts	  have	  been	  made	  to	  identify	  specific	  molecular	  events	  in	  vivo,	  and	  this	  has	  led	  to	  the	  design	  and	  development	  of	   specific	   molecules,	   so-­‐called	   contrast	   agents,	   to	   provide	   image	   contrast.	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Labelled	   antibodies,	   peptides,	   proteins	   and	   small	   molecules	   have	   each	   been	  employed	   in	   this	   manner,	   but	   in	   general	   it	   is	   often	   difficult	   to	   obtain	   a	   large	  enough	   signal	   intensity	   change,	   due	   to	   the	   relatively	   low	   probe-­‐target	   to	  background	  ratio.	  Furthermore,	   it	   is	  often	  the	  case	  that	   the	  target	  of	   interest	   is	  present	   in	   relatively	   low	   concentrations.	   Nevertheless,	   these	   issues	   can	   be	  overcome	   by	   improving	   the	   contrast	   agent’s	   pharmacokinetics	   and	   affinity,	  coupled	  with	  the	  use	  of	  rapid	  and	  sensitive,	  high-­‐resolution	  imaging	  techniques.	  The	   selection	   of	   a	   particular	   molecular	   imaging	   modality	   is	   highly	   dependent	  upon	   the	   biochemical	   process	   that	   is	   to	   be	   visualised,	   and	   exactly	   what	  information	  is	  needed.	  The	  factors	  that	  need	  to	  be	  addressed	  include:	  
• The	  spatial	  resolution	  required;	  
• the	  sensitivity	  required	  i.e.	  the	  likely	  concentration	  of	  your	  target;	  
• whether	  dynamic	  information	  is	  needed;	  
• whether	  whole	  body	  or	  regional	  imaging	  is	  required;	  
• the	  temporal	  resolution;	  
• the	  depth	  of	  penetration	  needed.	  By	   addressing	   these	   issues,	   it	   is	   possible	   to	   decide	   which	   is	   the	   best	   imaging	  technique	  to	  use.	  The	  work	  carried	  out	  in	  this	  thesis	  describes	  the	  use	  of	  three	  molecular	  imaging	  modalities:	  magnetic	  resonance,	  optical	  and	  photoacoustic	  imaging	  to	  visualise	  a	  subclass	   of	   glutamate	   receptors,	   which	   are	   abundantly	   present	   in	   the	   brain.	  Glutamate	  is	  the	  most	  abundant	  excitatory	  neurotransmitter	  and	  activation	  of	  its	  receptors	  plays	  key	  roles	  in	  normal	  brain	  function.	  However,	  mis-­‐regulation	  and	  overstimulation	  of	  receptors	  can	  often	  lead	  to	  cell	  death	  and	  disease.	  The	   remainder	   of	   this	   chapter	   will	   focus	   on	   the	   role	   of	   glutamate	   as	   a	  neurotransmitter,	   including	  a	  description	  of	   its	  receptors,	   followed	  by	  a	  review	  of	   the	   use	   of	   targeted	   MRI	   contrast	   agents	   to	   image	   intra-­‐and	   extra-­‐cellular	  receptors.	  	  
1.2	  	   Glutamate	  as	  a	  Neurotransmitter	  	  Every	   organism	   relies	   on	   the	   transfer	   of	   chemical	   signals	   in	   order	   to	   function.	  The	   ability	   of	   glutamate	   to	   act	   as	   a	   chemical	   stimulant	   for	   neurons	   was	   first	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demonstrated	   in	   1960.3	   Due	   to	   its	   ability	   to	   activate	   nearly	   all	   neurons,	  many	  people	   were	   sceptical	   as	   to	   whether	   glutamate	   behaved	   as	   a	   specific	  neurotransmitter.	   But	   now,	   it	   is	   correctly	   regarded	   as	   the	   most	   abundant	  excitatory	   neurotransmitter	   in	   the	   mammalian	   central	   nervous	   system,	   with	  concentrations	   between	   5-­‐15	   mmol/kg	   found	   in	   brain	   tissue.4	   Such	   a	   high	  concentration	  of	  glutamate	  means	  that	  approximately	  90%	  of	  all	  neurons	  in	  the	  brain	   use	   glutamate	   as	   their	   neurotransmitter,	   with	   the	   concentration	   of	  cytoplasmic	  neuronal	  glutamate	  typically	  between	  5-­‐10	  mM.5	  	  Glutamate	  is	  unable	  to	  penetrate	  the	  blood	  brain	  barrier	  and	  is	  thus	  synthesised	  in	  neuronal	  mitochondria,	  via	  the	  transamination	  of	  α-­‐ketoglutarate	  produced	  in	  the	   Krebs	   cycle	   from	   citrate.	   Glutamate	   then	   diffuses	   into	   the	   cytosol	   and	   is	  stored,	  at	  high	  concentration,	   in	  vesicles.6,	   7	  Changes	   in	  cytosolic	  calcium	  levels,	  in	   response	   to	   an	   action	  potential,	   trigger	   the	   vesicles	   to	   fuse	  with	   the	  plasma	  membrane	   and	   release	   glutamate	   into	   the	   synaptic	   cleft.	   Glutamate	   actively	  diffuses	   across	   the	   synapse	   to	   interact	  with	   receptor	   proteins	   localised	   on	   the	  post-­‐synaptic	   membrane,	   allowing	   transfer	   of	   the	   glutamatergic	   signals	   from	  pre-­‐	  to	  post-­‐synaptic	  cells	  (Figure	  1.1).	  	  
	  
	  
Figure	   1.1.	   An	   atypical	   glutamatergic	   synapse.	   (1)	   Glutamate	   is	   synthesised	   in	   the	  mitochondria,	  stored	  in	  vesicles	  and	  pumped	  into	  the	  extracellular	  space	  upon	  vesicular	  fusion.	   (2)	  An	   increase	   in	  synaptic	  glutamate	  concentration	   is	  observed.	   (3)	  Glutamate	  diffuses	  and	  binds	  to	  receptors	  located	  on	  the	  post-­‐synaptic	  membrane.	  (4)	  After	  signal	  transduction,	  glutamate	  is	  removed	  from	  synapse	  by	  EAATs.8	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Glutamate	   does	   not	   undergo	   any	  metabolic	   transformation	   in	   the	   extracellular	  space	  and	  so	  is	  removed	  by	  excitatory	  amino	  acid	  transporters	  (EAAT’s),	  which	  pump	   the	   glutamate	   into	   nearby	   astrocytes.	   The	   glutamate	   is	   converted	   into	  glutamine,	  exported	  back	  into	  the	  extracellular	  space	  and	  taken	  up	  by	  neurons.	  The	   glutamine	   is	   converted	   back	   to	   glutamate,	   which	   is	   again	   stored	   in	   the	  presynaptic	  vesicles.8	  	  Despite	   synaptic	   transmission	   leading	   to	   a	   high	   local	   concentration	   of	  extracellular	   glutamate	   (0.5-­‐5	   mM),	   this	   local	   increase	   is	   transient	   and	   only	  present	   for	   a	   few	  milliseconds.	   The	  major	   source	   of	   extracellular	   glutamate	   is	  nonvesicular	  in	  nature	  and	  comes	  from	  neighbouring	  glia,	  giving	  rise	  to	  a	  steady	  background	   concentration	   of	   glutamate,	   of	   between	   1-­‐5	   µM.9	   Given	   the	  difference	   in	   concentration	   between	   background	   and	   synaptic	   glutamate,	   it	  would	   seem	   reasonable	   to	   suggest	   that	   background	   glutamate	   has	   a	   negligible	  effect	   on	   the	   brain.	   However,	   changes	   in	   the	   concentration	   of	   this	   ambient	  extracellular	  glutamate	  have	  been	  associated	  with	  developmental,	  physiological	  and	  behavioural	  disorders.9-­‐11	  	  	  
1.2.1	  Glutamate	  Receptor	  Proteins	  	  Located	   within	   the	   central	   nervous	   system	   are	   glutamate	   receptor	   proteins,	  which	  bind	  synaptic	  glutamate	  and	  conduct	  the	  transfer	  of	  glutamatergic	  signals.	  There	   are	   two	   categories	   of	   glutamate	   receptor;	   ligand-­‐gated	   ionotropic	  receptors	   (iGluR’s)	   and	   G-­‐protein	   coupled	   metabotropic	   receptors	   (mGluR’s).	  The	  iGluR	  family	  is	  classified	  into	  three	  subtypes:	  N-­‐methyl-­‐D-­‐Aspartate	  (NMDA),	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Figure	  1.2.	  Classification	  of	  the	  glutamate	  receptor	  family.	  	  The	  mGluRs	   play	   a	  modulatory	   role,	   regulating	   slow	   neuronal	   excitability	   and	  synaptic	   transmission	   through	   secondary	   messengers.13	   The	   mGluRs	   are	  classified	   into	   three	   groups	   according	   to	   their	   amino	   acid	   sequence,	   agonist	  pharmacology,	   and	  most	   importantly,	   their	   secondary	  messenger	   transduction	  pathways.	   Group	   I	   mGluRs	   couple	   via	   Gq/G11	   to	   stimulate	   phospholipase	   C	  activity	  and	  increase	  the	  concentration	  of	  intracellular	  Ca2+.	  Group	  II	  and	  group	  III	  mGluRs	  are	  linked	  via	  Gi/Go	  to	  inhibit	  adenylate	  cyclase	  activity,	  slowing	  the	  conversion	  of	  ATP	  to	  cAMP	  and	  pyrophosphate.4,	  13,	  14	  In	  common	  with	  other	  G-­‐protein	  coupled	  receptors,	  the	  mGluRs	  comprise	  a	  large	  bi-­‐lobed	   extracellular	   amino-­‐termial	   domain	   (ATD),	   linked	   to	   a	   heptahelical	  transmembrane	   domain	   (TMD)	   and	   finally	   the	   intracellular	   C-­‐terminus	   (CTD).	  Glutamate	   binds	   at	   the	   agonist-­‐binding	   site	   in	   the	   ATD15	   whereas	   receptor	  activity	  is	  mediated	  at	  the	  CTD,	  through	  interaction	  with	  intracellular	  proteins.16	  	  The	  mGluRs	  are	  expressed	  on	  both	  pre-­‐	  and	  post-­‐synaptic	  membranes,	  as	  well	  as	  neighbouring	   glial	   cells,	   with	   different	   group	   members	   exhibiting	   a	   distinct	  spatial	   distribution	   within	   the	   central	   nervous	   system.	   Group	   I	   mGluRs	   are	  predominantly	   located	   on	   the	   post-­‐synaptic	   membrane,	   modulating	   the	   cells’	  synaptic	   sensitivity	   towards	   glutamate.	   In	   comparison,	   group	   II	   and	   group	   III	  mGluRs	  are	  pre-­‐synaptic	  receptors	  that	  mediate	  glutamate	  release.17-­‐19	  It	  should	  also	   be	   noted	   that	   mGluR6	   is	   the	   only	   receptor	   not	   located	   in	   the	   CNS,	   but	   is	  found	  in	  high	  density	  in	  the	  retina.20	  	  Unlike	   the	   mGluR	   family,	   the	   iGluRs	   are	   responsible	   for	   the	   majority	   of	   fast	  excitatory	   neurotransmission	   in	   the	   brain.12	   The	   iGluR	   family	   of	   receptors	  comprises	  the	  NMDA,	  AMPA	  or	  Kainate	  receptors,	  which	  are	  grouped	  based	  on	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their	  affinity	  for	  selective	  agonists,	  amino	  acid	  sequence	  and	  electrophysiological	  properties.	  There	  are	  a	  total	  of	  18	  different	  gene	  products	  (NR1,	  NR2A-­‐D,	  NR3A-­‐B,	   GluR1-­‐4,	   GluR5-­‐7,	   KA1-­‐2	   and	  GluD1-­‐2),	  which	   give	   rise	   to	   a	   large	   degree	   of	  variation	   between	   ion	   channels.21	   Despite	   this,	   there	   are	   still	   similarities	  between	  every	  iGluR.	  Each	   iGluR	   is	   a	   tetrameric	   complex,	   comprising	  more	   than	  one	   subunit	   to	   give	  rise	   to	   a	   central	   ion	   pore.	   A	   feature	   of	   the	   iGluRs	   is	   that	   different	   subunit	  combinations	   produce	   functionally	   different	   receptors.	   For	   example,	   all	   iGluRs	  transmit	   their	   currents	   using	   a	   variety	   of	   cations	   (K+,	   Na+	   and	   Ca2+).22	   Cation	  permeability	  is	  subunit	  specific	  in	  the	  AMPA	  and	  Kainate	  receptors,	  whereby	  the	  presence	   of	   the	   GluR2,	   GluK1	   and	   GluK2	   subunits	   renders	   the	   receptors	  impermeable	   to	   Ca2+.23,	   24	   A	   regional	   difference	   in	   expression	   of	   subunits	  illustrates	  the	  heterogenicity	  of	  the	  iGluRs,	  supporting	  the	  existence	  of	  multiple	  subtypes	  of	  NMDA,	  AMPA	  and	  Kainate	  receptors.4	  A	  functional	  iGluR	  subunit	  comprises	  four	  main	  domains;	  the	  extracellular	  amino	  terminal	   domain	   (ATD),	   the	   extracellular	   ligand	   binding	   domain	   (LBD),	   the	  transmembrane	   domain	   (TMD)	   and	   an	   intracellular	   C-­‐terminal	   domain	   (CTD)	  (Figure	  1.3).	  
	  	  
Figure	  1.3.	  The	  general	  structure	  of	  an	  iGluR	  subunit.25	  	  The	  ATD	  of	  iGluRs	  adopts	  a	  clamshell-­‐like	  structure	  resembling	  that	  of	  the	  LBD	  of	   mGluR1.26	   This	   suggests	   that	   the	   ATD	   could	   provide	   a	   secondary	   binding	  pocket	   for	   endogenous	   ligands.	   Indeed,	   this	   is	   the	   case	   for	   NMDA	   receptors.	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However,	  no	  ions	  or	  small	  molecules	  are	  known	  to	  bind	  to	  the	  ATD	  of	  AMPA	  or	  Kainate	  receptors.22	  Pore	  opening,	  deactivation	  and	  desensitisation	  of	  the	  receptor	  and	  regulation	  of	  subunit	   specific	   assembly	   are	   all	   dictated	   by	   the	   ATD.27-­‐30	   Such	   behaviour	   is	  consistent	   with	   the	   observation	   that	   glycosylation	   of	   the	   ATD	   of	   AMPA	   and	  Kainate	  receptors	  leads	  to	  desensitisation	  and	  a	  drop	  in	  transduction	  current.31	  Similar	   to	   the	  ATD,	   the	  LBD	  of	   iGluRs	  also	  adopt	  a	  clamshell-­‐like	  conformation	  and	   is	   formed	   from	   two	   extracellular	   peptide	   strands,	   S1	   and	   S2.32	   The	   cleft	  between	  these	  two	  peptide	  chains	  (D1	  and	  D2)	  forms	  the	  agonist-­‐binding	  pocket.	  The	  first	  step	  in	  activation	  of	  the	  iGluRs	  involves	  agonist	  binding,	  and	  this	  occurs	  when	   the	   α-­‐amino	   and	   α-­‐carboxylate	   fragments	   of	   the	   agonist	   interact	   with	  residues	  located	  inside	  D1.	  The	  residues	  responsible	  for	  binding	  these	  fragments	  of	  the	  agonist	  are	  fairly	  conserved	  throughout	  all	  iGluRs,	  with	  intrinsic	  selectivity	  for	  specific	  agonists	  towards	  a	  particular	  receptor	  gained	  from	  additional	  agonist	  functionalisation.22	  	  The	   activation	   of	   iGluRs	   involves	   a	   conformational	   change	   in	   the	   LBD.	   Agonist	  binding	   induces	   a	   transition	   in	   the	   D2	   lobes	   causing	   a	   rearrangement	   in	   the	  segments	  linking	  the	  ion-­‐channel	  (TMD)	  to	  the	  LBD,	  resulting	  in	  channel	  opening	  (Figure	  1.4).33	  
	  	  
Figure	   1.4.	   Conformational	   changes	   associated	   with	   activation	   of	   a	   functional	   AMPA	  receptor.22	  	  The	  LBD	  is	  connected	  to	  three	  trans-­‐membrane	  helices,	  M1,	  M3	  and	  M4,	  which	  form	  the	  core	  of	  the	  ion	  channel.	  The	  M2-­‐loop	  lines	  the	  inner	  cavity	  of	  the	  pore	  with	  M1	   lining	  the	  outer	  cavity.	   It	   is	  generally	   thought	   that	   the	  presence	  of	  M1	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and	   M2	   form	   the	   gating	   mechanism	   that	   obstructs	   the	   flux	   of	   ions	   when	   the	  channel	  is	  closed.22	  The	  intracellular	  CTD	  is	  the	  most	  diverse	  region	  of	  iGluR	  subunits,	  and	  very	  little	  is	  known	  about	   the	  structures	  between	  different	  subunits.	  Although	  the	  CTD	   is	  not	   essential	   for	   iGluR	   function,	   it	   is	   an	   important	   feature	   known	   to	   bind	   and	  interact	   with	   many	   intracellular	   proteins34,	   35	   in	   order	   to	   modulate	   receptor	  signalling.	  	  The	  three	  different	  iGluRs	  all	  have	  different	  functions	  and	  spatial	  locations.	  The	  AMPA	  receptors	  are	  located	  post-­‐synaptically	  and	  are	  responsible	  for	  most	  of	  the	  fast	   excitatory	   information	   transfer	   in	   the	   CNS,	   with	   desensitisation	   of	   the	  receptor	  occurring	  around	  1-­‐2	  ms	  after	  glutamate	  binding.36,	  37	  Similarly,	  NMDA	  receptors	  are	  also	  post-­‐synaptic	  receptors,	  but	  stay	  open	  for	  longer	  time	  periods	  then	   AMPA	   receptors,	   to	   allow	   for	   significant	   Ca2+	   influx.	   However,	   Kainate	  receptors	  are	  located	  on	  both	  pre-­‐	  and	  post-­‐synaptic	  neurons,	  typically	  activated	  after	  only	   short	  bursts	  of	  pre-­‐synaptic	  activity.	   In	  a	   similar	  manner	   to	  mGluRs,	  Kainate	  receptors	  serve	  to	  regulate	  vesicle	  formation	  and	  glutamate	  release.38	  	  
1.2.2	  The	  NMDA	  Receptor:	  Structure,	  Function	  and	  Ligands	  	  The	  NMDA	  receptor	   is	   the	  most	  characterised	  example	  within	  the	   iGluR	  family.	  Similar	   to	   the	   other	   iGluRs,	   the	   NMDA	   receptor	   is	   a	   tetrameric	   complex,	  composed	  of	  four	  of	  the	  possible	  seven	  subunits.	  The	  most	  common	  architecture	  consists	  of	   two	  GluN1	  and	  two	  GluN2	  subunits,	  organised	  as	  a	  dimer	  of	  dimers	  with	   an	   alternating	   pattern.	   The	   GluN1	   and	   GluN2	   subunits	   share	   a	   common	  topology	   with	   the	   other	   iGluRs,	   consisting	   of	   an	   extracellular	   ATD,	   an	  extracellular	  LBD,	  a	  TMD	  and	  an	  intracellular	  CTD.39	  	  The	   NMDA	   receptor	   is	   a	   structurally	   more	   complex	   receptor	   ion	   channel	  compared	   to	   the	   AMPA	   and	   Kainate	   receptors,	   and	   possesses	   a	   variety	   of	  different	  ligand	  binding	  sites	  within	  its	  subunits	  (Figure	  1.5).	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Figure	  1.6.	  	  Crystal	  structure	  of	  the	  GluN1-­‐GluN2B	  ATD	  in	  complex	  with	  ifenprodil,	  with	  an	  expansion	  of	  the	  phenylethanolamine-­‐binding	  site.42	  	  Polyamines	   such	   as	   spermine	   and	   spermidine	   act	   as	   positive	   allosteric	  modulators	   that	   can	   potentiate	   in	   either	   a	   glycine-­‐independent	   or	   glycine-­‐dependent	   manner.	   Glycine-­‐independent	   potentiation	   occurs	   only	   for	   the	  GluN2B	   subunit	   in	   saturating	   glycine	   conditions.	   NMDA	   receptors	   are	  approximately	   50%	   inhibited	   by	   protons	   at	   physiological	   pH,	   but	   polyamine	  binding	   can	   lead	   to	   a	   relief	   of	   this	   proton	   inhibition.43	   In	   contrast,	   the	   glycine-­‐dependant	  mechanism	   involves	   the	   GluN2A-­‐B	   subunits	   and	   potentiates	   via	   an	  enhancement	  of	  glycine	  binding.44	  The	  NMDA	   receptor	   differs	   from	   other	   iGluRs	   in	   that	   it	   requires	   two	   separate	  ligands	   to	  bind	  simultaneously	   to	   the	  LBD	   for	  activation.	  Glutamate	  acts	  as	   the	  primary	  agonist	  and	  binds	  to	  the	  GluN2	  subunit,	  whereas	  glycine	  is	  a	  co-­‐agonist,	  binding	  at	  the	  LBD	  on	  GluN1	  subunits.	  The	  glutamate	  binding	  site	  is	  highly	  conserved	  between	  all	  GluN2	  subunits,	  but	  differs	   between	   iGluRs.	   The	   α-­‐carboxylate	   of	   glutamate	   interacts	   with	   an	  aspartate	   residue	   in	  a	   similar	  manner	   to	   the	  other	   iGluRs.	  A	  glutamate	   residue	  present	  in	  the	  agonist-­‐binding	  site	  of	  AMPA	  and	  Kainate	  receptors	  is	  responsible	  for	   direct	   interaction	   with	   the	   α-­‐amino	   group	   on	   the	   agonist.	   However,	   it	   is	  replaced	   by	   aspartate731	   in	   NMDA	   receptors	   and	   the	   loss	   of	   the	   additional	  methylene	  group	  results	  in	  the	  α-­‐amino	  group	  of	  glutamate	  being	  unable	  to	  form	  a	   direct	   ionic	   interaction.	   Instead,	   the	   α-­‐amino	   group	   forms	   water-­‐mediated	  hydrogen	   bonds	   to	   glutamate413	   and	   tyrosine761,	   with	   displacement	   of	   the	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water	  molecule	   accounting	   for	   the	   selectivity	   for	   NMDA	   binding	   to	   the	   GluN2	  subunit.	   The	   γ-­‐carboxylate	   of	   glutamate	   binds	   with	   tyrosine730,	   a	   residue	  conserved	  in	  GluN2	  subunits,	  and	  this	  interaction	  coupled	  with	  an	  inter-­‐domain	  hydrogen	   bond	   between	   tyrosine730	   and	   glutamate413	   is	   responsible	   for	   the	  high	  affinity	  binding	  of	  glutamate	  to	  the	  NMDA	  receptor	  (Figure	  1.7).45	  Glycine	  acts	  as	  the	  co-­‐agonist	  and	  binds	  at	  the	  cleft	  between	  D1	  and	  D2	  domains	  in	  the	  GluN1	  subunit.	  The	  carboxylate	  of	  glycine	  forms	  several	  hydrogen	  bonds	  to	  arginine522,	  threonine518	  and	  serine688	  and	  the	  amino	  group	  interacts	  with	  the	   carbonyl	   group	   of	   proline516,	   the	   carboxylate	   of	   aspartate732	   and	   the	  hydroxyl	  of	  threonine518	  (Figure	  1.7).46	  	  	  
	  
	  
Figure	   1.7.	   The	   structure	   of	   the	   agonist	   binding	   sites	   on	   GluN2A	   (left)45	   and	   GluN1	  (right)46	  subunits.	  	  The	  agonist-­‐binding	  site	  in	  the	  GluN1	  subunit	  shows	  high	  selectivity	  for	  glycine	  over	  glutamate	  due	  to	  two	  factors.	  First,	  the	  presence	  of	  tryptophan731	  in	  GluN1	  subunits	  increases	  the	  steric	  demand	  around	  the	  region	  where	  the	  γ-­‐carboxylate	  of	  glutamate	  would	  potentially	  bind.	  Secondly,	  replacement	  of	   threonine690	  by	  valine689	   in	   GluN1	   subunits	   leads	   to	   a	   loss	   of	   a	   hydrogen-­‐bond	   donor,	   again	  destabilising	  γ-­‐carboxylate	  binding.46	  The	   TMD	   in	   NMDA	   receptors	   is	   structurally	   related	   to	   TMDs	   found	   in	   other	  iGluRs.	  The	  subtle	  difference	  is	  substitution	  of	  a	  key	  amino	  acid	  residue	  found	  in	  the	  re-­‐entrant	  loop,	  M2.	  This	  region	  is	  called	  the	  QRN	  site	  as	  it	  is	  occupied	  by	  an	  asparagine	  (N)	  residue	  in	  GluN2	  NMDA	  receptor	  subunits,	  and	  a	  glutamine	  (Q)	  or	  arginine	  (R)	  residue	  in	  non-­‐NMDA	  receptors.47	  In	  NMDA	  receptors,	  the	  QRN	  site	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is	   the	   home	   of	   the	   voltage-­‐dependent	   Mg2+	   block.	   At	   membrane	   potentials	  around	   -­‐50	   mV,	   the	   concentration	   of	   extracellular	   Mg2+	   is	   sufficiently	   high	   to	  block	   NMDA	   receptor	   ion	   transport,	   despite	   the	   presence	   of	   glutamate	   and	  glycine	   ‘activating’	   the	   neuron.	   However,	   as	   the	  membrane	   potential	   increases	  towards	   +40	  mV,	   the	   affinity	   for	   the	  QRN	   site	   to	   bind	  Mg2+	   decreases	   and	   the	  block	  becomes	  ineffective,	  allowing	  the	  influx	  of	  ions	  through	  the	  channel.39,	  48	  Activation	  of	  the	  NMDA	  receptor	  occurs	  when	  glutamate,	  released	  from	  the	  pre-­‐synaptic	   neuron,	   and	   glycine	   bind	   at	   the	   GluN1	   and	   GluN2	   subunits	  simultaneously.	  Binding	  of	  these	  agonists	  induces	  a	  conformational	  change,	  such	  that	   the	   LBD	   adopts	   a	   closed	   conformation.	   Meanwhile,	   synaptically	   released	  glutamate	   also	   activates	   AMPA	   receptors	   on	   the	   post-­‐synaptic	   neuron,	   which	  allows	   the	   flux	   of	   Na+	   ions	   through	   the	   channel,	   depolarising	   the	   membrane.	  Concurrent	  membrane	  depolarisation	  and	  the	  change	  in	  conformation	  of	  the	  LBD	  induces	   opening	   of	   the	   NMDA	   receptor	   ion	   channel	   and	   relief	   of	   the	   voltage	  dependent	   Mg2+	   blockade.	   Na+	   and	   K+	   ions	   flow	   into	   and	   out	   of	   the	   cell,	  respectively,	   through	   the	   NMDA	   receptor	   ion	   channel	   generating	   a	   short-­‐lived	  excitatory	   post-­‐synaptic	   potential.	   Ca2+	   ions	   also	   permeate	   the	   ion	   channel	   to	  induce	  a	   long-­‐lasting	  signal	   transmission	  enhancement,	   thought	   to	  be	   linked	   to	  synaptic	   plasticity,	   which	   underlies	   memory	   and	   learning.	   However,	   excessive	  Ca2+	  transport	  also	  has	  an	  excitotoxic	  effect	  leading	  to	  neurodegradation.39	  In	   contrast	   to	   other	   iGluRs,	   the	   NMDA	   receptor	   shows	   much	   slower	   gating	  kinetics,	   activating	   in	  milliseconds	   and	   deactivating	   over	  much	   longer	   periods,	  i.e.	   seconds,	  with	   little	   or	  no	  desensitisation.	  The	  kinetics	   of	   gating	  determines	  the	   time	   course	   of	   synaptic	   currents	   produced	   by	   the	   receptor	   and	   differs	  between	  each	  NMDA	  receptor	  subunit	  (Table	  1).22	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Table	  1.	  Kinetic	  parameters	  describing	  glutamate	  activation	  of	  NMDA	  receptors.	  	  	  








N1/N2A	   22-­‐230	   386-­‐750	   618	   1.3	  
N1/N2B	   538-­‐617	   100	   1014-­‐2100	   2-­‐3.2	  
N1/N2C	   260-­‐382	   59-­‐719	   NA	   0.6	  
N1/N2D	   1700-­‐4408	   NA	   NA	   0.9-­‐2.6	  
a	  average	  AMPA	  deactivation	  time	  is	  0.7	  ms,	  b	  average	  Kainate	  deactivation	  time	  is	  1.6-­‐2.5	  ms.	  	  The	   long	   deactivation	   time	   course	   for	   NMDA	   receptors	   is	   a	   direct	   result	   of	   its	  increased	  affinity	  for	  glutamate,	  relative	  to	  other	  iGluRs.	  	  	  
1.2.2.1	  Glutamate	  Binding-­Site	  Ligands	  for	  the	  NMDA	  Receptor	  	  Although	  it	  has	  been	  proposed	  that	  increasing	  the	  activity	  of	  the	  NMDA	  receptor	  can	  improve	  neurodegenerative	  disorders,	  over-­‐stimulation	  of	  the	  receptor	  has	  a	  related	  high	  excitotoxicity.	  This	  has	  led	  to	  the	  development	  of	  a	  range	  of	  NMDA	  receptor	   agonists	   and	   antagonists	   that	   could	   potentially	   serve	   as	   therapeutic	  agents	  against	  neurodegredation.	  Upon	  complexation	  of	  an	  agonist,	  the	  LBD	  undergoes	  a	  conformational	  switch	  to	  a	  closed	  state	  around	  the	  ligand,	  leading	  to	  channel	  opening.	  This	  means	  that	  the	  ligand	  is	  surrounded	  by	  the	  LBD,	  leaving	  little	  or	  no	  conformational	  freedom	  that	  could	   be	   exploited	   in	   the	   design	   of	   new	   agonist	   structures.	   Therefore,	   NMDA	  receptor	   agonists	   are	   generally	  α-­‐amino	   acids,	   with	   one	   or	   two	   stereocentres.	  Furthermore,	  they	  contain	  at	  least	  three	  charged	  functional	  groups	  and	  possess	  a	  charged	  side-­‐chain	  approximately	  3.5-­‐4	  Å	  away	  from	  the	  amino	  acid	  group.39,	  49	  	  An	   important	   consideration	   when	   designing	   an	   NMDA	   receptor	   agonist	   is	   its	  stereochemistry.	  Although	  all	   iGluRs	  exhibit	  a	  stereospecific	  preference	   for	  (S)-­‐agonists,	   the	   NMDA	   receptor	   is	   less	   strict	   and	   in	   some	   cases	   can	   bind	   (R)-­‐agonists	   with	   a	   higher	   affinity	   (Scheme	   1,	   Table	   1.1).50	   These	   straight	   chain	  agonists	   do	   not	   exhibit	   high	   subunit	   selectivity,	   except	   for	   SYM2081.	  Unfortunately,	   SYM2081	   activates	   all	   iGluRs	   with	   a	   preference	   for	   Kainate	  receptors.51	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Table	  1.1.	  Binding	  affinity	  of	  NMDA	  receptor	  agonists	  to	  different	  GluN2	  subunits	  using	  an	  electrophysiological	  assay.39	  	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  EC50	  	   (µM)	   	  
	   IC50	  
(µM)	  
GluN1/N2A	   GluN1/N2B	   GluN1/N2C	   GluN1/N2D	  
(S)-­Glu	   0.31	   3.30	   2.86	   1.68	   0.51	  
(R)-­Glu	   23.0	   249	   156	   111	   42.3	  
NMDA	   3.68	   94.10	   29.5	   21.7	   7.30	  
NMLA	   14.5	   581	   127	   154	   40	  
SYM2081	   NA	   144	   25.1	   18.2	   3.15	  	  Bioisosteric	  replacement	  of	  functional	  groups	  is	  a	  widely	  used	  strategy	  to	  obtain	  potent	   and	   selective	   ligands.	  Although	   the	  α-­‐carboxylate	   group	  of	   glutamate	   is	  critical	   for	   high	   affinity	   ligands,	   the	   γ-­‐carboxylate	   can	   tolerate	   changes	   and	   in	  some	  cases	   increased	  affinity	  and	  subunit	   selectivity	  has	  been	  observed	   (Table	  




Scheme	  1.	  Structures	  of	  NMDA	  receptor	  agonists.	  




















(S)-Homocysteate (S)-Homocysteinesulfinate Tetrazolylglycine (S)-CCG-IV
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agonist	  to	  date,	  with	  a	  three-­‐fold	  selectivity	  for	  the	  GluN2B	  and	  GluN2D	  subunits	  (Table	  1.2).50	  
	  
Table	  1.2.	  The	  effect	  of	  bioisosteric	  replacement	  and	  conformational	  restriction	  on	  the	  binding	  affinity	  of	  NMDA	  receptor	  agonists,	  using	  an	  electrophysiological	  assay.39	  	  	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  EC50	  	   (µM)	   	  
	   GluN1/N2A	   GluN1/N2B	   GluN1/N2C	   GluN1/N2D	  
Homocysteate	   34.1	   8.09	   11.6	   3.35	  
Homocysteinesulfinate	   73.2	   17.9	   13.7	   6.19	  
Tetrazolylglycine	   1.72	   0.518	   0.491	   0.0993	  
(S)-­CCG-­IV	   0.262	   0.083	   0.110	   0.036	  	  In	   comparison	   to	   NMDA	   receptor	   agonists,	   when	   antagonists	   bind	   at	   the	  glutamate	  binding-­‐site,	  they	  stabilise	  the	  open	  conformation	  of	  the	  LBD	  to	  hinder	  ion	  channel	  activation.	  Stabilising	  the	  open	  conformation	  results	  in	  there	  being	  a	  larger	  volume	  for	  the	  antagonist	  to	  interact	  with.39,	  49	  Generally,	   the	   design	   of	   most	   NMDA	   receptor	   antagonists	   employs	   the	   same	  methods	   as	   for	   agonist	  design;	   the	  major	  difference	   is	   to	   increase	   the	  distance	  between	  the	  α-­‐	  and	  distal	  carboxylate	  residues	  to	  approximately	  5.1-­‐6.6	  Å.49	  	  In	  the	  1980’s,	  two	  compounds,	  AP5	  and	  AP7	  (Scheme	  1.1),	  were	  developed,52,	  53	  which	   have	   since	   been	   used	   as	   the	   prototypical	   compounds	   to	   develop	   more	  potent	  and	  selective	  NMDA	  receptor	  antagonists.	  A	  stereochemical	  preference	  is	  found	  for	  (R)-­‐enantiomers	  over	  (S)-­‐enantiomers	  for	  antagonists	  that	  have	  been	  resolved,	  although	  there	  are	  a	  few	  exceptions	  to	  this	  generality.54	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Scheme	  1.1.	  Competitive	  NMDA	  receptor	  antagonists.	  	  By	  reducing	  the	  conformational	  freedom	  of	  AP5	  and	  AP7,	  cyclic	  derivatives	  such	  as	   (R)-­‐CPP	   were	   developed	   (Scheme	   1.1)	   in	   an	   attempt	   to	   increase	   NMDA	  receptor	   affinity	   and	   improve	   bioavailability.55	   This	  method	   proved	   successful	  and	  (R)-­‐CPP	  was	  found	  to	  be	  a	  potent	  NMDA	  receptor	  antagonist	  (Table	  1.3).	   It	  has	   approximately	   two-­‐times	   higher	   affinity	   compared	   to	   its	   one-­‐carbon	  homologue,	   PMPA.	   This	   is	   somewhat	   surprising,	   given	   that	   the	   piperidine	  analogue,	   CGS19755,56	   exhibits	   an	   even	   higher	   affinity	   than	   that	   of	   (R)-­‐CPP	  (Table	  1.3).	  The	  decrease	  in	  affinity	  of	  PMPA	  is	  most	  likely	  due	  to	  protonation	  of	  N4	  in	  the	  piperazine	  ring,	  stabilising	  an	  unfavourable	  conformation.57	  	  
Table	  1.3.	  Affinities	  of	  NMDA	  receptor	  antagonists	  measured	  by	  their	  ability	  to	  displace	  [3H]CPP	  from	  the	  glutamate	  binding-­‐site.39	  	  	   	   IC50	  (µM)a	   	   IC50	  (µM)a	  
AP5	   0.290	   Squaramide	  1	   2.30	  
AP7	   0.760	   Squaramide	  2	   0.470	  
(R)-­CPP	   0.079	   6-­ring	  Squaramide	   0.092	  
PMPA	   0.320	   7-­ring	  Squaramide	   0.030	  



























PMPA CGS19755 Squaramide 1
Squaramide 2 6-ringSquaramide
X = H; 7-ring Squaramide
X = OH; Hydroxysquaramide
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Bioisosteric	   replacement	   of	   functional	   groups	   has	   also	   been	   adopted	   for	   the	  development	  of	  NMDA	  receptor	  antagonists.	  The	  3,4-­‐diamino-­‐3-­‐cyclobutene-­‐1,2-­‐dione	  moiety	  represents	  an	  isosteric	  replacement	  of	  the	  α-­‐amino-­‐carboxylic	  acid	  functionality	  present	  in	  the	  majority	  of	  NMDA	  receptor	  agonists	  and	  antagonists.	  This	  cyclic	  group	  acts	  as	  an	  electronic	  mimic,	  possessing	  partial	  negative	  charges	  on	   the	   carbonyl	   oxygens	   and	   partial	   positive	   charges	   on	   the	   nitrogen	   atoms,	  generating	   a	   significant	   dipole	   moment.	   However,	   this	   bioisostere	   lacks	   other	  properties;	   it	   is	   not	   acidic	   or	  basic	   at	  physiological	  pH	  and	   the	   amino	  group	   is	  non-­‐nucleophilic.58	  Nevertheless,	  this	  isosteric	  replacement	  was	  shown	  to	  be	  active.	  The	  squaramide	  1	  (Scheme	  1.1)	  was	  able	  to	  function	  in	  a	  displacement	  assay,	  albeit	  binding	  at	  the	  NMDA	   receptor	  with	   30-­‐times	  weaker	   affinity	   compared	   to	   glutamate.	   Further	  extension	  of	  the	  pendant	  arm	  and	  substitution	  of	  the	  distal	  carboxylic	  acid	  for	  a	  phosphonic	  acid	  gave	  weak	  NMDA	  receptor	  antagonists	  with	  affinity	   in	  the	  low	  micromolar	  range	  (Table	  1.3).59	  The	   3,4-­‐diamino-­‐3-­‐cyclobutene-­‐1,2-­‐dione	   moiety	   is	   known	   to	   adopt	   different	  rotameric	   forms,	   which	   could	   lead	   to	   internal	   hydrogen-­‐bonding	   reducing	   the	  number	   of	   available	   hydrogen-­‐bond	   donors	   and	   acceptors	   for	   the	   glutamate	  binding	   site.	   Based	   on	   the	   argument	   that	   a	   compound	   that	   is	   more	   freely	  available	   to	   hydrogen-­‐bond	   to	   amino	   acid	   residues	   in	   the	   binding	   site	   should	  have	   a	   higher	   affinity	   for	   the	   NMDA	   receptor,	   bicyclic	   structures	   with	   further	  conformational	  restriction	  were	  developed.60	  The	  six-­‐membered	  ring	  derivative	  was	  found	  to	  exhibit	  a	  5-­‐times	  greater	  affinity	  for	  the	  NMDA	  receptor	  than	  its	  acyclic	  counterpart.	  Increasing	  the	  ring	  size	  from	  6-­‐	  to	  7-­‐	  increased	  the	  affinity	  further	  by	  a	  factor	  of	  3.	  This	  was	  attributed	  to	  the	  presence	  of	  a	  larger	  dipole	  moment	  in	  the	  7-­‐ring	  system	  giving	  increased	  charge	  separation,	  resulting	  in	  an	  increase	  in	  NMDA	  receptor	  affinity.	  Also,	  by	  including	  a	  hydroxyl	  substituent	  to	  act	  as	  a	  hydrogen-­‐bond	  donor,	  NMDA	  receptor	  affinity	  of	  this	  class	  of	  antagonists	  has	  been	  found	  to	  match	  the	  most	  potent	  antagonists	  to	  date.60	  Detection	   and	   imaging	   of	   neuronal	   transmission	   and	   monitoring	   receptor	  activity	   is	   of	   prime	   importance	   in	   cognitive	   neuroscience.	   This	   could	   help	  neuroscientists	   better	   understand	   brain	   function,	   as	   well	   as	   potentially	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diagnosing	   early	   stage	   diseases.	   Magnetic	   resonance	   imaging	   is	   a	   primary	  technique	  that	  could	  be	  used	  for	  these	  purposes.	  	  
1.3	  	   Magnetic	  Resonance	  Imaging	  	  Magnetic	   resonance	   imaging	   (MRI)	   is	   widely	   regarded	   as	   one	   of	   the	   most	  powerful	   imaging	   techniques	   used	   throughout	   clinical	  medicine,	  with	   over	   2.4	  million	   scans	   conducted	   by	   the	   NHS	   in	   the	   UK	   between	   2012	   and	   2013.	   This	  represents	  a	  12%	  growth	  in	  the	  use	  of	  MRI	  over	  a	  10-­‐year	  period,	  reflecting	  its	  diagnostic	   potential.61	   It	   has	   the	   ability	   to	   generate	   images	  with	   an	   impressive	  sub-­‐millimetre	   spatial	   resolution,	   which	   can	   give	   accurate	   physiological	   and	  pathological	  information	  on	  various	  tissues	  and	  organs	  within	  the	  human	  body.	  Furthermore,	  it	  is	  a	  non-­‐invasive	  technique	  without	  the	  need	  to	  employ	  harmful	  ionising	   radiation	   more	   commonly	   associated	   with	   other	   imaging	   modalities,	  such	  as	  X-­‐ray	  scanning.62	  The	   MRI	   technique	   is	   based	   upon	   fundamental	   NMR	   theory	   independently	  developed	   in	  1946	  by	  Bloch	  and	  Purcell,	  who	   later	   received	   the	  Nobel	  Prize	   in	  Physics	   in	   1952.63	   Expansion	   of	   the	   field	   led	   to	   the	   discovery	   that	   different	  relaxation	  times	  could	  be	  used	  to	  generate	  images,64,	  65	  and	  by	  1977	  the	  first	  MR	  scan	  on	  a	  human	  subject	  was	  performed.66	  The	  rapid	  rise	  and	  global	  importance	  of	  this	  diagnostic	  imaging	  tool	  was	  demonstrated	  in	  2003	  with	  the	  award	  of	  the	  Nobel	   Prize	   in	   Medicine	   jointly	   shared	   between	   Paul	   Lauterbur	   and	   Sir	   Peter	  Mansfield	  for	  their	  efforts	  in	  the	  development	  of	  MRI.	  Proton	   MRI	   utilises	   the	   strong	   1H	   NMR	   signal	   of	   water	   to	   generate	   images.	  Protons	  possess	  spin	  angular	  momentum	  I	  =	  ½,	  and	  a	  magnetic	  moment,	  µ,	  due	  to	   the	  presence	  of	   the	  positively	  charged	  nucleus.	  When	  a	  sample	  of	  protons	   is	  placed	   inside	   an	   external	   magnetic	   field,	   B0,	   they	   align	   themselves	   in	   definite	  directions,	  either	  parallel	   (+	  ½)	  or	  anti-­‐parallel	   (-­‐	  ½)	  and	  precess	  around	  B0	  at	  the	  Larmor	   frequency	   (Figure	  1.8A).	  The	  difference	   in	  energy	  between	   the	   two	  spin	  states	  is	  directly	  related	  to	  the	  strength	  of	  the	  external	  magnetic	  field,	  with	  the	   majority	   of	   spins	   aligned	   in	   the	   more	   energetically	   favourable	   parallel	  alignment.	  The	  vector	  sum	  of	  magnetic	  moments	  in	  the	  parallel	  state	  generates	  a	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net	  macroscopic	  magnetisation,	  M0,	  orientated	  along	  the	  z-­‐axis,	  making	  Mz	  non-­‐zero	  (Figure	  1.8B).	  Upon	  application	  of	  an	  RF	  pulse	  along	  the	  x-­‐axis,	  the	  spins	  occupying	  the	  lower	  energy	  parallel	  state	  absorb	  energy	  and	  make	  the	  transition	  to	   the	  higher	  anti-­‐parallel	   state,	   causing	  Mz	   to	   tip	   towards	   the	   x-­‐y	   plane,	   if	   assuming	   a	   90°	   pulse	  (Figure	  1.8C).	  The	  degree	  of	  which	  Mz	  is	  rotated	  away	  from	  B0	  depends	  upon	  the	  time	  frame	  of	  the	  RF	  pulse	  (Figure	  1.8D).67	  	  	  
	  
Figure	  1.8.	  (A)	  The	  magnetic	  moment	  of	  each	  proton	  nucleus	  precesses	  around	  B0	  at	  the	  Larmor	   frequency.	   (B)	   The	   vector	   sum	   of	   magnetic	   moments	   generates	   a	   net	  macroscopic	   magnetization,	  M0,	   orientated	   along	   the	   z-­‐axis.	   (C)	   Application	   of	   an	   RF	  pulse	  along	  the	  x-­‐axis	  generates	  a	  secondary	  magnetic	  field,	  causing	  Mz	  to	  tip	  away	  from	  z-­‐axis.	  (D)	  Assuming	  a	  90°	  pulse,	  the	  net	  magnetization	  will	  lie	  in	  the	  x-­‐y	  plane.	  (E)	  Over	  time,	   relaxation	   processes	   recover	   the	   magnetization	   to	   its	   equilibrium	   values.	   T1	  relaxation	  is	  responsible	  for	  Mz	  recovery.68	  	  Once	  the	  RF	  pulse	  is	  removed,	  the	  thermodynamic	  instability	  associated	  with	  the	  perturbed	  magnetic	   state	   results	   in	   the	   net	  magnetisation	   relaxing	   back	   to	   its	  equilibrium	  position	  along	   the	  z-­‐axis,	  with	  characteristic	   time	  constants	  T1	  and	  
T2	  (Figure	  1.8E).	  Spin-­‐lattice	  relaxation,	  T1,	  involves	  the	  equilibrium	  return	  of	  the	  spin	   states	   via	   the	   stimulated	   emission	   of	   energy,	   through	   interaction	   with	  nearby	   fluctuating	   magnetic	   fields,	   present	   in	   molecules	   in	   the	   surrounding	  medium.	  This	  random	  process	  recovers	  M0	  in	  an	  exponential	  manner,	  such	  that	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at	   time,	   t	   =	   T1,	   the	   longitudinal	   magnetisation	   has	   recovered	   to	   63%	   of	   its	  original	  value	  with	  almost	  full	  recovery	  achieved	  at	  t	  =	  5	  x	  T1.67	  	  Differential	   T1	   and	   T2	   relaxation	   rates	   provide	   the	   basis	   for	   signal	   intensity	  modulation	   in	  MRI,	  whereby	   the	  protons	  of	  water	  molecules	   in	  various	   tissues	  relax	  back	  to	  equilibrium	  at	  different	  rates,	  providing	  image	  contrast.	  	  
1.3.1	  Contrast	  Agents	  and	  Relaxivity	  
	  The	  main	  drawback	  of	  MRI	  is	  its	  intrinsically	  low	  sensitivity	  due	  to	  the	  fact	  that	  the	  technique	  is	  observing	  the	  protons	  from	  water	  molecules	  that	  are	  present	  at	  a	   concentration	   of	   55	   M.69	   Although	   there	   are	   changes	   in	   T1	   relaxation	   time	  between	  different	  tissues	  (i.e.	  healthy	  tissue	  has	  a	  significantly	  shorter	  T1,	  0.367	  s,	  compared	  to	  malignant	  breast	  tissue,	  1.080	  s)70,	  due	  to	  the	  large	  background	  of	  water	  it	  becomes	  difficult	  to	  detect	  changes	  in	  tissue	  types	  based	  on	  differences	  in	  longitudinal	  relaxation	  times.	  In	  order	  to	  induce	  additional	  contrast,	  synthetic	  compounds	  known	  as	  contrast	  agents	  are	  employed	  to	  affect	  the	  water	  protons’	  relaxation	  rate,	  Ri	  (Ri	  =	  1/Ti;	  i	  =	  1,2),	  such	  that	  differences	  in	  contrast	  are	  easier	  to	  observe.	  Contrast	   agents	   are	   paramagnetic,	   superparamagnetic	   or	   ferromagnetic	  compounds	   that	   shorten	   both	   T1	   and	   T2	   relaxation	   times	   of	   nearby	   water	  protons.	  This	  shortening	  of	  T1	  and	  T2	  is	  due	  to	  a	  dipolar	  interaction	  between	  the	  electronic	   magnetic	   moment	   of	   the	   contrast	   agent	   and	   the	   nuclear	   magnetic	  moment	   of	   the	  proton.	  A	   contrast	   agent	   is	   classified	   as	   either	   a	  T1	   or	  T2	   agent	  depending	  on	  which	  relaxation	  time	  it	  affects	  the	  most.	  The	  majority	  of	  contrast	  agents	   are	   T1	   agents	   and	   these	   induce	   a	   positive	   contrast,	   whereas	   T2	   agents	  provide	  a	  reduction	  in	  signal	  intensity	  and	  a	  negative	  image	  contrast.69	  The	   T1	   agents	   are	   typically	   paramagnetic	   compounds	   that	   employ	   Gd(III)	  chelates	  to	  increase	  the	  relaxation	  rates	  of	  water	  protons.	  The	  choice	  of	  Gd(III)	  is	  explained	   by	   its	   high	   spin	   paramagnetism	   and	   long	   electronic	   relaxation	   time	  (typically	   ms).	   Indeed,	   despite	   Dy(III)	   or	   Ho(III)	   having	   a	   larger	   magnetic	  moment,	  Gd(III)	  possesses	  a	  symmetrical	  S-­‐state	  which	  gives	  a	  slower	  electronic	  relaxation	  time	  more	  tuned	  to	  the	  proton	  Larmor	  frequency	  of	  water,	  leading	  to	  an	  increase	  in	  relaxation	  rate.71	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Similar	   to	   the	   rest	   of	   the	   lanthanide	   series,	   the	   free	   Gd(III)	   ion	   is	   highly	   toxic	  (LD50∼0.1	   mM/	   kg)	   and	   so	   must	   be	   encapsulated	   in	   a	   thermodynamic	   and	  kinetically	   stable	   multidentate	   ligand	   when	   administered	   as	   an	   MRI	   contrast	  agent.71	  There	   are	   countless	   examples	  of	   these	   coordinating	   ligands	  within	   the	  literature,	  and	  some	  will	  be	  reviewed	  later	  in	  this	  chapter.	  The	  first	  commercially	  approved	  Gd(III)-­‐based	  MRI	  contrast	  agent	  was	  [Gd(DTPA)(H2O)],	  marketed	  as	  Magnevist®	  in	  1988.	  Since	  then,	  eight	  further	  Gd(III)-­‐based	  contrast	  agents	  have	  been	  approved,	  with	  approximately	  35%	  of	  all	  MRI	  scans	  employing	  one	  of	  these	  contrast	  agents.72	  
	  	  
Scheme	  1.2.	  Structures	  of	  selected	  clinically	  approved	  MRI	  contrast	  agents.	  	  Upon	  administration	  of	  a	  Gd(III)	  contrast	  agent,	  the	  observed	  increase	  in	  solvent	  relaxation	  rate,	  1/T1obs,	  is	  the	  sum	  of	  the	  diamagnetic	  (1/Ti,d)	  and	  paramagnetic	  (1/Ti,p)	  relaxation	  rates	  (Equation	  1)73;	  	   	   	   i	  =	  1,2	   	   	   (1)	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The	  relaxivity	  is	  a	  direct	  measure	  of	  the	  ability	  of	  a	  complex	  to	  enhance	  the	  rate	  of	   relaxation	   of	   the	   water	   protons	   and	   is	   sometimes	   thought	   of	   as	   a	   catalytic	  property	  of	  these	  contrast	  agents.	  A	  complex	  displaying	  a	  larger	  r1	  will	  increase	  the	  contrast	  of	  an	  MR	  image	  more	  effectively.	  The	  presence	  of	   the	  paramagnetic	  species	  creates	  a	  strong	   local	  magnetic	   field,	  which	  can	   interact	  with	   the	  nuclear	  spins	  providing	  a	  more	  efficient	   relaxation	  mechanism	  for	  the	  water	  protons.	  However,	  this	  local	  magnetic	  field	  diminishes	  with	   distance	   and	   so	   specific	   chemical	   interactions	   coupled	   with	   random	  translational	   diffusion	   which	   bring	   water	   molecules	   in	   close	   proximity	   of	   the	  Gd(III)	   centre	   are	   crucial.	   This	   generally	   leads	   to	   the	   paramagnetic	   relaxation	  rate	   enhancement	   being	   divided	   into	   two	   contributions	   (Equation	   1.2,	   Figure	  
1.9)71,	  73;	  
	   	  i	  =	  1,2	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1.2)	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Figure	   1.9.	   Schematic	   representation	   of	   a	   Gd(III)	   complex,	   highlighting	   the	   factors	  affecting	  its	  relaxivity.	  
	  
1.3.1.1	  Inner	  Sphere	  Relaxation	  	  	  	  Although	   the	   overall	   contribution	   to	   relaxation	   rate	   enhancement	   is	  approximately	  equal	  for	  both	  inner	  and	  outer	  sphere	  mechanisms,	  the	  absence	  of	  detailed	  information	  on	  second	  and	  outer	  sphere	  water	  structure	  and	  exchange	  dynamics	  means	  that	  only	  the	  inner	  sphere	  term	  can	  be	  significantly	  controlled	  with	  confidence.73	  Inner	  sphere	  relaxation	  is	  defined	  by	  (Equation	  1.3);	  	   	   	   	   	   (1.3)	  	  where	  Pm	  is	  the	  mole	  fraction	  of	  bound	  water	  nuclei,	  q	  is	  the	  hydration	  number	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Increasing	  the	  hydration	  number	  of	  the	  contrast	  agent,	  such	  that	  q	  changes	  from	  1	  to	  2	  will	  result	   in	  an	  overall	   increase	  in	  inner	  sphere	  relaxation.	  However,	  an	  increase	   in	  hydration	  number	  effectively	   removes	  one	  permanent	   coordinating	  ligand	  donor	  from	  the	  Gd(III)	  centre,	  and	  as	  such	  results	  in	  a	  decrease	  in	  complex	  stability	  and	  compromises	  its	  kinetic	  inertness.71,	  73	  From	   the	  Solomon-­‐Bloembergen-­‐Morgan	  equations,74-­‐77	   it	   is	   apparent	  also	   that	  the	   water	   proton	   to	   metal	   ion	   distance	   is	   a	   factor	   that	   governs	   inner	   sphere	  relaxation.	  Due	  to	  the	  r-­‐6	  distance	  dependence,	  a	  small	  increase	  of	  0.2	  Å	  results	  in	  a	  50%	  decrease	  in	  proton	  relaxation.71	  The	  dipole-­‐dipole	  mechanism	  that	  dictates	  proton	  relaxation	  is	  governed	  by	  the	  effective	  correlation	  time,	  τci,	  such	  that;68,	  78	  	  	   	   	   i	  =	  1,2	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1.4)	  	  where	  Tie	   is	   the	  electronic	  spin	  relaxation	  times,	  τM	  is	   the	   lifetime	  of	   the	  bound	  water	  molecule	  and	  τR	  is	  the	  rotational	  correlation	  time.	  Theory	   predicts	   that	   the	   relaxivity	   maximum	   is	   attained	   when	   τci	   equals	   the	  inverse	   of	   the	   proton	   Larmor	   frequency.	   However,	   τM	   also	   enters	   equation	   1.3	  and	  predicts	  a	  higher	  inner	  sphere	  relaxation	  rate	  for	  a	  shorter	  τM.	  Consequently,	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1.3.2	  Receptor-­Targeted	  Gd(III)-­MR	  Contrast	  Agents	  	  Throughout	   the	   literature	   there	   are	   widespread	   examples	   of	   Gd(III)	   contrast	  agents	   that	   have	   been	   designed	   to	   report	   upon	   local	   changes	   in	   pH,	  metal	   ion	  concentration	   and	   enzyme	   activity.79-­‐81	   There	   are	   also	   detailed	   examples	   of	  contrast	  agents	   targeted	  towards	  abundantly	  present	  blood	  pool	  proteins,	  such	  as	  human	  serum	  albumin	   (HSA).82	  However,	   this	   review	  will	   focus	  only	  on	   the	  contrast	   agents	   that	   have	   been	   designed	   to	   change	   their	   relaxivity	   upon	  associating	  with	  cell-­‐surface	  and	  intracellular	  receptors,	  of	  which	  there	  are	  few.	  There	   are	   only	   a	   handful	   of	   reports	   of	   these	   contrast	   agents	   due	   to	   the	   low	  sensitivity	  of	   the	  MRI	  method.	  Even	  with	  a	   low	  cellular	  diamagnetic	   relaxation	  rate,	  upon	  administration	  of	   the	  Gd(III)	  complex,	   it	  has	  been	  hypothesised	   that	  there	  needs	  to	  be	  a	  10	  µM	  local	  Gd(III)	  concentration	  to	  observe	  a	  10%	  change	  in	  
R1	  for	  a	  contrast	  agent	  which	  possesses	  a	  typical	  relaxivity	  of	  5	  mM-­‐1	  s-­‐1.83	  This	  makes	   it	   difficult	   to	   image	   the	   majority	   of	   cell	   surface	   receptors,	   as	   they	   are	  believed	  to	  be	  present	  in	  the	  nanomolar	  range.	  	  
1.3.2.1	  Intracellular	  Receptor-­Targeted	  Contrast	  Agents	  	  Cancer	  cells	  are	  known	  to	  over-­‐express	  a	  variety	  of	  receptors	  that	  are	  present	  on	  or	  in	  healthy	  cells.	  The	  higher	  concentration	  of	  these	  receptors	  allows	  targeted-­‐contrast	  agents	  to	  overcome	  the	  inherent	  low	  sensitivity	  of	  MRI.	  The	  progesterone	  receptor	  (PR)	  is	  a	  useful	  marker	  for	  cancer	  progression	  and	  is	  frequently	  used	  to	  predict	  patient	  prognosis.	  Historically,	  progesterone	  receptor	  levels	   are	   determined	   from	   in	   vitro	   immunohistochemistry	   assays	   of	   patient	  samples	   gained	   by	   invasive	   biopsies.	   However,	   Meade	   and	   co-­‐workers	   have	  produced	   a	   series	   of	   reports	   on	   the	   development	   of	   progesterone	   receptor	  targeted	   MRI	   contrast	   agents,	   which	   could	   potentially	   report	   the	   degree	   of	  cancer	  progression.	  Although	   their	   initial	   complex,	   [Gd.L1.0]	   (Scheme	   1.3),	   induced	   a	   40%	  enhancement	   in	  R1	   upon	   incubation	  with	   progesterone	   receptor	   positive	   cells,	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the	  complex	  had	  a	  relatively	  weak	  affinity	  for	  the	  progesterone	  receptor	  (IC50	  =	  1.91	  µM).84	  	  In	   an	   effort	   to	   increase	   relaxation	   rate	   enhancement,	   four	   further	   complexes	  were	   synthesised	   (Scheme	  1.3),	   in	  order	   to	  optimise	   intracellular	   accumulation	  and	   progesterone	   receptor	   affinity.	   The	   effect	   of	   charge	   on	   the	   complex	  lipophilicity	   and	   cell	   permeability	   was	   assessed,	   along	   with	   the	   effect	   of	   the	  length	  of	  the	  spacer	  unit	  separating	  the	  progesterone	  motif	  and	  Gd(III)	  chelate.85	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The	  complex,	   [Gd.L1.2],	  was	  internalised	  in	  both	  progesterone	  receptor	  positive	  and	  negative	  cells,	  with	  progesterone	  receptor	  positive	  cells	  exhibiting	  twice	  the	  accumulation	   over	   a	   24	   hour	   period.	   This	   suggested	   that	   [Gd.L1.2]	   is	   retained	  longer	   in	   the	  progesterone	  receptor	  positive	  cells,	   through	   interaction	  with	   the	  intracellular	   receptor.	   The	   non-­‐specific	   uptake	   into	   progesterone	   receptor	  negative	  cells	  was	  attributed	  to	  the	  high	  hydrophobicity	  and	  cell	  permeability	  of	  the	  complex.86	  	  Retention	  of	  [Gd.L1.2]	  in	  the	  uterus,	  ovaries	  and	  mammary	  over	  a	  24	  hour	  period	  demonstrated	  its	  ability	  to	  target	  progesterone	  receptor	  rich	  tissue.	  Importantly,	  
[Gd.L1.2]	  did	  not	  accumulate	  in	  the	  abdominal	  tissue	  or	  fat.	  Finally,	   [Gd.L1.2]	  was	   shown	   to	   enhance	   the	   contrast	   of	   progesterone	   receptor	  positive	  tumours	   in	  the	  presence	  of	  progesterone	  receptor	  negative	  tumours	   in	  
vivo.	   Independent	   of	   the	   mode	   of	   administration	   (subcutaneous	   vs.	  intraperitoneal),	  a	  significant	  difference	  in	  the	  T1-­‐weighted	  MR	  images	  between	  the	  two	  tumours	  was	  evident	  2-­‐6	  hours	  post	  injection.86	  	  	  
Figure	  1.10.	  T1-­‐weighted	  MR	   images	   and	   contrast-­‐to-­‐noise	   plots	   (7	  T)	   of	   xenografted	  mice	   intraperitoneally	   injected	   with	   [Gd.DO3A]	   or	   [Gd.L1.2].	   A	   significant	   contrast	  enhancement	  is	  observed	  in	  both	  progesterone	  receptor	  positive	  and	  negative	  tumours	  over	  a	  6	  hour	  period	  when	  injected	  with	  [Gd.L1.2].86	  	  Despite	   the	  relative	  successes	  of	   [Gd.L1.2],	   it	   should	  be	  noted	   that	   this	  contrast	  agent	   is	   based	   on	   an	  N-­‐alkyl-­‐DO3A	   system.	   Such	   systems	   are	   likely	   to	   bind	   to	  protein	  non-­‐specifically87	  (approximately	  30%	  of	  [Gd.L1.2]	  was	  found	  to	  reside	  in	  the	   membrane	   and	   not	   interact	   with	   the	   progesterone	   receptor),	   or	   to	  endogenous	  anions	   (e.g.	  bicarbonate	  or	   lactate),	   leading	   to	  displacement	  of	   the	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coordinated	   water	   molecule.	   This	   will	   tend	   to	   reduce	   the	   relaxivity	   gain	   the	  authors	   observed	   upon	   receptor	   binding.	   Furthermore,	   the	   authors	   did	   not	  assess	  the	  effect	  of	  non-­‐specific	  protein	  binding	  on	  cellular	  uptake,	  which	  could	  be	  the	  reason	  for	  their	  relatively	  poor	  2:1	  cellular	  uptake	  specificity.	  Finally,	  the	  poor	   water	   solubility	   and	   intracellular	   uptake	   of	   [Gd.L1.2]	   resulted	   in	   a	  significant	  toxicity,	  most	  likely	  due	  to	  gadolinium	  retention.	  In	  an	  attempt	  to	  reduce	  the	  toxicity	  associated	  with	  [Gd.L1.2],	  the	  lipophilicity	  of	  the	  complex	  was	  adjusted	  through	  modification	  of	  the	  linker	  unit.88	  As	  expected,	  no	  change	  in	  progesterone	  receptor	  affinity	  was	  observed.	  However,	  an	  increase	  in	   cellular	   uptake	   of	   [Gd.L1.3]	   was	   achieved	   in	   progesterone	   positive	   tumours;	  90%	  of	   the	  complex	  was	   found	  to	   localise	   in	   the	  cytoplasm,	  where	  one	   form	  of	  the	  progesterone	  receptor	  is	  located.	  Contrast-­‐to-­‐noise	  ratios	  in	  T1-­‐weighted	  MR	  measurements	   of	   [Gd.L1.3]	   were	   comparable	   to	   that	   of	   [Gd.L1.2],	   but	   the	  increased	  water	  solubility	  resulted	  in	  an	  increase	  in	  cell	  viability.	  	  Despite	   the	   improvements,	   [Gd.L1.3]	   is	   based	   on	   a	   mono-­amide-­‐DO3A	   system.	  These	  types	  of	  system	  have	  inherently	  slower	  water	  exchange	  rates	  (kex	  ∼	  106	  s-­‐1)	  due	  to	  the	  presence	  of	  the	  weakly	  donating	  amide	  carbonyl	  and	  so	  relaxivity	  gain	  is	   limited.	   Furthermore,	   the	   receptor-­‐targeting	   moiety	   is	   attached	   through	   an	  ester	   linkage,	   which	   is	   well	   known	   to	   be	   susceptible	   to	   hydrolysis	   in	   vivo.	   A	  chemical	   linkage	   that	   is	  more	   stable	   to	   in	   vivo	   conditions	  would	   possibly	   give	  increased	   cellular	   retention	   in	   progesterone	   positive	   tumours,	   leading	   to	   an	  enhancement	  in	  signal	  contrast.	  	  
1.3.2.2	  Surface	  Receptor	  Targeted	  Contrast	  Agents	  	  In	  1995,	   a	   seminal	   paper	  by	  Meade	   and	   co-­‐workers89	   described	  how	  Gd-­‐DTPA	  chelates	  conjugated	  to	  polylysine,	  which	  were	  then	  loaded	  onto	  DNA	  containing	  transferrin,	   were	   able	   to	   label	   cells	   expressing	   the	   transferrin	   receptor.	   This	  resulted	   in	   a	   large	   enhancement	   in	   the	   T1-­‐weighted	   MR	   image	   contrast,	  compared	  to	  untreated	  cells.	  Furthermore,	  cells	  treated	  simultaneously	  with	  the	  Gd-­‐DTPA	   loaded	   DNA-­‐transferrin	   conjugate	   and	   also	   iron-­‐loaded	   transferrin	  resulted	   in	   a	   negligible	   enhancement	   in	   T1-­‐weighted	   MR	   contrast,	   due	   to	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competition	   for	   the	  receptor	  site.	  This	  demonstrated	   that	   internalisation	  of	   the	  contrast	  agent	  was	  mediated	  by	  the	  cell	  surface	  receptor.89	  	  Folate	   is	  an	  essential	  vitamin	   for	  cells	  and	  binds	  with	  high	  affinity	   to	   the	   folate	  receptor	   present	   on	   the	   cell	   surface.	   Upon	   the	   binding	   of	   folate,	   the	   folate	  receptor-­‐ligand	   conjugate	   undergoes	   receptor-­‐mediated	   endocytosis	   to	   deliver	  folate	  to	  the	  cytosol.	  Following	  dissociation	  of	  folate,	  the	  receptor	  returns	  to	  the	  cell	  surface	  ready	  for	  the	  next	  ligand	  to	  bind.	  There	  are	  several	  examples	  in	  the	  literature	  of	  polymeric,	  high	  molecular	  weight	  contrast	   agents	   that	   target	   the	   folate	   receptor.90-­‐92	   One	   example	   of	   a	   low	  molecular	  weight	  complex	   is	   from	  Kalber	  and	  co-­‐workers,93	  who	  synthesised	  a	  contrast	   agent	   by	   conjugation	   of	   folic	   acid	   to	   a	   monoamide	   GdDO3A	   chelate	  separated	  by	  an	  ethylene	  glycol	   spacer	   (Figure	  1.11).	   Inductively	   coupled	  mass	  spectrometry	   (ICP-­‐MS)	   measurements	   showed	   that	   the	   complex	   [Gd.L1.4]	   was	  internalised	   readily	   by	   folate	   receptor	   positive	   (FR+)	   cells	   after	   1	   hour,	   with	  more	  than	  double	  the	  accumulation	  than	  in	  folate	  receptor	  negative	  (FR-­‐)	  cells.	  Furthermore,	   the	   presence	   of	   free	   folic	   acid	   in	   the	   medium	   as	   a	   competitor	  resulted	  in	  a	  reduction	  in	  uptake	  of	  [Gd.L1.4]	  into	  FR+	  cells,	  suggesting	  receptor-­‐mediated	  internalisation.	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Despite	  confirmation	  of	  cellular	  labelling	  by	  ICP-­‐MS	  measurements,	  there	  was	  no	  increase	   in	   cellular	   relaxation	   rate	   in	   vitro,	   after	   incubation	   of	   [Gd.L1.4].	  Contrastingly,	   when	   [Gd.L1.4]	   was	   administered	   to	   nude	   mice	   bearing	   a	   FR+	  tumour	  xenograft,	  up	  to	  a	  50%	  enhancement	  in	  R1	  was	  observed	  over	  a	  14	  hour	  period,	   resulting	   in	   an	   increase	   in	   T1-­‐weighted	   MR	   contrast	   (Figure	   1.11).	   In	  comparison,	  there	  was	  no	  increase	  in	  R1	  for	  tumour	  xenografts	  baring	  FR-­‐	  cells,	  or	  when	  the	  non-­‐targeted	  [Gd.DOTA]	  was	  used.	  	  The	   contrasting	   in	   vitro	   and	   in	   vivo	   results	   are	   rather	   surprising.	   The	   authors	  suggest	  a	  significant	  degree	  of	  cellular	  variation	  in	  folate	  receptor	  expression	  as	  a	   possible	   reason	   for	   the	   contrasting	   results.	   This	   is	   a	   plausible	   assumption,	  although	   it	   is	   very	   difficult	   to	   determine	   the	   real	   mechanism	   by	   which	   R1	  increases	  in	  vivo.	  The	  intracellular	  fate	  of	  the	  complex	  is	  key.	  Once	  the	  complex	  is	  bound	  to	  the	  folate	  receptor,	  internalisation	  is	  likely	  to	  be	  quick	  resulting	  in	  the	  contrast	   agent	   residing	   in	   the	   cytosol.	   It	   can	   then	   theoretically	   bind	   non-­‐specifically	  to	  intracellular	  proteins,	  modulating	  τR,	  and	  increasing	  R1.	  However,	  the	   expected	   relaxivity	   gain	   in	   vitro	   could	  be	  quenched	   if	   the	   contrast	   agent	   is	  trapped	   in	   a	   sub-­‐cellular	   vesicle/endosome	   after	   internalisation,	   limiting	   kex.94	  Whatever	  the	  reasons	  for	  the	  discrepancies,	  the	  design	  of	  the	  complex	  could	  also	  limit	   the	   expected	   relaxivity	   gain.	   Monoamide	   Gd(III)	   chelates	   possess	   a	   sub-­‐optimal	  kex	  approximately	  four-­‐times	  slower	  than	  a	  tetra-­‐carboxylate	  derivative,	  resulting	  in	  a	  decrease	  in	  R1.	  	  One	   further	   example	   of	   a	   folate	   receptor-­‐targeted	   contrast	   agent	   is	   from	   some	  unpublished	   work	   in	   Durham.95	   In	   a	   similar	   approach	   to	   that	   outlined	   above,	  folic	  acid	  was	  conjugated	  to	  a	  Gd(III)	  chelate.	  However,	  the	  choice	  of	  ligand	  used	  to	   encapsulate	   the	   Gd(III)	   ion	   	   was	   derived	   from	   a	   tetra-­‐carboxy-­‐substituted	  DOTA	   ligand,	   giving	   the	   complex	  an	  overall	  negative	   charge.	  This	   complex	  was	  found	  to	  exhibit	  an	  80%	  increase	  in	  R1	  in	  the	  presence	  of	  folate	  binding	  protein	  (FBP),	  in	  comparison	  to	  a	  negligible	  increase	  in	  the	  presence	  of	  BSA.	  The	  use	  of	  carboxylate	  donors	  results	  in	  the	  complex	  having	  a	  fast	  water	  exchange	  rate	  (kex	  
∼	   107	   s-­‐1).	   This	   coupled	   with	   the	   overall	   negative	   charge,	   which	   hinders	   non-­‐specific	   protein	   binding,	   results	   in	   a	   large	  R1	   enhancement	   in	   the	   presence	   of	  FBP.	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The	  formyl	  peptide	  receptors	  (FPRs)	  are	  a	  class	  of	  G-­‐protein-­‐coupled	  receptors	  present	   on	   the	   surface	   of	   neutrophils.	   Their	   main	   function	   is	   to	   mediate	  migration	   of	   neutrophils	   to	   a	   site	   of	   injury	   causing	   an	   inflammatory	   response.	  Long	   and	   co-­‐workers96	   synthesized	   a	   FPR-­‐1-­‐targeted	  MR	   contrast	   agent	   based	  on	   the	   hexapeptide,	   cFLFLFK,	   known	   to	   be	   an	   antagonist	   for	   this	   receptor.	  Conjugation	   of	   the	   peptide	   fragment	   to	   the	   Gd(IIII)	   chelate	   through	   the	   lysine	  residue	  did	  not	  disrupt	  the	  affinity	  of	  the	  antagonist	  towards	  the	  receptor,	  with	  the	   apparent	   binding	   affinity	   only	   slightly	   decreasing	   (Kd	   =	   4.5	   vs	   2	   nM	   for	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The	   complex	   [Gd.L1.5]	   was	   then	   intravenously	   administered	   to	   mice	   (1	  mmol/kg),	   which	   had	   been	   pre-­‐injected	   with	   an	   inflammatory	   agent	   for	   24	  hours.	   Upon	   administration,	   a	   significant	   increase	   in	  T1-­‐weighted	  MR	   contrast	  ensued	   and	   was	   visible	   for	   up	   to	   80	   minutes	   post	   injection	   at	   the	   site	   of	  inflammation	   (Figure	   1.12A-­B).	   In	   comparison,	   the	   non-­‐targeted	   [Gd.DOTA]-­	  shows	   an	   initial	   increase	   in	  T1-­‐weighted	   contrast	   after	   1	  minute,	   but	   is	   totally	  undetectable	  80	  minutes	  post	   injection	  (Figure	  1.12	  C-­E).	  The	  authors	  attribute	  this	  difference	  in	  time-­‐dependent,	  T1-­‐weighted	  contrast	  to	  specific	  targeting	  and	  binding	  of	  [Gd.L1.5]	   to	   the	  neutrophils’	  FPR-­‐1	  receptor,	  prolonging	   the	  contrast	  agent’s	  lifetime	  at	  the	  site	  of	  inflammation.	  Of	  the	  examples	  of	  receptor-­‐targeted	  MR	  contrast	  agents	  in	  the	  literature,	  there	  are	   very	   few	   that	   are	   targeted	   towards	   cell	   surface	   receptors.	   Dopamine	   is	   an	  abundant	   neurotransmitter	   in	   the	   central	   nervous	   system	   and	   mediates	   its	  affects	   through	  metabotropic	  dopamine	   receptors.	  The	  dopaminergic	   system	   is	  related	  to	  many	  neurological	  and	  psychological	  disorders.	  The	  D2/D3	  dopamine	  receptors	  are	  the	  primary	  sites	  for	  anti-­‐Parkinsonic	  and	  anti-­‐psychotic	  drugs.	  	  	  
	  
	  













































[Gd.L1.6] [Gd.L1.7]; n = 9
[Gd.L1.8]; n = 3, X = CO
[Gd.L1.9]; n = 3, X = O
O
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modified	   dopamine	   receptor	   ligands	   (Scheme	   1.4).	   In	   an	   inhibition	   assay,	  complex	  [Gd.L1.6]	  was	  shown	  to	  possess	  a	   large	  decrease	  in	  binding	  affinity	  for	  the	  dopamine	  D2-­‐receptor,	   relative	   to	   the	   radiolabeled	   ligand,	  with	   an	   IC50	   for	  
[Gd.L1.6]	   of	   approximately	   10	   µM.	   The	   decrease	   in	   affinity	   reflects	   the	   large	  modification	   made	   to	   the	   spiperone	   ligand,	   inhibiting	   receptor	   binding.	   In	   an	  attempt	   to	   increase	   receptor	   affinity,	   further	   complexes	   were	   synthesised,	  reducing	   the	   number	   of	   structural	   modifications	   to	   the	   spiperone	   ligand	   and	  varying	   the	   length	   and	   nature	   of	   spacer.	   This	   resulted	   in	   an	   increase	   in	   D2	  receptor	  binding	  affinity	   for	   [Gd.L1.7-­1.8],	  demonstrating	   the	  need	   for	   the	  entire	  ligand	  moiety	  to	  be	  present	  in	  order	  to	  maintain	  affinity.	  	  	  
Table	  1.4.	  Comparative	  binding	  affinities	  and	  relaxivity	  values	  (9.4	  T,	  H2O/D2O	  1:1,	  298	  K)	  of	  dopamine	  receptor-­‐targeted	  contrast	  agents.97,	  98	  	   	   [Gd.L1.6]	   [Gd.L1.7]	   [Gd.L1.8]	   [Gd.L1.9]	  
IC50/	  M	   1x10-­‐5	   5x10-­‐9	   1x10-­‐8	   1x10-­‐6	  
r1/	  mM-­1s-­1	   5.9	   5.5	   7.8	   n.d	  	  Despite	  demonstrating	  the	  ability	  of	  these	  conjugates	  to	  bind	  at	  the	  dopamine	  D2	  receptor,	   there	   is	   a	   significant	   amount	   of	   work	   missing	   to	   fully	   characterise	  
[Gd.L1.6-­1.9]	  as	  dopamine-­‐receptor	  targeted	  contrast	  agents.	  Firstly,	  there	  are	  no	  
in	  vitro	  studies	  that	  demonstrate	  a	  change	  in	  relaxivity	  of	  these	  complexes	  upon	  binding	   to	   the	  dopamine	   receptor.	  The	  degree	  of	   relaxivity	   enhancement	  upon	  receptor	  binding	  would	  be	  limited	  due	  to	  the	  choice	  of	  the	  Gd(III)	  chelate,	  since	  
N-­‐alkyl-­‐DO3A	  systems	  are	  likely	  to	  bind	  non-­‐specifically	  to	  endogenous	  protein	  or	   anions.87	   This	   leads	   to	   displacement	   of	   the	   coordinated	   water	   molecule,	  reducing	  the	  relaxivity	  gain.	  Furthermore,	  specifically	   in	  [Gd.L1.8-­1.9],	   the	   ligand	  moiety	  is	  positioned	  at	  a	  considerable	  distance	  from	  the	  Gd(III)	  chelate.	  Although	  this	  will	  inevitably	  increase	  the	  affinity	  of	  the	  complex	  for	  the	  receptor	  based	  on	  steric	  arguments,	   it	  could	  hinder	  the	  relaxivity	  gain	  upon	  receptor	  binding.	  The	  expected	   increase	   in	   R1	   is	   modulated	   by	   the	   rotational	   correlation	   time,	   τR.	  Therefore,	  the	  large	  spacer	  in	  these	  systems	  may	  induce	  independent	  motion	  of	  the	   slowly	   tumbling	   macromolecule	   and	   the	   Gd(III)	   chelate,	   resulting	   in	   a	  decrease	  in	  relaxivity	  enhancement.	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1.4	  	   Molecular	  Imaging	  of	  Glutamate	  Receptors	  	  There	   have	   been	   several	   molecular	   imaging	   approaches	   used	   for	   the	  visualisation	   of	   glutamate	   receptors.	   The	   following	   summarises	   the	   current	  literature	   relating	   to	   the	   use	   of	   PET/SPECT,	   optical	   and	   MR	   for	   imaging	  glutamate	  receptors.	  	  
1.4.1	  PET	  and	  SPECT	  Radiotracers	  for	  Glutamate	  Receptors	  	  PET	   and	   SPECT	   are	   both	   radionuclide-­‐imaging	   techniques,	   which	   rely	   on	   the	  decay	   of	   radioactive	   isotopes	   via	   emission	   of	   a	   positron	   or	   gamma	   ray,	  respectively.	  Both	  techniques	  possess	  very	  high	  sensitivity	  (10-­‐11	  –	  10-­‐12	  M)	  and	  can	  be	  used	  to	  image	  whole	  bodied	  live	  subjects.1	  There	   have	   been	   several	   reports	   on	   the	   synthesis	   and	   application	   of	   PET	   and	  SPECT	   tracers	   for	   glutamate	   receptors.99	   The	   majority	   of	   these	   tracers	   are	  derived	  from	  well-­‐known	  ligands	  of	  glutamate	  receptors,	  with	  the	  incorporation	  of	  either	  an	  18F/11C	  radiolabel	  for	  PET	  tracers	  and	  123I/111In	  labels	  for	  SPECT.	  Of	  the	   examples	   in	   the	   literature,	   the	   most	   characterised	   PET	   tracer	   for	   mGluR5	  receptors	   is	   [18F]SP203	   (Scheme	   1.5).100	   This	   tracer	  was	   synthesised	   in	   a	   high	  radiochemical	   yield	   through	   nucleophillic	   substitution	   of	   the	   bromomethyl	  analogue	   with	   [18F]KF,101	   resulting	   in	   a	   ligand	  with	   an	   extremely	   high	   affinity	  (IC50	   =	   0.036	   nM)	   and	   selectivity	   for	   mGluR5.	   Rapid	   uptake	   into	   the	   brain	   of	  rhesus	   monkeys	   was	   observed,	   with	   accumulation	   residing	   in	   mGluR5-­‐rich	  regions.	  Although	  a	  moderate	  amount	  of	   radioactivity	  accumulated	   in	   the	   skull	  during	  the	  in	  vivo	  experiments	  with	  monkeys,102	  this	  was	  not	  observed	  in	  a	  pilot	  study	  with	  seven	  healthy	  human	  subjects.	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Among	   the	   iGluR	   imaging	   agents,	   there	  has	  been	   little	   progress	   in	   imaging	   the	  AMPA	  and	  Kainate	   receptors.	  However,	  of	   the	   several	   radiotracers	   synthesized	  for	  NMDA	  receptors,	   the	  SPECT	   ligand,	   [123I]CNS	  1261	  (Scheme	  1.5)	  has	  shown	  the	   most	   potential.103	   In	   human	   experiments,	   this	   tracer	   showed	   high	  distribution	   volumes	   in	   regions	   consistent	   with	   high	   NMDA	   receptor	  concentrations.	   Specific	   binding	   to	   the	   NMDA	   receptor	   was	   confirmed	   in	   a	  competition	   experiment	  with	   ketamine,	   but	   due	   to	   high	   degree	   of	   non-­‐specific	  binding,	  the	  ability	  to	  detect	  small	  changes	  in	  receptor	  availability	  was	  limited.	  Although	   there	   has	   been	   some	   success	   in	   the	   development	   of	   radiotracers	   for	  PET	   and	   SPECT	   imaging	   of	   glutamate	   receptors,	   there	   are	   many	   limitations	  associated	   with	   these	   methods.	   First,	   the	   resolution	   of	   these	   techniques	   is	  between	  1-­‐10	  mm,	  which	  limits	  the	  ability	  to	  observe	  small	  changes	  at	  a	  receptor	  site.	   Furthermore,	   these	  methods	   rely	   on	   efficient	   chemical	   synthesis	   of	   radio-­‐labelled-­‐tracers.	   This	   requires	   the	   use	   of	   a	   nearby	   cyclotron	   to	   generate	   the	  short-­‐lived	   radionuclide,	   which	   must	   be	   quickly	   reacted	   with	   a	   substrate	   in	   a	  high	   yielding	   reaction.	   The	   use	   of	   a	   radiotracer	   exposes	   both	   the	   patient	   and	  chemist	  to	  potentially	  harmful	  ionising	  radiation.	  	  
1.4.2.	  Optical	  Imaging	  of	  Glutamate	  Receptors	  	  Similar	  to	  PET	  and	  SPECT,	  optical	  imaging	  is	  endowed	  with	  excellent	  sensitivity	  (10-­‐9	   -­‐	   10-­‐12	   M)	   and	   can	   be	   used	   to	   image	   biomolecules,	   which	   are	   present	   in	  lower	   concentrations,	   such	   as	   the	   ionotropic	   glutamate	   receptors.	   Further	   to	  their	   sensitivity,	   fluorescently	   labelled	   ligands	   are	   superior	   to	   radioligands	   as	  they	  are	  generally	   safer	  and	  easier	   to	  handle.	  However,	   the	  major	   limitation	  of	  optical	  imaging	  is	  the	  poor	  tissue	  penetration	  of	  photons	  in	  the	  range	  of	  400-­‐900	  nm;	  no	  more	  than	  a	  cm	  or	  so	  is	  possible.	  
Figure	  1.13.	  Schematic	  representation	  of	  the	  mechanism	  of	  action	  of	  Cy3	  probe.104	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Chambers	   and	   co-­‐workers	   have	   developed	   a	   four-­‐component	  molecular	   probe	  for	  visualisation	  of	  AMPA	  receptors.104	  The	  design	  of	  the	  molecule	  is	  based	  on	  a	  polyamine	   ligand	   (known	   to	   bind	   in	   the	   AMPA	   channel),	   conjugated	   to	   a	   Cy3	  fluorescent	   reporter	   via	   a	   photo-­‐cleavable	   linker.	   The	   molecule	   also	   bears	   an	  electrophilic	  acrylamide	  moiety,	  which	  can	  undergo	  reaction	  with	  a	  nucleophilic	  partner,	   such	   as	   an	   amino	   acid	   side	   chain	   present	   on	   the	   AMPA	   receptor,	   to	  anchor	   the	   probe	   to	   the	   receptor	   (Figure	   1.13).	   The	   probe	  was	   found	   to	   block	  functional	   AMPA	   receptors	   in	   electrophysiology	   experiments,	   with	   removal	   of	  the	   polyamine	   block	   restoring	   the	   receptor	   to	   its	   native	   state	   after	   irradiation	  with	  380	  nm	  light.	  When	   cells	   were	   treated	   with	   Cy3-­‐probe	   for	   2	   mins	   and	   then	   continuously	  perfused	   with	   fresh	   buffer,	   fluorescence	   was	   observed	   around	   the	   synaptic	  junction,	   consistent	   with	   the	   expected	   distribution	   of	   AMPA	   receptors	   (Figure	  
1.14A-­B).	   The	   fluorescence	   intensity	   was	   time	   dependent,	   decreasing	   rapidly	  over	  a	  7	  minute	  period	  (Figure	  1.14C).	  In	  comparison,	  incubation	  of	  the	  Cy3	  unit	  missing	   the	   targeting	   ligand	   showed	   no	   cellular	   localisation	   in	   microscopy	  studies,	   suggesting	   that	   the	   acrylamide	   moiety	   does	   not	   react	   promiscuously	  with	  any	  nucleophile.104	  	  
	  
Figure	   1.14.	   (A)	   Fluorescent	   images	   of	   neurons	   30	   seconds	   after	   incubation	   of	   Cy3	  probe.	   (B)	   Magnified	   region	   after	   5	   minutes	   of	   washing	   with	   buffer.	   (C)	   Quantitative	  analysis	   showing	   a	   decrease	   in	   fluorescence	   intensity	   from	   the	   neuronal	   cells	   over	   a	  short	  period	  of	  time.104	  	  Despite	  the	  visualisation	  of	  AMPA	  receptors,	  there	  are	  some	  discrepancies	  within	  this	   article.	  The	  authors	  do	  not	   state	  whether	  or	  not	   the	   imaging	   is	  performed	  after	   photo-­‐dissociation	   of	   the	   polyamine	   ligand,	   and	   whether	   they	   are	  visualising	   the	   Cy3	   unit	   directly	   bound	   to	   the	   AMPA	   receptor.	   The	   fact	   the	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Figure	   1.15.	   (Top)	   Structure	   of	   iGluR-­‐targeted	   BODIPY	   probe.	   (Bottom)	   Confocal	  microscopy	   images	   of	   neurons	   expressing	   mCherry-­‐tagged	   NMDA	   receptors	   (red	  fluorescence).	   Cells	   were	   treated	   for	   2	   minutes	   with	   50	   nM	   of	   BODIPY	   probe	   (green	  fluorescence)	   and	   then	   imaged	   at	   beginning	   of	   washing	   stage	   (T0)	   and	   following	   five	  minutes	  continuous	  washing	  (T5).105	  	  The	  most	   promising	   BODIPY	   probe	   (Figure	   1.15)	  was	   used	   in	   cellular	   staining	  experiments	   of	   NMDA	   receptors	   transfected	   with	   the	   red	   fluorescent	   protein,	  mCherry.	   Upon	   incubation	   of	   BODIPY1,	   a	   considerable	   degree	   of	   non-­‐specific	  binding	   was	   observed	   due	   to	   interaction	   of	   the	   positively	   charged	   polyamine	  with	   the	   plasma	   membrane.	   However,	   following	   a	   continuous	   five	   minute	  washing	   period,	   the	   non-­‐specific	   staining	   was	   removed	   to	   reveal	   punctate	  fluorescence,	   overlapping	   with	   mCherry	   emission	   along	   the	   dendrites	   (Figure	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weaker	  affinity	  for	  the	  NMDA	  receptor	  showed	  no	  cellular	  localisation	  after	  the	  5	  minute	  washing	  period.105	  	  Recently,	  Perrio	  and	  co-­‐workers	  have	  synthesised	  three	  series	  of	  NMDA	  receptor	  NR2B	   subunit	   specific	   optical	   imaging	   probes	   by	   conjugation	   of	   fluoroscein	   to	  derivatives	  of	  the	  non-­‐competitive	  antagonist,	  ifenprodil.106,	  107	  The	  point	  of	  attachment	  and	  length	  of	  spacer	  unit	  connecting	  the	  fluorophore	  to	  the	  ligand	  moiety	  was	  found	  to	  strongly	  dictate	  probe	  affinity	  towards	  the	  NMDA	  receptor.	   By	   measuring	   Ca2+	   influx	   transients	   in	   a	   competitive	   assay,	   optimal	  affinity	  was	   demonstrated	  when	   conjugation	   occurred	   through	  modification	   of	  the	   benzylic	   hydroxyl	   of	   ifenprodil.	   Generally,	   a	   longer	   spacer	   also	   increased	  affinity	   for	   the	   NR2B	   subunit,	   although	   IC50	   values	   were	   approximately	   6-­‐fold	  higher	   as	   compared	   to	   ifenprodil.	   Other	   pharmacological	   properties,	   such	   as	  subunit	   selectivity	   and	   neuroprotective	   effects	   were	   not	   compromised	   by	   the	  conjugation	  of	  the	  fluorophore.	  When	  neuronal	   cells	   expressing	  DS-­‐red	   labelled	  NMDA	   receptors	  were	   treated	  with	   fluoroscein-­‐ifenprodil,	   a	   punctate	   fluorescence	   was	   observed	   from	   the	  fluoroscein	   moiety	   (Figure	   1.16B).	   This	   fluorescence	   overlayed	   with	   the	   red	  fluorescence	   from	   the	   genetically	   labelled	   NMDA	   receptors,	   demonstrating	   co-­‐localisation	   of	   fluroscein-­‐ifenprodil	   at	   the	   NMDA	   receptor	   (Figure	   1.16C).	  Furthermore,	  when	  cells	  were	  pre-­‐treated	  with	  ifenprodil	  and	  then	  loaded	  with	  fluoroscein-­‐ifenprodil,	   no	   fluorescence	   was	   observed,	   suggesting	   fluoroscein-­‐ifenprodil	   localises	   and	   binds	   in	   the	   same	   position	   on	   NMDA	   receptors	   as	   the	  native	  ligand	  (Figure	  1.16D-­F).	  Despite	  the	  increased	  sensitivity	  and	  resolution	  associated	  with	  optical	  imaging	  methods,	   this	   technique	   is	   limited	   by	   light	   scattering	   and	   absorbance	   in	   soft	  tissue,	  and	  has	  a	  low	  effective	  imaging	  depth	  of	  the	  order	  of	  10	  mm	  or	  so.	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Figure	   1.16.	   (Top)	   Structure	   of	   fluoroscein-­‐ifenprodil.	   (Bottom)	   Confocal	  microscopy	  imaging	  of	  DS-­‐red	  labelled	  NMDA	  receptors	  (red	  fluorescence).	  (A)	  DS-­‐red	  emission;	  (B)	  Visualisation	  of	  fluoroscein	  emission	  after	  incubation	  of	  fluorscein-­‐ifenprodil	  (10	  µM,	  15	  mins);	  (C)	  Merge	  image	  showing	  co-­‐localization.	  (D,	  E,	  F)	  are	  same	  as	  (A,	  B,	  C)	  but	  with	  a	  pre-­‐incubation	  of	  ifenprodil	  (10	  µM,	  15	  mins).106	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Figure	   1.17.	   (Top)	   Representative	   T1-­‐weighted	   MR	   images	   (3	   T)	   of	   1	   x	   107	   cells.	  (Bottom)	  Cellular	  relaxation	  rates,	  R1,cell,	  after	  treatment	  of	  primary	  rat	  astrocytes	  with	  (a)	  [Gd.DOTA],	  (b)	  [Gd.L1.10]	  and	  (c)	  [Gd.L1.12]	  (all	  200	  µM,	  45	  mins).109	  	  Following	  MR	  experiments,	  the	  cells	  treated	  with	  [Gd.L1.10]	  and	  [Gd.L1.12]	  were	  subject	  to	  ICP-­‐MS	  measurements	  to	  determine	  the	  total	  Gd(III)	  content.	  Between	  6-­‐60	  x	  107	  Gd(III)	   ions	  per	  cell	  were	  present,	  which	  is	  well	  above	  the	  detection	  limit	  of	  modern	  MRI	  experiments.	  However,	   the	  cellular	  relaxivites	  were	   found	  to	  differ	  substantially	  (2.9	  mM-­‐1	  s-­‐1	  and	  7.4	  mM-­‐1	  s-­‐1,	  for	  [Gd.L1.10]	  and	  [Gd.L1.12],	  respectively),	   suggesting	   a	   different	   mechanism	   for	   R1,cell	   enhancement.	   The	  enhancement	   due	   to	   [Gd.L1.10]	   can	   be	   assigned	   to	   the	   huge	   increase	   in	   cell-­‐associated	  Gd(III),	  whereas	   [Gd.L1.12]	   induces	  a	   comparable	  enhancement	  with	  only	   one	   third	   Gd(III)	   present.	   This	   suggests	   that	   [Gd.L1.12]	   induces	   R1,cell	  enhancement	  due	  to	  its	  higher	  affinity	  for	  the	  mGluR5	  receptor.109	  The	   enhancements	   in	   R1,cell	   were	   tentatively	   assigned	   to	   an	   increase	   in	   the	   τR	  value	   of	   the	   complex	   upon	   receptor	   binding.	   This	   is	   reflected	   in	   the	   ability	   of	  
[Gd.L1.12]	   to	   bind	   reversibly	   to	   cells	   possessing	   mGluR5	   in	   the	   presence	   of	  glutamate,	  when	  studied	  by	  fluorescence	  spectroscopy.108	  Internalisation	   of	   the	   contrast	   agents	   was	   ruled	   out	   by	   performing	   control	  experiments,	   where	   competition	   assays	   in	   the	   presence	   of	   unmodified	  antagonists	  resulted	  in	  no	  significant	  increase	  in	  R1,cell.	  Furthermore,	  derivatives	  of	   the	   lead	   compounds	   were	   synthesised	   which	   included	   a	   remote	   biotin	   tag.	  These	   derivatives	   were	   shown	   to	   label	   mGluR5	   receptors	   on	   the	   surface	   of	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primary	   rat	  astrocytes	  using	  confocal	   and	  TIRF	  microscopy	  after	   co-­‐incubation	  with	  AvidinAlexafluor®-­‐488	  conjugate	  (Figure	  1.18).110	  	  
	  
	  
Figure	   1.18.	   (A)	   TIRF	   and	   (B)	   confocal	  microscopy	   images	   of	   primary	   rat	   astrocytes	  after	   incubation	  with	   biotin	   derivative	   of	   [Gd.L1.12]	   showing	   predominate	   cell	   surface	  localisation.	   Green	   emission	   (avidinalexafluor®-­‐488)	   is	   labelled	   mGluR5	   receptors;	  orange	   emission	   (cell	   mask	   orange)	   is	   plasma	  membrane	   staining	   and	   blue	   emission	  (Hoechst)	  highlights	  the	  nucleus.110	  	  
1.5	  	   Aims	  and	  Objectives	  	  The	  aim	  of	  this	  project	  is	  to	  design,	  synthesise	  and	  evaluate	  a	  series	  of	  molecular	  imaging	   contrast	   agents	   that	   specifically	   target	   the	   NMDA	   receptor,	   with	   the	  majority	  focused	  towards	  MRI.	  	  Glutamate	   is	  the	  most	  abundant	  excitatory	  neurotransmitter	   in	  the	  mammalian	  central	   nervous	   system,	   having	   roles	   in	   a	   variety	   of	   neuronal	   processes.	   The	  NMDA	  receptor	  is	  an	  abundantly	  present	  glutamate	  receptor	  located	  on	  the	  post-­‐synaptic	   membrane	   and	   is	   responsible	   for	   excitatory	   neurotransmission,	  memory	   and	   learning.	   However,	   mis-­‐regulation	   and	   over	   stimulation	   of	   the	  receptor	  can	  often	   lead	   to	  a	  variety	  of	  neurodegenerative	  disorders.	  Therefore,	  NMDA	  receptor-­‐targeted	  MR	  contrast	   agents	   could	  provide	  a	  neurological	   tool,	  functioning	   both	   as	   a	  marker	   of	   receptor	   density	   and	   an	   indicator	   of	   neuronal	  activity.	  The	  design	  of	  these	  contrast	  agents	  must	  consider	  the	  following:	  i) The	  contrast	  agent	  should	  contain	  an	  MR-­‐active	  core,	  conjugated	  to	  a	  known	  NMDA	  receptor	  ligand.	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ii) There	  should	  be	  minimal/no	  pertubation	  to	  the	  receptor	  upon	  binding	  of	  the	  contrast	  agent.	  iii) The	  contrast	  agent	  should	  bind	  to	  the	  receptor	  in	  a	  reversible	  manner	  and	  with	  competative	  affinity	  to	  the	  endogenous	  ligand,	  glutamate.	  iv) The	   relaxivity	   enhancement	   upon	   receptor	   binding	   should	   be	   large	  enough	   to	   allow	   distinction	   between	   bound	   and	   unbound	   contrast	  agent.	  v) The	  contrast	  agent	  should	  exhibit	  a	  fast	  water	  exchange	  rate,	  such	  that	  
τR	   limits	   the	   relaxivity	   enhancement,	   and	   not	   the	   rate	   of	   water	  exchange	  on/off	  the	  Gd	  ion.	  
Chapters	   2	   and	   3	   describe	   the	  design,	   synthesis,	   characterisation	   and	   in	   cellulo	  evaluation	   of	   a	   number	   of	   NMDA	   receptor-­‐targeted	   MRI	   contrast	   agents.	   In	  
chapter	   4,	   derivatives	   of	   lead	   compounds	  were	   synthesised	   to	   allow	   for	   direct	  visualisation	  of	  NMDA	  receptors	  by	  optical	  microscopy.	  Chapter	  5	  describes	  the	  synthesis	   of	   a	   NMDA	   receptor-­‐targeted	   Eu(III)-­‐complex	   for	   time-­‐gated	  visualisation	   of	   these	   receptors.	   Finally,	   chapter	   6	   focuses	   on	   an	   emerging	  imaging	  modality,	  photoacoustic	  imaging,	  and	  details	  the	  design	  and	  synthesis	  of	  novel	  NMDA	  receptor-­‐targeted	  photoacoustic	  imaging	  agents.	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2.	  First	  Generation	  NMDA	  Receptor-­Targeted	  
MRI	  Contrast	  Agents	  	  
2.1	   	  Introduction	  	  The	  specification	  at	  the	  end	  of	  chapter	  1	  outlines	  key	  criteria	  to	  consider	  in	  the	  design	   of	   NMDA	   receptor-­‐targeted	   MRI	   contrast	   agents.	   Firstly,	   the	   receptor-­‐binding	   moiety	   must	   be	   a	   known	   ligand,	   with	   sufficient	   affinity	   to	   induce	   a	  detectable	  enhancement	   in	   relaxation	   rate.	  However,	   the	  affinity	   should	  not	  be	  too	  high	  so	  that	  it	  binds	  reversibly	  in	  competition	  with	  glutamate.	  The	  receptor-­‐binding	   moiety	   must	   also	   bind	   in	   such	   a	   way	   as	   to	   minimise	   perturbation	   of	  receptor	  homeostasis.	  The	  receptor-­‐binding	  moiety	  should	  be	   linked	   to	  a	  paramagnetic	  core.	  A	   larger	  enhancement	   in	   relaxation	   rate	   upon	   receptor	   binding	  will	   be	   observed	   if	   the	  most	   paramagnetically	   stable	   ion,	   Gd(III),	   is	   used.	   The	  high	   toxicity	   of	   the	   free	  metal	   results	   in	   the	  need	   for	   a	  multidentate,	  macrocyclic	   ligand	   to	   encapsulate	  the	  Gd(III)	   ion.	  The	   resultant	   complex	   should	  possess	   fast	  water	   exchange	  and	  some	   degree	   of	   motional	   coupling	   to	   optimise	   changes	   in	   inner	   sphere	  relaxation.	  Thus,	   the	   spacer	   unit	   linking	   the	   paramagnetic	   core	   to	   the	   receptor-­‐binding	  moiety	  must	   be	   of	   optimal	   length,	   so	   rotational	  motion	   between	   the	   two	   sites	  does	  not	  become	  decoupled.	  The	  target	  structures	  that	  were	  designed	  are	  shown	  below	  (Scheme	  2).	   	  
	  
	  

















R = CH2CO2H;                       [Gd.L1]
       CH2CH2CO2H;                [Gd.L2]
       CH2CH2PO3H2;               [Gd.L3]
       CH2CH2CH2PO3H2;        [Gd.L4]
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The	  target	  compounds	  are	  based	  on	  a	  [Gd.DOTA]	  core	  conjugated	  to	  derivatives	  of	   known	   competitive	   antagonists	   for	   the	   NMDA	   receptor.1	   A	   competitive	  antagonist	  was	   selected	   as	   it	  was	   expected	   to	   compete	  with	   glutamate	   for	   the	  ligand-­‐binding	   site,	   whilst	   not	   activating	   the	   NMDA	   receptor.	   As	   described	   in	  
chapter	   1,	   the	   3,4-­‐diamino-­‐3-­‐cyclobutene-­‐1,2-­‐dione	  moiety	   acts	   as	   an	   isosteric	  replacement	   of	   the	   α-­‐amino	   carboxylic	   acid	   functionality	   found	   within	   the	  majority	  of	   	  competitive	  NMDA	  receptor	  antagonists.	  Antagonists	  based	  on	  this	  structure	   are	   able	   to	   bind	   to	   the	   NMDA	   receptor	   with	   a	   lower	   affinity	   than	  glutamate,	   fulfilling	   the	   specification	   outlined	   in	   chapter	   1.	   Furthermore,	   the	  Gd(III)	  ion	  is	  encapsulated	  in	  the	  DOTA	  structure,	  with	  this	  ligand	  system	  chosen	  in	   order	   to	   maximise	   the	   water	   exchange	   rate,	   kex,	   and	   minimise	   non-­‐specific	  protein	  binding.	  The	  linker	  unit	  is	  derived	  from	  lysine,	  and	  was	  chosen	  because	  the	   receptor-­‐binding	   moiety	   is	   sufficiently	   spaced	   from	   the	   Gd(III)	   chelate	   in	  order	   to	   maintain	   antagonist	   affinity	   and	   yet	   retain	   some	   coupled	   rotational	  motion.	  	  
2.2	   	  Synthetic	  Details	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With	  compound	  2	  in	  hand,	  a	  divergent	  approach	  was	  adopted	  (Scheme	  2.2).	  For	  the	   synthesis	   of	   [Gd.L1],	   a	  Michael	   addition-­‐elimination	   reaction	   between	   tert-­‐butyl	   (2-­‐ethoxy-­‐3,4-­‐dioxocyclobut-­‐1-­‐en-­‐1-­‐yl)carbamate	   (2)	   and	   the	  hydrochloride	  salt	  of	  tert-­‐butyl	  glycine	  was	  conducted	   in	  anhydrous	  EtOH	  with	  diisopropylethylamine	   present	   to	   neutralise	   the	   hydrochloride	   salt.	   After	  removal	  of	   the	  solvent	  under	  reduced	  pressure,	   the	  crude	  residue	  was	  purified	  by	  column	  chromatography	  to	  afford	  3,	  in	  a	  high	  yield.	  	  The	  final	  step	  in	  the	  synthesis	  of	  the	  receptor-­‐binding	  moiety	  of	  [Gd.L1]	  involved	  introduction	  of	  a	   small	   linker,	  which	  would	  provide	   the	  point	  of	   attachment	   to	  the	  macrocyclic	  core.	  This	  was	  achieved	  through	  N-­‐alkylation	  of	  3	  in	  dry	  DMF	  at	  40	  °C,	  with	  methyl	  bromoacetate	  in	  the	  presence	  of	  NaH.	  Following	  work-­‐up	  and	  purification	   by	   column	   chromatography,	   the	   fully	   protected	   receptor-­‐binding	  moiety	  (4)	  was	  isolated	  as	  a	  light	  green	  oil.	  Due	  to	  the	  orthogonal	  nature	  of	  the	  protecting	  group	  strategies	  employed	  in	  the	  synthesis	   of	   4,	   this	   compound	   was	   subject	   to	   basic	   conditions	   in	   order	   to	  selectively	   remove	   the	   methyl	   ester.	   Rapid	   methyl	   ester	   hydrolysis	   was	  confirmed	  by	  1H	  NMR	  spectroscopy,	  with	  loss	  of	  the	  methyl	  singlet	  at	  3.76	  ppm	  to	  give	  5.	  	  
	  	  































3   n = 1; 82%
6   n = 2; 79%
4   n = 1; 94%
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2.2.2	  Receptor-­Binding	  Moieties	  of	  [Gd.L3]	  and	  [Gd.L4]	  	  The	  majority	  of	  NMDA	  receptor	  antagonists	  contain	  a	  phosphonic	  acid	  group	  to	  replace	   the	  distal	   carboxylic	  acid.	  This	  often	   leads	   to	   the	  antagonist	  possessing	  an	   increased	  NMDA	  receptor	  affinity,	  as	  was	   the	  case	  of	  AP5	  and	  AP7	  (chapter	  
1).3	   Similarly,	   in	   the	   original	   work	   describing	   the	   squaramide	   derived	   NMDA	  receptor	   antagonists,	   it	  was	   observed	   that	   substitution	   of	   the	   distal	   carboxylic	  acid	  with	  a	  phosphonic	  acid	  moiety	  resulted	  in	  a	  3-­‐fold	  enhancement	  in	  receptor	  affinity.1	   Baring	   this	   in	  mind,	   it	   was	   reasoned	   that	   the	   use	   of	   a	   higher	   affinity	  receptor-­‐binding	  moiety	  would	   offset	   the	   expected	   decrease	   in	   overall	   affinity	  upon	  conjugation	  to	  the	  relatively	  large	  Gd(III)	  chelate.	  The	  synthesis	  of	  the	  receptor-­‐binding	  moieties	  of	  [Gd.L3]	  and	  [Gd.L4]	  followed	  a	  similar	   route	   to	   that	  used	   in	   the	   synthesis	  of	   compounds	  5	   and	  8.	   Initially,	   the	  synthesis	  of	  the	  β-­‐	  and	  γ-­‐amino	  phosphonates	  was	  undertaken	  and	  were	  used	  in	  subsequent	   Michael	   addition-­‐elimination	   reactions	   with	   2.	   Following	   standard	  Gabriel	   synthesis	   methods,4	   the	   corresponding	   β-­‐	   and	   γ-­‐bromo	   phosphonates	  were	  stirred	  with	  potassium	  phthalamide	  and	  NaH	  in	  DMF	  at	  100	  °C.	  For	  the	  γ-­‐bromo	   phosphonate,	   the	   corresponding	   phthalamide-­‐phosphonate	   (9)	   was	  prepared	   in	   a	   reasonable	   yield	   after	   work-­‐up.	   Subsequent	   unmasking	   of	   the	  primary	  amine	  (10)	  was	  achieved	  in	  excellent	  yield,	  upon	  stirring	  with	  hydrazine	  in	  refluxing	  ethanol	  (Scheme	  2.3).	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the	   commercially	   available	   diethyl	   (2-­‐amino	   ethyl)	   phosphonate	   oxalate	   was	  considered	  a	  better	  precursor	  for	  the	  Michael	  addition-­‐elimination	  reaction.	  	  
	  	  
Scheme	  2.4.	  	  The	   remaining	   steps	   followed	   the	   previous	   route	   used	   for	   the	   synthesis	   of	   the	  receptor-­‐binding	  moieties	  of	  [Gd.L1]	  and	  [Gd.L2],	  giving	  the	  free	  carboxylic	  acids,	  
13	  and	  16	  (Scheme	  2.4),	  ready	  for	  conjugation	  to	  the	  macrocycle.	  	  























11   n = 2; 60%
14   n = 3; 42%
12   n = 2; 50%
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Scheme	  2.5.	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22    R = CH2CO2tBu;                19%    
23           CH2CH2CO2tBu;         14%
24          CH2CH2PO3Et2;          19%









































L1   R = CH2CO2H                 
L2          CH2CH2CO2H        
L3         CH2CH2PO3H2          
L4          CH2CH2CH2PO3H2
[Gd.L1]   R = CH2CO2H              
[Gd.L2]          CH2CH2CO2H         
[Gd.L3]         CH2CH2PO3H2          
[Gd.L4]          CH2CH2CH2PO3H2
GdCl3.6H2O, H2O
pH 6.5, 60 oC
21
DMF, RT
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In	   order	   to	   confirm	   the	   presence	   of	   complexes	   [Gd.L1-­4],	   high-­‐resolution	  mass	  spectrometry	   analysis	   was	   undertaken.	   Gadolinium	   has	   six	   stable	   isotopes,	  giving	   an	   observable	   characteristic	   isotope	   pattern	   in	  mass	   spectrometry.	   The	  presence	   of	   the	   isotope	   pattern	   of	   [Gd.L4]	   is	   shown	   (Figure	   2),	   comparing	  theoretical	  and	  experimental	  distrubutions.	  
	  
Figure	   2.	   (Left)	   Calculated	   and	   (Right)	   observed	   high-­‐resolution	   electrospray	   mass	  spectrum	   of	   [Gd.L4],	   showing	   the	   characteristic	   Gd-­‐isotope	   pattern;	   TOF-­‐MS	   negative	  mode.	  	  
2.3	   	  Relaxivity	  Properties	  	  The	  aqueous	  synthesis	  of	  complexes	  [Gd.L1-­4]	  results	   in	  contamination	  of	  these	  samples	  with	  various	  salts,	  which	  renders	  it	  difficult	  to	  obtain	  accurate	  weights	  of	   the	   complexes.	   Therefore,	   the	   Evans’	   bulk	   magnetic	   susceptibility	   (BMS)	  method6	   was	   employed	   to	   determine	   total	   complex	   concentration	   in	   a	   given	  volume.	   This	   NMR	   method	   relies	   on	   the	   phenomenon	   that	   a	   paramagnetic	  species	   can	   induce	   a	   chemical	   shift	   in	   nuclear	   frequencies	   via	   three	   general	  mechanisms,	  one	  of	  which	  is	  the	  BMS	  mechanism.	  The	  sample	  is	  dissolved	  in	  D2O	  (containing	   1%	   tert-­‐butanol)	   and	   placed	   inside	   an	   NMR	   tube.	   A	   co-­‐axial	   tube	  containing	  the	  same	  solvent	  mixture	  (minus	  the	  paramagnetic	  species)	  provides	  a	   reference	   point	   and	   the	   frequency	   difference	   (Δδppm)	   between	   the	   two	   tert-­‐butanol	  resonances	  represents	  the	  BMS	  shift	  (Δx).	  To	  a	  good	  approximation,	  the	  BMS	  shift	  is	  related	  to	  the	  total	  paramagnetic	  concentration	  (c)	  by	  equation	  2;7	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   (2)	  where	  T	   is	   the	   temperature	  and	  µeff[Gd]	   is	   the	  effective	  magnetic	  moment	  of	   the	  Gd(III)	  ion.	  Following	   the	   determination	   of	   the	   complex	   concentration,	   the	   water	   proton	  relaxation	  times,	  T1,	  were	  measured	  in	  aqueous	  solution	  (pH	  7.4),	  at	  310	  K	  and	  1.4	  T,	  on	  a	  Bruker	  Minispec	  mq60	  instrument	  (Table	  2).	  The	  mean	  value	  of	  three	  independent	  measurements	  was	  recorded	  and	  averaged.	  Relaxivities,	  r1p,	  of	  the	  complexes	   [Gd.L1-­4]	   were	   calculated	   as	   the	   slope	   of	   the	   function	   shown	   in	  
equation	   1.1,	   with	   T1,d	   calculated	   to	   be	   4000	  ms.	   The	   relaxivities	   for	   [Gd.L1-­4]	  were	  5.2	  (±0.3),	  5.3	  (±0.3),	  4.7	  (±0.2)	  and	  4.8	  (±0.2)	  mM-­‐1	  s-­‐1,	  respectively	  at	  60	  MHz.	   These	   values	   are	   typical	   and	   lie	   in	   the	   expected	   range	   for	   mono-­‐aqua	  gadolinium	   species	   of	   this	   molecular	   weight,	   where	   relaxivity	   scales	   with	  molecular	  volume	  as	  a	  function	  of	  τR.8	  	  
2.3.1	  The	  Effects	  of	  Albumin	  on	  Complex	  Relaxivity	  
	  In	  the	  low	  to	  medium	  field	  range,	  the	  relaxivity	  of	  [Gd.L1-­4]	  is	  largely	  dictated	  by	  
τR.	   Upon	   interaction	   with	   the	   NMDA	   receptor,	   the	   complexes	   [Gd.L1-­4]	   should	  increase	   their	   relaxivity	   leading	   to	  an	   increase	   in	  water	  proton	   relaxation	   rate.	  This	   is	   due	   to	   disruption	   of	   the	   rotational	   dynamics	   of	   the	   complex	   upon	  formation	  of	  a	  non-­‐covalent	  conjugate	  with	  the	  receptor.	  In	  order	  to	  assess	  the	  relaxivity	  properties	  of	  the	  receptor-­‐bound	  contrast	  agent,	  a	   relatively	   large	   concentration	   (typically	   high	   µM	   range)	   of	   isolated	   NMDA	  receptors	  is	  needed.	  Since	  this	  is	  impractical	  and	  expensive,	  it	  was	  decided	  that	  assessment	   of	   protein	   interaction	   would	   be	   conducted	   with	   a	   more	   readily	  available	  model	  protein.	  Human	  serum	  albumin	  (HSA)	  is	  a	  large	  globular	  protein	  and	  constitutes	  approximately	  4.5%	  of	  plasma.	  It	  contains	  a	  number	  of	  different	  binding	   sites	   for	   a	   variety	   of	   endogenous	   ligands	   and	   drug	   molecules,	  transporting	  them	  throughout	  the	  vascular	  network.9	  There	  is	  a	  large	  amount	  of	  data	   in	   the	   literature	   describing	   the	   interaction	   of	   this	   protein	   with	   various	  Gd(III)	   complexes.10,	   11	   In	   this	   study,	   the	   non-­‐covalent	   relaxation	   enhancement	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may	  reflect,	  to	  some	  extent,	  that	  which	  may	  occur	  through	  non-­‐specific	  binding	  to	  endogenous	  protein.	  At	  least,	  it	  may	  set	  the	  lower	  limit	  of	  enhancement	  when	  the	  complexes	  are	  bound	  to	  the	  NMDA	  receptor.	  Using	   the	   proton	   relaxation	   enhancement	   (PRE)	   technique,11	   incremental	  additions	  of	  up	   to	  1.6	  mM	  of	  HSA	   to	   aqueous	   solutions	  of	   [Gd.L1-­4]	   (all	   1	  mM)	  were	  made	  and	  the	  resulting	  relaxivity	  measured	  at	  310	  K	  and	  1.4	  T.	  Association	  constants	  were	  then	  estimated	  assuming	  a	  1:1	  stoichiometry	  of	  interaction	  from	  the	  ‘best-­‐fit’	  of	  an	  iterative	  least	  squares	  fitting	  (Figure	  2.1	  and	  Table	  2).	  	   	  	  
	  	  	  	  	  	  	  
	  
Figure	  2.1.	  Binding	  constant	  determination	  of	  [Gd.L2&4	  vs	  HSA]	  showing	  the	  fit(line)	  to	  the	   data	   derived	   by	   iterative	   least	   squares	   fitting,	   assuming	   a	   1:1	   binding	   interaction.	  Errors	  quoted	  are	  statistical	  errors	  in	  the	  fitting	  (1.4	  T,	  pH	  7,	  310	  K).	  	  
Table	   2.	   Binding	   affinities	   to	   serum	   albumin,	   a,b,c	   and	   relaxation	   properties	   of	   the	  complexes	  reported	  herein	  (310	  K,	  pH	  7.4,	  1.4	  T).	  	  	  
	   [Gd.L1]	   [Gd.L2]	   [Gd.L3]	   [Gd.L4]	  log	  K	   3.50a	   3.90b	   2.50a	   3.05b	  r1pinitial/mM-­‐1	  s-­‐1	   5.2	   5.3	   4.7	   4.8	  r1p	  at	  0.7	  mM	  HSA/	  mM-­‐1	  s-­‐1	   7.6	   11.4	   5.6	   6.7	  r1plimit/	  mM-­‐1	  s-­‐1	   11	   18	   14	   11	  
a	  error	  is	  ±	  0.03	  mM-­‐1	  s-­‐1;	  b	  error	  is	  ±	  0.02	  mM-­‐1	  s-­‐1	  ;	  c	  the	  	  relative	  affinities	  (IC50	  values,	  i.e.	  not	  the	  1:	   1	   binding	   constant),	   for	   the	   NMDA	   binding	   moiety	   in	   L1-­‐4	   are	   2.3,	   1.6,	   0.47	   and	   2.6	   µM	  respectively.1	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Log	  K	   for	  [Gd.L1-­4]	  with	  HSA	  were	  3.50	  (±0.03),	  3.90	  (±	  0.02),	  2.50	  (±0.03)	  and	  3.05	  (±	  0.02),	  respectively	  (Table	  2).	  These	  values	  are	  consistent	  with	  relatively	  weak	   binding,	   similar	   to	   that	   reported	   for	   a	   [Gd.DOTA]	   derivative	   with	   three	  benzyloxymethelene	   pendant	   groups	   (logK	   =	   3.2).11	   By	   comparing	   each	   pair	  ([Gd.L1-­2]	   vs.	   [Gd.L3-­4])	   it	   is	   apparent	   that	   increasing	   the	   chain	   length	   of	   the	  pendant	  acidic	  arm	  enhances	  the	  binding	   interaction	  between	  the	  complex	  and	  the	   protein.	   In	   the	   case	   of	   [Gd.L2],	   the	   limiting	   relaxivity	   value	   is	   significantly	  higher	   than	   the	   other	   complexes,	   as	   a	   direct	   result	   of	   a	   greater	  τR	  modulation.	  This	   is	  reflected	   in	  the	   larger	  association	  constant	  (cf.	  closer	  to	  that	  of	  MS-­‐325;	  logK	   =	   4.05	   at	   310	   K),9	   which	   is	   consistent	   with	   a	   stronger	   complex-­‐protein	  interaction.	   However,	   this	   interaction	   is	   relatively	  weak	   (Kd	   =100	  µM).	   This	   is	  promising,	  as	   it	   is	  expected	   that	  a	   larger	   relaxivity	  gain	  will	  be	  observed	  when	  the	  complexes	  bind	  to	  the	  NMDA	  receptor,	  which	  can	  be	  distinguished	  from	  the	  weaker	  non-­‐specific	  binding	  interaction	  examined	  here.	  	  	  
2.4	   	  Probe-­Receptor	  Binding	  Studies	  
2.4.1	  Development	  of	  a	  Neuronal	  Cell-­line	  Model	  	  To	   investigate	   the	   ability	   of	   [Gd.L1-­4]	   to	   act	   as	   NMDA	   receptor-­‐targeted	   MR	  contrast	   agents,	   a	   neuronal	   cell	   line	   model	   expressing	   functional	   NMDA	  receptors	  was	  needed.	  The	  majority	  of	  cell	   lines	  in	  the	  literature	  which	  possess	  glutamate	   receptors,	   are	   grown	   through	   differentiation	   of	   tumour	   cells.	  However,	  these	  cells	  do	  not	  fully	  represent	  a	  neuronal	  cell.	  In	  2000,	  Manning	  and	  co-­‐workers	  described	  the	  development	  of	  a	  glutamate-­‐sensitive	  hybrid	  cell-­‐line,	  derived	   from	   the	   fusion	   of	   motor-­‐neuron	   enriched	   mouse	   spinal	   cord	   and	  neuroblastoma	  cells.12	  After	  differentiation,	  these	  cells	  were	  reported	  to	  express	  the	   NR1	   and	   NR2A/B	   subunits	   that	   are	   responsible	   for	   the	   formation	   of	  functional	  NMDA	  receptors.	  These	  differentiated	  NSC-­‐34	  cells	  were	  also	  reported	  to	  express	  function	  AMPA	  and	  Kainate	  receptor	  subunits.	  In	  the	  original	  report,	  undifferentiated	  NSC-­‐34	  cells	  did	  not	  express	  any	  glutamate	  receptor	  density	  in	  immunofluorescence	   staining	   experiments,	   so	   it	  was	   envisaged	   that	   they	   could	  provide	  a	  negative	  control	  in	  the	  cellular	  labelling	  experiments.	  
First	  Generation	  NMDA	  Receptor-­Targeted	  	   	   Chapter	  2	  
MRI	  Contrast	  Agents	  
	   60	  
Cell	   culture	   of	   both	   undifferentiated	   and	   differentiated	   NSC-­‐34	   cells	   was	  performed	  by	  Dr.	   Joern	  Engelmann	   and	  Dr.	   Sven	  Gottschalk	   at	   the	  Max	  Planck	  Institute	   for	   Biological	   Cybernetics	   in	   Tuebingen.	   Cells	   were	   cultured	   in	   a	   1:1	  mixture	   of	   Dulbecco’s	   modified	   Eagle’s	   (DMEM)	   and	   Hams’	   F12	   media,	  supplemented	  with	  fetal	  bovine	  serum	  (10%).	  At	  approximately	  90%	  confluence,	  differentiation	  of	  the	  cells	  was	  induced	  through	  gradual	  serum	  depletion	  (10	  to	  1%).	  The	  cells	  were	  allowed	  to	  proliferate	  over	  the	  course	  of	  7	  days	  to	  allow	  for	  the	  growth	  of	  functional	  NMDA	  receptors.	  The	  expression	  of	  NMDA	  receptors	  was	  demonstrated	  on	  differentiated	  NSC-­‐34	  cells	  using	   immunofluorescence	  techniques.	  The	  cells	  were	   fixed	  to	  microscope	  slides	   and	   incubated	   for	   2	   hours	   with	   the	   primary	   antibodies	   for	   the	   NMDA	  receptor	   subunits,	   NR1	   and	  NR2B.	   After	  washing,	   the	   secondary	   antibody	  was	  loaded	   (2	   hours),	   followed	   by	   incubation	   with	   the	   nuclear	   stain,	   Hoechst.	  Visualisation	   of	   the	   differentiated	   NSC-­‐34	   cells	   by	   fluorescence	   microscopy	  demonstrated	   the	   presence	   of	   both	   NMDA	   receptor	   subunits,	   indicating	  functional	  NMDA	  receptors	  (Figure	  2.2).	  
	  
Figure	   2.2.	   Immunostaining	   of	   differentiated	   NSC-­‐34	   cells.	   (A)	   From	   left	   to	   right:	  differential	  interference	  contrast	  image	  showing	  cell	  morphology,	  NMDA	  NR2B	  (yellow,	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Cy	   3TM)	   visualised	   after	   staining	   with	   specific	   antibodies	   and	   overlay	   with	  counterstained	  cell	  nuclei	  (blue,	  Hoechst	  33342).	  (B)	  as	  (A)	  but	  with	  specific	  antibodies	  for	  the	  NMDAR1	  subunit	  on	  different	  cells.	  (C)	  Control	  staining	  for	  non-­‐specific	  binding	  of	   the	  2nd	  antibody	  (goat	  anti-­‐rabbit-­‐Cy	  3TM).	  The	  middle	   image	  was	  normalized	   to	   the	  brightness	  and	  contrast	  of	  the	  Cy	  3TM	  image	  in	  (A),	  demonstrating	  very	  low	  non-­‐specific	  binding	  of	  the	  2nd	  antibody.	  [Carried	  out	  at	  MPI,	  Germany].	  	  
2.4.2	  MRI	  Analysis	  of	  Cell	  Suspensions	  In	  vitro	  	  Following	   the	   positive	   expression	   of	   NMDA	   receptors,	   cellular	   labelling	   of	  differentiated	   and	   undifferentiated	   (control)	   NSC-­‐34	   cells	   with	   [Gd.L1-­4]	   was	  assessed	  by	  measuring	  the	  longitudinal	  relaxation	  time,	  T1,	  of	  the	  cells	  on	  a	  3	  T	  Siemens	   human	   whole	   body	   MR	   scanner,	   which	   allowed	   the	   calculation	   of	  cellular	  relaxation	  rates,	  R1,cell.	  All	  MR	  experiments	  were	  performed	  by	  Dr.	  Sven	  Gottschalk	   at	   the	   Max	   Planck,	   Tuebingen.	   Differentiated	   and	   undifferentiated	  NSC-­‐34	  cells	  were	  treated	  with	  200	  µM	  solutions	  of	  the	  complexes	  [Gd.L1-­4]	  for	  45	   minutes	   at	   310	   K	   and	   5%	   CO2.	   After	   this	   period,	   the	   cells	   were	   washed	  thoroughly	  with	  Hank’s	  buffered	  saline	  solution	  (HBSS)	  to	  remove	  any	  unbound	  complex,	   re-­‐suspended	   in	   fresh	   buffer	   and	   the	   T1-­‐weighted	   MR	   images	   were	  acquired	   overnight,	   using	   a	   spin-­‐echo	   inversion	   recovery	   method.	   Untreated	  cells	  and	  cells	  treated	  with	  the	  non-­‐targeted,	  clinically	  approved	  contrast	  agent,	  [Gd.DOTA],	  were	  also	  imaged	  to	  serve	  as	  controls.	  By	  normalising	  the	  untreated	  cells	  to	  100%	  it	  was	  then	  possible	  to	  determine	  the	  influence	   of	   each	   complex	   on	   R1,cell.	   Initial	   studies	   showed	   positive	   signs	   of	  cellular	   labelling	  by	  [Gd.L1],	  [Gd.L2]	  and	  [Gd.L4]	  on	  differentiated	  NSC-­‐34	  cells,	  represented	  as	  a	  percentage	  increase	  in	  cellular	  relaxation	  rate	  of	  120%,	  195%	  and	  170%,	  respectively.	  However,	  treatment	  of	  the	  same	  concentration	  of	  these	  three	   complexes	   induced	   increases	   in	   R1,cell	   of	   130%,	   186%	   and	   115%	   on	  undifferentiated	   NSC-­‐34	   cells.	   This	   suggests	   that	   these	   complexes	   either	  possessed	   the	   ability	   to	   label	   cells	   through	   non-­‐specific	   interactions,	   or	   that	  undifferentiated	  NSC-­‐34	   cells	   also	   possessed	  NMDA	   receptor	   density,	   reducing	  their	   potential	   as	   a	   control	   cell	   line.	   In	   order	   to	   elucidate	  which	  was	   the	  more	  likely,	   immunofluorescence	   techniques	   were	   performed	   on	   undifferentiated	  NSC-­‐34	  cells,	  to	  look	  for	  the	  expression	  of	  NMDA	  receptors.	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Figure	   2.3.	   (A)	   Visualisation	   of	   the	   NMDA	   receptor	   NR2B	   subunit	   after	   staining	  undifferentiated	  NSC-­‐34	  cells	  with	  NR2B	  specific	  antibodies	  and	  overlaying	  with	  nuclear	  stain,	  Hoechst.	  (B)	  Transmission	  image.	  
	  In	  contrast	  to	  the	  report	  by	  Manning	  and	  co-­‐workers,12	  undifferentiated	  NSC-­‐34	  cells	   were	   found	   to	   express	   both	   NMDA	   receptor	   subunits,	   NR1	   and	   NR2B	  (Figure	   2.3).	   This	   explains	   the	   observed	   increases	   in	   R1,cell	   for	   the	  undifferentiated	   cells	  which	  were	   incubated	  with	   [Gd.L1],	   [Gd.L2]	   and	   [Gd.L4].	  Since	  there	  is	  no	  way	  to	  quantify	  the	  receptor	  density	  present	  on	  each	  cell	  type,	  it	  was	  thought	  best	  to	  avoid	  the	  use	  of	  the	  undifferentiated	  cells	  as	  a	  control.	  The	  differentiated	  NSC-­‐34	  cells	  should	  possess	  a	  higher	  NMDA	  receptor	  density	  and	  therefore,	  more	  closely	  resemble	  the	  in	  vivo	  situation.	  To	   allow	   for	   a	   statistically	   relevant	   measure	   of	   R1,cell	   enhancement	   for	   each	  complex,	  T1	  measurements	  were	  conducted	  several	  times	  on	  differentiated	  NSC-­‐34	   cells,	   that	  were	   continuously	   cultured	  before	  differentiation.	  However,	   each	  time	  the	  T1	  was	  measured,	  a	  much	  lower	  value	  of	  R1,cell	  was	  found	  in	  comparison	  to	   the	   previous	   measurement,	   resulting	   in	   a	   statistically	   lower	   average	   R1,cell	  enhancement	   for	   each	   complex.	   This	   suggested	   that	   the	   receptor	   density	  decreased	   over	   prolonged	   cell	   culture	   periods.	   Taking	   this	   into	   account,	   the	  continuous	   growth	  of	   cells	   before	  differentiation	  was	   stopped.	  The	   cell	   culture	  protocol	  was	  modified	   so	   that	   fresh,	  undifferentiated	  NSC-­‐34	  cells	  were	  grown	  and	   then	   differentiated	   for	   each	   T1-­‐measurment,	   and	   this	   led	   to	   reproducible	  changes	  in	  R1,cell	  (Figure	  2.4).	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   [Gd.DOTA]	   [Gd.L1]	   [Gd.L2]	   [Gd.L3]	   [Gd.L4]	  
R1,cell/	  %	  control	   99±1%	   118±2%	   170±11%	   91±2%	   176±4%	  	  
Figure	   2.4.	   (Top)	   Representative	   T1-­‐weighted	   MR-­‐images	   of	   1	   x	   107	   untreated	  differentiated	  cells	  (control)	  and	  differentiated	  cells	  treated	  for	  45	  min	  with	  200	  µM	  of	  
[Gd.DOTA]	   or	   [Gd.L1-­4].	   (Bottom)	   Cellular	   1H	   MR	   relaxation	   rates	   R1,cell	   in	   cell	  suspensions	   (3	   T,	   298	   K)	   after	   treatment	   of	   differentiated	   NSC-­‐34	   cells	   with	   200	  µM	  
[Gd.DOTA]	  or	  [Gd.L1-­4]	  for	  45	  min.	  [Gd.DOTA]	  served	  as	  a	  negative	  control.	  Values	  are	  mean	  ±	  SEM	  (n=3-­‐6).	  ns:	  not	  significant,	  ***P<0.001	  ANOVA	  with	  Bonferroni’s	  multiple	  comparison	  post	  test.	  ###P<0.001	  Student’s	  t-­‐test.	  Both	  tests	  vs.	  untreated	  control	  using	  Graphpad	  Prism	  5.02.[Carried	  out	  at	  MP,	  Germany].	  	  The	   presence	   of	   an	   α-­‐amino	   carboxylic	   acid	   functionality	   is	   essential	   for	   a	  compound	   to	   serve	   as	   an	   NMDA	   receptor	   antagonist.	   The	   complexes	   [Gd.L1-­4]	  contain	   an	   isosteric	   replacement	   for	   the	  α-­‐amino	   carboxylic	   acid	   functionality,	  linked	   to	   a	   pendant	   acidic	   group	   of	   varying	   length,	   which	   gives	   the	   NMDA	  receptor-­‐binding	   moiety	   of	   these	   contrast	   agents.	   The	   complexes	   [Gd.L1-­2]	  employ	  a	  carboxylic	  acid	  with	  a	  one	  or	  two	  carbon	  spacer,	  as	  the	  pendant	  acidic	  group.	   Although	   [Gd.L1]	   induces	   an	   increase	   in	   R1,cell	   when	   incubated	   with	  differentiated	   NSC-­‐34	   cells	   (118%	   of	   control),	   the	   two-­‐carbon	   homologue,	  
[Gd.L2],	   displays	  a	   statistically	  higher	   increase	   in	  R1,cell	   (170%	  of	   control).	  This	  suggests	   that	   [Gd.L2]	   binds	   to	   the	  NMDA	   receptor	  with	   a	   greater	   affinity	   than	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that	  of	  [Gd.L1],	  and	  this	  is	  consistent	  with	  the	  reported	  trend	  in	  affinity	  constants	  of	  the	  small	  molecule	  antagonists.1	  	  The	   original	   small	   molecule	   work	   suggested	   that	   substitution	   of	   the	   pendant	  carboxylic	  acid	  with	  phosphonic	  acid	  results	   in	  a	  NMDA	  receptor-­‐binding	  motif	  with	  a	  greater	  affinity.	  Therefore,	   it	  was	  expected	   that	   [Gd.L3-­4]	   should	  bind	   to	  the	  NMDA	   receptor	  with	   a	   greater	   affinity,	   leading	   to	   a	   larger	   enhancement	   of	  
R1,cell.	   Interestingly,	   [Gd.L3]	   showed	   no	   apparent	   receptor	   specific	   interaction	  (R1,cell	   =	   91%	   of	   control),	   despite	   the	   antagonist	   it	   was	   derived	   from	   being	  reported	  as	   the	  most	  potent	  of	   the	  series.1	   In	  contrast,	   [Gd.L4],	  with	   the	   three-­‐carbon	   linker	   induces	   a	   large	   enhancement	   in	   R1,cell	   (176%	   of	   control)	   when	  incubated	  with	  differentiated	  NSC-­‐34	  cells.	  Previous	   work	   in	   the	   Durham	   group	   has	   shown	   that	   appending	   a	   sterically	  demanding	  Gd(III)	   chelate	   to	   a	   known	   receptor-­‐binding	  moiety	   can	   result	   in	   a	  marked	  decrease	  in	  affinity	  for	  a	  specific	  receptor.13	  It	  is	  possible	  that	  this	  is	  the	  reason	   for	   the	   lack	   of	   binding	  of	   [Gd.L3]	   to	   the	  NMDA	   receptor.	  However,	   it	   is	  also	   plausible	   that	   the	   squaramide	   moiety	   in	   [Gd.L3]	   adopts	   an	   unfavourable	  conformation	  for	  receptor	  binding.	  Due	  to	  rotation	  around	  the	  C-­‐N	  bond,	  several	  rotameric	   forms	  of	   squaramides	   exist.14	  This	   can	  give	   rise	   to	  8/9-­‐ring	   chelates	  that	   are	   stabilised	   through	   intramolecular	   hydrogen	   bonding,	   which	   will	  decrease	  the	  likelihood	  of	  intermolecular	  bonding	  to	  specific	  residues	  present	  on	  the	  NMDA	  receptor	  (Scheme	  2.7).15	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2.4.3	  Analysis	  of	  Metal	  Ion	  Concentration	  In	  Cellulo	  	  In	  the	  receptor-­‐labelling	  experiments,	  [Gd.L4]	  induced	  the	  largest	  enhancements	  in	  R1,cell.	   In	  order	   to	  assess	  whether	   the	   large	   in	  vitro	   changes	   in	  R1,cell	   could	  be	  visible	  in	  vivo,	  the	  number	  of	  [Gd.L4]	  complexes	  per	  cell	  was	  determined.	  It	  has	  been	  proposed	  that	  in	  order	  to	  observe	  a	  10%	  increase	  in	  the	  water	  proton	  relaxation	  rate,	  R1,	  for	  a	  contrast	  agent	  possessing	  a	  typical	  relaxivity	  of	  5	  mM-­‐1	  s-­‐1,	  a	  10	  µM	  local	  concentration	  of	  the	  contrast	  agent	  is	  needed.	  This	  corresponds	  to	   107	   Gd(III)	   chelates	   per	   cell,	   suggesting	   that	   this	   is	   the	   required	   NMDA	  receptor	  density	  needed	  to	  observe	  a	  10%	  change	  in	  MR	  contrast.16	  At	  present,	  there	  is	  no	  typical	  value	  reported	  for	  the	  NMDA	  receptor	  density.	  However,	  even	  if	  the	  bulk	  receptor	  density	  is	  low,	  the	  receptors	  can	  still	  be	  imaged	  successfully	  at	   below	  10	  µM	   local	   concentration	   if	   the	   receptors	   cluster	   together	   and	   form	  microdomains	  in	  high	  concentrations.17	  	  Therefore,	   the	   cell	   pellets	   that	   were	   incubated	   with	   [Gd.L4]	  were	   digested	   by	  heating	  to	  50	  °C	  overnight,	  in	  the	  presence	  of	  aqueous	  HNO3.	  The	  cell	  associated	  Gd(III)	  content	  was	  then	  measured	  by	  ICP-­‐MS,	  giving	  an	  average	  Gd(III)	  content	  of	  2022	  ppb.	  Using	  this	  number	  it	  was	  possible	  to	  estimate	  the	  number	  of	  [Gd.L4]	  complexes	  per	  cell;	  	   Average	  Gd(III)	  content	  =	  2022	  ppb	  =	  2.022	  ppm	  =	  2.022	  mg/L	  Using	  157Gd	  (mass	  =	  157000	  mg/mol),	  Concentration	  =	  
€ 
2.022mg /L
157000mg /mol 	  =	  1.29	  x	  105	  mol	  dm-­‐3,	  Number	  of	  moles	  =	  1.29	  x	  105	  mol	  dm-­‐3	  x	  0.0012	  dm3	  =	  1.55	  x	  10-­‐8	  moles,	  Number	  of	  complexes	  =	  1.55	  x	  10-­‐8	  mols	  x	  6.022	  x	  1023	  mol-­‐1	  =	  9.32	  x	  1015	  complexes.	  Using	  1	  x	  107	  cells.	  Complexes/cell	  =	  
€ 
9.32 ×1015complexes
1×107cells 	  =	  9.3	  x	  108	  complexes/cell.	  	  By	   using	   an	   estimate	   for	   the	   volume	   of	   each	   cell	   (5000	  µm3),18	   the	   number	   of	  
[Gd.L4]	   complexes	  per	  cell	   revealed	  an	  estimated	   local	  Gd(III)	   concentration	  of	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310	  µM.	  This	  value	  is	  well	  beyond	  the	  proposed	  theoretical	  detection	  limit,	  and	  is	  consistent	  with	  the	  large	  enhancement	  in	  R1,cell	  observed	  for	  [Gd.L4].	  	  
2.5	   	  Toxicity	  Studies	  	  When	  designing	  imaging	  probes	  for	  use	  with	  live	  cells,	  a	  critical	  property	  that	  the	  probe	  must	  posses	  is	  that	  it	  be	  non-­‐toxic	  towards	  the	  cell	  in	  any	  way,	  and	  should	  minimally	   perturb	   cell	   homeostasis.	   	   The	   concentration	   dependence	   of	   the	  toxicity	  is	  also	  important,	  as	  all	  compounds	  are	  toxic	  to	  some	  degree,	  if	  used	  at	  a	  high	  enough	  concentration.	  However,	   it	   is	   the	  applied	  concentration	   that	   is	   the	  dominant	  factor.	  There	  are	  several	  assays	  available	  to	  deduce	  whether	  a	  compound	  is	  toxic.19	  The	  MTT	  assay20	  is	  a	  colorimetric	  assay	  that	  measures	  the	  reducing	  potential	  of	  a	  cell.	  Mitochondrial	   reductase	   enzymes	   of	   viable	   cells	   reduce	  MTT	   into	   an	   insoluble	  purple	   formazan	   product.	   This	   can	   be	   solubilised	   and	   its	   concentration	  quantified	   spectrophotometrically.	   The	   amount	   of	   formazan	   produced	   is	  proportional	  to	  the	  number	  of	  viable	  cells.	  Utilizing	  the	  MTT	  assay,	  approximately	  5	  x	  103	  differentiated	  NSC-­‐34	  cells	  in	  100	  μL	  culture	  medium	  were	  seeded	   into	  each	  well	  of	   flat-­‐bottomed	  96-­‐well	  plates	  and	   allowed	   to	   attach	   overnight.	   Complex	   solutions	   were	   added	   to	   triplicate	  wells	  to	  give	  final	  concentrations	  over	  a	  2-­‐log	  range.	  Following	  24	  h	  incubation,	  MTT	  (1.0	  mM)	  was	  added	  to	  each	  well,	  and	  the	  plates	  incubated	  for	  a	  further	  4	  h.	  The	   culture	   medium	   was	   removed,	   and	   DMSO	   was	   added	   to	   solubilise	   the	  formazan	  product.	  The	  plates	  were	   shaken	   for	  20	   seconds	   and	   the	   absorbance	  measured	  immediately	  at	  540	  nm	  in	  a	  microplate	  reader.	  To	  process	  the	  results,	  the	  percentage	  viability	  of	  a	  well	  was	  calculated	  from	  the	  relative	   absorbance	  of	   the	  well,	   compared	   to	   a	  well	   containing	  untreated	   cells.	  IC50	  values	  were	  determined	  as	  the	  probe	  concentration	  required	  to	  reduce	  the	  absorbance	   to	   50%	   of	   that	   in	   the	   untreated,	   control	   wells,	   and	   represent	   the	  mean	  for	  data	  from	  at	  least	  three	  independent	  experiments	  (Table	  2.1).	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Table	  2.1.	  Observed	  absorbance	  at	  540	  nm	  of	  [Gd.L1-­4]	  at	  varying	  concentrations	  giving	  IC50	  >	  200	  µM.	  (control	  blank	  wells	  and	  untreated	  cells	  (7	  well	  each)	  gave	  an	  averaged	  absorbance	  value	  of	  0.26	  and	  1.69,	  respectively).	  	  
Concentration/	  µM	   [Gd.L1]	   [Gd.L2]	   [Gd.L3]	   [Gd.L4]	  5	   1.75	   1.61	   1.63	   1.82	  10	   1.59	   1.80	   1.76	   1.55	  30	   1.50	   1.43	   1.49	   1.82	  50	   1.43	   1.47	   1.46	   1.68	  100	   1.49	   1.76	   1.78	   1.43	  150	   1.82	   1.77	   1.55	   1.48	  200	   1.65	   1.49	   1.85	   1.72	  	  	  For	  each	  of	   the	   four	  complexes,	   [Gd.L1-­4],	   IC50	  values	  were	   found	   to	  be	  greater	  than	  200	  µM,	  which	   is	   the	  concentration	  used	  throughout	  the	  MR-­‐experiments.	  Therefore,	   it	   can	   be	   assumed	   that	   the	   probes	   are	   non-­‐toxic,	   under	   these	  conditions.	  	  
2.6	   	  Conclusions	  	  The	  initial	  aim	  of	  this	  chapter	  was	  to	  design,	  synthesise	  and	  evaluate	  the	  in	  vitro	  behaviour	  of	  a	  small	  series	  of	  NMDA	  receptor-­‐targeted	  MR	  contrast	  agents.	  The	  contrast	  agents,	  [Gd.L1-­4],	  use	  an	  antagonist-­‐mediated	  approach,	  with	  the	  aim	  of	  binding	   competitively	   at	   the	   glutamate-­‐binding	   site	   located	   on	   the	   NMDA	  receptor.	  These	  compounds	  have	  been	  fully	  characterised,	   including	  a	  study	  on	  their	  potential	  to	  bind	  non-­‐specifically	  to	  a	  model	  protein,	  HSA.	  	  Of	   the	   four	   compounds	   synthesised,	   [Gd.L2]	   and	   [Gd.L4]	   induced	   large	  enhancement	   in	   cellular	   relaxation	   rate	   (170	   and	   176%,	   respectively),	   upon	  incubation	   with	   differentiated	   NSC-­‐34	   cells,	   possessing	   functional	   NMDA	  receptors.	   These	   enhancements	   in	  R1,cell	   have	   been	   tentatively	   assigned	   to	   the	  contrast	  agent	  binding	  to	  the	  NMDA	  receptor,	  modulating	  τR.	  This	   is	   in	  keeping	  with	  the	  observation	  that	  none	  of	  the	  complexes	  exhibited	  any	  cytotoxic	  effects	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on	  these	  cells,	  up	  to	  200	  µM,	  suggesting	  that	  the	  complexes	  do	  not	  penetrate	  the	  cells	  and	  instead	  remain	  attached	  to	  the	  cell-­‐surface	  receptor.	  It	  was	  surprising	  that	  the	  most	  potent	  receptor-­‐binding	  motif	  used	  in	  [Gd.L3]	  did	  not	   result	   in	   any	   enhancement	   in	  R1,cell.	   This	  has	  been	   tentatively	   attributed	   to	  the	   formation	   of	   stable	   chelates	   through	   intramolecular	   hydrogen	   bonding,	   as	  previously	  described.	  In	  order	  to	  further	  increase	  affinity	  and	  potentially	  gain	  further	  enhancements	  in	  
R1,cell,	   chapter	   3	   will	   discuss	   the	   synthesis	   of	   higher	   affinity	   receptor-­‐binding	  moieties	   and	   their	   conjugation	   to	   Gd(III)	   chelates,	   to	   give	   a	   series	   of	   second-­‐generation	  NMDA	  receptor-­‐targeted	  MRI	  contrast	  agents.	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3.	  Second-­Generation	  NMDA	  Receptor-­
Targeted	  MRI	  Contrast	  Agents	  	  
3.1	   	  Introduction	  	  The	   first-­‐generation	   series	   of	   NMDA	   receptor	   targeted	   MRI	   contrast	   agents	  showed	   that	   employing	   a	  modified	  NMDA	   receptor	   antagonist	   as	   the	   receptor-­‐binding	  moiety	  allowed	  for	  cellular	  labelling	  of	  differentiated	  NSC-­‐34	  cells.	  Two	  complexes,	   [Gd.L2]	   and	   [Gd.L4],	   exhibited	   large	   enhancements	   in	   R1,cell,	  consistent	  with	  modulation	  of	   the	  rotational	  dynamics	  of	   these	  contrast	  agents	  upon	  NMDA	  receptor-­‐binding.	  Surprisingly,	   [Gd.L3],	   the	   contrast	   agent	   bearing	   the	   most	   potent	   antagonistic	  moiety,	   appeared	   to	   show	   no	   receptor-­‐specific	   interactions,	   leading	   to	   no	  enhancement	   in	   R1,cell.	   This	   was	   attributed	   to	   the	   squaramide	   motif	   adopting	  several	   rotameric	   conformations,	   stabilised	   by	   internal	   hydrogen	   bonding.1	  Based	   on	   the	   assumption	   that	   a	   molecule	   that	   does	   not	   undergo	   significant	  hydrogen	  bonding	  would	  be	  more	  available	  to	  hydrogen	  bond	  to	  complementary	  sites	  on	  the	  NMDA	  receptor,	  and	  so	  possess	  a	  greater	  binding	  affinity,	  a	  second	  series	  of	  NMDA	   receptor-­‐binding	  moieties	  has	  been	  derived	   (Scheme	  3).	   These	  are	   again	   based	   on	   competitive	   NMDA	   receptor	   antagonists	   first	   reported	   by	  Kinney.	   The	   bicyclic	   nature	   rigidifies	   the	   compound	   and	   restricts	   it	   to	   a	  conformational	   form	   that	   is	   similar	   in	   structure	   to	   several	   other	   highly	   potent	  NMDA	  receptor	  antagonists.	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The	   macrocyclic	   Gd(III)	   core	   was	   chosen	   to	   be	   similar	   to	   that	   used	   for	   the	  complexes	  [Gd.L1-­4],	  since	  tetra-­‐carboxylate	  macrocyclic	  complexes	  possess	  fast	  water	  exchange	  rates	  and	  help	  minimise	  non-­‐specific	  protein	  binding.	  However,	  the	   length	   of	   the	   spacer	   that	   links	   the	   Gd(III)	   chelate	   to	   the	   NMDA	   receptor	  binding	  moiety	  has	  been	  varied.	  A	  varying	  chain	  length	  was	  used	  in	  an	  attempt	  to	  study	   the	   effect	   of	   chain	   length	   on	   the	   binding	   affinity	   of	   each	   complex	   to	   the	  receptor,	  and	  how	  this	  modulates	  τR.	  	  
3.2	   	  Synthetic	  Details	  
3.2.1	   Synthetic	   Approaches	   to	   Second-­Generation	   Receptor-­
Binding	  Moieties	  	  Initial	  work	  was	  based	  on	  Kinney’s	  antagonist	  (Scheme	  3),	  allowing	  modification	  of	  the	  free	  alcohol	  to	  an	  amine	  in	  the	  final	  step,	  which	  would	  provide	  the	  linkage	  point	   to	   the	   macrocycle.	   Therefore,	   the	   initial	   synthetic	   pathway	   to	   29,	   the	  precursor	  to	  Kinney’s	  antagonist	  followed	  the	  literature	  method	  (Scheme	  3.1).1	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With	  the	  no	  reaction	  of	  29	  observed	  under	  the	  Mitsunobu	  conditions,	  an	  attempt	  to	   functionalise	  via	   substitution	  of	   the	  alcohol	  was	  performed	  (Scheme	  3.2).	  To	  this	   end,	  29	   was	   dissolved	   in	   DMF	   and	   treated	  with	  methanesulfonyl	   chloride	  and	  triethylamine	  at	  0	  °C.	  Mesylation	  reactions	  usually	  proceed	  very	  quickly	   in	  near	  quantitative	  yields,	  but	  formation	  of	  the	  mesylated	  product	  never	  surpassed	  80%,	   even	   after	   prolonged	   reaction	   times.	   Nevertheless,	   the	   in-­situ	   generated	  mesylate	   was	   treated	   with	   N-­‐Boc	   ethylenediamine	   and	   triethylamine	   and	   the	  reaction	  allowed	  to	  warm	  to	  room	  temperature	  overnight.	  The	  reaction	  progress	  was	  monitored	  by	  ESI–MS.	  Analysis	   of	   the	  ESI-­‐MS	  data	   after	   one	  hour	   showed	  the	  presence	  of	  only	  one	  major	  product,	  with	  m/z	  =	  633.9.	  This	  corresponded	  to	  the	   doubly	   alkylated	   product,	   with	   no	  mono-­‐substitution	   observed	   by	   ESI-­‐MS,	  even	  after	  shorter	  reaction	  periods.	  With	   activation	   and	   substitution	   of	   the	   alcohol	   in	   29	   proving	   difficult,	   a	   new	  synthetic	   route	   was	   devised,	   which	   incorporates	   the	   amine	   earlier	   in	   the	  synthetic	  sequence	  (Scheme	  3.3).	  	  
	  	  

































































1) MsCl, NEt3, DCM
2) NaN3, DMF, 60 oC 
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(3-­‐Amino-­‐2-­‐hydroxypropyl)carbamic	   acid-­‐1,1-­‐dimethylethylester,	   26,	   was	  synthesised	  as	  described	  above.	  Orthogonal	  protection	  of	  the	  second	  amine	  was	  achieved	  through	  reaction	  with	  benzyl	  chloroformate	  and	  diisopropylethylamine	  in	  anhydrous	  DCM,	  to	  give	  30	  in	  a	  high	  yield.	  With	  both	  amine	  groups	  protected,	  selective	  activation	  and	  substitution	  of	  the	  alcohol	  moiety	  of	  30	  was	  conducted	  through	  generation	  of	   the	  mesylate.	  After	  work-­‐up,	   the	  mesylate	  was	  dissolved	  in	   anhydrous	   DMF	   and	   treated	   with	   sodium	   azide	   at	   60	   °C,	   overnight.	   After	  work-­‐up	   and	   purification	   by	   column	   chromatography,	   the	   azide,	   31	   (which	  would	  serve	  as	  a	  ‘masked	  amine’)	  was	  isolated	  in	  a	  good	  yield.	  A	  reagent	  for	  the	  selective	  removal	  of	  the	  Cbz	  protecting	  group	  from	  31	  was	  then	  needed.	   This	   ruled	   out	   the	   use	   of	   standard	   deprotection	   methods,	   such	   as	  hydrogenation	   over	   a	   palladium	   catalyst,	   as	   this	   would	   also	   reduce	   the	   azide	  group.	   Instead,	  Ba(OH)2	   in	   refluxing	   aqueous	   glyme	  was	   employed.3	  This	  basic	  hydrolysis	   step	   yielded	   the	   free	   amine	   32	   after	   subsequent	   work-­‐up	   and	  purification	   through	   adjustment	   of	   the	   pH.	   Following	   the	   methods	   outlined	  above,	   the	   primary	   amine,	   32,	   was	   alkylated	   with	   diethyl-­‐(2-­‐bromo)ethyl	  phosphonate	  under	  basic	  conditions	   to	  give	   the	  secondary	  amine,	  33.	  This	  was	  subject	   to	   a	   Michael	   addition-­‐elimination	   reaction	   with	   3,4-­‐diethoxy-­‐3-­‐cyclobutene-­‐1,2-­‐dione	   to	   obtain	   34	   as	   a	   pair	   of	   rotamers,	   in	   a	   1:1.2	   ratio	   as	  deduced	  by	  31P	  NMR	  spectroscopy.	  Cyclisation	  to	  35	  was	  achieved	  in	  a	  high	  yield	  by	  selective	  acidic	  hydrolysis	  of	  the	  N-­‐Boc	  group	  to	  yield	  the	  TFA	  salt,	  which	  was	  then	  treated	  with	  an	  excess	  of	  triethylamine	  in	  refluxing	  ethanol.	  Triethylamine	  was	  employed	  over	  diisopropylethylamine	   in	  order	   to	   simplify	   the	  purification	  step.	  By	  studying	  the	  1H	  NMR	  spectrum	  of	  the	  cyclised	  azide,	  35	  (Figure	  3),	  it	  was	  possible	   to	   deduce	   that	   the	   conformation	   adopted	   by	   this	   and	   related	   bicyclic	  intermediates	   in	   solution	   involves	   preferential	   population	   of	   a	   twist-­‐chair	  isomer.	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Figure	  3.	  Partial	   1H	  NMR	   spectrum	  of	   the	  bicyclic	   azide,	  35	   (295	  K,	   CDCl3,	   700	  MHz),	  showing	   the	   twist	   chair	   conformation	   of	   the	   ring	   that	   is	   likely	   to	   be	   preferentially	  populated.	  	  Heterocyclic	   seven-­‐membered	   rings	   can	  adopt	   several	   conformations,	   of	  which	  the	  twist-­‐chair	   is	  normally	   lowest	   in	  energy,	  with	  bulky	  substituents	   in	  the	  six-­‐position	  preferring	  the	  equatorial	  site.4	  Based	  on	  this,	  the	  conformation	  in	  figure	  
3	   is	   proposed.	   The	   axial	   proton,	  Haax,	   is	   coupled	   to	   the	   equatorial	   proton,	  Haeq,	  with	  a	  coupling	  constant	  of	  -­‐14	  Hz.	  It	  is	  also	  coupled	  to	  Hb	  with	  a	  3-­‐bond	  coupling	  of	   7	   Hz,	   and	   finally	   to	   the	   NH	   proton	   with	   a	   3-­‐bond	   coupling	   of	   4	   Hz.	   This	  splitting	  pattern	  gives	  Haax	  as	  a	  ddd,	  observed	  at	  around	  3.68	  ppm.	  	  Using	  2D	  1H-­‐13C	  HSQC	  NMR	  spectroscopy,	  it	  was	  possible	  to	  identify	  Haeq	  as	  the	  doublet	   at	   3.55	  ppm.	  A	   coupling	   constant	   of	   14	  Hz	   represents	   that	   of	   the	   two-­‐bond	  coupling	  to	  Haax.	  There	  also	  appeared	  to	  be	  some	  fine	  splitting	  associated	  with	  the	  peak	  at	  3.55	  ppm,	  and	  this	  reflects	  the	  small	  coupling	  to	  either	  Hb	  or	  NH	  due	  to	  the	  twisted	  nature	  of	  the	  7-­‐ring.	  Since	  Hcax	  is	  almost	  eclipsing	  Hb,	  it	  becomes	  apparent	  that	  the	  doublet	  of	  doublets	  at	  3.49	  ppm	  corresponds	  to	  Hcax.	  This	  arises	  due	  to	  the	  coupling	  with	  Hceq	  and	  Hb.	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Finally,	  with	  Hceq	  close	   to	  90°	   in	  correlation	   to	  Hb,	  no	  real	  coupling	   is	  observed	  between	  these	  two	  resonances,	  and	  this	   is	  reflected	  in	  the	  very	  small	  degree	  of	  fine	  splitting	  in	  the	  Hceq	  resonance	  at	  3.64	  ppm.	  With	   the	   azide	  35	   in	   hand	   and	   characterised,	   a	  mild	   selective	   reduction	  of	   the	  azide	  group	  to	  unmask	  the	  primary	  amine	  functionality	  was	  accomplished	  using	  a	   standard	  Staudinger	   reduction	   reaction,	  which	   employed	   triphenylphosphine	  in	   a	   THF/H2O	   solvent	   mixture.	   The	   H2O	   is	   present	   in	   order	   to	   hydrolyse	   the	  intermediate	   iminophosphorane.	   This	   reaction	   proceeded	   efficiently	   and	   non-­‐stereospecifically,	  to	  yield	  36	  as	  a	  pair	  of	  enantiomers,	  after	  simple	  purification.	  With	  this	  synthetic	  route	  providing	  access	  to	  the	  functionalised	  receptor-­‐binding	  fragment,	   the	   same	   route	   was	   repeated	   for	   the	   synthesis	   of	   the	   C1-­‐	   and	   C2-­‐carboxylate	  and	  C3-­‐phosphonate	  analogues	  (Scheme	  3.4).	  	  
	  	  












37, n = 1, R = CO2Me/Et; 34%41, n = 2, R = CO2Me;      79%45, n = 3, R = PO3Et2;      55%
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During	  the	  synthesis	  of	  these	  small	  molecule	  NMDA	  receptor-­‐binding	  moieties,	  a	  pair	  of	  rotamers	  is	  formed	  upon	  the	  Michael	  addition-­‐elimination	  reaction	  onto	  3,4-­‐diethoxy-­‐3-­‐cyclobutene-­‐1,2-­‐dione.	  An	  example	  of	   this	   is	   in	   the	   formation	  of	  compound	  46,	  wherein	  at	  room	  temperature,	  two	  resonances	  are	  present	  in	  the	  31P	   NMR	   spectrum.	   The	   pair	   of	   rotamers	   arises	   due	   to	   the	   donation	   of	   the	  nitrogen	   lone	   pair	   into	   the	   cyclobutene	   moiety,	   leading	   to	   restricted	   rotation	  around	  the	  C-­‐N	  enamine	  bond.	  
	  
Figure	   3.1.	   Variable	   temperature	   31P	   NMR	   spectra	   of	   46	   (DMSO-­‐d6,	   700	   MHz).	   The	  upper	  spectrum	  shows	  the	  two	  resonances	  reappearing	  upon	  cooling	  from	  338	  to	  298K.	  	  Variable	  temperature	  31P	  NMR	  spectroscopy	  was	  used	  to	  examine	  the	  behaviour	  of	   the	   rotamers	   and	   deduce	   the	   free	   energy	   of	   rotation	   around	   the	   C-­‐N	   bond	  (Figure	  3.1).	  Upon	  warming	  from	  298	  to	  348	  K,	  the	  two	  phosphorus	  resonances	  begin	  to	  broaden	  and	  coalescence	  was	  observed	  with	  Tc	  estimated	  to	  be	  337	  K.	  At	   this	   temperature,	   the	   rate	   constant	   for	   interconversion,	   kc	   was	   calculated,	  using	  equation	  3,	  to	  be	  180	  s-­‐1.	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2 	   	   	   	   	   (3)	  	  Using	  equation	  3.1,	  an	  estimate	  of	  the	  free	  energy	  of	  activation	  (ΔGc)	  associated	  with	  this	  dynamic	  process	  could	  be	  made.	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⎟ 	   	   	   (3.1)	  	  where	  R	   is	   the	  molar	  gas	  constant,	  Tc	   is	   the	  coalescence	   temperature	  and	  Δv	   is	  the	   difference	   in	   frequencies.	   Based	   on	   an	   Eyring	   analysis,	   the	   free	   energy	   of	  activation	  was	  estimated	  to	  be	  70.4	  ±	  0.2	  kJ	  mol-­‐1.	  This	  relatively	  high	  energy	  of	  activation	   reflects	   the	   significant	   degree	   of	   double	   bond	   character	   associated	  with	  the	  C-­‐N	  bond.	  	  
3.2.2	  Linker	  and	  Macrocycle	  Synthesis	  	  In	  order	  to	  determine	  the	  optimal	   length	  of	  the	  linker	  between	  the	  Gd(III)	  core	  and	  the	  pendant	  NMDA	  receptor	  binding	  moiety,	  two	  varying	  spacer	  units	  were	  used.	  The	  first	   linker	  was	  derived	  from	  the	  commercially	  available	  (S)-­‐glutamic	  acid	   5-­‐benzyl	   ester.	   Derivitisation	   via	   diazotisation	   of	   the	   α-­‐amino	   group,	  followed	   by	   in-­situ	   bromination	   gave	   the	   (S)-­‐brominated	   derivative,	   49.	   After	  purification,	  the	  free	  carboxylic	  acid	  was	  esterified	  using	  tert-­‐butyl	  acetate	  in	  the	  presence	  of	  a	  catalytic	  amount	  of	  acid,	  to	  give	  the	  orthogonally	  protected	  ester,	  
50.5	  Alkylation	  of	  ester	  50	  onto	  DO3AtBu,	  19,	  was	  performed	  in	  a	  similar	  manner	  as	  in	  the	  synthesis	  of	  compound	  20.	  Finally,	  the	  benzyl-­‐protecting	  group	  of	  51	  was	  removed	  under	  high-­‐pressure	  hydrogenation,	  in	  the	  presence	  of	  a	  Pd/C	  catalyst.	  Filtration	   of	   the	   catalyst	   and	   removal	   of	   the	   solvent	   yielded	   the	   hygroscopic	  carboxylic	  acid,	  52	  (Scheme	  3.5).6	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Scheme	  3.5.	  
	  The	   second	  macrocycle	   and	   linker	  unit	  was	  derived	   from	  compound	  21.	   Chain	  extension	  of	  the	  pendant	  free	  amine	  was	  performed	  through	  nucleophilic	  attack	  onto	  succinic	  anhydride,	  leading	  to	  ring	  opening	  of	  the	  anhydride.	  This	  gave	  53	  with	  an	  elongated	  chain	  possessing	  a	  terminal	  carboxylic	  acid	  (Scheme	  3.6).	  	  
	  	  
Scheme	  3.6.	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acid	   of	   52	   or	   53	   (Scheme	   3.7).	   This	   was	   achieved	   by	   stirring	   52	   or	   53	   as	   a	  solution	   in	   anhydrous	   DMF	   with	   EDC.HCl	   and	   HOBt	   for	   20	   minutes.	   After	  formation	   of	   the	   active	   ester,	   a	   solution	   of	   the	   amine	   and	   NMM	   was	   added	  dropwise	   and	   the	   reaction	  monitored	   by	   ESI-­‐MS.	   Formation	   of	   the	   conjugates	  appeared	   to	   proceed	   more	   quickly	   than	   previously	   observed	   for	   that	   of	  
[conjugates	   1-­4].	   After	   work-­‐up	   and	   purification	   by	   column	   chromatography,	  
[conjugates	   5-­10]	   (54-­59),	   were	   isolated	   as	   pairs	   of	   diasteroisomers,	   in	   a	  slightly	  greater	  yield	  than	  for	  [conjugates	  1-­4].	  	  
	  	  
Scheme	  3.7.	  	  Characterisation	   of	   [conjugates	   5-­10]	   (54-­59)	  was	   undertaken	   using	   1H,	   13C,	  and	   when	   applicable,	   31P	   NMR	   spectroscopies,	   as	   well	   as	   HRMS,	   with	   each	  technique	   consistent	  with	   the	   formation	   of	   the	   desired	   product.	   The	   final	   two	  steps	   in	   the	   synthesis	   of	   L5-­10	   before	   metal	   complexation	   involved	   global	  deprotection	  of	  the	  protecting	  groups.	  In	   the	   case	   of	   L5	   and	   L6,	   methyl/ethyl	   ester	   hydrolysis	   was	   achieved	   under	  standard	  basic	   conditions,	  utilising	  NaOH	   in	  an	  aqueous	  methanol	   solvent.	  The	  crude	  carboxylic	  acids	  were	  then	  subject	  to	  tert-­‐butyl	  ester	  cleavage	  using	  a	  1:1	  mixture	  of	  trifluoroacetic	  acid	  and	  DCM	  at	  room	  temperature,	  overnight	  (Scheme	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54    R = CH2CO2tBu;                26%    
55           CH2CH2CO2tBu;         26%
56          CH2CH2PO3Et2;          21%
57           CH2CH2CH2PO3Et2;   28%
58    R =  CH2CH2PO3Et2;         22%    
59           CH2CH2CH2PO3Et2;   22%
52
53
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For	  L7-­10,	  hydrolysis	  of	  the	  tert-­‐butyl	  ester	  groups	  of	  [conjugates	  7-­10]	  (56-­59)	  was	   achieved	   using	   a	   1:1	   mixture	   of	   trifluoracetic	   acid	   and	   DCM.	   The	   crude	  phosphonate	   ethyl	   ester	   was	   dissolved	   in	   DMF	   and	   heated	   to	   60	   °C	   in	   the	  presence	   of	   an	   excess	   of	   bromotrimethylsilane	   (Scheme	   3.8).	   Complete	  hydrolysis	   was	   again	   confirmed	   through	   analysis	   of	   the	   mass	   spectra	   (734.9,	  748.7,	  833.7	  and	  847.8,	  [M+H]+,	  for	  L7-­10,	  respectively).	  	  
	  	  






























54    R = CH2CO2tBu                   
55            CH2CH2CO2tBu         
56           CH2CH2PO3Et2          
57            CH2CH2CH2PO3Et2
58    R = CH2CH2PO3Et2       
59            CH2CH2CH2PO3Et2
1) NaOH, MeOH, H2O, RT
2) TFA/DCM (1:1), RT
OR
1) TFA/DCM (1:1), RT
2) TMSBr, DMF, 60 oC
3) GdCl3.6H2O, H2O


































[Gd.L5]    R = CH2CO2H                   
[Gd.L6]            CH2CH2CO2H         
[Gd.L7]           CH2CH2PO3H2          
[Gd.L8]            CH2CH2CH2PO3H2
[Gd.L9]    R = CH2CH2PO3H2       
[Gd.L10]            CH2CH2CH2PO3H2
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Figure	   3.2.	   Calculated	   (left)	   and	   observed	   (right)	   high-­‐resolution	   electrospray	   mass	  spectra	   of	   [Gd.L6],	   showing	   the	   characteristic	   Gd-­‐isotope	   pattern;	   TOF-­‐MS	   positive	  mode.	  	  
3.3	   	  Relaxivity	  Properties	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two	  isomers	  are	  distinguishable	  by	  the	  angle	  between	  the	  N4	  and	  O4	  planes,	  with	  the	  TSAP	  angle	  approximately	  25°,	  compared	  to	  the	  SAP	  angle,	  which	  is	  larger	  at	  40°.8	  As	  a	  result	  of	  the	  increased	  steric	  repulsion	  between	  the	  chelating	  nitrogen	  and	  oxygen	  atoms	  in	  the	  TSAP	  conformation,	  the	  distance	  between	  the	  N4	  and	  O4	  planes	  is	  greater.9	  This	  means	  that	  the	  inner-­‐sphere	  water	  molecule	  must	  come	  in	  close	  proximity	  to	  the	  plane	  of	  negatively	  charge	  oxygen	  atoms,	  or	  the	  Gd-­‐OH2O	  bond	  must	   increase,	  when	  binding	   to	   the	  Gd(III)	   centre.	  This	  has	   resulted	   in	   it	  being	  widely	  accepted	  that	  the	  TSAP	  isomer	  possesses	  a	  greater	  kex	  than	  that	  of	  the	  SAP	  isomer,	  leading	  to	  a	  greater	  relaxivity	  for	  the	  TSAP	  conformation.	  
	  
Figure	  3.3.	  (Top)	  Possible	  isomers	  for	  Ln(III)	  complexes	  of	  DOTA-­‐like	  ligands;	  (Bottom)	  The	   coordination	  polyhedra	   of	   the	   SAP	   and	  TSAP	   isomers,	   showing	   the	   average	   angle	  rotations	  between	  the	  N4	  (blue)	  and	  O4	  (red)	  planes.9	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Despite	  this,	  recent	  studies	  by	  Woods	  and	  co-­‐workers10	  has	  shown	  that	  a	  greater	  relaxivity	   can	   be	   obtained	   from	   the	   SAP	   isomer	   of	   structurally	   related	   Gd(III)	  complexes.	   This	   is	   due	   to	   the	  TSAP	   isomer	   possessing	   a	   lower	   hydration	   state	  (q/rGdH6),	  which	   limits	   the	  overall	   relaxivity	  of	   the	  complex.	  On	   the	  other	  hand,	  the	   SAP	   isomer	   possesses	   a	   greater	   hydration	   state	   leading	   to	   a	   greater	  relaxivity.	   Therefore	   it	   is	   not	   just	   water	   exchange	   rate,	   but	   also	   the	   Gd-­‐HH2O	  distance	  of	  a	  complex	  that	  has	  a	  profound	  effect	  on	  relaxivity.10	  Bearing	  the	  above	  in	  mind,	  the	  isomeric	  ratio	  of	  SAP	  and	  TSAP	  conformations	  of	  a	  Eu(III)	  complex	  of	  a	  structurally	  related	  ligand	  to	  that	  of	  L5-­8	  was	  deduced	  by	  1H	   NMR	   spectrometry.	   SAP	   complexes	   are	   known	   to	   exhibit	   a	   larger	  paramagnetic	  shift	  (for	  q=1	  complexes),	  and	  the	  most	  shifted	  axial	  ring	  protons	  of	   SAP	   isomers	   of	   EuDOTA-­‐type	   complexes	   resonate	   between	   30-­‐50	   ppm.	   In	  contrast,	  the	  corresponding	  TSAP	  resonances	  are	  at	  approximately	  20	  ppm.11	  	  
	  
Figure	  3.4.	  1H	  NMR	  spectrum	  of	  [EuDOTAGlu]	  (298	  K,	  D2O,	  700	  MHz).	  (Inset)	  Enlarged	  region	  showing	  the	  most	  shifted	  axial	  protons	  of	  each	  isomer.	  	  Analysis	  of	  the	  1H	  NMR	  spectrum	  of	  [EuDOTAGlu]	  (Figure	  3.4)	  shows	  a	  ratio	  of	  SAP	  to	  TSAP	  isomers	  in	  solution	  that	   is	  slightly	  greater	  than	  2:1.	  This	   is	  a	  good	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approximation	  of	  the	  likely	  isomer	  distribution	  of	  complexes	  [Gd.L5-­10],	  which	  all	  bear	  the	  same	  core	  structure	  as	  [EuDOTAGlu].	  	  	  
3.3.2	  Relaxivities	  of	  [Gd.L5-­10]	  in	  Aqueous	  Solution	  and	  the	  Effect	  
of	  Added	  Protein	  
	  The	  longitudinal	  proton	  relaxivities	  of	  the	  six	  Gd(III)	  complexes,	  [Gd.L5-­10],	  were	  measured	  in	  water	  at	  1.4	  T	  and	  310	  K	  (Table	  3).	  The	  values	  fell	  in	  the	  expected	  range	  for	  such	  mono-­‐aqua	  complexes	  of	  molecular	  weight	  in	  the	  range	  of	  850	  to	  1450,	  for	  which	  the	  relaxivity	  value	  increases	  with	  molecular	  volume,	  as	  it	  scales	  with	  the	  overall	  rotational	  correlation	  time.12	  	  	  
Table	   3.	   Relaxation	   properties	   of	   [Gd.L5-­10]	   and	   their	   estimated	   binding	   affinities	   for	  serum	  albumina,	  b	  (310	  K,	  pH	  7.4,	  1.4	  T).	  	  
	   [Gd.L5]	   [Gd.L6]	   [Gd.L7]	  	   [Gd.L8]	   [Gd.L9]	   [Gd.L10]	  log	  K	   2.16	  	  (±0.01)	   1.91	  	  (±0.01)	   3.69	  	  (±0.04)	   1.60	  	  (±0.01)	   1.61	  	  (±0.01)	   3.68	  	  (±0.04)	  
r1pinitial/mM-­‐1	  s-­‐1	   4.9	  (±0.2)	   4.5	  (±0.2)	   5.8	  (±0.3)	   5.2	  (±0.3)	   5.0	  (±0.3)	   5.2	  (±0.3)	  
r1plimit/	  mM-­‐1	  s-­‐1	  
r1p/mM-­‐1	  s-­‐1	  (0.7	  mM	  HSA)	  
18.0	  6.0	  (±0.3)	  
22.0	  5.4	  (±0.3)	  
7.50	  6.6	  (±0.3)	  
30.0	  5.9	  (±0.3)	  
25.0	  5.5	  (±0.3)	  
8.50	  6.8	  (±0.3)	  	  
a	   the	  r1plimit	   	   values	  were	  derived	   from	  the	   iterative	   least-­‐squares	   fitting	  analysis;	  values	   for	   the	  complexes	  of	  L8	  and	  L9	  are	  subject	  to	  the	  largest	  error;	  b	  the	  	  relative	  affinity	  constant	  (IC50	  values,	  i.e.	   not	   the	   1:	   1	   binding	   constant	   that	   is	   assumed	   here	   in	   the	   data	   analysis)	   for	   a	   structurally	  similar	  NMDA	  binding	  moiety	  (Kinney’s	  antagonist)	  was	  reported	  to	  be	  19	  nM,	  determined	  using	  a	  radiolabelled	  competition	  assay.1	  	  The	  contrast	  agents,	  [Gd.L5-­10],	  can	  each	  bind	  non-­‐specifically	  to	  protein	  to	  some	  extent,	  which	  will	  disrupt	  their	  rotational	  dynamics	  and	  lead	  to	  an	  enhancement	  of	   the	   longitudinal	   water	   proton	   relaxation	   rate.	   As	   discussed	   in	   section	   2.3.1,	  HSA	   is	   the	  major	  protein	   constituent	   in	   the	   circulatory	   system.	  Therefore,	   as	   a	  control	  experiment,	  the	  effect	  of	  added	  HSA	  on	  the	  measured	  relaxivity	  of	  [Gd.L5-­
10]	  (each	  at	  1	  mM)	  was	  assessed	  at	  1.4	  T,	  following	  incremental	  addition	  of	  up	  to	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2	  mM	  HSA.	   Increases	   in	   r1p	  were	  observed	  and	   the	   association	   constants	  were	  estimated	  by	  assuming	  a	  1:1	  stoichiometry	  of	  interaction.	  The	   association	   constants	   for	   [Gd.L5-­10]	   with	   HSA	   were	   2.16	   (±0.01),	   1.91	  (±0.01),	   3.69	   (±0.04),	   1.60	   (±0.01),	   1.61	   (±0.01)	   and	   3.68	   (±0.04),	   respectively	  (Table	  3).	  These	  are	  all	  much	  lower	  values	  than	  those	  calculated	  for	  the	  acyclic	  analogues	  [Gd.L1-­4],	  with	  [Gd.L7]	  and	  [Gd.L10]	   the	  only	  two	  complexes	  to	  show	  any	  apparent	  binding	  to	  HSA.	  	  No	  particular	  trend	  was	  evident	  correlating	  log	  K	  values	  with	  molecular	   structure;	   indeed	   the	  weakest	   interaction	  occurred	  with	  the	  phosphonates,	   [Gd.L8]	   and	   [Gd.L9],	  whilst	   the	   analogues	  with	  one	   less	   and	  one	   more	   methylene	   groups,	   [Gd.L7]	   and	   [Gd.L10],	   respectively,	   bound	   to	  albumin	  100	  times	  more	  strongly	  in	  each	  case.	  	  The	   concentration	   of	   HSA	   in	   plasma	   is	   approximately	   0.67	  mM.13	   At	   a	   protein	  concentration	  of	  0.7	  mM,	  the	  highest	  relaxivity	  values	  were	  measured	  to	  be	  6.63	  and	   6.82	   mM-­‐1	   s-­‐1	   for	   [Gd.L7]	   and	   [Gd.L10],	   reflecting	   their	   higher	   binding	  affinities	  for	  HSA.	  This	  constitutes	  a	  small	  15	  and	  32%	  enhancement	  in	  r1p,	  which	  is	   promising	   as	   a	   much	   greater	   enhancement	   should	   be	   expected	   when	   these	  complexes	   bind	   to	   the	   cell	   surface	   NMDA	   receptor.	   Of	   course,	   such	   behaviour	  requires	  that	  non-­‐specific	  binding	  of	  the	  probes	  be	  minimal	  and	  that	  they	  bind	  to	  the	  NMDA	  receptors	  with	  high	  selectivity.	  	  
3.4	   	  Toxicity	  Studies	  	  The	  NMDA	  receptor-­‐targeted	  MR	  contrast	   agents,	   [Gd.L5-­10],	  were	  assessed	   for	  their	   toxicity.	   The	   MTT	   assay,	   as	   described	   in	   chapter	   2,	   was	   performed	   on	  differentiated	  NSC-­‐34	  cells	  with	  incubations	  of	  up	  to	  200	  µM	  of	  each	  complex.	  As	  found	   for	   the	   first-­‐generation	  NMDA	   receptor-­‐targeted	  MR	   contrast	   agents,	   no	  significant	   toxicity	   was	   observed	   for	   the	   probe	   concentrations	   used,	   giving	   an	  IC50	  value	  for	  [Gd.L5-­10]	  greater	  than	  200	  µM.	  Such	  behaviour	  is	  consistent	  with	  the	  absence	  of	  probe	  internalisation.	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3.5	   	  MRI	  Analysis	  of	  Cell	  Suspensions	  In	  Vitro	  	  A	   neuronal	   cell	   line	   model	   expressing	   functional	   NMDA	   receptors	   was	  established	  in	  chapter	  2.	  The	  cellular	  labeling	  of	  differentiated	  NSC-­‐34	  cells	  with	  
[Gd.L5-­10]	  was	  assessed	  by	  measuring	  the	  longitudinal	  relaxation	  times,	  T1,	  of	  the	  water	  signal	  in	  cell	  suspensions	  using	  a	  Siemens	  human	  whole	  body	  MR	  scanner,	  equipped	  with	   a	   head	   coil	   operating	   at	   3	   T.	   These	  measurements	   allowed	   the	  calculation	   of	   cellular	   relaxation	   rates,	   R1,cell.	   Following	   the	   same	   procedure	  outlined	   in	   chapter	   2,	   differentiated	  NSC-­‐34	   cells	  were	   incubated	  with	  200	  µM	  
[Gd.L5-­10]	   for	   45	   minutes.	   The	   cells	   were	   washed	   with	   HBSS	   to	   remove	   any	  unbound	   complex,	   re-­‐suspended	   in	   fresh	   buffer	   and	   T1-­‐weighted	   MR	   images	  acquired	   overnight.	   Analysis	   of	   the	   T1-­‐weighted	   images	   allowed	   calculation	   of	  
R1,cell	  (Figure	  3.5).	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pendant	   acidic	   groups.	   When	   incubated	   with	   the	   differentiated	   NSC-­‐34	   cells,	  these	  four	  complexes	  induced	  negligible	  enhancements	  in	  R1,cell	  of	  105,	  103,	  104	  and	   106%,	   respectively.	   These	   enhancements	   are	   not	   significantly	  distinguishable	   from	   the	   enhancements	   gained	   when	   using	   the	   clinically	  approved,	  non-­‐targeted	  contrast	  agent,	  [Gd.DOTA].	  The	   complexes,	   [Gd.L9]	   and	   [Gd.L10]	   incorporate	   the	   same	   receptor	   binding	  moieties	   as	   [Gd.L7]	   and	   [Gd.L8],	   respectively,	   but	   have	   a	   longer	   spacer	   unit	  between	  the	  NMDA	  receptor	  binding	  moiety	  and	  the	  Gd(III)	  chelate.	  The	  complex	  
[Gd.L9]	   induces	   a	   relatively	   large	   enhancement	   in	  R1,cell	   of	   123%,	  whereas	   the	  addition	   of	   a	   single	  methylene	   group	   to	   the	   targeting	  moiety	   results	   in	   only	   a	  104%	  enhancement	  in	  R1,cell	  for	  [Gd.L10].	  Since	   the	   set	   of	   complexes,	   [Gd.L5-­8],	   each	   gave	   less	   than	   6%	   enhancement	   in	  
R1,cell,	   it	   suggests	   that	   these	   complexes	   could	  be	   inhibited	   in	  binding	   to	   the	   cell	  surface	  NMDA	  receptor.	  This	   could	  either	  be	  due	   to	   the	  alteration	  made	   to	   the	  NMDA	   receptor	   binding	   moieties,	   leading	   to	   decreased	   affinities	   towards	   the	  receptor,	   or	   that	   the	   sterically	   demanding	   Gd(III)	   chelate	   is	   too	   close	   to	   the	  targeting	   moiety	   to	   allow	   for	   receptor	   binding.	   Given	   that	   [Gd.L9],	   with	   the	  longer	   spacer	   induces	   a	   significant	   enhancement	   in	   R1,cell,	   it	   suggests	   that	   the	  targeting	   moieties	   do	   possess	   reasonable	   affinity	   for	   the	   NMDA	   receptor.	  Therefore,	   it	  must	  be	   that	  receptor	  binding	   is	   inhibited	   for	  [Gd.L5-­8]	  due	   to	   the	  close	  proximity	  of	  the	  Gd(III)	  chelate.	  The	  lower	  R1,cell	  observed	  for	  [Gd.L10]	  is	  in	  keeping	   with	   the	   lower	   receptor	   affinity	   of	   such	   antagonists	   in	   the	   small	  molecule	  work.1	  Despite	   the	  observable	  enhancement	   in	  R1,cell	   for	  [Gd.L9],	   it	   is	  much	   lower	  than	  the	   enhancements	   observed	   for	   [Gd.L2]	   and	   [Gd.L4],	   notwithstanding	   the	   fact	  that	   the	   receptor	   binding	   moiety	   is	   reported	   to	   possess	   an	   increased	   NMDA	  receptor	  affinity.	  This	   is	  most	   likely	  due	  to	  the	   length	  of	  the	  spacer	  unit	   linking	  the	  targeting	  moiety	  to	  the	  Gd(III)	  chelate,	  which	  is	  longer	  in	  the	  case	  of	  [Gd.L9].	  This	   could	   lead	   to	   a	   decrease	   in	   the	   rotational	   coupling	   between	   the	   Gd(III)	  chelate	   and	   the	   receptor	  bound	   targeting	  moiety,	   resulting	   in	   the	   global	  τR	   not	  being	  modulated	  as	  much.	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3.6	   	  Conclusions	  	  The	  aim	  of	  this	  chapter	  was	  to	  build	  on	  the	  results	  from	  chapter	  2.	  The	  goal	  was	  to	  develop	  a	  second	  generation	  of	  NMDA	  receptor-­‐targeted	  MR	  contrast	  agents,	  with	   an	   improved	   receptor	   affinity,	   by	   using	   the	   modified	   bicyclic	   antagonist	  proposed	  by	  Kinney.	  A	  novel	  route	  has	  been	  designed	  to	  synthesise	  the	  four	  new	  receptor-­‐binding	  moieties,	  and	  they	  have	  been	  conjugated	  to	  Gd(III)	  chelates	  to	  give	   the	   complexes	   [Gd.L5-­10].	   In	   order	   to	   study	   the	   effect	   of	   linker	   length	   on	  relaxivity	   gain,	   the	   complexes	   [Gd.L5-­8]	   possess	   a	   linker	   derived	   from	   glutaric	  acid,	  whereas	  [Gd.L9-­10]	   incorporate	  a	  longer	  chain	  which	  further	  separates	  the	  receptor-­‐binding	   moiety	   and	   the	   Gd(III)	   chelate.	   The	   compounds	   were	   fully	  characterised	   and	   their	   potential	   to	   bind	   non-­‐specifically	   to	   HSA	   has	   been	  assessed.	  Upon	   incubation	   with	   a	   neuronal	   cell	   line	   model,	   the	   complexes	   [Gd.L5-­8]	  induced	  an	  increase	  in	  cellular	  relaxation	  rate	  of	  no	  more	  than	  106%.	  In	  contrast,	  
[Gd.L9],	  with	  the	  longer	  spacer,	  induced	  an	  enhancement	  in	  R1,cell	  of	  123%.	  This	  suggests	  that	  the	  complexes	  [Gd.L5-­8]	  are	  unable	  to	  bind	  to	  the	  NMDA	  receptor,	  most	   likely	   due	   to	   the	   close	   proximity	   of	   the	   large	   Gd(III)	   chelate.	   However,	  
[Gd.L9]	  can	  bind	  to	  the	  cell	  surface	  NMDA	  receptor,	  modulating	  τR	  of	  the	  complex	  leading	   to	  an	   increase	   in	  R1,cell.	  Whilst	   an	  enhancement	   in	  R1,cell	   is	  observed	   for	  
[Gd.L9],	   it	   is	  much	   smaller	   than	   that	   observed	   for	   [Gd.L2]	   and	   [Gd.L4].	   This	   is	  either	  due	  to	  the	  receptor-­‐binding	  moiety	  of	  [Gd.L9]	  possessing	  a	  lower	  receptor	  affinity,	   or	   the	   increased	   spacer	   length	   in	   [Gd.L9]	   leads	   to	   a	   greater	   degree	   of	  decoupled	  rotation,	  limiting	  the	  relaxivity	  gain.	  At	  present,	   the	  variation	   in	  R1,cell	   of	  NSC-­‐34	   cells	  when	   incubated	  with	   [Gd.L2],	  
[Gd.L4]	   and	   [Gd.L9]	   is	   consistent	  with	  an	   increase	   in	  τR	   that	   is	   associated	  with	  slower	  molecular	  tumbling	  of	  the	  complex	  when	  bound	  to	  the	  cell	  surface	  NMDA	  receptor.	   However,	   internalisation	   of	   the	   complex	   via	   receptor-­‐mediated	  endocytosis	   or	   non-­‐specific	   binding	   to	   the	   cell	   membrane	   are	   also	   possible	  mechanisms	  that	  could	  lead	  to	  an	  increase	  in	  R1,cell.	  In	  order	  to	  establish	  which	  of	  these	   possibilities	   was	   responsible	   for	   the	   observed	   increases	   in	   R1,cell,	   direct	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visualisation	   of	   the	   complex	   on	   the	   cell	   surface	   is	   needed.	   Due	   to	   the	   limiting	  resolution	  associated	  with	  MRI,	  a	  different	  imaging	  technique	  was	  needed.	  
Chapter	   4	   will	   discuss	   the	   design	   and	   synthesis	   of	   two	   new	   NMDA	   receptor-­‐targeted	  conjugates	   for	  optical	   imaging.	  Based	  on	   the	  structures	  of	  [Gd.L4]	   and	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4.	  Direct	  Visualisation	  of	  NMDA	  Receptors	  By	  
Optical	  Microscopy	  	  
4.1	   	  Introduction	  	  Ten	   NMDA	   receptor-­‐targeted	   MRI	   contrast	   agents	   have	   been	   synthesised,	   of	  which	  three,	  [Gd.L2],	  [Gd.L4]	  and	  [Gd.L9],	  showed	  considerable	  enhancements	  in	  
R1,cell	   when	   incubated	   with	   a	   neuronal	   cell	   line	   model	   possessing	   functional	  NMDA	   receptors.	   The	   variation	   of	   R1,cell	   of	   differentiated	   NSC-­‐34	   cells	   in	   the	  presence	  of	  these	  three	  contrast	  agents	  is	  consistent	  with	  an	  increase	  in	  τR	  that	  is	  associated	  with	   slower	  molecular	   tumbling	   of	   the	   complex	  when	  bound	   to	   the	  cell-­‐surface	  receptor.	  However,	  due	  to	  the	  intrinsic	   insensitivity	  of	  MR	  imaging,	  direct	   visualisation	   of	   the	   complexes	   is	   prohibited,	  meaning	   there	   is	   no	   direct	  proof	  of	  cell-­‐surface	  receptor	  localisation.	  The	  observed	  increases	  in	  R1,cell	  could	  also	   result	   from	   internalisation	   of	   the	   complex,	   via	   receptor-­‐mediated	  endocytosis,	   or	   through	   the	   complex	   non-­‐specifically	   binding	   to	   the	   cell	  membrane.	   In	   order	   to	   establish	   which	   mechanism	   is	   responsible	   for	   the	  increases	  in	  R1,cell,	  two	  new	  complexes	  were	  designed	  and	  synthesised,	  allowing	  complex	  visualisation	  using	  high-­‐resolution	  laser-­‐scanning	  confocal	  microscopy.	  As	   discussed	   in	   chapter	   1,	   appending	   a	   fluoroscein	   label	   to	   a	   non-­‐competitive	  antagonist	   has	   recently	  been	   shown	   to	   allow	   for	   the	  direct	   visualisation	  of	   the	  NR2B	   subunit.1,	   2	   However,	  work	   by	   Barton	   and	   co-­‐workers3,	   4	   and	  within	   the	  Durham	   group5-­‐8	   has	   shown	   that	   appending	   a	   relatively	   lipophilic	   fluorescent	  moiety	   to	   a	   complex	   can	   perturb	   cell	   uptake	   mechanisms,	   promoting	   non-­‐specific	  cellular-­‐uptake.	  In	  order	  to	  target	  and	  visualise	  NMDA	  receptors	  on	  the	  cell	  surface	  selectively,	  the	  structures	  of	  [Gd.L2],	  [Gd.L4]	  and	  [Gd.L9]	  needed	  to	  be	   perturbed	   minimally,	   limiting	   the	   changes	   to	   overall	   complex	   charge	   and	  hydrophilicity.	  The	   new	   complexes,	   [Gd.L11]	   and	   [Gd.L12],	   comprise	   the	   receptor-­‐binding	  moieties	  of	  the	  most	  promising	  MRI	  contrast	  agents,	  [Gd.L4]	  and	  [Gd.L9]	  (largest	  increases	   in	   R1,cell	   for	   each	   series),	   with	   a	   trans-­‐substituted	   D-­‐biotin	   moiety	  appended	  to	  the	  macrocyclic	  core.	  This	  design	  was	  based	  on	  the	  hypothesis	  that	  if	   the	   cell-­‐surface	   NMDA	   receptor-­‐binding	   is	   responsible	   for	   the	   increases	   in	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R1,cell	  of	  [Gd.L4]	  and	  [Gd.L9],	   the	  receptor-­‐binding	  moieties	  of	  [Gd.L11-­12]	  would	  interact	  with	  the	  NMDA	  receptors.	  The	  remote	  biotin	  moiety	  would	  then	  act	  as	  a	  tag,	   binding	   to	   an	   added	  AvidinAlexaFluor®488	   conjugate,	  which	  would	   allow	  visualisation	  of	  the	  avidin-­‐biotin	  conjugate	  by	  optical	  microscopy.	  	  
	  	  
Scheme	  4.	  Structures	  of	  the	  target	  complexes,	  [Gd.L11]	  and	  [Gd.L12].	  	  
4.2	   	  Synthetic	  Details	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techniques	   as	   previously	   used	   gave	   [conjugate	  11]	   (69),	   in	   a	   poor	   yield,	   after	  subsequent	  work	  up	  and	  purification	  by	  preparative	  RP-­‐HPLC.	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4.2.2	  Synthesis	  of	  [Conjugate	  12]	  	  During	  the	  synthesis	  of	  [conjugate	  11]	  (69),	  the	  hydrogenation	  step	  to	  remove	  the	   Cbz	   protecting	   group	   was	   slow,	   taking	   several	   days	   for	   complete	  deprotection.	  This	  was	  attributed	  to	  the	  presence	  of	  the	  sulfur	  atom	  of	  the	  biotin	  moiety,	  which	  may	  possibly	  poison	   the	  catalyst	  and	  decrease	   the	  reaction	  rate.	  The	   synthesis	   of	   [conjugate	   12]	   (75)	   followed	   a	  modified	   route	   (Scheme	   4.3),	  which	  would	  allow	  for	  incorporation	  of	  the	  biotin	  moiety	  in	  the	  final	  step	  of	  the	  conjugate	  synthesis.	  Therefore,	  there	  was	  a	  slight	  change	  in	  the	  protecting	  group	  strategies	  employed.	  A	   simple	   methyl	   ester	   group	   replaced	   the	   benzyl-­‐protecting	   group	   of	   the	  bromoglutarate	   arm.	   This	   compound	   was	   synthesised	   from	   the	   commercially	  available	   (S)-­‐glutamic	   acid	   5-­‐methyl	   ester.	  Diazotisation	   of	   the	  α-­‐amino	   group,	  followed	   by	   in-­situ	   bromination	   gave	   the	   brominated	   derivative	   70,	   after	  purification	   by	   column	   chromatography.	   Subsequent	   esterification	   of	   the	  carboxylic	   acid	   group,	   using	   tert-­‐butyl	   acetate	   in	   the	   presence	   of	   a	   catalytic	  amount	  of	  acid,	  gave	  the	  orthogonally	  protected	  ester,	  71.	  N-­‐alkylation	  of	  63	  by	  
71	  was	  achieved	  by	  stirring	  in	  anhydrous	  acetonitrile	  at	  60	  °C	  in	  the	  presence	  of	  K2CO3.	  Removal	  of	   the	  Cbz	  protecting	  group	   from	  the	  N-­‐terminus	  of	   the	  penta-­‐ester,	  72,	  followed	  by	  chain	  extension	  via	  reaction	  with	  succinic	  anhydride	  gave	  the	   free	   carboxylic	   acid,	  73,	   after	   purification	  by	   column	   chromatography.	   The	  acid,	  73,	  was	  then	  coupled	  to	  the	  primary	  amine	  of	  the	  receptor-­‐binding	  moiety	  of	  [Gd.L9]	  (36),	  using	  the	  amide	  bond	  forming	  techniques	  previously	  established,	  to	  yield	  74	  as	  a	  diastereoisomeric	  mixture.	  Finally,	  methyl	  ester	  hydrolysis	  under	  ambient	  basic	  conditions,	   followed	  by	  a	  second	  amide	  bond	  formation	  with	  the	  TFA	  salt	  of	  biotin	  ethylene	  diamine,	  67,	  gave	  [conjugate	  12]	  (75),	  albeit	  in	  a	  low	  yield,	  after	  purification	  by	  column	  chromatography.	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4.2.3	  Complex	  Synthesis	  and	  Characterisation	  	  With	   [conjugates	   11-­12]	   in	   hand,	   the	   final	   step	   before	   metal	   complexation	  involved	  global	  hydrolysis	  of	  all	  protecting	  groups	  (Scheme	  4.4).	  In	  the	  formation	  of	   L11,	   basic	   hydrolysis	   of	   the	   phosphonate	   ethyl	   esters	   was	   undertaken	   by	  stirring	   in	   THF	   with	   aqueous	   KOH	   at	   60	   °C	   for	   four	   hours.	   Removal	   of	   the	  phosphonate	  ethyl	  esters	  after	  this	  time	  was	  verified	  by	  ESI-­‐MS,	  at	  which	  point	  the	  crude	  phosphonic	  acid	  was	  dissolved	  in	  a	  1:1	  mixture	  of	  trifluoroacetic	  acid	  and	  DCM	  and	  stirred	  at	   room	   temperature	  overnight.	  Complete	   removal	  of	   the	  
tert-­‐butyl	   ester	   and	   carbamate	   protecting	   groups	   gave	   L11,	   with	   its	   presence	  confirmed	  through	  analysis	  of	  the	  crude	  mass	  spectrum	  (545.1,	  [M+2H]2+).	  In	   the	  synthesis	  of	  L12,	   it	  was	  decided	   that	  a	  better	  approach	  was	   to	  hydrolyse	  the	  tert-­‐butyl	  ester	  protecting	  groups	  first.	  This	  was	  again	  achieved	  using	  a	  1:1	  solution	  of	   trifluoroacetic	   acid	   and	  DCM.	   Following	  hydrolysis	   of	   the	   tert-­‐butyl	  esters,	  the	  crude	  phosphonate	  ethyl	  ester	  was	  dissolved	  in	  DMF	  and	  heated	  to	  60	  
°C	   in	   the	  presence	  of	  an	  excess	  of	  bromotrimethylsilane.	  Global	  hydrolysis	  was	  confirmed	   after	   16	   hours,	   through	   analysis	   of	   the	   mass	   spectrum	   (587.0,	  [M+2H]2+).	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Finally,	  complexation	  of	  the	  corresponding	  TFA	  salts	  of	  L11-­12	  was	  carried	  out	  by	  reaction	  with	  GdCl3.6H2O	   in	  H2O	   (pH	  6-­‐6.5)	   at	  60	   °C	  overnight	   (Scheme	  4.4).	  A	  slight	  excess	  of	  the	  gadolinium	  salt	  led	  to	  rapid	  complexation.	  Upon	  completion,	  the	  excess	  Gd(III)	  was	  removed	  via	  complexation	  to	  Chelex-­‐100™	  resin,	  and	  the	  complexes	   [Gd.L11-­12]	   purified	   by	   preparative	   RP-­‐HPLC.	   Confirmation	   of	   the	  presence	  of	   the	  complexes	  [Gd.L11-­12]	  was	  achieved	  using	  high-­‐resolution	  mass	  spectrometry	  analysis.	  The	   theoretical	  and	  experimental	  mass	  distributions	   for	  
[Gd.L12]	  showed	  good	  agreement	  (Figure	  4).	  
	  
Figure	   4.	   Calculated	   (left)	   and	   observed	   (right)	   high-­‐resolution	   electrospray	   mass	  spectra	  of	  [Gd.L12],	  showing	  the	  characteristic	  Gd-­‐isotope	  pattern;	  TOF	  positive	  mode.	  	  The	  longitudinal	  proton	  relaxivities	  of	  [Gd.L11-­12]	  were	  measured	  in	  water	  at	  1.4	  T	   and	   310	   K.	   The	   relaxivities	   of	   [Gd.L11-­12]	   were	   both	   7.2	   (±	   0.4)	  mM-­‐1	   s-­‐1.	   In	  contrast	  to	  the	  parent	  compounds,	  these	  higher	  relaxivity	  values	  are	  associated	  with	   an	   increased	  molecular	   volume	   of	   the	   complexes,	   giving	   rise	   to	   a	   slower	  rotational	   correlation	   time.	   Also,	   there	   is	   an	   increased	   likelihood	   of	   second	  sphere	   hydration	   through	  multiple	   hydrogen	   bonding	   interactions,	   which	   also	  tends	  to	  increase	  r1p.13	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4.3	   	  Comparative	  Studies	  Using	  Confocal	  Microscopy	  
4.3.1	  Localisation	  Studies	  	  In	  order	   to	  study	   the	   localisation	  profiles	  of	   [Gd.L11-­12],	   live-­‐cell	   laser	  scanning	  confocal	  microscopy	  (LSCM)	  imaging	  studies	  were	  carried	  out	  using	  a	  Leica	  SP5	  II	  microscope	  by	  Dr	  Robert	  Pal,	  Durham	  University.	  Differentiated	  NSC-­‐34	  cells	  expressing	   functional	  NMDA	  receptors	  were	  grown	  (as	  described	   in	  chapter	  2)	  on	   specially	   designed	   microscope	   slides,	   comprising	   a	   100	   µL	   flow-­‐through	  channel	  and	  subjected	  to	  various	  experimental	  conditions.	  Initially,	   differentiated	   NSC-­‐34	   cells	   were	   incubated	   simultaneously	   with	  solutions	  of	  [Gd.L11]	  or	  [Gd.L12]	  (10	  µM)	  and	  AvidinAlexaFluor®	  488	  conjugate	  (2.5	  µM),	   for	   10	  minutes	   at	   37	   °C	   and	   5%	   CO2.	   After	   this	   time,	   the	   cells	  were	  washed	   three	   times	   with	   fresh	   buffer	   to	   remove	   any	   unbound	   complex	   and	  imaged.	  Both	  [Gd.L11]	  and	  [Gd.L12]	  showed	  a	  localisation	  profile	  resembling	  ‘pit-­‐like’	  regions	  at	  the	  cell	  surface	  (Figure	  4.1	  A	  and	  D).	  By	  keeping	  the	  microscope	  settings	   constant	   throughout	   all	   imaging	   studies,	   a	   comparison	   of	   the	  fluorescence	   intensities	   gave	   an	   idea	   of	   the	   relative	   affinities	   of	   each	   complex.	  Cells	  that	  were	  treated	  with	  [Gd.L12]	  appeared	  38%	  brighter	  than	  those	  treated	  with	   [Gd.L11].	  This	   suggests	   that	   the	   receptor-­‐binding	  moiety	  of	   [Gd.L12]	   has	  a	  higher	  affinity	  for	  the	  NMDA	  receptor	  than	  the	  acyclic	  analogue	  used	  in	  [Gd.L11],	  which	   is	   in	   keeping	   with	   the	   relative	   affinities	   of	   the	   small	   molecule	  antagonists.14	  Unequivocal	  evidence	  of	  the	  selective	  localisation	  of	  [Gd.L11-­12]	  at	  the	   cell	   membrane	   was	   obtained	   using	   the	   commercially	   available	   dye,	  CellMask™	  Orange,	  which	  non-­‐specifically	  stains	  the	  plasma	  membrane.	  A	  repeat	  of	   the	   simultaneous	   loading	   experiments	   of	   [Gd.L11]	   or	   [Gd.L12]	   (10	   µM)	   and	  AvidinAlexaFluor®	   488	   conjugate	   (2.5	  µM,	   10	  mins)	   on	   differentiated	   NSC-­‐34	  cells,	   with	   a	   co-­‐incubation	   of	   CellMask™	   Orange	   (5	   µg/mL,	   5	   mins),	  demonstrated	  that	  the	  signal	  from	  the	  complex-­‐Avidin	  conjugate	  was	  residing	  at	  the	  cell	  surface,	  with	  no	  intracellular	  staining	  observed	  at	  all	  (Figure	  4.1	  A-­F).	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Figure	   4.1.	   Live	   cell	   LSCM	   images	   of	   differentiated	   NSC-­‐34	   cells	   following	   treatment	  with	   [Gd.L11-­12]	  showing	  cell	   surface	   localisation.	   (A)	  Simultaneous	   loading	  of	  [Gd.L11]	  (10	  µM),	  and	  AvidinAlexaFluor®	  488	  conjugate	  (2.5	  µM,	  10	  mins)	  allowing	  visualisation	  of	  AvidinAlexaFluor®	  488	  conjugate	  λex/λem	  =488/505-­‐555	  nm;	  (B)	  As	  (A)	  but	  with	  a	  5	  minute	   CellMask™	   Orange	   incubation	   allowing	   visualisation	   of	   CellMask™	   Orange	  
λex/λem	   =	   543/550-­‐660	   nm;	   (C)	   RGB	   merge	   showing	   co-­‐localisation	   of	   the	  AvidinAlexaFluor®	   488	  conjugate	  and	  CellMask™	  Orange	  on	   the	   cell	   surface;	   (D-­‐F)	  As	  images	  (A-­‐C)	  but	  using	  [Gd.L12].	  Scale	  bars	  are	  17.0	  µm	  for	  (A-­‐C)	  and	  20.0	  µm	  for	  images	  (D-­‐F).	  	  In	  order	   to	   confirm	   that	   the	   fluorescence	  profiles	   are	  due	   to	   the	   strong	  biotin-­‐avidin	   interaction	   between	   the	   complexes	   [Gd.L11]	   and	   [Gd.L12]	   and	   the	  AvidinAlexaFluor®	  488	   conjugate,	   three	   control	   experiments	  were	   carried	   out	  (Figure	  4.2).	  First,	   in	  order	   to	  demonstrate	   that	   the	  observed	   fluorescence	  was	  not	  due	  to	  cellular	  autofluorescence,	  untreated	  differentiated	  NSC-­‐34	  cells	  were	  imaged.	   Secondly,	   to	   demonstrate	   that	   AvidinAlexaFluor®	   488	   conjugate	   was	  not	  able	  to	  bind	  to	  differentiated	  NSC-­‐34	  cells,	  these	  cells	  were	  treated	  only	  with	  a	   solution	   of	   AvidinAlexaFluor®	   488	   conjugate	   (2.5	   µM,	   10	   mins).	   Finally,	   in	  order	   to	   show	   that	   the	   complexes	   [Gd.L11-­12]	   are	   non-­‐fluorescent	   themselves,	  differentiated	  NSC-­‐34	  cells	  were	  treated	  with	  solutions	  of	  these	  complexes	  alone	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(10	  µM,	  10	  mins).	  In	  every	  case,	  no	  observable	  fluorescence	  signal	  in	  the	  visible	  region	  of	   the	  spectrum	  was	  detected,	   indicating	   that	   the	   fluorescence	  observed	  in	   figure	   4.1	   A	   and	  D	   is	   due	   to	   the	   strong	   (logKa	   >15)	   biotin-­‐avidin	   interaction	  between	  the	  gadolinium	  complexes	  and	  the	  fluorescent	  conjugate.	  	  
Figure	   4.2.	   (Top)	   No	   observable	   fluorescence	   signal	   from	   cells;	   (bottom)	  transmission	   image,	   showing	   cell	   morphology.	   (Left	   to	   right)	   Untreated	  differentiated	  NSC-­‐34	  cells,	  cells	  treated	  with	  AvidinAlexaFluor®	  488	  conjugate	  alone	  (2.5	  µM,	  10	  mins),	  and	  cells	  treated	  with	  [Gd.L12]	  alone	  (10	  µM,	  10	  mins).	  	  The	  cell	  surface	  localisation	  of	  the	  Avidin	  conjugates	  of	  [Gd.L11-­12]	  was	  found	  to	  be	   independent	   of	   the	   loading	   concentration	   (up	   to	   100	   µM),	   time	   (up	   to	   45	  minutes)	   and	   the	   order	   of	   addition	   of	   AvidinAlexaFluor®	   488	   conjugate	  (stepwise	  vs	  simultaneous).	  	  
4.3.2	  Establishing	  Cellular	  Specificity	  of	  Binding	  	  The	   potential	   of	   [Gd.L4]	   and	   [Gd.L9]	   to	   bind	   non-­‐specifically	   to	   endogenous	  protein	  was	  studied	   in	  chapters	  2	  and	  3,	  using	  HSA	  as	  a	  model.	  However,	  a	  key	  characteristic	  needed	   for	   these	   contrast	   agents	   is	   to	  have	   cellular	   specificity	  of	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binding,	  meaning	   that	   they	   can	   only	   bind	   to	   cells	   expressing	   functional	  NMDA	  receptors.	   Therefore,	   the	   potential	   of	   [Gd.L11-­12]	   to	   bind	   to	   NMDA	   receptor-­‐negative	  cells	  was	  assessed.	  NIH-­‐3T3	  cells	  are	  mouse	  skin	  fibroblasts,	  and	  do	  not	  express	   any	  NMDA	   receptors.	   These	   cells	  were	   incubated	   simultaneously	  with	  solutions	  of	  [Gd.L11]	  or	  [Gd.L12]	  (10	  µM)	  and	  AvidinAlexaFluor®	  488	  conjugate	  (2.5	  µM)	   for	   10	  minutes,	  washed	   three	   times	  with	   fresh	   buffer	   to	   remove	   any	  unbound	   complex	   and	   then	   imaged.	   No	   localisation	   profile	   of	   any	   kind	   (cell	  surface	   or	   intracellular)	   was	   observed,	   strengthening	   the	   argument	   of	   a	  receptor-­‐mediated	  localisation	  effect	  observed	  when	  [Gd.L11-­12]	  were	  incubated	  with	   NSC-­‐34	   cells.	   This	   behaviour	   further	   suggests	   that	   the	   enhancements	   in	  
R1,cell	  of	  NSC-­‐34	  cells	  which	  were	  incubated	  for	  [Gd.L4]	  and	  [Gd.L9]	  results	  from	  the	  complexes	  binding	  to	  the	  NMDA	  receptor,	  modulating	  τR	  of	  the	  complexes,	  as	  opposed	  to	  non-­‐specific	  membrane	  labelling.	  	  
4.3.3	  Assessing	  the	  Reversibility	  of	  Binding	  	  One	   of	   the	   key	   design	   characteristics	   needed	   for	   an	   NMDA	   receptor-­‐targeted	  contrast	  agent	  was	  for	  it	  to	  possess	  the	  ability	  to	  bind	  to	  the	  NMDA	  receptor	  in	  a	  reversible	   manner,	   with	   a	   competitive	   affinity	   to	   the	   endogenous	   ligand	  glutamate.	  Since	  optical	  microscopy	  has	  a	  superior	  sensitivity	  and	  resolution,	   it	  was	  thought	  best	  to	  assess	  the	  ability	  of	  [Gd.L4]	  and	  [Gd.L9]	  to	  bind	  reversibly	  at	  the	   NMDA	   receptor	   by	   visualising	   the	   fate	   of	   their	   fluorescent-­‐conjugate	  analogues,	  [Gd.L11-­12],	  after	  a	  simulated	  ‘glutamate	  burst’.	  	  Differentiated	   NSC-­‐34	   cells	   were	   simultaneously	   incubated	   with	   solutions	   of	  
[Gd.L11]	  or	  [Gd.L12]	  (10	  µM)	  and	  AvidinAlexaFluor®	  488	  conjugate	  (2.5	  µM)	  for	  10	   minutes,	   washed	   three	   times	   with	   fresh	   buffer	   to	   remove	   any	   unbound	  complex	   and	   then	   imaged.	   The	   average	   image	   intensity	   for	   each	   complex	  was	  assessed	  as	  triplicates	  using	  three	  cells	  (excluding	  the	  axon),	  which	  gave	  rise	  to	  a	  maximum	   contrast	   transfer	   function	   (CTF)	   displaying	   a	   Gaussian	   distribution.	  The	  CTFs	  of	  [Gd.L11]	  and	  [Gd.L12]	  were	  found	  to	  be	  173	  and	  239	  counts	  (out	  of	  256),	  demonstrating	  that	  [Gd.L12]	   is	  38%	  brighter	  than	  that	  of	  [Gd.L11]	  (Figure	  
4.3	  A	  and	  D).	  These	  cells	  were	  then	  washed	  with	  five	  successive	  aliquots	  (Vtot	  =	  500	  µL)	  of	  a	  glutamate-­‐rich	  (1	  mM)	  culture	  media	  and	  imaged	  again.	  A	  ten-­‐	  and	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nine-­‐fold	   drop	   in	   fluorescence	   intensity	   was	   observed	   for	   cells	   treated	   with	  
[Gd.L11]	   and	   [Gd.L12],	   respectively,	   compared	   to	   the	   original	   cell	   staining	  experiment	   (Figure	   4.3	   B	   and	   E).	   Furthermore,	   when	   cells	   were	   sequentially	  treated	  with	  the	  avidin/biotin	  components	  and	  with	  five	  volumetric	  aliquots	  of	  a	  glutamate-­‐rich	   (1	  mM)	   culture	  media,	   then	  washed	  with	  normal	   culture	  media	  and	   finally	   re-­‐incubated	   with	   solutions	   of	   [Gd.L11]	   or	   [Gd.L12]	   (10	   µM)	   and	  AvidinAlexaFluor®	  488	  conjugate	  (2.5	  µM)	  for	  10	  minutes,	  35%	  and	  38%	  of	  the	  fluorescence	  signal	  was	  recovered	  for	  [Gd.L11]	  and	  [Gd.L12],	  respectively	  (Figure	  
4.3	  C	  and	  F).	  The	  fluorescence	  intensity	  could	  be	  almost	  fully	  recovered	  (98%	  of	  the	   original	   intensity)	   when	   prolonging	   the	   re-­‐incubation	   of	   [Gd.L12]	   to	   45	  minutes.	  	  
Figure	  4.3.	   Live	   cell	   LSCM	   images	   of	   differentiated	  NSC-­‐34	   cells	   following	   treatment	  with	  [Gd.L11-­12].	  (A)	  Simultaneous	  loading	  of	  [Gd.L11]	   (10	  µM),	  and	  AvidinAlexaFluor®	  488	   conjugate	   (2.5	   µM,	   10	   mins)	   allowing	   visualisation	   of	   AvidinAlexaFluor®	   488	  conjugate	  λex/λem	  =488/505-­‐555	  nm;	  (B)	  As	  (A)	  but	  with	  a	  post	  glutamate	  (1	  mM)	  wash	  showing	   [Gd.L11]	   is	   removed	   from	   the	   cell	   surface;	   (C)	   As	   image	   (B)	   and	   then	  simultaneous	   loading	   of	   [Gd.L11]	   (10	  µM),	   and	   AvidinAlexaFluor®	   488	   conjugate	   (2.5	  
µM,	  10	  mins)	  showing	  signal	  recovery;	  (D-­‐F)	  As	   images	  (A-­‐C)	  but	  using	  [Gd.L12].	  Scale	  bars	  are	  17.0	  µm	  for	  (A-­‐C)	  and	  20.0	  µm	  for	  images	  (D-­‐F).	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  Aspartate	   is	  a	  weaker	  natural	  agonist	   for	  the	  NMDA	  receptor15	  and	  should	  also	  possess	   the	   ability	   to	   displace	   the	   contrast	   agents	   from	   the	   glutamate-­‐binding	  site.	  A	  repeat	  of	  the	  simulated	  glutamate	  burst	  experiment	  detailed	  above,	  with	  substitution	   of	   glutamate	   with	   aspartate	   in	   the	   washing	   step,	   led	   to	   the	  fluorescence	   intensity	  decreasing	   to	  38%	  and	  50%	  of	   the	  original	   intensity	   for	  
[Gd.L11]	   and	   [Gd.L12],	   respectively.	   This	   result	   is	   in	   keeping	  with	   the	   fact	   that	  aspartate	  has	  a	  lower	  affinity	  than	  glutamate	  for	  the	  NMDA	  receptor,	  and	  cannot	  fully	   displace	   the	   contrast	   agents	   from	   the	   binding	   site.i	   Also,	   since	   [Gd.L11]	   is	  removed	   by	   aspartate	   to	   a	   larger	   extent,	   this	   reflects	   the	   lower	   affinity	   of	   the	  receptor-­‐binding	  moiety	  of	  [Gd.L11]	  with	  respect	  to	  the	  receptor-­‐binding	  moiety	  of	  [Gd.L12].	  These	   results	   further	   suggest	   that	   these	   contrast	   agents	   are	   binding	   to	   the	  glutamate	   binding	   site,	   present	   on	   the	   NMDA	   receptor.	   The	   results	   also	  demonstrate	  that	  the	  contrast	  agents	  are	  displaced	  easily	  enough	  by	  glutamate,	  and	  can	  compete	  to	  bind	  again	  after	  a	  simulated	  pre-­‐synaptic	  glutamate	  burst.	  	  
4.3.4	  Competition	  Experiments	  Involving	  [Gd.L12]	  	  Since	  [Gd.L12]	  appeared	  to	  possess	  a	  higher	  affinity	  for	  the	  NMDA	  receptor	  over	  
[Gd.L11],	   and	   in	   order	   to	   further	   confirm	   cell	   surface	   NMDA	   receptor	   tagging,	  competitive	  binding	  experiments	  were	  conducted	  with	  [Gd.L12].	  	  At	   the	   outset	   it	   was	   expected	   that	   appending	   a	   sterically	   demanding	   Gd(III)	  chelate	   to	   a	   known	   NMDA	   receptor	   antagonist	   would	   result	   in	   a	   drop	   in	   the	  affinity	  of	  that	  antagonist	  towards	  the	  receptor.	  The	  complex	  [Gd.L12]	  is	  derived	  from	  Kinney’s	  antagonist,	  76,	  which	  was	  synthesised	  in	  one	  step	  from	  compound	  
29	  (Scheme	  4.5).14	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  i	  The	  IC50	  value	  of	  glutamate	  and	  aspartate	  are	  0.31	  and	  1.18	  µM,	  respectively.15	  	  
Direct	  Visualisation	  of	  NMDA	  Receptors	   	   Chapter	  4	  
By	  Optical	  Microscopy	  
	   106	  
	  
Scheme	  4.5.	  	  The	  competitive	  antagonist,	  76,	  binds	  to	  the	  NMDA	  receptor	  with	  a	  dissociation	  constant	  of	   the	  order	  of	  20	  nM.	   In	  order	   to	  study	   the	  effect	  of	   conjugation	  of	  a	  Gd(III)	   chelate	   to	   a	   known	   antagonist,	   on	   the	   antagonist’s	   NMDA	   receptor	  affinity,	  a	  series	  of	  competition	  experiments	  was	  performed.	  First,	  differentiated	  NSC-­‐34	  cells	  were	  incubated	  simultaneously	  with	  a	  solution	  of	  [Gd.L12]	  (10	  µM)	  and	   AvidinAlexaFluor®	   488	   conjugate	   (2.5	   µM)	   for	   10	   minutes,	   washed	   with	  fresh	  buffer	  and	  then	  incubated	  with	  compound	  76	  (10	  µM,	  10	  mins).	  After	  this	  period,	  the	  cells	  were	  washed	  with	  buffer	  and	  imaged,	  giving	  rise	  to	  less	  than	  5%	  signal	  intensity,	  compared	  to	  the	  original	  cell	  staining	  experiment	  (Figure	  4.4	  A).	  Reversing	   the	   order	   of	   incubation	   by	   first	   loading	   compound	   76	   (10	   µM,	   10	  mins)	  and	  then	  incubating	  a	  solution	  of	  [Gd.L12]	  (10	  µM)	  and	  AvidinAlexaFluor®	  488	   conjugate	   (2.5	   µM,	   10	   mins),	   led	   to	   less	   than	   7%	   of	   the	   original	   signal	  intensity	  being	  observed	  (Figure	  4.4	  B).	  In	  a	  final	  experiment,	  differentiated	  NSC-­‐34	   cells	  were	   incubated	  with	   compound	  76	   (10	  µM,	   10	  mins),	   washed	  with	   a	  glutamate-­‐rich	  (1	  mM)	  culture	  media	  and	  then	  incubated	  with	  [Gd.L12]	  (10	  µM)	  and	  AvidinAlexaFluor®	  488	  conjugate	   (2.5	  µM)	   for	  10	  minutes.	  This	   increased	  the	  	  observed	  signal	  intensity	  to	  18%	  (Figure	  4.4	  C).	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original	   intensity;	   (B)	   As	   image	   (A)	   but	   order	   of	   addition	   reversed,	   giving	   <7%	   of	  original	   intensity;	   (C)	  As	   image	  (B)	  but	  with	  a	  glutamate	  wash	  before	   loading	  [Gd.L12]	  (10	  µM)	  and	  AvidinAlexaFluor®	  488	  conjugate	   (2.5	  µM),	   showing	  18%	  of	   the	  original	  intensity.	  	  Evidently,	   these	   results	   suggest	   that	   compound	  76	   has	  a	  higher	  affinity	   for	   the	  NMDA	  receptor	  than	  [Gd.L12],	  but	  the	  restoration	  of	  some	  signal	  (18%)	  after	  the	  glutamate	  wash	  suggests	  that	  it	  is	  important	  not	  to	  have	  a	  probe	  which	  is	  bound	  too	   tightly,	   or	   glutamate	   will	   not	   compete	   for	   receptor	   binding.	   The	   ability	   of	  
[Gd.L12]	   to	  bind	   reversibly	   in	   the	  presence	  of	   glutamate	   suggests	   this	   complex	  possesses	  an	  affinity	  for	  the	  NMDA	  receptor	  with	  the	  correct	  order	  of	  magnitude.	  The	  complex	  [Gd.L12]	  is	  derived	  from	  the	  parent	  complex,	  [Gd.L9],	  but	  comprises	  a	  pendant	  biotin	  moiety	   in	  the	  trans-­‐position.	   In	  order	  to	  establish	   if	   the	  biotin	  moiety	  is	  influencing	  the	  localisation	  profile	  of	  [Gd.L12],	  and	  more	  importantly	  to	  determine	   if	   [Gd.L12]	   acts	   as	   a	   suitable	  model	   and	   binds	   at	   the	   same	   place	   as	  
[Gd.L9],	  a	  second	  series	  of	  competition	  experiments	  were	  performed.	  First,	  when	  differentiated	  NSC-­‐34	  cells	  were	  incubated	  with	  a	  solution	  of	  [Gd.L9]	  (10	  µM,	  10	  mins),	  washed	  with	  fresh	  buffer	  and	  then	  incubated	  simultaneously	  with	  a	  solution	  of	  [Gd.L12]	   (10	  µM)	  and	  AvidinAlexaFluor®	  488	  conjugate	  (2.5	  
µM)	   for	   10	   minutes,	   the	   signal	   intensity	   dropped	   to	   25%	   of	   the	   original	   cell	  staining	   experiment	   (Figure	   4.5	   A).	   A	   complete	   recovery	   of	   the	   fluorescence	  signal	   could	   be	   obtained	   when	   the	   cells	   were	   washed	   with	   a	   glutamate-­‐rich	  culture	  media	  (1	  mM)	  and	  then	  re-­‐incubated	  with	  a	  solution	  of	  [Gd.L12]	  (10	  µM)	  and	  AvidinAlexaFluor®	  488	  conjugate	  (2.5	  µM)	  for	  45	  minutes.	  In	  a	  similar	  experiment,	  when	  differentiated	  NSC-­‐34	  cells	  were	  first	  treated	  with	  a	   solution	  of	   [Gd.L12]	   (10	  µM)	  and	  AvidinAlexaFluor®	  488	  conjugate	   (2.5	  µM)	  for	  10	  minutes,	  washed	  with	  fresh	  buffer	  and	  then	  incubated	  with	  a	  solution	  of	  
[Gd.L9]	  (10	  µM,	  10	  mins),	  the	  signal	  intensity	  was	  62%,	  compared	  to	  the	  original	  cell	   staining	   experiment	   (Figure	   4.5	   B).	   These	   results	   suggest	   that	   [Gd.L9]	   and	  
[Gd.L12]	   have	   a	   comparable	   affinity	   for	   the	   NMDA	   receptor,	   and	   this	   was	  confirmed	   when	   a	   simultaneous	   incubation	   of	   all	   components	   ([Gd.L12],	  AvidinAlexaFluor®	   488	   and	   [Gd.L9])	   led	   to	   an	   intensity	   drop	   to	   56%	   of	   the	  original	   signal	   (Figure	   4.5	   C).	   The	   observation	   that	   approximately	   50%	   of	   the	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original	   signal	   remains	   is	   consistent	   with	   the	   hypothesis	   that	   [Gd.L9]	   and	  
[Gd.L12]	  bind	  at	  the	  same	  place	  on	  the	  NMDA	  receptor	  with	  similar	  affinities.	  	  	  
	  
Figure	  4.5.	  Live	  cell	  LSCM	  images	  of	  differentiated	  NSC-­‐34	  cells.	   (A)	  Cells	   loaded	  with	  
[Gd.L9]	  (10	  µM,	  10	  mins),	  washed	  with	  buffer	  and	  then	  incubated	  with	  [Gd.L12]	  (10	  µM)	  and	  AvidinAlexaFluor®	  488	  conjugate	  (2.5	  µM)	  for	  10	  minutes,	  showing	  25%	  of	  original	  intensity;	   (B)	   As	   image	   (A)	   but	   order	   of	   addition	   reversed,	   giving	   62%	   of	   original	  intensity;	   (C)	   Simultaneous	   loading	   of	   [Gd.L12]	   (10	   µM)	   and	   AvidinAlexaFluor®	   488	  conjugate	  (2.5	  µM)	  and	  [Gd.L9],	  showing	  56%	  of	  the	  original	  intensity.	  	  The	  complex	  [Gd.L12]	  also	  possesses	  the	  same	  NMDA	  receptor-­‐binding	  moiety	  as	  
[Gd.L7].	   However,	   the	   relatively	   short	   chain	   between	   the	   receptor-­‐binding	  moiety	   and	   sterically	   demanding	  Gd(III)	   chelate	   in	   [Gd.L7]	   brings	   the	   two	   into	  close	   proximity.	   In	   the	  MRI	   experiments,	   [Gd.L7]	   induced	   a	   negligible	   (104%)	  enhancement	  in	  R1,cell	  when	  incubated	  with	  differentiated	  NSC-­‐34	  cells.	  This	  was	  attributed	   to	   the	   close	   proximity	   of	   the	   Gd(III)	   chelate	   to	   the	  NMDA	   receptor-­‐binding	   moiety,	   inhibiting	   receptor-­‐binding.	   In	   order	   to	   verify	   whether	   this	  conclusion	   is	   reasonable,	   one	   final	   series	   of	   competition	   experiments	   was	  performed	  between	  [Gd.L12]	  and	  [Gd.L7].	  First,	  differentiated	  NSC-­‐34	  cells	  were	   incubated	  with	  a	  solution	  of	  [Gd.L7]	   (10	  
µM,	  10	  mins),	  washed	  with	  fresh	  buffer	  and	  then	  incubated	  simultaneously	  with	  a	   solution	  of	   [Gd.L12]	   (10	  µM)	  and	  AvidinAlexaFluor®	  488	  conjugate	   (2.5	  µM)	  for	   10	   minutes.	   This	   led	   to	   a	   signal	   intensity	   drop	   to	   7%	   of	   the	   original	   cell	  staining	   experiment	   (Figure	   4.6	   A).	   A	   complete	   recovery	   of	   the	   fluorescence	  signal	   could	   be	   obtained	   when	   the	   cells	   were	   washed	   with	   a	   glutamate-­‐rich	  culture	  media	  (1	  mM)	  and	  then	  re-­‐incubated	  with	  a	  solution	  of	  [Gd.L12]	  (10	  µM)	  and	  AvidinAlexaFluor®	  488	  conjugate	  (2.5	  µM)	  for	  45	  minutes.	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Reversing	   the	   order	   of	   addition,	   when	   differentiated	   NSC-­‐34	   cells	   were	   first	  treated	   with	   a	   solution	   of	   [Gd.L12]	   (10	   µM)	   and	   AvidinAlexaFluor®	   488	  conjugate	  (2.5	  µM)	  for	  10	  minutes,	  washed	  with	  fresh	  buffer	  and	  then	  incubated	  with	   a	   solution	   of	   [Gd.L7]	   (10	   µM,	   10	   mins),	   the	   signal	   intensity	   was	   88%	  compared	   to	   the	   original	   cell	   staining	   experiment	   (Figure	   4.6	   B).	   Finally,	   a	  simultaneous	   incubation	   of	   all	   components	   ([Gd.L12],	   AvidinAlexaFluor®	   488	  and	  [Gd.L7])	  with	  differentiated	  NSC-­‐34	  cells	  led	  to	  an	  intensity	  drop	  to	  43%	  of	  the	  original	  signal	  (Figure	  4.6	  C).	   	  
	  
Figure	  4.6.	  Live	  cell	  LSCM	  images	  of	  differentiated	  NSC-­‐34	  cells.	   (A)	  Cells	   loaded	  with	  
[Gd.L7]	  (10	  µM,	  10	  mins),	  washed	  with	  buffer	  and	  then	  incubated	  with	  [Gd.L12]	  (10	  µM)	  and	  AvidinAlexaFluor®	  488	  conjugate	  (2.5	  µM)	  for	  10	  minutes,	  showing	  7%	  of	  original	  intensity;	   (B)	   As	   image	   (A)	   but	   order	   of	   addition	   reversed,	   giving	   88%	   of	   original	  intensity;	   (C)	   Simultaneous	   loading	   of	   [Gd.L12]	   (10	   µM)	   and	   AvidinAlexaFluor®	   488	  conjugate	  (2.5	  µM)	  and	  [Gd.L7],	  showing	  43%	  of	  the	  original	  intensity.	  	  Surprisingly,	   these	   results	   suggest	   that	   [Gd.L7]	   has	   a	   comparable	   affinity,	   and	  binds	  at	   the	  same	  place	  on	  the	  NMDA	  receptor	  as	  [Gd.L12],	  despite	   there	  being	  no	  observed	  increase	  in	  R1,cell	  during	  the	  MR	  experiments.	  Without	  further	  more	  detailed	   studies,	   the	   explanation	   of	   this	   behaviour	   is	   difficult	   to	   rationalise.	  However,	   one	   potential	   explanation	   is	   that	   upon	   NMDA	   receptor-­‐binding,	   the	  short	  spacer	  limits	  the	  flexibility	  of	  the	  Gd(III)	  chelate,	  which	  becomes	  buried	  in	  the	  receptor-­‐binding	  cavity	  and	  shielded	  from	  the	  bulk	  solvent.	  This	  could	  inhibit	  the	   Gd(III)	   core	   from	   being	   sufficiently	   hydrated	   to	   allow	   for	   fast	   water	  exchange,	  which	  may	  limit	  the	  expected	  relaxivity	  gain	  upon	  τR	  modulation.	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4.4	   	  Conclusions	  and	  Summary	  	  The	   aim	   of	   this	   chapter	   was	   to	   gain	   further	   insight	   into	   the	   origins	   of	   the	  enhancements	   in	  R1,cell	  when	   [Gd.L2],	   [Gd.L4]	   and	   [Gd.L9]	  were	   incubated	  with	  differentiated	  NSC-­‐34	  cells.	  Due	  to	  the	  inherently	  low	  sensitivity	  and	  resolution	  associated	   with	   MRI,	   optical	   microscopy	   was	   employed	   in	   order	   to	   directly	  observe	  whether	  the	  complexes	  were	  bound	  to	  the	  cell	  surface	  NMDA	  receptor.	  Two	  new	  conjugates,	  [Gd.L11]	  and	  [Gd.L12],	  have	  been	  synthesised	  based	  on	  the	  most	   promising	   contrast	   agents,	   [Gd.L4]	   and	   [Gd.L9],	   but	   with	   a	   trans-­‐substituted	   biotin	   moiety	   to	   allow	   for	   complex	   visualisation	   by	   optical	  microscopy,	   following	   addition	   of	   an	   AvidinAlexaFluor®	   488	   conjugate.	   The	  complexes	   [Gd.L11-­12]	  were	   studied	  under	  a	  variety	  of	   experimental	   conditions	  using	  live-­‐cell	  laser	  scanning	  confocal	  microscopy	  (LSCM)	  on	  differentiated	  NSC-­‐34	  cells	  expressing	  functional	  NMDA	  receptors.	  Simultaneous	  loading	  of	  either	  [Gd.L11]	  or	  [Gd.L12]	  and	  AvidinAlexaFluor®	  488	  conjugate	  on	  differentiated	  NSC-­‐34	   cells	   gave	   a	   ‘pit-­‐like’	   localisation	   at	   the	   cell	  surface,	  with	  no	  intracellular	  staining	  observed.	  The	  complex	  [Gd.L12]	  appeared	  38%	  brighter,	   indicating	   this	   complex	  possesses	  a	  higher	  affinity	   than	   [Gd.L11]	  for	   the	  NMDA	  receptor.	  The	   lower	  R1,cell	   enhancement	   for	   [Gd.L9]	   compared	   to	  
[Gd.L4]	  must	   therefore	  be	   a	   result	   of	   the	   increased	   length	  between	   the	  Gd(III)	  chelate	  and	   the	  NMDA	  receptor-­‐binding	  moiety,	   leading	   to	  a	  drop	   in	   rotational	  coupling.	  The	  ability	  of	  [Gd.L11]	  and	  [Gd.L12]	  to	  bind	  only	  to	  cells	  which	  express	  functional	  NMDA	   receptors	   was	   demonstrated	   through	   a	   repeat	   of	   the	   simultaneous	  loading	  experiment	  with	  AvidinAlexaFluor®	  488	  conjugate,	  on	  NIH	  3T3	  mouse	  skin	  fibroblast	  cells,	  whereby	  no	  fluorescence	  signal	  was	  observed.	  This	  result	  is	  promising,	   indicating	   that	   [Gd.L4]	   and	   [Gd.L9]	   should	   only	   give	   rise	   to	   an	  enhancement	   in	   R1,cell	   upon	   binding	   to	   cells	   which	   possess	   NMDA	   receptor	  density.	  It	   was	   also	   demonstrated	   that	   [Gd.L11]	   and	   [Gd.L12]	   are	   displaced	   from	   their	  binding	  site	  after	  a	  simulated	  glutamate	  burst,	  suggesting	  they	  bind	  at	  the	  NMDA	  receptor,	   at	   the	   same	  site	   as	   glutamate	  but	  with	  a	   lower	  affinity.	  However,	   the	  affinity	   is	   sufficient	   such	   that	   [Gd.L11]	   and	   [Gd.L12]	   were	   able	   to	   displace	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glutamate	   from	   the	   binding	   site,	   leading	   to	   a	   restoration	   of	   the	   initial	   signal	  intensity	  after	  45	  minutes.	  Finally,	  several	  competition	  experiments	  showed	  that	  the	  modifications	  made	  in	  the	  design	  of	  [Gd.L12]	  have	  not	  perturbed	   its	   localisation	  behaviour	  away	   from	  the	  parent	  complex,	  [Gd.L9].	  Both	  complexes	  were	  shown	  to	  localise	  in	  the	  same	  place,	  with	  a	  comparable	  affinity,	  demonstrating	  that	  [Gd.L12]	  acts	  as	  a	  suitable	  optical	  imaging	  derivative	  of	  the	  MR	  contrast	  agent,	  [Gd.L9].	  As	  detailed	  at	   the	  end	  of	  chapter	  1,	   one	  of	   the	  main	  goals	  of	   this	   thesis	  was	   to	  design	  and	  synthesise	  a	  series	  of	  NMDA	  receptor-­‐targeted	  MRI	  contrast	  agents.	  Of	   the	   ten	   complexes	   made,	   three,	   [Gd.L2],	   [Gd.L4]	   and	   [Gd.L9],	   were	   able	   to	  induce	   large	   measureable	   enhancements	   in	   cellular	   relaxation	   rates	   when	  incubated	   with	   a	   neuronal	   cell	   line	   model.	   Derivatives	   of	   [Gd.L4]	   and	   [Gd.L9]	  allowed	   further	   studies	   of	   these	   complexes	   using	   optical	   microscopy.	   These	  complexes,	  [Gd.L11]	  and	  [Gd.L12],	  reside	  on	  the	  cell	  surface	  and	  bind	  specifically	  to	  cells	  which	  possess	  NMDA	  receptor	  density.	  They	  also	  bind	  reversibly	  at	  the	  NMDA	   receptor	   after	   a	   simulated	   glutamate	   burst,	   and	   can	   displace	   glutamate	  competitively	  upon	  restoration	  of	  equilibrium.	  Taken	  together,	  the	  results	  gained	  throughout	  chapters	  2,	  3	  and	  4	   suggest	   that	   the	  gadolinium	  complexes	  of	  L2,	  L4	  and	   L9	   are	   promising	   MR	   contrast	   agents	   for	   reporting	   or	   monitoring	   NMDA	  receptor	  density,	  and	  possess	  the	  ability	  to	  report	  on	  synaptic	  glutamate	  activity.	  
Chapter	  5	  follows	  on	  from	  the	  promising	  optical	  microscopy	  work	  detailed	  in	  this	  chapter,	   and	   focuses	   on	   replacing	   the	   biotin-­‐avidin	   conjugate	   approach	  with	   a	  single	  compound.	  A	  bright	  Eu(III)	  complex	  for	  NMDA	  receptor	  visualisation	  has	  been	  synthesised	  which	  incorporates	  the	  receptor-­‐binding	  moiety	  of	  [Gd.L9],	  as	  this	  has	  been	  shown	  to	  be	  the	  motif	  with	  the	  highest	  affinity.	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5.	  A	  Bright	  Europium	  Complex	  for	  NMDA	  
Receptor	  Visualisation	  
	  
5.1	   	  Introduction	  	  The	   previous	   chapter	   discussed	   the	   synthesis	   and	   direct	   visualisation	   of	   two	  NMDA	  receptor-­‐targeted	  optical	   imaging	  probes,	  which	  were	  able	   to	  mimic	   the	  behaviour	   and	   elucidate	   the	   mechanism	   of	   the	   R1,cell	   enhancements	   observed	  with	   the	   most	   promising	   MRI	   contrast	   agents.	   The	   complexes	   [Gd.L11-­12]	   are	  structurally	   related	   to	   the	  parent	  complexes,	  [Gd.L4]	   and	  [Gd.L9],	  with	  a	   trans-­‐substituted	  biotin	  moiety,	  which	  allowed	  complex	  visualisation	  on	  differentiated	  NSC-­‐34	  cells	  upon	  addition	  of	  the	  fluorescent	  conjugate,	  AvidinAlexaFluor®	  488.	  Although	   this	   approach	   worked	   well	   and	   allowed	   deduction	   of	   complex	  localisation,	   reversibility	   and	   cellular	   specificity	   of	   binding,	   it	  was	   desirable	   to	  devise	  a	  single	  component	  optical	  imaging	  probe.	  	  The	   potential	   limitations	   of	   appending	   a	   fluorescent	   motif	   to	   a	   complex	   were	  briefly	   discussed	   in	   chapter	   4.	   Instead,	   a	   new	   approach	   was	   investigated	  whereby	   conjugation	   of	   the	   most	   potent	   NMDA	   receptor-­‐binding	   moiety	   to	   a	  hydrophilic	  Eu(III)	  complex	  would	  generate	  a	  single	  component	  NMDA	  receptor-­‐targeted	  optical	  imaging	  probe.	  Not	  only	  could	  this	  be	  useful	  for	  NMDA	  receptor	  visualisation,	   but	   also	   it	   could	   be	   highly	   advantageous	   in	   numerous	   biological	  assays,	  through	  replacement	  of	  standard	  radiolabelled	  ligands.	  	  
5.1.1	  A	  Brief	  Introduction	  to	  Lanthanide	  Photochemistry	  	  Luminescence	  from	  the	  lanthanide	  series	  involves	  f-­‐f	  transitions	  and	  so,	  with	  the	  exception	   of	   lanthanum	   and	   lutetium	   which	   do	   not	   possess	   any	   unpaired	  electrons,	   all	   lanthanide(III)	   ions	   are	   luminescent.	   However,	   f-­‐f	   transitions	   are	  very	   weak	   as	   they	   are	   formally	   Laporte	   forbidden.	   This	   cannot	   be	   overcome	  through	  ligand	  field	  interactions	  because	  of	  the	  high	  degree	  of	  shielding	  of	  the	  f-­‐orbitals	  by	  the	  filled	  5p	  and	  5s/6s	  sub-­‐shells.	  	  Despite	  this,	  a	  major	  advantage	  of	  the	   contracted	   nature	   of	   the	   f-­‐orbitals	   is	   that	   the	   excited	   state	   lifetime	   is	  
A	  Bright	  Europium	  Complex	  for	  NMDA	   	   Chapter	  5	  
Receptor	  Visualisation	  
	   114	  
prolonged	   (ms	   in	   the	   case	   of	   Eu(III)),	   allowing	   time-­‐gated	   studies	   which	   can	  distinguish	   lanthanide	   emission	   from	   the	   short-­‐lived	   background	   biological	  fluorescence.	   This	   is	   highly	   advantageous	   in	   the	   design	   of	   an	   optical	   probe	   for	  NMDA	   receptor	   visualisation.	   Unfortunately,	   the	   forbidden	   f-­‐f	   transitions	   give	  rise	   to	   low	  molar	   extinction	   coefficients	   for	   Ln(III)	   ions,	   leading	   to	   inefficient	  population	   of	   the	   lanthanide	   excited	   states	   following	   irradiation.	   In	   order	   to	  circumvent	   this,	   sensitised	  emission	   (also	  known	  as	   the	  antenna	  effect)	   can	  be	  employed,	  which	  utilises	   a	  proximal	   sensitiser	   group	   to	   absorb	   light	   efficiently	  and	   then	   transfer	   the	   energy	   to	   the	   lanthanide	   excited	   state.1	   Initially,	   the	  sensitiser	  absorbs	  a	  photon	  and	   is	  excited	  to	  a	  vibrationally	  excited	  state.	  Non-­‐radiative	   decay	   quickly	   relaxes	   this	   to	   the	   lowest	   lying	   excited	   state,	   S1.	   The	  sensitiser	  then	  undergoes	  intersystem	  crossing	  to	  the	  longer-­‐lived	  triplet	  excited	  state,	  T1,	  which	  can	  transfer	  energy	  to	  one	  of	  the	  excited	  states	  of	  the	  Ln(III)	  ion.	  Non-­‐radiative	   decay	   brings	   this	   to	   the	   lowest	   emissive	  manifold	   of	   the	   Ln(III)	  excited	  state,	  before	  emission	  of	  photons	  occurs	  via	  transitions	  to	  the	  7F	  ground	  state	  (Figure	  5).2,	  3	  
	  	  
Figure	  5.	  A	  simplified	  Jablonski	  diagram	  demonstrating	  sensitised	  Ln(III)	  emission.	  	  The	  Eu(III)	  ion	  is	  one	  of	  the	  most	  studied	  of	  the	  lanthanide	  series	  with	  respect	  to	  luminescence.	  It	  possesses	  a	  7F	  ground	  state,	  which	  is	  split	  into	  seven	  manifolds.	  The	   non-­‐degenerate	   electronically	   excited	   state,5D0,	   resides	   at	   approximately	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17,200	   cm-­‐1	   and	   radiative	   decay	   from	   5D0	  →	   7Fn	   (n	   =	   0-­‐4)	   results	   in	   emission	  spectra	   with	   several	   transitions,	   denoted	   by	   their	   ΔJ	   value	   (Figure	   5.1).4	  Generally,	  the	  contracted	  nature	  of	  the	  f-­‐orbitals	  means	  that	  the	  emission	  spectra	  of	   Eu(III)	   complexes	   are	   sharp	   and	   relativley	   independent	   of	   coordination	  environment.	   However,	   fine-­‐structure	   can	   be	   observed	   within	   some	   emission	  bands	  and	   is	  known	   to	  be	  dependent	  on	   local	   symmetry	  and	   the	  nature	  of	   the	  coordinating	  group	  to	  the	  Eu(III)	  centre.	  	  
	  
Figure	  5.1.	  Typical	  emission	  spectrum	  and	  partial	  energy	  level	  diagram	  for	  Eu(III).3	  	  
5.1.2	  Design	  of	  a	  NMDA	  Receptor-­Targeted	  Eu(III)	  Complex	  	  Recently,	  the	  Durham	  group	  has	  designed	  a	  series	  of	  Eu(III)	  complexes	  to	  act	  as	  alternative	  organelle	  stains	  for	  cellular	  imaging.5,	  6	  These	  C3-­‐symmetrical	  Eu(III)	  complexes	   were	   all	   based	   on	   the	   9-­‐N-­‐3-­‐tris-­‐arylalkynylpyridyl	   ligand,	   with	  conjugation	   of	   a	   targeting	   vector	   to	   the	   periphery	   of	   one	   of	   the	   chromophore	  arms	   allowing	   selective	   localisation	   of	   the	   complexes	   to	   specific	   sub-­‐cellular	  compartments.	   These	   complexes	   exhibited	   large	   molar	   extinction	   coefficients	  (55-­‐60,000	  M-­‐1	  cm-­‐1	  at	  330-­‐350	  nm)	  and	  quantum	  yields	  in	  the	  region	  of	  20-­‐38%	  in	   H2O.	   Drawing	   inspiration	   from	   this,	   the	   NMDA	   receptor-­‐targeted	   complex,	  
[Eu.L13],	  was	  designed	  (Scheme	  5).	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5.2	   	  Synthetic	  Details	  
5.2.1	  Macrocycle	  Synthesis	  	  The	   synthesis	   of	   the	   macrocycle8,	   9	   started	   from	   the	   commercially	   available	  hydrochloride	   salt	   of	   (2S)-­‐lysine	   ethyl	   ester	   (Scheme	   5.1).	   The	   ethyl	   ester	  was	  reacted	   with	   neat	   ethylenediamine	   at	   120	   °C	   for	   three	   hours.	   After	   this	   time,	  purification	   by	   vacuum	  distillation	   afforded	   the	   amide,	  77,	   as	   a	   yellow	  oil	   in	   a	  good	   yield.	   The	   degree	   of	   racemisation	   during	   this	   step	   has	   previously	   been	  analysed	  using	  1H	  NMR	  spectroscopy.10	  Addition	  of	  the	  chiral	  solvating	  agent,	  R-­‐
O-­‐acetyl	  mandelic	  acid	  (1.2	  equivalents),	   to	  a	  sample	  of	   the	  amide,	  77,	   in	  CDCl3	  showed	  the	  presence	  of	  only	  one	  amide	  NH	  resonance	  around	  8.52	  ppm	  (Figure	  
5.2).	   This	   was	   consistent	   with	   the	   presence	   of	   only	   one	   enantiomer.	  Racemisation	  would	  have	   led	   to	   the	   formation	  of	   two	  diasteroisomeric	   salts	   in	  which	  the	  amide	  NH	  protons	  are	  (up	  to)	  0.25	  ppm	  non-­‐equivalent.10	  
	  	  







A	  Bright	  Europium	  Complex	  for	  NMDA	   	   Chapter	  5	  
Receptor	  Visualisation	  
	   118	  
Reduction	  of	  the	  amide,	  77,	  was	  achieved	  by	  stirring	  at	  70	  °C	  with	  BH3-­‐THF	  for	  24	  hours.	  Completion	  of	  the	  reaction	  was	  verified	  using	  IR	  spectroscopy,	  with	  no	  carbonyl	   stretch	   observed	   between	   1700-­‐1900	   cm-­‐1.	   After	   stirring	   the	   amino-­‐borane	   complex	   in	   refluxing	   HCl	   overnight,	   compound	   78	   was	   isolated	   as	   the	  tetrahydrochloride	  salt.	  The	  next	  step	  involved	  selective	  protection	  of	  the	  distal	  amine.	  This	  was	  undertaken	   through	  reaction	  of	   the	  diethylenetriamine	  unit	  of	  
78	  with	  basic	  copper	  carbonate	  at	  50	  °C.	  The	  intense	  blue	  solution	  confirmed	  the	  presence	  of	   a	   copper(II)	   complex.	  The	   solution	  was	   cooled	   to	  0	   °C	  and	   treated	  with	  benzoyl	   chloride,	  maintaining	   the	  pH	  between	  8	   and	  9	  by	   the	   addition	  of	  KOH.	  This	  procedure	  permitted	   selective	   acylation	  of	   the	   remote	   amino	  group.	  Treatment	  of	   the	  copper	  complex	  with	  H2S	  allowed	   isolation	  of	   the	  benzamide,	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Cyclisation	   to	   the	  9-­‐membered	  macrocycle	  was	  achieved	  through	  condensation	  of	  80	   with	   ethylene	   glycol	   distosylate	   in	   the	   presence	   of	   Cs2CO3	   in	   anhydrous	  DMF	   at	   65	   °C.	   Purification	   of	   the	   crude	   product	   by	   column	   chromatography	  afforded	   81,	   which	   was	   subject	   to	   global	   deprotection.	   Dissolving	   metal	  reduction	  conditions,	  which	  generate	  solvated	  electrons	  through	  the	  reaction	  of	  lithium	   in	   liquid	  ammonia,	   led	   to	  efficient	  detosylation.	  However,	   this	  was	  also	  accompanied	  by	  partial	  reduction	  of	   the	  aromatic	  ring	   in	   the	  benzoyl	  group,	  as	  observed	  by	  ESI-­‐MS	  and	   1H	  NMR	  spectroscopy,	   and	   so	   the	   crude	   triamine	  was	  stirred	   in	   refluxing	   HCl	   to	   complete	   hydrolysis	   and	   furnish	   82	   as	   the	  tetrahydrochloride	   salt.	   Finally,	  differentiation	  of	   the	  macrocyclic	   triamine	  was	  achieved	  by	  selective	  protection	  of	   the	  remote	  amino	  group.	  Again,	  copper	  was	  employed	  to	  complex	  the	  triazacyclononane	  core,	  allowing	  Boc-­‐protection	  of	  the	  free	   amine	   to	   be	   carried	   out	   using	   an	   excess	   of	   di-­‐tert-­‐butyl-­‐dicarbonate	   in	   a	  water-­‐dioxane	   mix.	   Decomplexation	   of	   the	   copper	   using	   H2S,	   followed	   by	  adjustment	   of	   the	   pH	   and	   exhaustive	   extraction	   into	   DCM	   and	   chloroform	  afforded	  the	  free	  triamine,	  83,	  in	  a	  37%	  yield.	  	  
5.2.2	  Chromophore	  Synthesis	  	  A	   simple	   retrosynthetic	   analysis	   shows	   that	   the	  extended	  chromophore	   can	  be	  synthesised	  from	  a	  Sonogashira	  cross	  coupling	  between	  the	  para-­‐bromopyridine	  platform	  and	  the	  para-­‐substituted	  alkyne	  (Scheme	  5.2).	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Synthesis	  of	  the	  alkyne	  moiety	  resulted	  from	  deprotection	  of	  the	  trimethylsilane-­‐protected	  alkynei	  using	  a	  slight	  excess	  of	   triethylammonium	  dihydrofluoride	   in	  anhydrous	   THF	   at	   35	   °C	   (Scheme	   5.3).6	   After	   purification	   by	   column	  chromatography,	  the	  alkyne,	  84,	  was	  isolated	  as	  a	  colourless	  oil	  in	  a	  72%	  yield.	  A	  palladium-­‐catalysed	  Sonogashira	   cross-­‐coupling	   reaction6	  with	   the	  para-­‐bromo	  pyridine	  was	  undertaken	  next.ii	  A	  solution	  of	  the	  pyridine	  in	  anhydrous	  THF	  was	  degassed	  using	  a	  freeze-­‐pump-­‐thaw	  cycle,	  before	  the	  addition	  of	  84,	  Pd(dppf)Cl2	  and	   NEt3.	   The	   solution	   was	   further	   degassed,	   CuI	   added	   and	   the	   resultant	  mixture	  heated	  to	  65	  °C	  under	  argon	  for	  18	  hours.	  After	  subsequent	  work-­‐up	  and	  purification	   by	   column	   chromatography,	   the	   extended	   chromophore,	   85,	   was	  isolated	   in	   55%	   yield.	   Finally,	   the	   hydroxyl	   group	   was	   activated	   towards	  nucleophilic	   substitution,	   through	   generation	   of	   the	   mesylate,	   86,	   by	   reaction	  with	  methanesulfonyl	  chloride	  under	  basic	  conditions	  in	  anhydrous	  THF.6	  	  
	  	  
Scheme	  5.3	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substituted	   compound,	   87,	   some	   mono-­‐	   and	   di-­‐substituted	   products	   were	  observed	  in	  the	  crude	  mass	  spectrum,	  and	  account	  for	  the	  moderate	  (30%)	  yield	  of	   87	   after	   column	   chromatography.	   The	   hydrolysis	   of	   the	   methyl	   and	  phosphinate	  ethyl	  esters	  was	  carried	  out	  using	  KOH	   in	  a	  mixture	  of	  MeOD	  and	  D2O,	   which	   allowed	   the	   reaction	   to	   be	   monitored	   by	   1H	   and	   31P	   NMR	  spectroscopy.	   Complete	   hydrolysis	   of	   the	   phosphinate	   ethyl	   esters	   was	  confirmed	  by	   a	   characteristic	   shift	   in	   the	   31P	  NMR	   spectrum	   from	  39.2	   to	  26.4	  ppm.	  Once	  hydrolysis	  was	  complete,	  the	  pD	  of	  the	  solution	  was	  adjusted	  to	  7	  and	  Eu(OAc)3.H2O	  was	  added.	  The	  reaction	  mixture	  was	  heated	  to	  60	  °C	  overnight,	  at	  which	   point	   the	   solvent	   was	   removed	   and	   the	   crude	   product	   purified	   by	   RP-­‐HPLC	   (mobile	   phase	   comprising	   MeOH/H2O	   +	   0.1%	   formic	   acid),	   to	   give	   the	  Eu(III)	  complex,	  88,	  as	  a	  white	  solid.	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The	  sulfonate	  groups	  were	  introduced	  around	  the	  periphery	  of	  the	  complex	  via	  amide	   bond	   formation	   between	   the	   three	   carboxylates	   of	   88	   and	   3-­‐amino-­‐1-­‐propanesulfonic	  acid.11	  Rapid	  tris-­‐sulfonation	  was	  achieved	  using	  approximately	  two	  equivalents	  of	  amine	  per	  carboxyate,	  in	  the	  presence	  of	  HATU	  in	  DMSO.	  The	  crude	   reaction	  mixture	  was	  purified	  by	  RP-­‐HPLC	   (mobile	  phase	   comprising	  25	  mM	   triethylammonium	   acetate	   buffer	   and	   acetonitrile),	   to	   give	   the	   mono-­‐Boc	  triethylammonium	  salt	  of	  the	  tris-­‐sulfonate	  Eu(III)-­‐complex,	  89,	  as	  a	  white	  solid	  (Scheme	  5.5).	  Concurrent	  synthesis	  of	  the	  NMDA	  receptor-­‐binding	  moiety	  was	  undertaken	  by	  reaction	  of	  36	  with	  succinic	  anhydride,	  in	  the	  presence	  of	  diisopropylethylamine	  in	  anhydrous	  DMF	  (Scheme	  5.5).	  	  Complete	  conversion	  was	  observed	  by	  analysis	  of	   the	   crude	   mass	   spectrum	   after	   one	   hour,	   at	   which	   point	   an	   excess	   of	  bromotrimethylsilane	   was	   added.	   The	   reaction	   was	   heated	   to	   60	   °C	   and	   the	  hydrolysis	   monitored	   by	   ESI-­‐MS.	   After	   three	   hours,	   complete	   hydrolysis	   was	  achieved	  and	  the	  crude	  product	  purified	  by	  preparative	  RP-­‐HPLC,	  to	  give	  the	  free	  phosphonic	  acid,	  90.	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Finally,	  the	  complex,	  [Eu.L13],	  was	  synthesised	  by	  conjugation	  of	  90	  to	  the	  Eu(III)	  complex,	  89.	   Initially,	   the	  Boc-­‐protecting	  group	  of	   the	  remote	  amine	  moiety	  on	  
89	  was	  hydrolysed	  using	  dilute	  TFA	  in	  anhydrous	  DCM	  at	  5	  °C.	  The	  solution	  was	  stirred	  for	  twenty	  minutes	  at	  this	  temperature	  before	  the	  solvents	  were	  removed	  under	   reduced	   pressure	   on	   a	   high	   vacuum	   line.	   Excess	   TFA	   was	   removed	   by	  repeated	  addition	  and	  removal	  of	  DCM.	  This	  yielded	   the	  TFA	  salt	  of	   the	  Eu(III)	  amino	  complex,	  which	  was	   taken	  up	   into	  DMSO	  and	  added	   to	  a	   solution	  of	  90,	  HATU	  and	  diisopropylethylamine	  in	  anhydrous	  DMF.	  The	  solution	  was	  stirred	  at	  room	  temperature	  overnight	  and	  then	  diluted	  with	  H2O.	  The	  crude	  product	  was	  subject	  to	  purification	  by	  preparative	  RP-­‐HPLC	  (mobile	  phase	  comprising	  25	  mM	  triethylammonium	   acetate	   buffer	   and	   acetonitrile),	   to	   give	   [Eu.L13]	   as	   a	  white	  solid.	  Confirmation	  of	  the	  presence	  of	  [Eu.L13]	  was	  demonstrated	  by	  comparison	  of	   the	   theoretical	   and	   experimental	   high-­‐resolution	  mass	   distributions	   (Figure	  
5.3).	  
	  
Figure	   5.3.	   Observed	   (left)	   and	   calculated	   (right)	   high-­‐resolution	   mass	   spectra	   of	  
[Eu.L13];	  TOF	  negative.	  	  
5.3	  	   Photophysical	  Characterisation	  	  The	   photophysical	   characterisation	   of	   [Eu.L13]	   was	   carried	   out	   in	   water.	   The	  absorption	  spectrum	  of	  [Eu.L13]	  shows	  a	  broad	  absorption	  band	  centred	  at	  328	  nm,	  with	  a	  slight	  shoulder	  at	  338	  nm	  (Figure	  5.4).	  This	  is	  characteristic	  of	  an	  ICT	  transition,	  with	  electrons	   flowing	   from	  the	  aryl	  oxygen	   to	   the	  pyridyl	  nitrogen.	  The	  extinction	  coefficient	  of	  [Eu.L13]	  at	  328	  nm	  was	  estimated	  to	  be	  58,000	  M-­‐1	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cm-­‐1,	   which	   is	   similar	   to	   reported	   systems	   that	   lack	   the	   receptor-­‐binding	  moiety.11	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Figure	  5.5.	  Emission	  Spectrum	  of	  [Eu.L13]	  (H2O,	  λex	  =	  328	  nm,	  295	  K).	  
	  
5.4	   	  Cellular	  Localisation	  Studies	  	  In	   order	   to	   study	   the	   localisation	   profile	   of	   [Eu.L13],	   live-­‐cell	   laser	   scanning	  confocal	   microscopy	   imaging	   studies	   were	   carried	   out	   on	   a	   Leica	   SP5	   II	  microscope	   by	   Dr	   Robert	   Pal,	   Durham	   University.	   In	   the	   same	   manner	   as	  described	   in	   chapter	   4,	   differentiated	  NSC-­‐34	   cells	   expressing	  NMDA	   receptors	  were	  grown	  on	  specially	  designed	  microscope	  slides,	  comprising	  a	  100	  µL	  flow-­‐through	  channel.	  Initially,	   differentiated	   NSC-­‐34	   cells	   were	   incubated	   with	   a	   10	   µM	   solution	   of	  





















A	  Bright	  Europium	  Complex	  for	  NMDA	   	   Chapter	  5	  
Receptor	  Visualisation	  
	   127	  
	  
	  
Figure	  5.6.	  LSCM	  images	  of	  differentiated	  NSC-­‐34	  cells	  upon	  incubation	  of	  [Eu.L13]	  (10	  
µM,	   45	   mins),	   showing	   a	   small	   amount	   of	   intracellular	   localisation.	   (Left	   to	   right)	  Transmission	   image,	   visualisation	   of	   europium	   emission	   and	   merge	   image	   (λex/λem	   =	  355	  nm/	  605-­‐720	  nm).	  	  In	   order	   to	   gain	   insight	   into	   whether	   the	   small	   amount	   of	   internalisation	   of	  
[Eu.L13]	   in	   differentiated	   NSC-­‐34	   cells	   was	   NMDA	   receptor-­‐mediated,	   three	  control	   experiments	   were	   undertaken.	   Firstly,	   a	   competition	   experiment	   was	  designed	  using	  Kinney’s	  NMDA	  receptor	  antagonist,	  76.	   It	  was	  envisaged	  that	  if	  receptor-­‐mediated	   uptake	   was	   the	   primary	   internalisation	   mechanism,	   then	  blocking	   the	   NMDA	   receptor	  with	   compound	  76	   before	   incubation	   of	   [Eu.L13]	  would	   lead	   to	   a	   decrease	   in	   signal	   intensity	   from	   within	   the	   cells.	   Therefore,	  differentiated	  NSC-­‐34	  cells	  were	  treated	  with	  a	  solution	  of	  compound	  76	  (10	  µM,	  10	  mins),	  washed	  three	  times,	  and	  then	  incubated	  with	  a	  solution	  of	  [Eu.L13]	  (10	  
µM,	  45	  mins).	  After	  washing,	  the	  cells	  were	  imaged	  but	  there	  appeared	  to	  be	  no	  change	  in	  signal	  intensity	  from	  within	  the	  cells	  (Figure	  5.7),	  as	  compared	  to	  the	  original	  cell	  staining	  experiment,	  suggesting	  that	  any	  cell	  uptake	  is	  not	  receptor-­‐mediated.	  	  
A	  Bright	  Europium	  Complex	  for	  NMDA	   	   Chapter	  5	  
Receptor	  Visualisation	  
	   128	  
	  
Figure	   5.7.	   LSCM	   images	   of	   differentiated	   NSC-­‐34	   cells	   upon	   incubation	   of	   Kinney’s	  antagonist,	   76	   (10	   µM,	   10	   mins),	   followed	   by	   washing	   the	   cells	   and	   then	   incubating	  	  	  
[Eu.L13]	   (10	   µM,	   45	   mins).	   There	   is	   no	   change	   in	   intracellular	   signal	   intensity	   as	  compared	   to	   figure	   5.6.	   (Left	   to	   right)	   Transmission	   image,	   visualisation	   of	   europium	  emission	  and	  merge	  image	  (λex/λem	  =	  355	  nm/	  605-­‐720	  nm).	  	  Secondly,	   NIH-­‐3T3	   skin	   fibroblast	   cells,	   which	   do	   not	   express	   any	   NMDA	  receptors,	  were	  incubated	  with	  a	  10	  µM	  solution	  of	  [Eu.L13]	   for	  45	  minutes.	  As	  expected,	  no	  cell	  surface	   localisation	  was	  observed,	  but	  there	  was	  a	  discernible	  intracellular	   distribution	   of	   [Eu.L13],	   further	   strengthening	   the	   argument	   of	   a	  competitive	  non-­‐receptor-­‐mediated	  uptake	  mechanism	  (Figure	  5.8).	  	  
	  
Figure	  5.8.	  LSCM	  images	  of	  NIH-­‐3T3	  cells	  upon	  incubation	  of	  [Eu.L13]	  (10	  µM,	  45	  mins).	  (Left	  to	  right)	  Transmission	  image,	  visualisation	  of	  europium	  emission	  and	  merge	  image	  (λex/λem	  =	  355	  nm/	  605-­‐720	  nm).	   	  Finally,	   a	   structurally	   related	   europium	   complex	   lacking	   the	   NMDA	   receptor-­‐binding	  moiety	  was	  synthesised	  (Scheme	  5.6)	  and	  incubated	  with	  differentiated	  NSC-­‐34	  cells.	  Incubation	  of	  [Eu.L	  14]	  (10	  µM,	  45	  mins)	  with	  differentiated	  NSC-­‐34	  cells	  again	  showed	  no	  cell	  surface	  localisation,	  as	  expected.	  However,	  there	  was	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an	   increased	   intracellular	   localisation	  of	   this	   complex	  as	   compared	   to	   [Eu.L13],	  with	   68%	   more	   signal	   observed	   from	   within	   the	   cells	   (Figure	   5.9).	   Taken	  together,	  these	  results	  suggest	  that	  the	  overall	  structure	  of	  the	  Eu(III)	  complex,	  and	   not	   the	   relatively	   small	   NMDA	   receptor	   binding	   moiety,	   is	   dictating	   the	  localisation	  profile	  of	  [Eu.L13].	   	  
Scheme	  5.6.	  	  
	  
Figure	  5.9.	  LSCM	  images	  of	  differentiated	  NSC-­‐34	  cells	  upon	  incubation	  of	  [Eu.L14]	  (10	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quenched,	   or	   can	   be	   ascribed	   to	   poor	   complex	   accumulation.	   To	   investigate	  whether	  the	  europium	  emission	  was	  being	  quenched,	  the	  emission	  spectrum	  of	  
[Eu.L13]	  was	  measured	  in	  cell	  culture	  media	  and	  in	  an	  aqueous	  solution	  of	  HSA,	  and	  compared	  to	  that	  measured	  in	  water	  (Figure	  5.10).	  The	   [Eu.L13]	   emission	   spectra	  were	  measured	   using	   a	  modified	   Zeiss	   Axiovert	  200M	   inverted	   microscope.13	   Using	   the	   same	   concentrations	   of	   [Eu.L13],	   it	   is	  apparent	  that	  the	  relative	  intensity	  of	  the	  europium	  emission	  is	  quenched	  in	  cell	  culture	  media	   to	  approximately	  30%	  of	   the	   intensity	  when	  measured	   in	  water.	  Human	  serum	  albumin	  is	  a	  major	  constituent	  of	  the	  cell	  culture	  media	  and	  it	  was	  thought	  that	  non-­‐specific	  binding	  of	  [Eu.L13]	  to	  HSA	  could	  be	  the	  reason	  for	  the	  quenched	   emission	   of	   the	   complex	   in	   the	   cell	   culture	   media.	   However,	   the	  relative	   intensity	   of	   [Eu.L13]	   in	   an	   aqueous	   HSA	   solution	   remained	   at	  approximately	  90%,	  suggesting	  a	  different	  component	  of	  the	  cell	  culture	  medium	  is	  responsible	  for	  quenching	  the	  europium	  emission.	  	  
	  
Figure	  5.10.	  Emission	  spectra	  of	  [Eu.L13]	  (10	  µM)	  in	  water,	   in	  the	  presence	  of	  0.4	  mM	  HSA	  and	  in	  cell	  culture	  media,	  showing	  a	  significant	  drop	  in	  emission	  intensity	  in	  the	  cell	  culture	  medium.	  	  In	  order	  to	  confirm	  that	  the	  NMDA	  receptor-­‐binding	  moiety	  of	  [Eu.L13]	  was	  not	  influencing	   the	   emission	   properties,	   the	   complex,	   [Eu.L14],	   was	   subject	   to	   the	  same	  comparative	  analysis.	  Again,	  the	  emission	  intensity	  dropped	  significantly	  in	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cell	   culture	  media,	   as	   compared	   to	   in	  water,	  with	  HSA	  binding	  again	  not	  being	  the	  reason	  for	  the	  decreased	  emission	  (Figure	  5.11).	  
	  
Figure	  5.11.	  Emission	  spectra	  of	  [Eu.L14]	  (10	  µM)	  in	  water,	   in	  the	  presence	  of	  0.4	  mM	  HSA	  and	  in	  cell	  culture	  media,	  showing	  a	  significant	  drop	  in	  emission	  intensity	  the	  in	  cell	  culture	  medium.	  	  
5.5	   	  Conclusions	  	  The	   aim	   of	   this	   chapter	  was	   to	   build	   on	   the	  work	   discussed	   in	   chapter	   4,	   and	  develop	  a	  single	  component	  probe	  for	  NMDA	  receptor	  visualisation.	  Luminescent	  lanthanide	   complexes	   offer	   a	   superior	   alternative	   to	   standard	   organic	  fluorophores	  and	   so	   the	  main	  goal	  was	   to	  develop	  an	  NMDA	  receptor-­‐targeted	  Eu(III)	  complex.	  The	  new	  complex,	  [Eu.L13],	  is	  derived	  from	  a	  series	  of	  previously	  studied	  Eu(III)	  complexes	   with	   three	   arylalkynylpyridyl	   chromophores.	   These	   complexes	   are	  inherently	   bright	   and	   have	   been	   shown	   to	   be	   useful	   as	   alternative	   organelle	  stains,	   or	   to	   detect	   ligand	   binding	   using	   time-­‐resolved	   FRET.6,	   11	   The	   Eu(III)	  complex	  was	  conjugated	  to	  the	  most	  potent	  NMDA	  receptor-­‐binding	  moiety	  via	  a	  similar	  spacer	  unit	  to	  that	  used	  in	  the	  design	  of	  [Gd.L12],	  which	  was	  considered	  to	  sufficiently	  space	  the	  receptor-­‐binding	  motif	  from	  the	  large	  complex	  core.	  The	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presence	   of	   the	   NMDA	   receptor-­‐binding	   moiety	   did	   not	   perturb	   the	  photophysical	   properties	   of	   the	   complex,	   with	   [Eu.L13]	   showing	   similar	  absorption	  and	  emission	  profiles	  as	  the	  parent	  compounds.	  The	   localisation	   profile	   of	   [Eu.L13]	   was	   studied	   by	   live-­‐cell	   laser	   scanning	  confocal	  microscopy	  on	  differentiated	  NSC-­‐34	  cells	  expressing	  NMDA	  receptors.	  Disappointingly,	   incubation	  of	   [Eu.L13]	   on	  differentiated	  NSC-­‐34	   cells	   for	  up	   to	  45	  minutes	  led	  to	  no	  cell-­‐surface	  localisation.	  Instead	  a	  small	  degree	  of	  complex	  internalisation	   was	   observed.	   The	   mechanism	   of	   cellular	   uptake	   was	   partially	  investigated	   through	   a	   series	   of	   control	   experiments,	   and	   found	   not	   to	   be	  receptor-­‐mediated.	  Following	  the	  observation	  of	  some	  weak	  intracellular	  fluorescence,	  the	  emission	  properties	  of	  [Eu.L13]	  were	  recorded	  in	  the	  cell	  culture	  medium	  and	  compared	  to	  those	   recorded	   in	   water.	   It	   was	   found	   that	   the	   emission	   of	   [Eu.L13]	   is	  significantly	  quenched	   in	   the	  cell	   culture	  medium	  to	  approximately	  30%	  of	   the	  observed	  signal	  intensity	  in	  water.	  It	  was	  initially	  thought	  that	  if	  HSA	  were	  able	  to	  bind	   to	   the	  rod-­‐like	  arms	  of	   the	  chromophore,	   this	  would	  be	   the	  most	   likely	  quencher	  of	  excited	  state	  emission.	  However,	  the	  emission	  intensity	  and	  spectral	  form	  of	  [Eu.L13]	  did	  not	  change	  upon	  the	  addition	  of	  a	  large	  excess	  of	  HSA	  to	  an	  aqueous	   solution	  of	   the	   complex.	  This	   suggested	   that	   a	  different	   constituent	  of	  the	  cell	  culture	  medium,	   led	  to	  quenching	  of	   the	  europium	  emission.	  Without	  a	  full	   investigation	   into	   the	   effect	   of	   each	   component	   of	   the	   medium	   on	   the	  photophysical	  properties,	  it	  is	  difficult	  to	  decipher	  what	  is	  causing	  this	  effect.	  	  Nevertheless,	   it	   is	   reasonable	   to	   hypothesise	   that	   the	   localisation	   profile	   of	  
[Eu.L13]	  is	  dominated	  by	  the	  large	  nature	  of	  the	  parent	  Eu(III)	  complex	  and	  not	  by	  the	  small	  NMDA	  receptor-­‐binding	  moiety.	   It	   is	   likely	   that	   the	  complex	  binds	  non-­‐specifically	   to	   a	   protein	   in	   the	   cell	   culture	   medium,	   via	   the	   rod-­‐like	  chromophore	  units,	  and	  is	  then	  trafficked	  into	  the	  cell	  through	  some	  endocytocic	  mechanism,	  leading	  to	  the	  observed	  intracellular	  localisation.	  In	   Chapter	  6	   an	   emerging	   imaging	   technique	   is	  described	  and	  work	   is	  detailed	  towards	   an	  NMDA	   receptor-­‐targeted	  NIR	   probe	   for	   optoacoustic	   imaging.	   Two	  new	  optoacoustic	   imaging	  contrast	  agents	  have	  been	  designed	  and	  synthesised	  and	  their	  potential	  to	  bind	  and	  image	  NMDA	  receptors	  is	  evaluated	  in	  vitro	  and	  in	  
vivo.	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6.	  NMDA	  Receptor-­Targeted	  Photoacoustic	  
Contrast	  Agents	  
	  
6.1	   	  Introduction	  	  The	   two	  previous	   chapters	  have	  described	   the	  development	  of	   optical	   imaging	  probes	   for	   visualisation	   of	  NMDA	   receptors.	   Although	   the	   antagonist	   approach	  for	   NMDA	   receptor	   visualisation	   was	   demonstrated	   using	   the	   biotin-­‐avidin	  conjugates,	   [Gd.L11-­12],	   the	   localisation	  profile	  of	   the	  bright	  europium	  complex,	  
[Eu.L13],	   appeared	   to	   be	   dictated	   by	   the	   overall	   complex	   structure	   and	   not	  directed	   by	   the	   NMDA	   receptor-­‐binding	   moiety.	   Nevertheless,	   the	   exceptional	  sensitivity	   and	   resolution	   associated	   with	   optical	   imaging	   has	   provided	   a	  complementary	  technique,	  giving	  information	  on	  the	  reversibility	  and	  specificity	  of	   binding	   of	   the	   NMDA	   receptor-­‐targeted	   MRI	   contrast	   agents.	   However,	   the	  major	  drawback	  associated	  with	  optical	  imaging,	  which	  limits	  its	  in	  vivo	  use,	  is	  its	  lack	  of	  deep	  tissue	  penetration.	  	  One	   emerging	   imaging	   modality	   with	   the	   potential	   to	   limit	   the	   problems	  associated	  with	  the	  issue	  of	  depth	  penetration,	   is	  photoacoustic	  (also	  known	  as	  optoacoustic)	   imaging.	   Photoacoustic	   imaging	   is	   claimed	   to	   have	   a	   penetration	  depth	   of	   up	   to	   5	   cm,1	   which	   is	   far	   superior	   to	   most	   optical	   techniques.	  Furthermore,	   it	   possesses	   good	   spatial	   and	   temporal	   resolution	   by	   encoding	  optical	  contrast	  information	  onto	  acoustic	  waves.1	  Photoacoustic	  imaging	  offers	  another	   complementary	   imaging	   modality	   to	   MRI,	   for	   imaging	   and	   studying	  NMDA	  receptors	  in	  vivo.	  	  
6.1.1	  Principles	  of	  Photoacoustic	  Imaging	  	  The	  basic	  principles	  of	  photoacoustic	  imaging	  are	  shown	  below	  (Figure	  6).	  First,	  a	  pulsed	  laser	  light,	  lasting	  several	  nanoseconds,	  is	  directed	  at	  a	  point	  of	  interest.	  Providing	   that	   the	   light	   is	   absorbed	   quickly	   at	   the	   region	   of	   interest	   by	   a	  photoabsorber,	   there	   is	   an	   increase	   in	   local	   pressure	   and	   temperature.	   This	  thermoelastic	   expansion	   releases	   energy	   in	   the	   form	   of	   acoustic	  waves,	  which	  then	   propagate	   back	   to	   the	   detector	   due	   to	   the	   elastic	   nature	   of	   tissue.	   The	  
NMDA	  Receptor-­Targeted	  Photoacoustic	   	   Chapter	  6	  
Contrast	  Agents	  
	   135	  
acoustic	  waves	  are	  detected	  in	  close	  proximity	  to	  the	  illuminated	  tissue	  and	  can	  be	  mathematically	  decoded	  and	  reconstructed	  to	  form	  images.2	  	  
	  	  
Figure	  6.	  Basic	  principle	  of	  photoacoustic	  imaging.3	  	  Although	   the	   photoacoustic	   phenomenon	   was	   first	   discovered	   by	   Alexander	  Graham	  Bell	  in	  1880,4	  its	  utilisation	  in	  biomedical	  spectrometry	  and	  imaging	  has	  only	  been	  considered	  over	   the	  past	   few	  decades.5	  Photoacoustic	   imaging	   relies	  on	   efficient	   photoabsorbing	   agents,	   such	   as	   oxygenated	   and	   deoxygenated	  haemoglobin,	  and	  the	  majority	  of	  the	  literature	  to	  date	  utilises	  these	  endogenous	  photoabsorbers	  for	  visualising	  and	  imaging	  blood	  vessels	  with	  high	  resolution.2	  In	   addition	   to	   haemoglobin,	   a	   variety	   of	   other	   intrinsic	   tissue	   photoabsorbers	  exist,	   such	   as	   melanin,	   lipids	   and	   water,	   which	   each	   generate	   their	   own	  photoacoustic	  signal.	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Figure	  6.1.	   Images	  of	  (A)	  arteries,	   (B)	  a	  melanoma	  and	  (C)	  a	   lipid	  plaque	  from	  within	  a	  mouse,	  generated	  by	  photoacoustic	  imaging	  of	  oxygenated	  haemoglobin	  (blood),	  melanin	  and	  lipid,	  respectively.3	  	  	  Although	   the	  presence	  of	   endogenous	  photoabsorbers	   can	  be	  used	   to	   generate	  high-­‐quality	   images	   (Figure	   6.1),	   they	   can	   also	   give	   rise	   to	   a	   large	   amount	   of	  background	   noise.	   However,	   this	   can	   be	   overcome	   by	   using	   multispectral	  optoacoustic	  tomography	  (MSOT).	  Employing	  a	  synthetic	  photoabsorbing	  agent	  and	  using	  light	  pulses	  of	  different	  wavelengths,	  allows	  the	  photoacoustic	  signals	  of	  the	  endogenous	  and	  synthetic	  photoabsorbers	  to	  be	  differentiated,	  giving	  rise	  to	  an	  increased	  sensitivity.	  Furthermore,	  by	  conjugating	  a	  targeting	  vector	  onto	  the	  photoabsorber,	  image	  specificity	  can	  be	  enhanced.	  	  
6.1.2	   Design	   of	   an	   NMDA	   Receptor-­Targeted	   Photoacoustic	  
Contrast	  Agent	  	  In	   order	   to	   provide	   sufficient	   contrast,	   a	   synthetic	   photoabsorbing	   agent	  must	  possess	  different	  absorption	  properties	  to	  the	  endogenous	  photoabsorbers.	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Figure	  6.2.	  Absorption	  spectra	  of	  the	  major	  endogenous	  photoabsorbers.	  	  The	   absorption	   spectrum	   of	   each	   of	   the	   major	   endogenous	   photoabsorbers	  (figure	   6.2)	   demonstrates	   that	   between	   600	   and	   900	   nm,	   the	   majority	   of	   the	  endogenous	  photoabsorbers	  do	  not	  absorb	   light	  very	  well,	  providing	  an	  optical	  window	  in	  which	  to	  image.	  Also	  in	  this	  region,	   light	  scattering	  is	  relatively	   low,	  resulting	   in	   greater	   light	   penetration	   allowing	   images	   to	   be	   obtained	   from	  deeper	   within	   the	   body.	   Therefore,	   the	   major	   requirements	   for	   synthetic	  photoabsorbers	  for	  photoacoustic	   imaging	  are	  that	  they	  absorb	  light	  within	  the	  optical	   window,	   with	   a	   high	   molar	   absorption	   coefficient	   allowing	   detection	  above	  the	  intrinsic	  photoacoustic	  tissue	  signal.6	  	  Recently,	   various	   gold	   nanostructures7,	   8	   and	   single-­‐walled	   carbon	   nanotubes9,	  have	  been	  conjugated	  to	  specific	  antibodies	  and	  directing	  vectors	  and	  have	  been	  employed	   as	   photoacoustic	   contrast	   agents.	   Their	   selection	  was	  made	   because	  they	  possess	  exceptionally	  high	  molar	  absorption	  coefficients.	  However,	  they	  are	  relatively	  large	  and	  the	  concentration-­‐normalised	  absorptivity	  (representing	  the	  optical	   absorption	   coefficient	   using	   a	   concentration	   of	   1	   mg/mL)	   of	   these	  structures	   is	   actually	   quite	   low.2	   In	   comparison,	   although	  organic	  dyes	   tend	   to	  have	  lower	  molar	  absorption	  coefficients,	  they	  possess	  a	  greater	  concentration-­‐
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normalised	   absorptivity	   and	   can	   out-­‐perform	   the	   nanostructures	   as	  photoacoustic	  contrast	  agents.2	  With	   this	  background	   in	  mind,	  we	  have	  set	  out	   to	  synthesise	  and	  evaluate	   two	  NMDA	   receptor-­‐targeted	   photoacoustic	   contrast	   agents,	   [NIR-­1]	   and	   [NIR-­2].	  Their	  structures	  are	  shown	  below	  (Scheme	  6).	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NMDA	  receptor	  are	  15012	  and	  19	  nM13,	  respectively.	  However,	  these	  values	  are	  not	  directly	  comparable	  due	  to	  the	  different	  methods	  used	  in	  their	  determination	  (the	  IC50	  for	  ifenprodil	  was	  determined	  by	  voltage	  clamp	  recordings,	  whereas	  the	  IC50	   of	   the	   alcohol	   derivative	   of	   the	  NMDA	   receptor-­‐binding	  moiety	   of	   [NIR-­2]	  was	  determined	  using	  a	  radiolabel	  displacement	  assay).12,	  13	  The	  heptamethine	  cyanine	  dye	   is	  derived	   from	  the	  commercially	  available	  dye,	  IRDye®-­‐800CW	   (Scheme	   6).	   This	   dye	   is	   well	   suited	   to	   act	   as	   a	   synthetic	  photoacoustic	   absorber.	   It	   possesses	   an	   extremely	   large	   molar	   absorption	  coefficient	   of	   approximately	   240,000	   M-­‐1	   cm-­‐1,	   with	   an	   absorption	   maximum	  centred	   around	   790	   nm,	   which	   is	   located	   well	   within	   the	   optical	   window.14	  Furthermore,	   the	   quantum	   yield	   of	   IRDye®-­‐800CW	   is	   approximately	   5-­‐10%,	  meaning	  that	   the	  energy	  build	  up	  from	  the	  absorption	  of	   the	  pulsed	   light	  has	  a	  greater	  probability	  of	  leading	  to	  thermal	  elastic	  expansion	  and	  releasing	  acoustic	  waves,	  rather	  than	  being	  dissipated	  as	  fluorescence.	  Finally,	  the	  presence	  of	  the	  sulfonate	  groups	  around	  the	  periphery	  of	  the	  dye	  enhances	  the	  water	  solubility	  and	   should	   reduce	   the	   potential	   to	   bind	   non-­‐specifically	   to	   endogenous	  proteins.15	  	  	  	  	  
6.2.	   	  Synthetic	  Details	  
6.2.1	  Synthesis	  of	  the	  Heptamethine	  Cyanine	  Dye	  	  The	   synthesis	  of	   the	  heptamethine	   cyanine	  dye	  began	  with	   construction	  of	   the	  hetrocyclic	   indole	   ring,	   using	   standard	   Fischer	   indole	   synthesis	   conditions	  (Scheme	  6.1).16	  Hydrazinobenzene	   sulfonic	  acid	  and	  3-­‐methyl-­‐2-­‐butanone	  were	  stirred	   in	  acetic	  acid	  at	  120	  °C	   for	   three	  hours,	   at	  which	  point	   the	   solvent	  was	  removed	  to	  give	  the	  crude	  indole.	  Purification	  by	  precipitation	  of	  the	  potassium	  salt	   gave	  91	   in	   a	   75%	   yield.	   This	  was	   then	   subject	   to	   an	  N-­‐alkylation	   through	  reaction	   with	   1,4-­‐butanesultone	   in	   anhydrous	   toluene	   at	   100	   °C	   for	   twelve	  hours.17	   Upon	   completion	   of	   the	   reaction,	   as	   confirmed	   by	   ESI-­‐MS,	   the	   solvent	  was	   decanted	   from	   the	   purple	   precipitate.	   Trituration	   with	   cold	   propan-­‐2-­‐ol	  yielded	  the	  quaternary	  ammonium	  salt,	  92,	  as	  a	  free	  flowing	  pink	  powder.	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Classical	  syntheses	  of	  heptamethine	  cyanine	  dyes	  involve	  condensation	  of	  the	  2-­‐methyl	  substituted	  quaternary	  indole	  with	  a	  bis-­‐aldehyde,	  and	  this	  strategy	  was	  employed	   here.	   The	   bis-­‐aldehyde	   was	   synthesised	   according	   to	   a	   literature	  procedure.18	   Initially,	   anhydrous	   DMF	   and	   POCl3	   were	   stirred	   as	   a	   solution	   in	  anhydrous	   DCM	   at	   0	   °C	   to	   allow	   for	   in-­situ	   formation	   of	   the	   Vilsmeier-­‐Haak	  reagent.	   To	   this	   solution	   was	   added	   cyclohexanone	   and	   the	   resulting	   mixture	  was	   heated	   to	   80	   °C	   and	   reaction	   progress	   monitored	   by	   TLC.	   Complete	  conversion	  was	  achieved	  after	  3	  hours,	  at	  which	  point	  the	  reaction	  was	  cooled	  to	  room	  temperature	  and	  poured	  onto	  ice	  and	  left	  overnight.	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precipitate	   formed.	   The	   presence	   of	   the	   desired	   compound	   was	   confirmed	  through	   observation	   of	   an	   absorption	   band	   centred	   around	   784	   nm,	   which	   is	  consistent	  with	  heptamethine	  cyanine	  dyes	  of	  this	  nature.	  Removal	  of	  the	  solvent	  and	   washing	   with	   diethyl	   ether	   gave	   the	   chloro-­‐substituted	   heptamethine	  cyanine	  dye,	  94,	  as	  a	  green	  powder.19	  	  Due	   to	   the	   electron-­‐deficient	   nature	   of	   the	  π-­‐system,	   the	   chlorine	   group	   at	   the	  meso-­‐position	   of	   the	   cyclohexyl	   ring	   in	   heptamethine	   dyes	   is	   known	   to	   be	  susceptible	   to	   nucleophillic	   substitution.	   Compound	   94	   was	   subject	   to	  nucleophillic	   displacement	   by	   reaction	   with	   4-­‐hydroxy	   benzoic	   acid	   in	   the	  presence	  of	  an	  excess	  of	  NaH	  in	  anhydrous	  DMF	  at	  70	  °C	  [note:	  may	  take	  several	  additions	   of	   reagents].	   The	   likely	  mechanism	   of	   this	   reaction	   involves	   an	   SNR1	  pathway,	   initiated	   by	   a	   single	   electron	   transfer	   from	   the	   nucleophile	   to	   the	  cationic	   π-­‐system.20	   The	   progress	   of	   the	   reaction	  was	  monitored	   by	   analytical	  RP-­‐HPLC	  and	  upon	  completion	  of	  the	  reaction,	  the	  solvent	  was	  removed	  and	  the	  crude	   residue	   purified	   by	   preparative	   RP-­‐HPLC	   (mobile	   phase	   comprising	   25	  mM	  triethylammonium	  acetate	  buffer	  and	  acetonitrile),	  to	  give	  the	  heptamethine	  cyanine	   dye,	   95,	   as	   a	   green	   powder.	   Confirmation	   of	   the	   substitution	   of	   the	  chlorine	   atom	   was	   achieved	   by	   comparison	   of	   the	   maximum	   absorption	  wavelength	  of	  95	  and	  94.	  A	  hypsochromic	  shift	  of	  12	  nm	  was	  observed	   for	  95,	  consistent	  with	  substitution	  by	  an	  electron	  rich	  ether	  group.21	  	  
6.2.2	  Synthesis	  of	  the	  NMDA	  Receptor-­Binding	  Moieties	  	  The	   synthesis	   of	   the	   NMDA	   receptor-­‐binding	   moiety	   of	   [NIR-­1]	   followed	   the	  reported	   literature	   method	   (Scheme	   6.2).22	   Initially,	   the	   benzyl-­‐protected	   4-­‐hydroxypropiophenone	   underwent	  α-­‐bromination,	   via	   reaction	  with	  molecular	  bromine	   in	   anhydrous	  diethyl	   ether.	  After	   stirring	  at	   room	   temperature	   for	  30	  minutes,	   a	   colour	   change	  was	  observed	   and	   the	   reaction	  was	  quenched	  by	   the	  addition	   of	   water.	   After	   work-­‐up	   and	   subsequent	   purification	   by	   column	  chromatography,	   compound	   96	   was	   isolated	   in	   an	   82%	   yield.	   Reaction	   of	   96	  with	   4-­‐benzylpiperidine	   was	   carried	   out	   in	   refluxing	   ethanol	   overnight.23	   The	  progress	  of	  the	  reaction	  was	  monitored	  by	  TLC	  and	  upon	  completion,	  the	  solvent	  was	  removed	  to	  give	  the	  crude	  product.	  Purification	  by	  column	  chromatography	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afforded	   97	   as	   a	   yellow	   oil,	   which	   was	   then	   reduced	   to	   the	   corresponding	  alcohol,	  98.	  Ketone	  reduction	  was	  carried	  out	  using	  two	  equivalents	  of	  LiAlH4	  in	  anhydrous	  THF	  at	  0	  °C.	  These	  conditions	  had	  previously	  been	  reported	   to	  give	  only	  the	  threo-­‐diastereoisomer	  of	  ifenprodil,	  whereas	  NaBH4	  reduction	  often	  led	  to	  diastereoisomeric	  mixtures.23	  Upon	  completion	  of	  the	  reaction,	  as	  verified	  by	  ESI-­‐MS,	  the	  reaction	  was	  quenched	  and	  the	  lithium	  salts	  removed.	  Compound	  98	  was	  isolated	  as	  a	  white	  solid	  in	  a	  76%	  yield.	  Confirmation	  of	  the	  presence	  of	  only	  the	  threo-­‐diastereoisomer	  was	  based	  on	  1H	  NMR	  analysis,	  by	  comparison	  to	  the	  reported	   literature	   data	   (Figure	   6.3).23	   The	   proton	   next	   to	   the	   hydroxyl	   group	  resonated	  at	  4.28	  ppm,	  and	  split	  into	  a	  doublet	  through	  coupling	  to	  the	  adjacent	  proton,	   with	   a	   coupling	   constant	   of	   10	   Hz.	   If	   the	   erythro	   diastereoisomer	   had	  been	   present,	   the	   doublet	   would	   have	   been	   shifted	   to	   higher	   frequency	   by	  approximately	   0.90	   ppm,	   with	   a	   much	   smaller	   coupling	   constant	   due	   to	   the	  relative	  position	  of	  the	  nearest	  proton.23	   	   	  
Figure	  6.3.	  1H	  NMR	  spectrum	  of	  compound	  98	  showing	  the	  presence	  of	  only	  one	  diastereoisomer.	   (Inset)	   Expanded	   region	   between	   3.50-­‐6.00	   ppm	   showing	   the	  presence	  of	  the	  doublet	  at	  4.28	  ppm	  (J	  =	  10	  Hz)	  assigned	  to	  the	  proton	  adjacent	  to	   the	  hydroxyl	  group	   in	  benzyl-­‐protected	  threo	   ifenprodil,	  98.	   (Literature	  data	  for	  98:	  δH	  4.1-­‐4.2	  ppm,	  J	  =	  8.5-­‐10	  Hz).23	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Racemic	  benzyl-­‐protected	  threo-­‐ifenprodil,	  98,	  was	  subjected	  to	  a	  stereospecific	  mesylation-­‐amination	  sequence	  to	  form	  99.11	  The	  alcohol,	  98,	  was	  first	  activated	  towards	  nucleophilic	  substitution	  via	   in-­situ	   formation	  of	  the	  reactive	  mesylate,	  by	   reaction	   with	   methanesulfonylchloride	   in	   anhydrous	   THF	   under	   basic	  conditions.	  The	  presence	  of	  the	  mesylate	  was	  confirmed	  by	  TLC	  analysis	  after	  30	  minutes.	  After	  this	  time,	  N-­‐Boc-­‐1,6-­‐hexyldiamine	  and	  triethylamine	  were	  added	  and	  the	  resulting	  solution	  stirred	  at	  room	  temperature	  overnight.	  Work-­‐up	  and	  subsequent	   purification	   by	   column	   chromatography	   gave	   99	   in	   a	   63%	   yield.	  Confirmation	  of	  a	  stereospecific	  reaction	  was	  again	  obtained	  through	  analysis	  of	  the	  proton	   resonances	  at	   the	  asymmetric	   centres,	  using	   1H	  NMR	  spectrometry,	  similar	  to	  the	  conformational	  analysis	  of	  98.	  Finally,	  compound	  99	  was	  subject	  to	  acidic	   double	   deprotection	   to	   remove	   the	   benzyl	   and	   carbamate	   protecting	  groups.	   This	  was	   achieved	   by	   stirring	  99	   in	   aqueous	  HBr	   at	   100	   °C	   overnight,	  which	   gave	   the	   free	   amine,	   100,	   as	   a	   pale	   yellow	   solid	   after	   purification	   by	  column	  chromatography.11	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The	   synthesis	   of	   the	   NMDA	   receptor-­‐binding	   moiety	   of	   [NIR-­2]	   followed	   the	  sequence	   shown	   in	   scheme	  6.3.	   First,	   the	  primary	  amine,	  36,	   underwent	  amide	  bond	   formation	   with	   N-­‐Boc-­‐6-­‐aminohexanoic	   acid	   to	   form	   101.	   This	   reaction	  was	   undertaken	   by	   stirring	   the	   acid	   as	   a	   solution	   in	   anhydrous	   DMF	   with	  HDC.HCl	  and	  HOBt	   for	  20	  minutes.	  After	   this	   time,	   a	   solution	  of	   the	  amine,	  36,	  and	  NMM	  was	  added	  dropwise	  and	  the	  reaction	  progress	  monitored	  by	  ESI-­‐MS.	  Upon	   consumption	   of	   the	   starting	   materials	   after	   five	   hours,	   the	   solvent	   was	  removed	   to	   give	   the	   crude	   product.	   After	  work-­‐up	   and	   purification	   by	   column	  chromatography,	  the	  carbamate,	  101,	  was	  isolated	  as	  a	  yellow	  oil	  in	  a	  43%	  yield.	  The	  final	  step	  before	  conjugation	  to	  the	  heptamethine	  cyanine	  dye,	  95,	  involved	  hydrolysis	   of	   the	   carbamate	   protecting	   group.	   This	   was	   achieved	   using	   a	   1:1	  mixture	  of	  trifluoroacetic	  acid	  and	  DCM	  at	  room	  temperature	  for	  30	  minutes,	  at	  which	  point	  the	  solvent	  was	  removed	  under	  reduced	  pressure.	  Excess	  TFA	  was	  removed	   via	   repeated	   addition	   and	   removal	   of	   DCM	   under	   reduced	   pressure.	  This	  yielded	  the	  TFA	  salt	  of	  the	  amine,	  which	  was	  used	  directly	  in	  the	  coupling	  to	  
95,	  without	  further	  purification.	  	  
	  	  
Scheme	  6.3.	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reaction	   of	   the	   starting	  materials	  was	   observed,	   the	   solvent	  was	   removed	   and	  the	  crude	  residue	  that	  remained	  purified	  by	  preparative	  RP-­‐HPLC	  (mobile	  phase	  comprising	   25	  mM	   triethylammonium	   acetate	   buffer	   and	   acetonitrile).	   	   In	   the	  case	   of	   [NIR-­2],	   one	   final	   step	   was	   carried	   out	   in	   which	   hydrolysis	   of	   the	  phosphonate	   ethyl	   esters	   occurred	   by	   reaction	   with	   an	   excess	   of	  bromotrimethylsilane	  in	  anhydrous	  DMF	  at	  60	  °C.	  This	  step	  was	  conducted	  prior	  to	  the	  final	  HPLC	  purification.	  Accordingly,	  the	  compounds,	  [NIR-­1]	  and	  [NIR-­2],	  were	  obtained	  as	  green	  solids.	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Figure	   6.4.	   Calculated	   (left)	   and	   observed	   (right)	   high-­‐resolution	   electrospray	   mass	  spectra	  of	  [NIR-­1];	  TOF	  negative	  mode.	  
	  
6.3	   	  Photophysical	  Characterisation	  	  The	   photophysical	   characterisation	   of	   [NIR-­1]	   and	   [NIR-­2]	   was	   carried	   out	   in	  water.	   The	   absorption	   spectra	   of	   [NIR-­1]	   and	   [NIR-­2]	   each	   show	   broad	  absorption	   bands	   centred	   around	   776	   nm,	   with	   a	   bathochromatically	   shifted	  secondary	  band	  around	  712	  nm	  (Figure	  6.5).	  The	  extinction	   coefficient	  of	   each	  dye	  at	  776	  nm	  was	  estimated	  to	  be	  240,000	  M-­‐1	  cm-­‐1,	  and	  is	  consistent	  with	  an	  intense	   π→π∗	   transition,	   representing	   the	   0→0	   transition	   in	   a	   vibronic	  progression.	  The	  shoulder	  at	  712	  nm	  is	  also	  a	  π→π∗	  transition,	  but	  relates	  to	  the	  0→1	   or	   0→2	   vibronic	   transition.24	   The	   absorption	   properties	   of	   [NIR-­1]	   and	  
[NIR-­2]	  make	   them	   ideal	   candidates	  as	  NMDA	  receptor-­‐targeted	  photoacoustic	  agents,	   with	   the	   maximum	   wavelength	   of	   absorption	   falling	   in	   the	   optical	  window	  where	  endogenous	  photoabsorbers	  are	  poorly	  absorbing.	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Figure	  6.5.	  Absorption	  (blue)	  and	  emission	  (red)	  spectra	  of	  [NIR-­1].	  (H2O,	  λex	  =	  776	  nm,	  
λem	  =	  801	  nm,	  298	  K).	  	  The	   emission	   spectra	   of	   [NIR-­1]	   and	   [NIR-­2]	   were	   measured	   following	  excitation	  at	  776	  nm.	  Again	  the	  emission	  spectra	  were	  structurally	   the	  same	   in	  each	  case,	  with	  one	  main	  emission	  band	  centred	  at	  801	  nm,	  resulting	  in	  a	  Stokes’	  shift	  of	  25	  nm.	  Unfortunately,	  the	  quantum	  yields	  of	  fluorescence	  of	  [NIR-­1]	  and	  
[NIR-­2]	  were	  not	  measured,	  as	  this	  would	  require	  the	  use	  of	  a	  silicon	  detector,	  which	   was	   unavailable	   at	   the	   time	   of	   this	   work.	   However,	   previous	   literature	  suggests	  that	  similar	  structures	  possess	  a	  quantum	  yield	  between	  5-­‐10%.14	  	  
6.4	   	  Cellular	  Fluorescence	  Studies	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The	   first,	   performed	   by	   Dr	   Robert	   Pal,	   involved	   using	   [NIR-­1]	   and	   [NIR-­2]	   as	  FRET	   acceptors,	  which	  were	   excited	   using	   a	   Eu(III)	   complex	  which	   acted	   as	   a	  FRET	   donor.	   Excitation	   of	   the	   Eu(III)	   complex	   at	   365	   nm	   led	   to	   sensitised	  population	  of	  the	  dye	  excited	  state.	  An	  overlap	  of	  the	  emission	  spectrum	  of	  the	  donor	  and	  the	  absorption	  spectrum	  of	  the	  acceptor	  leads	  to	  excitation	  of	  [NIR-­1]	  or	   [NIR-­2],	   providing	   both	   donor	   and	   acceptor	   are	   close	   in	   space.	   This	   allows	  emission	   from	  the	  acceptor	   to	  be	  observed.	  A	  Stern-­‐Volmer	  analysis	  conducted	  by	   Martina	   Delbianco	   showed	   that	   65%	   energy	   transfer	   could	   be	   achieved	  between	   the	  Eu(III)	   complex,	   [Eu.LMD]	   (Scheme	  6.5)	   and	  heptamethine	   cyanine	  dye,	  95,	  demonstrating	  the	  feasibility	  of	  the	  experiment.	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demonstrated	  that	  both	  [NIR-­1]	  and	  [NIR-­2]	  showed	  a	  localisation	  profile	  at	  the	  cell	   surface	   (Figure	  6.6),	  with	  [NIR-­1]	   appearing	   to	   label	   the	  cells	  more	  readily	  than	  [NIR-­2],	  suggesting	  a	  higher	  affinity	  for	  [NIR-­1]	  toward	  the	  NMDA	  receptor.	  Further	   confirmation	   of	   the	   cell-­‐surface	   localisation	   for	   both	   probes	   was	  achieved	  through	  a	  repeat	  of	   the	   loading	  experiment	  detailed	  above,	  with	  a	  co-­‐incubation	  of	  the	  commercially	  available	  cell	  mask-­‐orange	  (Figure	  6.6).	  	  
	  
Figure	   6.6.	   Live	   cell	   fluorescence	   microscopy	   images	   of	   differentiated	   NSC-­‐34	   cells	  following	   treatment	  with	   either	   [NIR-­1]	   or	   [NIR-­2]	   (10	  µM,	  30	  minutes)	   showing	   cell	  surface	   localisation.	   (A)	   Transmission	   image;	   (B)	   visualisation	   of	   [NIR-­1]	   (λex/λem	   =	  365/780	  nm);	   (C)	   visualisation	  of	   cell	  mask	  orange	   (λex/λem	   =	  525/590	  nm);	   (D-­‐F)	  As	  images	  (A-­‐C)	  but	  with	  [NIR-­2].	  	  The	   second	  method	   for	   probe	   visualisation	   on	   differentiated	  NSC-­‐34	   cells	  was	  performed	   by	   Dr	   Sven	   Gottschalk	   at	   the	   institute	   for	   biological	   and	   medical	  imaging,	  Munich.	  This	  method	   involved	  direct	   excitation	  of	   [NIR-­1]	   or	   [NIR-­2]	  upon	  incubation	  with	  differentiated	  NSC-­‐34	  cells	  (Figure	  6.7).	  Similar	  to	  the	  experiment	  above,	  differentiated	  NSC-­‐34	  cells	  were	  incubated	  with	  a	  10	  µM	  solution	  of	  either	  [NIR-­1]	  or	  [NIR-­2]	  for	  30	  minutes,	  washed	  to	  remove	  any	  unbound	  probe	   and	   then	   imaged	  using	   epifluorescence	  microscopy.	  Again,	  more	  signal	  was	  detected	  from	  the	  cells	  treated	  with	  [NIR-­1]	  (Figure	  6.7A	  vs	  B),	  suggesting	  this	  compound	  bound	  with	  a	  higher	  affinity	  to	  the	  cell	  surface	  NMDA	  receptor.	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Figure	   6.7.	   Live	   cell	   fluorescence	   microscopy	   images	   of	   differentiated	   NSC-­‐34	   cells	  (λex/λem	   =	   780/800	   nm).	   (A)	   Treatment	   with	   [NIR-­1]	   (10	   µM,	   30	   minutes);	   (B)	  Treatment	  with	  [NIR-­2]	  (10	  µM,	  30	  minutes);	  (C)	  Treatment	  with	  compound	  95	  (10	  µM,	  30	  minutes).	  	  In	  order	  to	  confirm	  that	  the	  localisation	  profiles	  of	  [NIR-­1]	  and	  [NIR-­2]	  are	  due	  to	   the	   presence	   of	   the	   NMDA	   receptor-­‐binding	   moieties	   interacting	   with	   the	  receptor	  and	  not	  due	  to	   the	  heptamethine	  cyanine	  dye	  binding	  non-­‐specifically	  to	  the	  cell	  membrane,	  a	  control	  experiment	  was	  conducted.	  Differentiated	  NSC-­‐34	   cells	  were	   treated	  with	   a	   10	  µM	   solution	   of	   compound	  95	   for	   30	  minutes.	  After	  washing,	   the	  cells	  were	   imaged	  which	   led	   to	  no	   fluorescence	  signal	  being	  observed	  (Figure	  6.7C).	  This	  demonstrated	  the	  lack	  of	  non-­‐specific	  binding	  of	  the	  dye,	  and	  suggests	  that	  the	  observed	  localisation	  profiles	  are	  due	  to	  the	  presence	  of	   the	   NMDA	   receptor-­‐binding	   moieties	   binding	   to	   the	   NMDA	   receptor,	   in	   a	  similar	  fashion	  to	  what	  was	  observed	  for	  [Gd.L11-­12].	  	  	  
6.4.2	  Establishing	  Cellular	  Specificity	  of	  Binding	  	  A	   key	   characteristic	   needed	   for	   these	   NMDA	   receptor-­‐targeted	   photoacoustic	  contrast	  agents	  is	  to	  have	  cellular	  specificity	  of	  binding,	  meaning	  that	  they	  only	  bind	   to	   cells	  which	   express	   functional	  NMDA	   receptors.	   It	  was	   shown	   that	   the	  heptamethine	   cyanine	   dye	   itself	   does	   not	   bind	   to	   differentiated	   NSC-­‐34	   cells	  (Figure	  6.7C).	  However,	   the	  potential	   of	   [NIR-­1]	   and	   [NIR-­2]	   to	  bind	   to	  NMDA	  receptor-­‐negative	  cells	  was	  assessed	  using	  NIH	  3T3	  mouse	  skin	  fibroblast	  cells,	  which	  do	  not	  express	  any	  NMDA	  receptors.	  These	  cells	  were	  incubated	  with	  a	  10	  
µM	  solution	  of	  either	  [NIR-­1]	  or	  [NIR-­2]	  for	  30	  minutes	  (37	  °C,	  5%	  CO2),	  washed	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three	   times	   to	   remove	   any	   unbound	   probe	   and	   then	   treated	  with	   fresh	   buffer	  containing	  20	  µM	  of	  the	  Eu(III)	  complex,	  [Eu.LMD].	  No	  localisation	  profile	  of	  any	  kind,	  cell-­‐surface	  or	  intracellular,	  was	  observed,	  strengthening	  the	  argument	  of	  a	  receptor-­‐mediated	  localisation	  effect	  observed	  when	  [NIR-­1]	  and	  [NIR-­2]	  were	  incubated	   with	   differentiated	   NSC-­‐34	   cells.	   These	   promising	   results	   further	  enhance	  the	  potential	  of	  [NIR-­1]	  and	  [NIR-­2]	  to	  act	  as	  NMDA	  receptor-­‐targeted	  photoacoustic	  contrast	  agents.	  	  
6.4.3	  Assessing	  the	  Reversibility	  of	  Binding	  	  Having	  demonstrated	  that	  [NIR-­1]	  and	  [NIR-­2]	  only	  bind	  to	  cells	  which	  express	  NMDA	   receptors,	   one	   further	   characteristic	   needed	   for	   these	   probes	   was	   to	  possess	  the	  ability	  to	  bind	  at	  the	  NMDA	  receptor	  in	  a	  reversible	  manner,	  with	  a	  competitive	   affinity	   to	   the	   endogenous	   ligand	   glutamate.	   Since	   it	   was	   much	  easier	  to	  visualise	  [NIR-­1]	  on	  the	  surface	  of	  differentiated	  NSC-­‐34	  cells,	  the	  fate	  of	  this	  probe	  after	  a	  stimulated	  ‘glutamate	  burst’	  was	  assessed.	  	  Using	   a	   similar	   contrast	   transfer	   function	   experiment	   to	   that	   described	   in	  
Chapter	  4,	  differentiated	  NSC-­‐34	  cells	  were	   incubated	  with	  a	  10	  µM	  solution	  of	  
[NIR-­1]	   for	   30	   minutes	   (37	   °C,	   5%	   CO2),	   washed	   three	   times	   to	   remove	   any	  unbound	   probe	   and	   then	   treated	   with	   fresh	   buffer	   containing	   20	   µM	   of	   the	  Eu(III)	  complex,	  [Eu.LMD].	  The	  cells	  were	  imaged	  and	  the	  average	  intensity	  was	  recorded	   in	   triplicate	   using	   three	   cells	   (Figure	   6.8A).	   These	   cells	   were	   then	  washed	  with	  five	  successive	  aliquots	  (Vtot	  =	  500	  µL)	  of	  a	  glutamate-­‐rich	  (1	  mM)	  culture	   medium	   and	   then	   treated	   with	   fresh	   buffer	   containing	   20	   µM	   of	   the	  Eu(III)	   complex,	   [Eu.LMD].	   This	   sequence	   resulted	   in	   a	   ten-­‐fold	   drop	   in	  fluorescence	  intensity,	  compared	  to	  the	  original	  cell	  staining	  experiment	  (Figure	  
6.8B).	   Furthermore,	  when	  differentiated	  NSC-­‐34	   cells	  were	   first	   treated	  with	   a	  glutamate-­‐rich	  (1	  mM)	  solution	  to	  block	  the	  NMDA	  receptor,	  washed	  with	  fresh	  buffer	  and	  then	  re-­‐incubated	  sequentially	  with	  both	  components	  (10	  µM	  of	  [NIR-­
1]	  for	  30	  mins	  and	  20	  µM	  [Eu.LMD]	  in	  the	  medium),	  the	  fluorescence	  signal	  could	  be	  fully	  recovered	  to	  the	  original	  value	  (Figure	  6.8C).	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Figure	   6.8.	   (A)	   Live	   cell	   fluorescence	  microscopy	   images	   (λex/λem	   =	   365/780	   nm)	   of	  differentiated	  NSC-­‐34	  cells	   following	  treatment	  with	  [NIR-­1]	   (10	  µM,	  30	  minutes);	   (B)	  As	  image	  (A)	  but	  with	  a	  post	  glutamate	  (1	  mM)	  wash,	  showing	  [NIR-­1]	  is	  removed	  from	  the	   cell	   surface;	   (C)	   Cells	   first	   treated	  with	   a	   glutamate	   (1	  mM)	   rich	   culture	  media	   to	  block	   the	   receptor,	   washed	   and	   then	   re-­‐incubated	   with	   both	   [NIR-­1]	   (10	   µM,	   30	  minutes)	  and	  the	  europium	  complex	  (20	  µM)	  showing	  the	  ability	  of	  [NIR-­1]	  to	  compete	  and	  bind	  in	  the	  presence	  of	  glutamate.	  	  The	   quality	   of	   the	   images	   in	   figures	   6.6	   and	   6.8	   are	   much	   worse	   than	   those	  obtained	  in	  chapter	  4	  and	  5.	  This	  is	  due	  to	  the	  decreased	  detector	  sensitivity	  at	  780	   nm,	   resulting	   in	   the	   images	   being	   obtained	   at	   the	   detection	   limit.	  Nevertheless,	   these	   results	   obtained	   throughout	   the	   fluorescence	   microscopy	  studies	  on	  the	  localisation,	  cellular	  specificity	  and	  reversibility	  of	  binding	  suggest	  that	   the	   probes,	   [NIR-­1]	   and	   [NIR-­2],	   are	   binding	   via	   their	   receptor-­‐binding	  moieties	  to	  the	  cell	  surface	  NMDA	  receptor.	  	  	  	  
6.5	   	  Photoacoustic	  Imaging	  of	  [NIR-­1]	  and	  [NIR-­2]	  
6.5.1	  Preliminary	  Evaluation	  of	  the	  Cellular	  Photoacoustic	  Signal	  	  Having	  established	  sufficient	  evidence	   that	   [NIR-­1]	   and	   [NIR-­2]	   can	  both	   label	  the	  cell	  surface	  NMDA	  receptor	  on	  differentiated	  NSC-­‐34	  cells,	  the	  ability	  of	  the	  contrast	   agents	   to	   generate	   a	   significant	   photoacoustic	   signal	   was	   evaluated.	  These	  experiments	  were	  undertaken	   in	  Germany,	  by	  Dr	  Sven	  Gottschalk,	  using	  multi-­‐spectral	  optoacoustic	  tomography	  performed	  on	  an	  inVision	  256-­‐TF	  small	  animal	   scanner	   (iThera).	   Approximately	   10	  million	   differentiated	   NSC-­‐34	   cells	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were	  treated	  with	  a	  10	  µM	  solution	  of	  either	  [NIR-­1]	  or	  [NIR-­2]	  for	  30	  minutes	  at	  37	  °C	  and	  5%	  CO2.	  After	  this	  time,	  the	  cells	  were	  washed	  thoroughly	  to	  remove	  any	  unbound	  probe	  and	  then	  re-­‐suspended	  in	  a	  1:1	  mixture	  of	  fresh	  buffer	  and	  a	  3%	   agar	   solution.	   The	   presence	   of	   the	   agar	   solution	   generated	   a	   scattering	  pattern	   that	  mimicked	   tissue	   scattering.	   The	   cells	  were	   then	  warmed	   to	   37	   °C	  and	   loaded	   into	   short	   plastic	   straws.	   At	   this	   temperature,	   the	   agar	   solution	  solidified	  and	  generated	  a	  ‘stationary	  solution’	  of	  cells	  from	  which	  the	  phantom	  MSOT	   images	  were	  acquired.	  The	   images	  were	  obtained	  by	  defining	   regions	  of	  interest	   from	   the	   locations	   of	   the	   straws,	   scanning	   the	   wavelengths	   between	  680-­‐900	  nm,	  using	  5	  nm	  intervals	  and	  10	  averages	  per	  wavelength.	  Initial	   studies	   showed	   that	   [NIR-­1]	   clearly	   labels	   differentiated	   NSC-­‐34	   cells,	  generating	   a	   large,	   detectable	   photoacoustic	   signal	   (Figure	   6.9	   green).	   As	   a	  control,	   cells	   alone	   (Figure	   6.9	   brown)	   and	   cells	   treated	  with	   the	   non-­‐targeted	  heptamethine	   cyanine	   dye,	   95	   (Figure	   6.9	   cyan)	   did	   not	   give	   rise	   to	   any	  observable	  MSOT	  signal,	  suggesting	  that	  the	  receptor-­‐binding	  moiety	  of	  [NIR-­1]	  binds	   to	   the	   cell	   surface	   NMDA	   receptor	   and	   is	   responsible	   for	   the	   observed	  signal.	  	   	  	  	  	   	  	  	  	  	  
Figure	   6.9.	   Live	   cell	   MSOT	   of	   differentiated	   NSC-­‐34	   cells	   under	   different	   conditions.	  (Green)	   Cells	   treated	   with	   [NIR-­1]	   (10	   µM,	   30	   minutes)	   showing	   large	   MSOT	   signal;	  (Brown)	  Cells	  treated	  with	  the	  non-­‐targeted	  heptamethine	  cyanine	  dye,	  95	   (10	  µM,	  30	  minutes),	  showing	  no	  MSOT	  signal;	  (Cyan)	  Untreated	  cells	  showing	  no	  MSOT	  signal.	  	  
Figure	   6.10	   shows	   the	   wavelength	   dependence	   of	   the	   photoacoustic	   signal	   of	  cells	   treated	   with	   [NIR-­1].	   This	   photoacoustic	   spectrum	   clearly	   resembles	   the	  absorbance	   spectrum	   of	   [NIR-­1]	   and	   suggests	   that	   this	   compound	   should	   be	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observable	   in	   an	   in	   vivo	   model,	   in	   the	   presence	   of	   the	   endogenous	  photoabsorbers.	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	   6.10.	   (Top)	   Absorbance	   spectrum	   of	   [NIR-­1]	   which	   is	   fed	   into	   the	   unmixing	  algorithm.	   (Bottom)	   Wavelength-­‐dependent	   analysis	   (photoacoustic	   spectrum)	  obtained	  from	  the	  unmixing	  algorithm	  of	  differentiated	  NSC-­‐34	  cells	  labelled	  with	  [NIR-­
1]	  (10	  µM,	  30	  minutes).	  	  Surprisingly,	  when	  the	  same	  cell-­‐labelling	  analysis	  was	  performed	  using	  [NIR-­2]	  (10	  µM,	  30	  minutes),	  no	  photoacoustic	   signal	  was	  detected	   from	  differentiated	  NSC-­‐34	   cells.	   Instead,	   a	   large	   signal	   was	   observed	   from	   the	   supernatant	  suggesting	  that	  [NIR-­2]	  does	  not	  bind	  to	  the	  cell	  surface	  NMDA	  receptor.	  This	  is	  a	   contradiction	   to	   the	   results	   obtained	   from	   the	   fluorescence	   microscopy	  experiments,	   which	   despite	   the	   signal	   being	  weak,	   demonstrated	   that	   [NIR-­2]	  was	   present	   on	   the	   surface	   of	   differentiated	   NSC-­‐34	   cells.	   One	   possible	  explanation	  for	  this	  result	  is	  that	  the	  receptor	  density	  during	  the	  time	  of	  analysis	  of	   [NIR-­2]	   was	   low,	   meaning	   that	   [NIR-­2]	   could	   not	   sufficiently	   label	  
NMDA	  Receptor-­Targeted	  Photoacoustic	   	   Chapter	  6	  
Contrast	  Agents	  
	   155	  
differentiated	  NSC-­‐34	   cells.	   Alternatively,	   a	   larger	   probe	   concentration	  may	   be	  needed	  in	  order	  to	  give	  a	  detectable	  photoacoustic	  signal.	  In	  order	  to	  assess	  the	  effect	  of	  conjugation	  of	  the	  large	  heptamethine	  cyanine	  dye	  to	  the	  NMDA	  receptor-­‐binding	  moiety	  of	  [NIR-­1],	  a	  competition	  experiment	  was	  performed	  to	  assess	  the	  cellular	  labelling	  of	  [NIR-­1]	  in	  the	  presence	  of	  the	  small	  molecule	  antagonist,	   ifenprodil.	  Differentiated	  NSC-­‐34	  cells	  were	  treated	  with	  a	  40	   µM	   solution	   of	   ifenprodil	   for	   10	   minutes,	   washed	   to	   remove	   any	   excess	  antagonist	  and	  then	  incubated	  with	  a	  20	  µM	  solution	  of	  [NIR-­1]	  for	  30	  minutes.	  After	  this	  time,	  the	  cells	  were	  washed	  and	  imaged	  using	  MSOT	  (Figure	  6.11).	  	  	  	  	  	  	  	  	  	   	  
Figure	  6.11.	   Live	   cell	  MSOT	   of	   differentiated	  NSC-­‐34	   cells	   under	   different	   conditions.	  (A)	  Cells	  treated	  with	  [NIR-­1]	  (10	  µM,	  30	  minutes)	  showing	  large	  MSOT	  signal;	  (B)	  Cells	  treated	   with	   the	   NMDA	   receptor-­‐binding	   moiety	   of	   [NIR-­1],	   ifenprodil	   (40	   µM,	   10	  minutes),	   followed	   by	   treatment	   with	   [NIR-­1]	   (20	   µM,	   30	   minutes)	   showing	   no	   a	  decrease	   in	   MSOT	   signal	   consistent	   with	   lower	   cellular	   labelling	   of	   [NIR-­1]	   in	   the	  presence	  of	  the	  small	  molecule	  antagonist.	  	  
Figure	  6.11A	  shows	  the	  large	  photoacoustic	  signal	  observed	  from	  the	  original	  cell	  labelling	   experiment	   using	   [NIR-­1].	   However,	   pre-­‐treating	   the	   cells	   with	   the	  NMDA	  receptor-­‐binding	  moiety	  of	  [NIR-­1]	  before	  loading	  the	  cells	  with	  [NIR-­1]	  resulted	   in	  a	   significantly	  diminished	  photoacoustic	   signal	   (Figure	  6.11B).	   Such	  behaviour	  suggests	  that	  the	  presence	  of	  the	  large	  heptamethine	  cyanine	  dye	  does	  not	  affect	  binding	  too	  much	  and	  that	  [NIR-­1]	  binds	  to	  the	  same	  position	  on	  the	  NMDA	  receptor	  as	  the	  small	  molecule	  antagonist,	  albeit	  with	  a	  weaker	  affinity,	  as	  expected.	   Such	   behaviour	   is	   similar	   to	   that	   observed	   when	   the	   pentamethine	  cyanine	  dye	  was	  conjugated	  to	  ifenprodil.11	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Finally,	   the	   ability	   of	   [NIR-­1]	   to	   be	   displaced	   from	   the	   NMDA	   receptor	   by	   the	  natural	   ligand,	   glutamate,	   was	   demonstrated	   using	   MSOT.	   Approximately	   10	  million	  differentiated	  NSC-­‐34	  cells	  were	  treated	  with	  a	  10	  µM	  solution	  of	  [NIR-­1]	  for	  30	  minutes	  (Figure	  6.12A).	  This	  gave	  a	  large,	  detectable	  photoacoustic	  signal	  similar	   to	   that	   detected	   in	   figure	   6.9.	   The	   cells	   were	   then	   washed	   with	   a	  glutamate-­‐rich	  (1	  mM)	  culture	  medium	  before	  being	  re-­‐suspended	  and	  imaged.	  This	   resulted	   in	   a	   significantly	   diminished	   photoacoustic	   signal	   (Figure	   6.12B),	  demonstrating	   the	   ability	   of	   [NIR-­1]	   to	   be	   displaced	   following	   a	   simulated	  glutamate	  burst.	  This	  result	  is	  in	  keeping	  with	  the	  findings	  from	  the	  fluorescence	  microscopy	  experiments.	  	   	  	  	  	  	  	  
Figure	  6.12.	   Live	   cell	  MSOT	   of	   differentiated	  NSC-­‐34	   cells	   under	   different	   conditions.	  (A)	  Cells	  treated	  with	  [NIR-­1]	   (10	  µM,	  30	  minutes)	  showing	  large	  MSOT	  signal;	  (B)	  As	  image	  (A)	  but	  with	  a	  post	  (1	  mM)	  glutamate	  wash,	  showing	  the	  ability	  of	  [NIR-­1]	  to	  be	  displaced	  from	  the	  NMDA	  receptor.	  	  
6.5.2	  Preliminary	  In	  Vivo	  Studies	  With	  [NIR-­1]	  	  Following	  the	  encouraging	  in	  vitro	  results	  of	  [NIR-­1],	  preliminary	  in	  vivo	  studies	  were	   carried	   out	   by	   Dr.	   Sven	   Gottschalk,	   at	   the	   Institute	   for	   Biological	   and	  Medical	   Imaging,	   Munich,	   on	   female	   athymic	   nude	   mice	   (aged	   8	   weeks).	   The	  contrast	  agent,	  [NIR-­1],	  will	  not	  be	  able	  to	  enter	  the	  brain	  via	  blood	  flow,	  since	  such	  an	  anionic	   species	  of	   this	  volume	  will	  not	  be	  able	   to	  penetrate	   the	  blood-­‐brain-­‐barrier.	   Therefore,	   administration	   of	   [NIR-­1]	   was	   undertaken	   through	  direct	   injection	  into	  the	  brain	  parenchyma	  of	  an	  anaesthetised	  mouse	  (oxygen/	  2%	   isofluorane).	   The	   coordinates	   of	   the	   injections	   were	   from	   the	   Bregma:	  anterior	   1.10	   mm	   and	   1.75	   mm	   left	   or	   right,	   with	   an	   injection	   depth	   of	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approximately	  2.00	  mm,	  placing	  the	  injection	  inside	  the	  M1	  motorcortex,	  which	  is	  a	  region	  known	  to	  possess	  a	  high	  expression	  of	  NMDA	  receptors.25	  Due	   to	   the	  symmetrical	  nature	  of	   the	  brain,	   two	   injections	  per	  mouse	  could	  be	  made,	  allowing	  comparative	  analysis.	  Initially,	  1	  µL	  of	  a	  3.6	  mM	  solution	  of	  [NIR-­
1]	  was	   injected	   into	   the	   right	  hemisphere,	  with	   the	  same	  volume	  of	  phosphate	  buffered	   saline	   (PBS)	   injected	   into	   the	   left	   hemisphere,	   to	   serve	   as	   a	   negative	  control.	   The	   mouse	   was	   then	   loaded	   into	   an	   inVision	   256-­‐TF	   small	   animal	  scanner	  and	  continuously	  imaged	  over	  a	  one	  hour	  period	  (Figure	  6.13).	  	  
	  
Figure	   6.13.	   In	   vivo	   imaging	   by	  MSOT	   of	   the	   brain	   of	   an	   8	  week	   old	   female	   athymic	  nude	  mouse	  following	  intracranial	  injection	  of	  [NIR-­1]	  (3.6	  nmol)	  or	  PBS	  into	  the	  right	  and	  left	  hemispheres,	  respectively.	  The	  mouse	  is	  lying	  on	  its	  back	  resulting	  in	  right	  and	  left	  being	  swapped	  over	  in	  MSOT	  images.	  Images	  (A-­‐C)	  show	  different	  slice	  thicknesses	  ranging	   from	   11.5,	   12.0	   and	   12.5	  mm.	   Green	   is	   the	   unmixed	   signal	   of	   [NIR-­1],	   red	   is	  unmixed	  signal	  of	  oxygenated	  haemoglobin	  and	  grey	  is	  the	  spectrally	  anatomical	  image	  at	  776	  nm.	  	  In	  figure	  6.13,	  the	  green	  signal	  represents	  the	  unmixed	  photoacoustic	  signal	  from	  
[NIR-­1],	   the	   red	   is	   the	   unmixed	   photoacoustic	   signal	   from	   oxygenated	  haemoglobin	   and	   the	   grey	   is	   the	   anatomical	   image	   generated	   through	   spectral	  unmixing	  of	  the	  photoacoustic	  signal	  at	  776	  nm.	  These	  images	  show	  that	  [NIR-­1]	  is	  readily	  identified	  in	  the	  presence	  of	  endogenous	  photoabosrbers	  in	  the	  brain	  of	   a	   live	  mouse.	   Furthermore,	   no	   photoacoustic	   signal	   was	   observed	   from	   the	  PBS	   injection	   site,	   demonstrating	   that	   this	   technique	  of	   drilling	   a	   hole	   through	  the	  skull	  and	  injecting	  a	  needle	  does	  not	  generate	  artefacts	  that	  would	  decrease	  the	  signal	  to	  noise	  ratio.	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In	   order	   to	   demonstrate	   that	   [NIR-­1]	   is	   binding	   to	   the	   cell	   surface	   NMDA	  receptors	   in	   vivo,	   a	   preliminary	   comparative	   analysis	   of	   the	   clearance	   rate	   of	  
[NIR-­1]	  versus	  the	  non-­‐targeted	  heptamethine	  cyanine	  dye,	  95,	  was	  undertaken.	  It	  was	  envisaged	   that	   if	   [NIR-­1]	   is	  bound	   to	   the	   cell	   surface	  NMDA	  receptor,	   it	  should	   preferentially	   be	   retained	   in	   the	   brain	   for	   longer	   than	   compound	   95,	  showing	  a	  slower	  clearance	  rate.	  To	  investigate	  this,	  1	  µL	  of	  a	  3.6	  mM	  solution	  of	  
[NIR-­1]	  was	  injected	  into	  the	  right	  hemisphere,	  with	  the	  same	  concentration	  of	  compound	  95	  injected	  into	  the	  left	  hemisphere.	  After	  the	  slow	  injection,	  the	  skin	  above	  the	  injection	  site	  was	  sealed	  and	  the	  mouse	  imaged	  (Figure	  6.14).	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  
Figure	   6.14.	   In	   vivo	   imaging	   by	  MSOT	   of	   the	   brain	   of	   an	   8	  week	   old	   female	   athymic	  nude	  mouse	  following	  intracranial	  injection	  of	  [NIR-­1]	  (3.6	  nmol)	  or	  compound	  95	  (3.6	  nmol)	   into	   the	  right	  and	   left	  hemispheres,	   respectively.	  The	  mouse	   is	   lying	  on	   its	  back	  resulting	  in	  right	  and	  left	  being	  swapped	  over	  in	  MSOT	  image.	  The	  image	  clearly	  shows	  
[NIR-­1]	  is	  detectable	  whereas	  compound	  95	  has	  leaked	  from	  the	  injection	  site.	  	  Similar	  to	  figure	  6.13,	  a	  large	  signal	  is	  easily	  observed	  from	  the	  injection	  of	  [NIR-­
1],	  while	  no	  signal	  is	  detected	  from	  compound	  95.	  This	  is	  surprising	  considering	  
95	   possesses	   essentially	   the	   same	   absorption	   properties	   as	   [NIR-­1].	   However,	  due	  to	  the	  large	  amount	  of	  signal	  around	  the	  outside	  of	  the	  injection	  site	  of	  95,	  it	  is	  likely	  that	  the	  injection	  of	  compound	  95	  was	  unsuccessful	  and	  the	  compound	  leaked	   out	   of	   the	   site	   before	   the	   wound	   was	   sealed.	   Nevertheless,	   regions	   of	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interest	   were	   defined	   around	   the	   injection	   site	   of	   [NIR-­1],	   and	   were	   imaged	  continuously	   for	   90	   minutes.	   An	   increase	   in	   signal	   intensity	   was	   observed	  initially,	  and	  this	  decreased	  slowly	  over	  time,	  which	  can	  tentatively	  be	  assigned	  to	  [NIR-­1]	  binding	   to	   the	  cell	   surface	  NMDA	  receptors.	  However,	  a	  much	  more	  thorough	   analysis	   and	   comparison	   to	   the	   clearance	   rate	   of	   compound	   95	   is	  needed	  in	  order	  to	  fully	  relate	  this	  observation	  to	  NMDA	  receptor	  binding.	  
	  
6.6	   	  Conclusions	  	  The	  initial	  aim	  of	  this	  chapter	  was	  to	  design,	  synthesise	  and	  evaluate	  two	  NMDA	  receptor-­‐targeted	   photoacoustic	   contrast	   agents.	   The	   contrast	   agents,	   [NIR-­1]	  and	   [NIR-­2]	   are	   derived	   from	  a	   strongly	   absorbing	  heptamethine	   cyanine	  dye,	  conjugated	  to	  the	  non-­‐competitive	  NMDA	  receptor	  antagonist,	  ifenprodil,	  and	  the	  receptor-­‐binding	  moiety	   of	   [Gd.L12],	   respectively.	   These	   two	   compounds	  were	  fully	  characterised	  before	  analysis	  of	  their	  receptor	  binding	  properties.	  Two	   fluorescence	   microscopy	   methods	   were	   used	   to	   study	   the	   localisation	  profiles	  of	  [NIR-­1]	  and	  [NIR-­2]	  on	  differentiated	  NSC-­‐34	  cells.	  Under	  each	  set	  of	  conditions,	   the	   contrast	   agents	   were	   found	   to	   localise	   on	   the	   cell	   surface,	  consistent	   with	   NMDA	   receptor	   labelling.	   Receptor	   binding	   was	   further	  established	  in	  a	  control	  experiment,	  where	  no	  localisation	  profile	  was	  observed	  when	  NMDA	   receptor-­‐negative	   cells	  were	   treated	  with	   solutions	   of	   [NIR-­1]	   or	  
[NIR-­2].	  Finally,	  the	  most	  promising	  contrast	  agent,	  [NIR-­1],	  was	  found	  to	  bind	  to	   differentiated	   NSC-­‐34	   cells	   in	   a	   reversible	   manner	   in	   the	   presence	   of	   the	  natural	  ligand	  glutamate.	  The	   cellular	   labelling	   ability	   of	   [NIR-­1]	   and	   [NIR-­2]	   was	   also	   assessed	   by	  measuring	   the	   cellular	  photoacoustic	   signal	  using	  MSOT	  on	  differentiated	  NSC-­‐34	   cells.	   The	   contrast	   agent	   [NIR-­1]	   demonstrated	   a	   large	   and	   detectable	  photoacoustic	   signal,	   whereas	   [NIR-­2]	   did	   not	   appear	   to	   label	   cells	   efficiently.	  This	   was	   surprising	   based	   on	   the	   results	   from	   the	   fluorescence	   microscopy	  experiments,	  but	  may	  be	  explained	  by	  either	  a	  reduction	  in	  the	  NMDA	  receptor	  density	  at	  the	  time	  of	  imaging,	  or	  due	  to	  the	  probe	  concentration/affinity	  being	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too	   low.	   In	   either	   case	   this	  would	   result	   in	   [NIR-­2]	   being	   unable	   to	   label	   cells	  efficiently	  well.	  	  Conjugation	   of	   the	   relatively	   large	   heptamethine	   cyanine	   dye	   to	   the	   NMDA	  receptor	   antagonist,	   ifenprodil,	   did	   not	   appear	   to	   alter	   receptor	   binding	  properties.	  A	  competition	  experiment	  whereby	  differentiated	  NSC-­‐34	  cells	  were	  pre-­‐treated	   with	   ifenprodil	   before	   loading	   [NIR-­1]	   resulted	   in	   a	   decrease	   in	  cellular	   photoacoustic	   signal.	   This	   suggested	   that	   [NIR-­1]	   binds	   in	   the	   same	  place	  on	  the	  NMDA	  receptor	  as	  ifenprodil,	  but	  with	  a	  lower	  affinity,	  as	  would	  be	  expected.	  Finally,	  preliminary	   in	  vivo	   studies	  were	  carried	  out	   through	  direct	   injection	  of	  
[NIR-­1]	   into	   the	   primary	   motorcortex	   of	   female	   athymic	   nude	   mice.	   The	  photoacoustic	  signal	  was	  easily	  identified	  and	  an	  anatomical	  image	  of	  the	  brain	  generated	   from	   the	   signal	   at	   776	   nm,	   using	  MSOT.	   This	   promising	   result	   was	  extended	   slightly	   by	   a	   preliminary	   study	   of	   the	   probe	   clearance	   rate.	   Upon	  injection	   an	   initial	   increase	   in	   photoacoustic	   signal	   could	   be	   observed,	   which	  slowly	   decreased	   over	   time.	   This	   could	   tentatively	   be	   assigned	   to	   [NIR-­1]	  binding	  to	  the	  cell	  surface	  NMDA	  receptors	  and	  then	  being	  displaced	  over	  time	  and	  removed	  from	  the	  region	  of	   interest.	  Only	  further	  analysis	  and	  comparison	  of	   the	  clearance	  rate	  to	  that	  of	   the	  non-­‐targeted	  heptamethine	  cyanine	  dye,	  95,	  will	  allow	  a	  better	  understanding	  of	  the	  dynamics	  of	  NMDA	  receptor	  binding.	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7.1	   	  General	  Conclusions	  	  At	  the	  outset	  of	  the	  project,	  the	  objective	  was	  to	  design,	  synthesise	  and	  evaluate	  a	  series	   of	   contrast	   agents	   that	   specifically	   targeted	   the	   NMDA	   receptor.	   Initial	  work	   was	   directed	   towards	   the	   development	   of	   NMDA	   receptor-­‐targeted	   MRI	  contrast	   agents,	   since	   this	   imaging	   modality	   is	   regarded	   as	   one	   of	   the	   most	  powerful	  for	  neurological	  research.	  	  Two	  groups	  of	  NMDA	  receptor-­‐targeted	  MRI	  contrast	  agents	  were	  synthesised.	  The	   first	   generation	   contrast	   agents	  were	  based	  on	   a	  paramagnetic	   [Gd.DOTA]	  core,	   conjugated	   via	   a	   pendant	   lysine	   arm	   to	   derivatives	   of	   competitive	  NMDA	  receptor	   antagonists	   derived	   from	   the	   acyclic	   3,4-­‐diamino-­‐3-­‐cyclobutene-­‐1,2-­‐dione	  moiety.	   Of	   the	   four	   first	   generation	   contrast	   agents,	   [Gd.L2]	   and	   [Gd.L4]	  induced	   large	   enhancements	   in	   cellular	   relaxation	   rate	   (170	   and	   176%,	  respectively),	  upon	  incubation	  with	  a	  neuronal	  cell	  line	  model.	  The	  surprising	  result	  that	  the	  most	  potent	  NMDA	  receptor-­‐binding	  moiety	  used	  in	  [Gd.L3]	  did	  not	  induce	  any	  enhancement	  in	  R1,cell	  led	  to	  the	  design	  of	  a	  series	  of	  second	   generation	  NMDA	   receptor-­‐targeted	  MRI	   contrast	   agents.	   Based	   on	   the	  assumption	  that	   intramolecular	  hydrogen	  bonding	  was	  responsible	   for	  the	   lack	  of	   receptor	   binding	   of	   [Gd.L3],	   the	   receptor-­‐binding	  moiety	  was	   rigidified	   in	   a	  bicyclic	   structure,	   so	   that	   the	   conformation	   was	   restricted	   to	   similar	   highly	  potent	  NMDA	  receptor	  antagonists.	  Four	  bicyclic	  NMDA	  receptor-­‐binding	  moieties	  were	  synthesised	  and	  conjugated	  to	   a	   [Gd.DOTA]	   core	   via	   a	   glutaric	   acid	   linker,	   giving	   the	   complexes,	   [Gd.L5-­8].	  Unfortunately,	  upon	  incubation	  of	  these	  contrast	  agents	  with	  differentiated	  NSC-­‐34	   cells,	   no	   significant	   enhancements	   in	   R1,cell	   were	   observed.	   Since	   it	   was	  envisaged	  that	  the	  second	  generation	  receptor-­‐binding	  moieties	  should	  possess	  a	   greater	   receptor	   affinity,	   the	   observation	   of	   no	   relaxation	   rate	   enhancement	  was	   attributed	   to	   the	   close	  proximity	   of	   the	   large	  Gd(III)	   chelate	   to	   the	  NMDA	  receptor-­‐binding	   moiety,	   restricting	   receptor	   binding.	   Therefore,	   the	   chain	  length	   of	   the	   linker	   unit	   was	   extended	   to	   space	   the	   receptor-­‐binding	   moiety	  further	  away	   from	  the	  sterically	  demanding	  paramagnetic	  core,	  generating	  two	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more	   complexes,	   [Gd.L9-­10].	   Incubation	   of	   [Gd.L9]	   with	   differentiated	   NSC-­‐34	  cells	  led	  to	  a	  measureable	  increase	  in	  R1,cell	  	  of	  123%.	  	  Of	   the	   ten	   NMDA	   receptor-­‐targeted	   MRI	   contrast	   agents	   synthesised,	   [Gd.L2],	  
[Gd.L4]	  and	  [Gd.L9]	  gave	  rise	  to	  large	  enhancements	  in	  R1,cell	  consistent	  with	  an	  increase	   in	  rotational	  correlation	  time	  that	   is	  associated	  with	  slower	  molecular	  tumbling	   of	   the	   receptor-­‐bound	   complex.	   In	   order	   to	   further	   confirm	   this,	  derivatives	  of	  [Gd.L4]	  and	  [Gd.L9]	  were	  synthesised	  which	  allowed	  study	  of	  the	  localisation	   profile,	   reversibility	   and	   cellular	   specificity	   of	   binding,	   by	   optical	  microscopy.	   The	   complexes,	   [Gd.L11]	   and	   [Gd.L12]	   (derived	   from	   [Gd.L4]	   and	  
[Gd.L9],	   respectively),	  were	   found	  to	  reside	  on	  the	  cell	  surface	  of	  differentiated	  NSC-­‐34	  cells	  and	  bind	  specifically	  to	  cells	  which	  possess	  NMDA	  receptor	  density.	  The	  complexes	  could	  also	  bind	  reversibly	  at	  the	  NMDA	  receptor	  after	  a	  simulated	  glutamate	   burst,	   with	   the	   ability	   to	   displace	   glutamate	   competitively	   upon	  restoration	  of	  equilibrium.	  The	  complex,	  [Gd.L12],	  was	  found	  to	  label	  cells	  more	  readily	  than	  [Gd.L11],	  suggesting	  that	  the	  affinity	  of	  the	  receptor	  binding	  moiety	  of	   [Gd.L12]	   is	   higher	   than	   the	   receptor-­‐binding	  moiety	   of	   [Gd.L11].	   This	   result	  demonstrated	   that	   the	   length	   of	   the	   spacer	   unit	   between	   the	   receptor-­‐binding	  moiety	  and	  the	  paramagnetic	  core	  can	  have	  a	  significant	  effect	  on	  the	  expected	  gain	  in	  relaxation	  rate.	  Taken	  together,	  these	  results	  suggest	  that	  the	  gadolinium	  complexes	   of	  L2,	  L4	   and	  L9	   are	   promising	  MR	   contrast	   agents	   for	   reporting	   or	  monitoring	  NMDA	  receptor	  density,	  and	  possess	  the	  ability	  to	  report	  on	  synaptic	  glutamate	  activity.	  Following	  the	  success	  achieved	  with	  the	  two-­‐component	  optical	  imaging	  probes,	  
[Gd.L11]	  and	  [Gd.L12],	   it	  was	  reasoned	  that	  a	  single	  component	  optical	   imaging	  contrast	   agent	   may	   be	   more	   desirable	   and	   could	   potentially	   replace	   standard	  radiolabelled	  ligands	  in	  biological	  assays.	  A	  new	  complex,	  [Eu.L13],	  was	  designed	  and	   synthesised	   based	   on	   the	   europium	   complex	   of	   a	   9-­‐N-­‐3-­‐tris-­‐arylalkynylpyridyl	   ligand	  with	   a	   pendant	   lysine	   arm,	   conjugated	   to	   the	   NMDA	  receptor-­‐binding	   moiety	   of	   [Gd.L12].	   The	   localisation	   profile	   of	   [Eu.L13]	   on	  differentiated	   NSC-­‐34	   cells	   was	   studied	   using	   live-­‐cell	   laser	   scanning	   confocal	  microscopy.	   Disappointingly,	   there	   was	   no	   cell-­‐surface	   localisation	   and	   only	   a	  small	   degree	   of	   complex	   internalisation	   was	   observed.	   The	   internalisation	  mechanism	   was	   found	   to	   be	   non-­‐receptor	   mediated	   and	   it	   is	   reasonable	   to	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assume	   that	   the	   localisation	   of	   [Eu.L13]	   is	   dictated	   by	   the	   large	   nature	   of	   the	  parent	  Eu(III)-­‐complex	  and	  not	  by	   the	   relatively	   small	  NMDA	  receptor-­‐binding	  moiety.	  
Chapter	   6	   described	   the	  development	  of	   two	  NMDA	   receptor-­‐targeted	   contrast	  agents	   for	   photoacoustic	   imaging.	   The	   contrast	   agents	   were	   based	   on	  conjugation	  of	  the	  non-­‐competitive	  NMDA	  receptor	  antagonist,	  ifenprodil,	  or	  the	  receptor-­‐binding	   moiety	   of	   [Gd.L12],	   to	   a	   strongly	   absorbing	   heptamethine	  cyanine	   dye.	   The	   cellular	   labelling	   ability	   of	   [NIR-­1]	   and	   [NIR-­2]	   on	  differentiated	  NSC-­‐34	  cells	  was	  first	  assessed	  by	  fluorescence	  microscopy.	  Under	  two	  separate	  sets	  of	  conditions,	  the	  contrast	  agents	  were	  found	  to	  reside	  on	  the	  cell	   surface,	   consistent	   with	   NMDA	   receptor	   labelling.	   Further	   fluorescence	  microscopy	  experiments	  demonstrated	  that	  [NIR-­1]	  and	  [NIR-­2]	  only	  label	  cells	  that	   express	   functional	   NMDA	   receptors,	   and	   that	   [NIR-­1]	   can	   bind	   in	   a	  reversible	   manner	   after	   a	   simulated	   glutamate	   burst.	   Such	   behaviour	   is	  consistent	  with	  [NIR-­1]	  and	  [NIR-­2]	  binding	  to	  the	  cell-­‐surface	  NMDA	  receptor.	  The	   cellular	   labelling	   ability	   of	   [NIR-­1]	   and	   [NIR-­2]	   was	   also	   assessed	   by	  measuring	   the	  photoacoustic	   signal	  using	  MSOT	  on	  differentiated	  NSC-­‐34	  cells.	  Whilst	   incubation	   of	   [NIR-­1]	   generated	   a	   large	   and	   detectable	   cellular	  photoacoustic	  signal	  consistent	  with	  the	  fluorescence	  microscopy	  results,	  [NIR-­
2]	   did	   not	   appear	   to	   label	   differentiated	   NSC-­‐34	   cells	   at	   all.	   Although	   this	  contradictive	  result	  for	  [NIR-­2]	  was	  surprising,	  [NIR-­1]	  was	  further	  evaluated	  in	  
vivo.	  Direct	  injection	  of	  [NIR-­1]	  into	  the	  primary	  motorcortex	  of	  female	  athymic	  nude	  mice	  resulted	  in	  a	  large,	  detectable	  photoacoustic	  signal,	  which	  only	  slowly	  decreased	  over	  time.	  Despite	  these	  being	  preliminary	  studies,	  the	  results	  gained	  so	   far	   are	  promising	  and	   can	   tentatively	  be	   assigned	   to	   [NIR-­1]	   binding	   to	   the	  cell-­‐surface	  NMDA	  receptors	  in	  a	  mouse	  brain.	  	  
7.2	   	  Future	  Work	  	  The	   cellular	   labelling	   ability	   (R1,cell	   enhancements),	   cellular	   specificity	   and	  reversibility	   of	   binding	   of	   [Gd.L2],	   [Gd.L4]	   and	   [Gd.L9]	  make	   these	   complexes	  very	  promising	  as	  NMDA	  receptor-­‐targeted	  MRI	  contrast	  agents.	  It	  is	  difficult	  to	  envisage	  improvements	  in	  their	  receptor-­‐binding	  properties	  without	  moving	  to	  a	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completely	   new	   receptor-­‐binding	   moiety.	   However,	   it	   may	   be	   possible	   to	  improve	   the	   relaxation	   rate	   enhancement	   of	   [Gd.L9]	   towards	   similar	  enhancements	  gained	  by	  [Gd.L2]	  and	  [Gd.L4].	  Optical	  microscopy	  studies	  suggest	  that	  [Gd.L9]	  possesses	  the	  receptor-­‐binding	  moiety	  with	  the	  highest	  affinity	  and	  so	  the	  lower	  R1,cell	  enhancement	  may	  be	  due	  to	  the	  chain	  length	  of	  the	  linker	  unit.	  By	  reducing	  the	  length	  of	  the	  linker	  in	  [Gd.L9],	  such	  that	  receptor-­‐binding	  is	  not	  inhibited	   and	   rotational	   motion	   remains	   coupled,	   an	   optimal	   linker	   unit	   may	  increase	  the	  R1,cell	  enhancement.	  It	  is	  also	  recognised	  that	  [Gd.L9]	  is	  present	  as	  a	  racemic	  mixture	  when	  incubated	  with	   differentiated	   NSC-­‐34	   cells.	   The	   stereochemical	   preference	   for	   ligand	  binding	   is	   partially	   described	   in	   chapter	   1,	   and	   it	   is	   envisaged	   that	   one	  enantiomer	   of	   [Gd.L9]	  might	   exhibit	   a	   higher	  NMDA	   receptor	   affinity	   than	   the	  other.	  Therefore,	   it	  may	  be	  worthwhile	   to	  separate	   the	   two	  enantiomers	  of	   the	  precursor	  amine	  and	  evaluate	  the	  derived	  complexes	  in	  terms	  of	  their	  ability	  to	  induce	  enhancements	  in	  R1,cell.	  A	  considerable	  amount	  of	  progress	  has	  been	  made	  over	  the	  last	  three	  years	  and	  the	  next	   step	   in	   assessment	  of	   [Gd.L2],	   [Gd.L4]	   and	   [Gd.L9]	   as	  potential	  NMDA	  receptor-­‐targeted	  MR	  contrast	  agents	   is	  to	  evaluate	  these	  complexes	   in	  vivo.	  As	  these	   complexes	   will	   be	   unable	   to	   penetrate	   the	   blood-­‐brain-­‐barrier,	   direct	  injection	  of	   the	   contrast	  agent	   into	   regions	  of	   the	  brain	  expressing	  high	  NMDA	  receptor-­‐density,	   to	   create	   a	   steady-­‐state	   local	   concentration,	   will	   allow	   real-­‐time	   monitoring	   of	   probe-­‐receptor	   binding	   during	   application	   of	   an	   external	  stimulus.	   Furthermore,	   by	   using	   an	   appropriate	   animal	   model,	   these	   contrast	  agents	  have	  the	  potential	  to	  report	  upon	  diseased	  states	  where	  NMDA	  receptor	  density	  is	  decreased	  or	  receptor	  binding	  is	  inhibited.	  A	   second	   area	   of	   future	   development	   is	   to	  modify	   the	   complex,	   [Eu.L13],	   such	  that	  the	  NMDA	  receptor-­‐binding	  moiety	  will	  dictate	  the	  localisation	  profile	  of	  the	  complex.	  One	  possible	  way	  is	  by	  changing	  the	  conjugation	  point	  of	  the	  receptor-­‐binding	   moiety	   (Scheme	   7).	   Positioning	   the	   receptor-­‐binding	   moiety	   at	   the	  periphery	   of	   the	   arylalkynylpyridyl	   chromophores	   may	   increase	   receptor	  binding	  and	  limit	  the	  degree	  of	  non-­‐specific	  protein	  binding	  leading	  to	  complex	  internalisation.	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The	  complex,	  [Eu.LMD],	  was	  used	  as	  a	  FRET	  donor	  to	  excite	  [NIR-­1]	  and	  [NIR-­2]	  in	   the	   fluorescence	   microscopy	   experiments	   in	   chapter	   6.	   This	   complex	   was	  observed	  everywhere	  in	  the	  cell	  culture	  medium	  and	  did	  not	  bind	  to,	  or	  be	  taken	  up	   by,	   differentiated	   NSC-­‐34	   cells.	   Therefore,	   elaboration	   of	   the	  triazacyclononane	  core	  of	  this	  complex	  with	  a	  pendant	  lysine	  arm,	  conjugated	  to	  an	  NMDA	  receptor-­‐binding	  moiety,	  may	  give	  rise	  to	  a	  Eu(III)-­‐complex	  which	  has	  the	  ability	  to	  label	  the	  NMDA	  receptor	  of	  differentiated	  NSC-­‐34	  cells	  (Scheme	  7).	  Providing	  one	  of	  these	  complexes	  is	  successful,	  they	  have	  the	  potential	  to	  replace	  standard	  radiolabelled	  ligands,	  or	  two	  component	  immunoflourescence	  ligands,	  used	  in	  biological	  assays.	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neuroscience	   research	   in	  diseased-­‐based	  circumstances,	  when	   the	  blood-­‐brain-­‐barrier	  is	  damaged.	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8.	  Experimental	  
8.1	  Experimental	  Procedures	  
	  
8.1.1	  General	  Procedures	  
	  All	  solvents	  used	  were	  laboratory	  grade	  and	  anhydrous	  solvents,	  when	  required,	  were	  freshly	  distilled	  over	  the	  appropriate	  drying	  agent.	  Water	  was	  purified	  by	  the	  ‘PuriteSTILLplus’	  system,	  with	  conductivity	  of	  ≤	  4	  μS	  cm-­‐1.	  All	  reagents	  used	  were	   purchased	   from	   commercial	   suppliers	   (Acros,	   Aldrich,	   Fluka,	   Merck	   and	  Strem)	   and	   were	   used	   without	   further	   purification	   unless	   otherwise	   stated.	  Reactions	   requiring	   anhydrous	   conditions	  were	   carried	   out	   using	   Schlenk	   line	  techniques	  under	  an	  atmosphere	  of	  argon.	  	  	  Thin	  layer	  chromatography	  was	  performed	  on	  neutral	  aluminium	  sheet	  silica	  gel	  plates	  (Merck	  Art	  5554)	  and	  visualised	  under	  UV	  irradiation	  (254	  nm),	  or	  using	  specific	   reagent	   staining.	   Preparative	   column	   chromatography	   was	   performed	  using	  silica	  gel	  (Merck	  Silica	  Gel	  60,	  230-­‐400	  mesh).	  	  	  1H,	  13C	  and	  31P	  NMR	  spectra	  were	  recorded	  in	  commercially	  available	  deuterated	  solvents	  on	  a	  Varian	  Mercury-­‐400	  (1H	  399.960,	  13C	  100.572),	  Bruker	  Avance-­‐400	  (1H	   400.052,	   13C	   100.603	   and	   31P	   161.91),	   Varian	   Inova-­‐500	   (1H	   499.722,	   13C	  125.671,),	   Appleby	  VNMRS-­‐600	   (1H	  599.832,	   13C	   	   150.828),	   or	  Varian	  VNMRA-­‐700	  (1H	  699.731,	  13C	  	  175.948	  and	  31P	  283.26)	  spectrometer.	  All	  chemical	  shifts	  are	   given	   in	   ppm	   and	   all	   coupling	   constants	   are	   three-­‐bond,	   unless	   otherwise	  stated,	  and	  are	  reported	  in	  Hz.	  	  	  Low-­‐resolution	   electrospray	  mass	   spectra	   (LR-­‐MS)	  were	   recorded	   on	   a	   Fisons	  VG	  Platform	  II,	  Waters	  Micromass	  LCT	  or	  Thermo-­‐Finnigan	  LTQ	  FT	   instrument	  operating	  in	  positive	  or	  negative	  ion	  mode	  as	  stated,	  with	  MeOH	  or	  MeCN	  as	  the	  carrier	   solvent.	   High-­‐resolution	   electrospray	   mass	   spectra	   (HR-­‐MS)	   were	  recorded	  using	  the	  Thermo-­‐Finnigan	  LTQ	  FT	  mass	  spectrometer.	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Reverse	   phase	   HPLC	   was	   performed	   at	   298	   K	   on	   a	   Perkin	   Elmer	   system,	  comprising	   a	   Perkin	   Elmer	   Series	   200	   pump,	   Perkin	   Elmer	   Series	   200	   auto-­‐sampler,	  Perkin	  Elmer	  Series	  200	  UV/Vis	  detector	  and	  Perkin	  Elmer	  Series	  200	  fluorescence	   detector.	   Either	   an	   XBridge	   C18	   column,	   4.6	   x	   100	  mm,	   i.d.	   5	   µm	  (flow	  rate	  2	  mL/minute)	  or	  an	  XBridge	  C18	  column,	  19	  x	  100	  mm,	  i.d.	  5	  µm	  (flow	  rate	   17	   mL/	   minute)	   was	   used	   with	   run	   times	   varying	   between	   20	   and	   30	  minutes.	  Solvent	  systems	  comprising	  gradient	  elusions	  of	  H2O	  (0.1%	  FA)/	  MeOH	  (0.1%	  FA)	  or	  25	  mM	  triethylammonium	  acetate	  buffer	  (pH	  7)/	  MeCN	  were	  used.	  	  Melting	   points	   were	   recorded	   using	   a	   Gallenkamp	   (Sanyo)	   apparatus	   and	   are	  uncorrected.	  	  	  Relaxivity	  measurements	  were	  carried	  out	  at	  310	  K,	  60	  MHz	  (1.4	  T)	  on	  a	  Bruker	  Minispec	  mq60	  instrument.	  The	  mean	  value	  of	  three	  independent	  measurements	  was	  recorded	  and	  averaged.	  The	  relaxivities	  of	   the	  compounds	  were	  calculated	  as	  the	  slope	  of	  the	  function	  shown	  in	  equation	  8,	  	  	  	   	   	   	   	   	  (8)	  	  where	   T1,obs	   is	   the	   measured	   T1,	   T1,d	   is	   the	   diamagnetic	   contribution	   of	   the	  solvent	  (calculated	  to	  be	  4000	  ms)	  and	  [Gd.Ln]	  is	  the	  concentration	  in	  mM	  of	  the	  appropriate	  Gd3+	  complex	  (n	  =	  1	  -­‐	  12).	  	  	  The	   apparent	   binding	   constant	   for	   the	   interaction	   of	   the	   Gd3+	   complexes	  with	  Human	  Serum	  Albumin	  (HSA)	  was	  calculated	  using	  equation	  8.1:	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where:	   [X]:	   the	   total	   concentration	   of	   HSA	   in	   the	   solution;	   [Gd.Ln]:	   the	   total	  concentration	   of	   the	   complex;	   K:	   the	   binding	   constant;	   R:	   relaxation	   rate	   of	   a	  given	  concentration	  of	  X;	  R0:	   the	   initial	  relaxation	  rate;	  R1:	   final	  relaxation	  rate;	  [Gd.X]:	   the	   concentration	   of	   the	   HSA-­‐	   coordinated	   complex;	   [Xf]:	   the	  concentration	   of	   free	   HSA	   in	   the	   mixture;	   [Gdf]:	   the	   concentration	   of	   the	   free	  complex.	  	  All	   samples	   for	  optical	   analyses	  were	   contained	   in	  quartz	   cuvettes	  with	   a	  path	  length	   of	   1	   cm	   and	   a	   polished	   base.	   Measurements	   were	   recorded	   at	   298	   K.	  UV/Vis	   absorbance	   spectra	   were	   measured	   on	   a	   Perkin	   Elmer	   Lambda	  900UV/Vis/NIR	   spectrometer	   using	   FL	   Winlab	   software.	   Samples	   were	  measured	   relative	   to	   a	   reference	   of	   pure	   solvent	   contained	   in	   a	   matched	   cell.	  Emission	   spectra	   were	   measured	   on	   a	   ISA	   Joblin-­‐Yvon	   Spex	   Fluorolog-­‐3	  luminescent	   spectrometer	   using	   DataMax	   v2.20	   software.	   Excitation	  wavelengths	   were	   selected	   according	   to	   the	   specific	   measurement.	   An	  integration	  time	  of	  0.5	  seconds,	  increment	  of	  0.5	  nm	  and	  scitation	  and	  emission	  slit	   widths	   of	   2.5	   and	   1.5	   nm,	   respectively,	   were	   used	   throughout.	   Lifetime	  measurements	   were	   carried	   out	   on	   a	   Perkin	   Elmer	   LS55	   luminescence	  spectrometer.	  
	  
8.1.2	  Cell	  culture	  	  
	  Cell	  culture	  was	  performed	  by	  Dr’s	  Robert	  Pal	  or	  Sven	  Gottschalk.	   In	  short,	   the	  NSC-­‐34	   cells	   were	   cultured	   in	   a	   1:1	   mixture	   of	   Dulbecco’s	   modified	   Eagle’s	  (DMEM)	   and	   F12	   medium	   supplemented	   with	   fetal	   bovine	   serum	   (FBS,	   10%	  v/v),	   non	   essential	   amino	   acids	   (0.5%)	   and	   Penicillin/Streptomycin	   (0.1%).	   At	  approximately	  90%	  confluence	  after	  3	  healthy	  passages,	  cells	  were	  sub-­‐cultured	  into	  a	  different	  growth	  medium,	  which	  contained	  a	  mixture	  of	  DMEM/Ham’s	  F12	  (1:1),	   FBS	   (1%),	   non-­‐essential	   amino	   acids	   (1%)	   and	   Penicillin/Streptomycin	  (0.1%).	  Cells	  were	  allowed	  to	  proliferate	  over	  a	  period	  of	  several	  days	  to	  allow	  for	  the	  growth	  of	  functional	  NMDA	  receptors.	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NIH-­‐3T3	   cells	  were	  maintained	   in	   an	   exponential	   growth	   as	  monolayers	   in	   an	  appropriate	   medium,	   which	   was	   supplemented	   with	   10%	   fetal	   bovine	   serum	  (FBS)	  and	  1%	  penicillin	   and	   streptomycin.	  Cells	  were	   incubated	  at	  37	   °C,	  20%	  average	  humidity	  and	  5%	  (v/v)	  CO2.	  	  
8.1.2.1	  Immunofluorescence	  measurements	  
	  NSC-­‐34	   cells	   grown	   and	   differentiated	   for	   1	   week	   on	   surface-­‐modified	   glass	  chamber	   slides	   (Thermo	   Scientific	   Nunc,	   Denmark)	   were	   fixed	   for	   10	   min	   at	  room	   temperature	   with	   4%	   paraformaldehyde	   (Roti®-­‐Histofix	   4%,	   Roth,	  Germany).	  Non-­‐specific	  antibody	  binding	  sites	  were	  blocked	  by	  incubating	  for	  30	  min	  with	  10%	  (v/v)	  goat-­‐serum	  in	  PBST.	  Fixed	  cells	  were	  then	   incubated	  for	  2	  hours	  with	  the	  primary	  antibodies	  for	  the	  NMDA	  receptor	  subunits	  NMDAR-­‐1	  or	  NMDAR-­‐2B	   (diluted	   in	   1%	   BSA	   (Roth,	   Germany)	   in	   PBST)	   in	   a	   humidified	  chamber	  at	  RT.	  After	  washing,	  cells	  were	  incubated	  with	  secondary	  antibodies	  in	  1%	  BSA	  in	  PBST	  in	  the	  humidified	  chamber	  in	  the	  dark.	  Afterwards	  cellular	  DNA	  was	  stained	  with	  16.2µM	  Hoechst	  33342	  (Merck,	  Germany)	  for	  15	  min	  and	  slides	  were	   mounted	   overnight	   with	   Mowiol	   4-­‐88	   (Roth,	   Germany)	   containing	   50	  mg/mL	   of	   the	   anti-­‐bleaching	   reagent	   1,4-­‐diaza-­‐bicyclo[2.2.2]octane	   (Roth,	  Germany).	  Microscopic	  images	  were	  taken	  on	  a	  Zeiss	  Axiovert	  200	  M	  microscope	  (Germany)	  using	  appropriate	  fluorescence	  filters	  and	  a	  Zeiss	  Plan	  APOCHROMAT	  63x/1.4	   oil	   DIC	   objective.	   Volocity	   acquisition	   and	   visualisation	   software	   5.2.0	  (Perkin	   Elmer,	   USA,	   MA)	   was	   used	   for	   image	   capture	   and	   analysis.	   The	   used	  antibodies	  were	   as	   follows	   and	   all	   antibodies	  were	   obtained	   from	  Abcam	   (UK,	  Cambridge).	   Primary	   antibodies,	   rabbit	   polyclonal	   to	   NMDAR2B	   or	   NMDAR1;	  secondary	  antibody,	  goat	  polyclonal	  to	  rabbit	  IgG	  –	  H&L	  conjugated	  to	  Cy3.	  	  
8.1.2.2	  Cytotoxicity	  	  IC50	   values	   were	   determined	   using	   the	   MTT	   assay,	   which	   makes	   use	   of	   the	  conversion	   of	   MTT	   (3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐diphenyltetrazolium	  bromide)	  to	  a	  purple	  formazan	  product	  by	  the	  mitochondrial	  dehydrogenase	  of	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viable	   cells.	   This	   insoluble	   formazan	   was	   quantified	   spectrophotometrically	  upon	  dissolution	   in	  DMSO.	  Approximately	  5	  x	  103	  differentiated	  NSC-­‐34	  cells	   in	  100	   μL	   culture	   medium	  were	   seeded	   into	   each	   well	   of	   flat-­‐bottomed	   96-­‐well	  plates	   and	   allowed	   to	   attach	   overnight.	   Complex	   solutions	   were	   added	   to	  triplicate	  wells	   to	   give	   final	   concentrations	   over	   a	   2-­‐log	   range.	   Following	   24	   h	  incubation,	  MTT	  (1.0	  mM)	  was	  added	  to	  each	  well,	  and	  the	  plates	  incubated	  for	  a	  further	  4	  h.	  The	  culture	  medium	  was	  removed,	  and	  DMSO	  (150	  μL)	  was	  added.	  The	   plates	   were	   shaken	   for	   20	   seconds	   and	   the	   absorbance	   measured	  immediately	  at	  540	  nm	  in	  a	  microplate	  reader.	   IC50	  values	  were	  determined	  as	  the	  drug	  concentration	  required	  to	  reduce	  the	  absorbance	  to	  50%	  of	  that	  in	  the	  untreated,	   control	   wells,	   and	   represent	   the	   mean	   for	   data	   from	   at	   least	   three	  independent	  experiments	  	  
8.1.3	  Measurement	  of	  Cellular	  Relaxation	  Rates	  at	  3	  T	  	  
	  Differentiated	   NSC-­‐34	   cells	   were	   grown	   to	   confluency	   and	   trypsinised	   with	  Trypsin/EDTA	  0.05/0.02%	  (w/v)	  (Biochrom	  AG,	  Germany),	  centrifuged	  and	  re-­‐suspended	  to	  1	  x	  107	  cells/	  500	  μL	  HBSS	  in	  750	  μL	  Eppendorf	  tubes.	  A	  maximum	  of	  20	  μL	  of	  highly	  concentrated	  stock	  solutions	  of	  the	  compounds	  were	  added	  to	  give	   200	   μM	   solutions;	   cells	   were	   incubated	   for	   45	   min.	   at	   37°C,	   10%	   CO2.	  Afterwards,	  cells	  were	  centrifuged	  (300×g,	  5	  min.,	  RT)	  and	  the	  supernatant	  was	  kept	   for	   MR-­‐	   measurements.	   Cells	   were	   washed	   once	   with	   HBSS,	   centrifuged	  again	  (300×g,	  5	  min.,	  RT)	  and	  re-­‐suspended	  carefully	  in	  500	  μL	  of	  HBSS.	  In	  some	  experiments	  the	  wash-­‐solution	  was	  also	  kept	  for	  MR-­‐measurements.	  Cells	  were	  allowed	  to	  settle	  down	  before	  making	  MR-­‐measurements.	  MR	  imaging	  of	  the	  cell	  pellets	   and	   supernatants,	   data	   analysis	   and	   determination	   of	   the	   cellular	  relaxation	  rates	  R1,cell	  were	  assessed	  from	  the	  measured	  T1	  values,	  	  according	  to	  the	  literature.	  Briefly,	   MR	   measurements	   were	   performed	   on	   a	   clinical	   3T	   (128	   MHz,	   21°C)	  human	   MR	   scanner	   (MAGNETOM	   Tim	   Trio,	   Siemens	   Healthcare,	   Germany).	  Longitudinal	   relaxation	   times	   (T1)	  were	  measured	  using	   an	   inversion	   recovery	  sequence	   to	   obtain	   images	   from	   a	   1	  mm	   thick	   slice	   through	   the	   samples.	   The	  inversion	   time	   (Ti)	   was	   varied	   from	   23	  ms	   to	   3000	  ms	   in	   about	   12-­‐17	   steps.	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Images	  were	  read	  out	  with	  a	  turbo	  spin	  echo	  technique,	  acquiring	  5	  echoes	  per	  scan.	  The	   repetition	   time	   (TR)	  was	  10.000	  ms	   to	  ensure	  complete	   relaxation.	  A	  matrix	  of	  256	  x	  256	  voxels	  was	  used	  over	  a	  field-­‐of-­‐view	  of	  110	  x	  110	  mm2.	  Six	  averages	  per	  Ti	  were	  possible	  within	  18	  min.	  	  Fitting	  to	  relaxivity	  curves	  was	  done	  using	  self-­‐written	  routines	  in	  MATLAB	  6.5	  R13	  (The	  Mathworks	  Inc.,	  USA).	  T1	  relaxation	  data	  with	  varying	  t	  =	  TR	  were	  fitted	  to	  S=S0(1-­‐a	  ×	  exp(-­‐	  t/T1)).	  Nonlinear	  least-­‐squares	  fitting	  of	  three	  parameters	  S0	  (initial	  signal	  at	  t=0),	  T1	  and	  a	  was	  done	  for	  each	  voxel	  with	  the	  Gauss-­‐Newton	  method	   (MATLAB	   function	   nlinfit).	   For	   each	   fitted	   parameter,	   the	   95%	  confidence	   intervals	   were	   calculated	   (MATLAB	   functions	   nlparci,	   nlpreci)	   and	  used	   as	   an	   error	   estimate	   of	   the	   fitted	   relaxation	   times	   T1	   and	   S0.	   The	   fit	  procedure	   resulted	   in	  parameter	  maps	  of	  T1,	   S0	  and	  corresponding	  error	  maps	  σT1,	  σS0.	  	  Circular	   image-­‐regions	   in	  the	  tubes	  were	  defined	  as	  Regions	  Of	  Interest	  (ROIs),	  and	  the	  means	  and	  distribution	  width	  of	  the	  relaxation	  times	  of	  voxels	   in	  these	  regions	  were	   calculated.	  An	   iterative	  Gaussian	   fit	  was	  used	   to	  determine	  mean	  and	  standard	  deviation	  (SD)	  of	  a	  distribution	  with	  outliers’	   correction.	  For	   this	  purpose,	   a	  distribution	  histogram	  was	   first	   fitted	   to	  a	  Gaussian	   to	  estimate	   the	  mean	   and	   SD.	   The	   tails	   of	   the	   distribution	   were	   then	   discarded	   by	   using	   a	  threshold	  of	  three	  SDs.	  A	  repeated	  fit	  proved	  to	  be	  robust	  and	  converged	  to	  the	  'true'	  Gaussian	  mean	  and	  width	  of	  the	  distribution	  barring	  the	  outliers,	  observed	  as	  a	  result	  of	  the	  non-­‐linear	  fit	  of	  noisy	  voxels.	  The	  processing	  of	  the	  relaxation	  data	  thus	  resulted	  in	  specific	  R1	  =	  1/T1	  values	  for	  each	  tube	  sample,	  including	  the	  standard	  deviation	   in	   the	   selected	  ROI	   ensemble.	  The	  ensemble	  error	  matched	  closely	  the	  errors	  of	  a	  single-­‐voxel	  fit,	  which	  showed	  that	  no	  further	  systematic	  errors	  were	  introduced	  by	  the	  image	  encoding.	  	  
8.1.4	  Confocal	  Microscopy	  and	  Cell	  Spectral	  Imaging	  
	  Cell	   images	   and	   co-­‐localisation	   experiments	   of	   [Gd.L11-­12]	   and	   [Eu.L12-­14]	  were	  obtained	  using	  a	  Leica	  SP5	  II	  microscope.	  A	  HeNe	  laser	  was	  used	  to	  visualise	  SA-­‐AF488	  fluorescence.	  The	  microscope	  was	  equipped	  with	  a	  triple	  channel	  imaging	  detector,	  comprising	  two	  conventional	  PMT	  systems	  and	  a	  HyD	  hybrid	  avalanche	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photodiode	  detector.	  The	   latter	  part	  of	   the	  detection	  system,	  when	  operated	   in	  the	  BrightRed	  mode,	   is	  capable	  of	   improving	   imaging	  sensitivity	  above	  550	  nm	  by	   25%,	   reducing	   signal	   to	   noise	   by	   a	   factor	   of	   5.	   The	   pinhole	   was	   always	  determined	  by	   the	  Airy	  disc	   size,	   calculated	   from	   the	  objective	   in	  use	   (HCX	  PL	  APO	  63x/1.40	  NA	   LbdBlue),	   using	   the	   lowest	   excitation	  wavelength	   (488	   nm).	  Scanning	  speed	  was	  adjusted	  to	  400	  Hz	  in	  a	  bidirectional	  mode,	  to	  ensure	  both	  sufficient	   light	   exposure	   and	   enough	   time	   to	   collect	   the	   emitted	   light	   from	   the	  optical	  probes	  (1024	  x	  1024	  frame	  size,	  a	  pixel	  size	  of	  120	  x	  120	  nm	  and	  depth	  of	  0.89	  μm).	  	  The	  average	  image	  intensity	  of	  each	  phase	  was	  assessed	  as	  triplicates	  using	  3	  cells	  (excluding	  the	  axon)	  within	  each	  image.	  	  Cell	   Microscopy	   and	   spectral	   imaging	   of	   [NIR-­1]	   and	   [NIR-­2]	   in	   cells	   was	  achieved	  using	  a	  custom	  built	  microscope	  (modified	  Zeiss	  Axiovert	  200M),	  using	  a	  Zeiss	  APOCHROMAT	  63x/1.40	  NA	  objective	  combined	  with	  a	   low	  voltage	  365	  nm	   pulsed	   UV	   LED	   focused,	   collimated	   excitation	   source	   (1.2W).	   For	   rapid	  spectral	  acquisition	   the	  microscope	  was	  equipped	  at	   the	  X1	  port	  with	  a	  Peltier	  cooled	   2D-­‐CCD	   detector	   (Ocean	   Optics)	   used	   in	   an	   inverse	   100	   Hz	   time	   gated	  sequence.	   The	   spectrum	  was	   recorded	   from	   400-­‐800	   nm	  with	   a	   resolution	   of	  0.24	   nm	   and	   the	   final	   spectrum	  was	   acquired	   using	   an	   averaged	   10,000	   scan	  duty	   cycle.	   Probe	   lifetimes	   were	   measured	   on	   the	   same	   microscope	   platform	  using	  a	  novel	  cooled	  PMT	  detector	  (Hamamatsu	  H7155)	  interchangeable	  on	  the	  X1	  port.	  Both	  the	  control	  and	  detection	  algorithm	  were	  written	  in	  LabView2011.	  	  	  
8.1.5	  Multispectral	  Optoacoustic	  Imaging	  
	  In	   short,	   a	   tunable	   optical	   parametric	   oscillator	   pumped	   by	   an	   Nd:YAG	   laser	  	  allows	  	  excitation	  	  from	  	  680	  	  nm	  	  to	  	  980	  	  nm.	  	  Laser	  pulse	  duration	  is	  below	  10	  ns	   and	   the	   pulse	   repetition	   frequency	   is	   10	   Hz.	   The	   beam	   is	   coupled	   into	   a	  custom	   fiber	   bundle	   that	   is	   divided	   into	   10	   output	   arms,	   allowing	   even	  illumination	  around	  the	  circumference	  of	  the	  mouse	  with	  a	  ring-­‐shape	  pattern.	  	  A	  custom-­‐made	  piezo	  composite	  ultrasonic	  cylindrically	  focused	  transducer	  array	  with	   256	   elements	   and	   a	   central	   frequency	   of	   5	   MHz	   is	   used	   for	   detection.	  	  Transducer	   array,	   fiber	  bundle	   outputs	   and	   sample	  holder	   are	   submerged	   in	   a	  water	   bath	   maintained	   at	   34	   °C.	   Samples	   are	   placed	   in	   a	   horizontal	   position	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8.2	   	  Synthetic	  Procedures	  	  
3-­Amino-­4-­ethoxy-­3-­cyclobutene-­1,2-­dione,	  11	  
	  
	  	  To	   a	   solution	   of	   3,4-­‐diethoxy-­‐3-­‐cyclobutene-­‐1,2-­‐dione	   (888	   µL,	   6.0	   mmol)	   in	  anhydrous	   EtOH	   (15	   mL),	   was	   added	   a	   solution	   of	   NH3	   in	   EtOH	   (3.3	   mL,	   6.6	  mmol)	  and	  the	  reaction	  mixture	  was	  stirred	  at	  room	  temperature	  for	  16	  hours.	  EtOH	  was	  removed	  under	  reduced	  pressure	  and	  the	  solid	  residue	  triturated	  with	  cold	  hexane	  to	  reveal	  the	  title	  compound	  as	  a	  white	  powder	  (815	  mg,	  96%).	  1H	  NMR	  (CDCl3,	  400	  MHz)	  δ	  1.47	  (3H,	  t,	  J	  =	  7,	  OCH2CH3),	  4.47	  (2H,	  q,	  J	  =	  7,	  OCH2CH3),	  5.83	   (2H,	   s,	   br,	   NH2).	   13C	   NMR	   (CDCl3,	   400	   MHz)	   δ	   15.9	   (OCH2CH3),	   70.1	  (OCH2CH3),	   173.4	   (C=CNH2),	   179.2	   (C=COEt),	   184.4,	   189.2	   (CO).	   MS	   (ES-­‐)	  m/z	  140.1	   [M-­‐H]-­‐;	   C6H7NO3Na	   requires	   164.0315;	   found	   164.0324.	   Rf	   =	   0.28	  (DCM/MeOH,	  95:5).	  M.	  Pt.	  143-­‐145	  °C.	  	  	  
tert-­Butyl	  (2-­ethoxy-­3,4-­dioxocyclobut-­1-­en-­1-­yl)carbamate,	  2	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g,	   55%).	   1H	  NMR	   (CDCl3,	   400	  MHz)	  δ	   1.51	   (3H,	   t,	   J	   =	  7,	  OCH2CH3),	   1.54	   (9H,	   s,	  C(CH3)3),	  4.89	  (2H,	  q,	  J	  =	  7,	  OCH2CH3),	  7.53	  (1H,	  s,	  br,	  NH).	  13C	  NMR	  (CDCl3,	  101	  MHz)	  δ	   16.0	   (OCH2CH3),	   28.1	   (C(CH3)3),	   70.8	   (OCH2CH3),	   84.6	   (C(CH3)3),	   149.0	  (C=CNH),	   167.2	   (C=COEt),	   182.3,	   187.1,	   187.8	   (CO).	   MS	   (ES+)	   m/z	   =	   242.1	  [M+H]+;	  C11H15NO5	  requires	  242.1022;	  found	  242.1023.	  M.	  Pt.	  163-­‐165	  °C.	  	  	  
tert-­Butyl	   2-­((2-­((tert-­butoxycarbonyl)amino)-­3,4-­dioxocyclobut-­1-­en-­1-­
yl)amino)acetate,	  3	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tert-­Butyl	   2-­((2-­((tert-­butoxycarbonyl)amino)-­3,4-­dioxocyclobut-­1-­en-­1-­
yl)(2-­methoxy-­2-­oxoethyl)amino)acetate,	  4	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2-­((2-­(tert-­Butoxy)-­2-­oxoethyl)(2-­((tert-­butoxycarbonyl)amino)-­3,4-­




tert-­‐Butyl	   2-­‐((2-­‐((tert-­‐butoxycarbonyl)amino)-­‐3,4-­‐dioxocyclobut-­‐1-­‐en-­‐1-­‐yl)(2-­‐methoxy-­‐2-­‐oxoethyl)amino)acetate	   (116	   mg,	   0.29	   mmol)	   was	   dissolved	   in	   a	  mixture	  of	  THF	   (3	  mL)	   and	  methanol	   (2	  mL).	  To	   the	   solution	  was	  added	  LiOH	  powder	  (7	  mg,	  0.29	  mmol)	  as	  a	  solution	  in	  H2O	  (1	  mL).	  The	  reaction	  was	  stirred	  at	  room	  temperature	  for	  1	  hour	  with	  loss	  of	  methyl	  ester	  verified	  by	  ESI-­‐MS,	  1H	  NMR	  (loss	  of	  methyl	  singlet	  at	  3.76	  ppm)	  and	  TLC.	  At	  this	  point,	  the	  solvent	  was	  evaporated	   under	   reduced	   pressure	   and	   the	   glassy	   yellow	   solid	   taken	   up	   into	  purite	   H2O.	   The	   pH	   was	   adjusted	   to	   pH	   7	   and	   the	   solution	   lyophilized.	   This	  revealed	   the	   title	   compound,	   which	  was	   used	   directly	   in	   the	   next	   step	  without	  further	  purification.	  1H	  NMR	  (D2O,	  400	  MHz)	  δ	  1.36-­‐1.42	  (18H,	  s,	  C(CH3)3),	  3.92-­‐4.92	  (4H,	  m,	  CH2NCH2).	  MS	  (ES-­‐)	  m/z	  =	  403.2	  [M-­‐2H+3Li]+.	  	  
tert-­Butyl	   2-­((2-­((tert-­butoxycarbonyl)amino)-­3,4-­dioxocyclobut-­1-­en-­1-­
yl)amino)propanoate,	  6	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monitored	  by	  TLC.	  Upon	  consumption	  of	  starting	  materials,	  excess	  ethanol	  was	  removed	   under	   reduced	   pressure	   and	   the	   crude	   residue	   purified	   by	   column	  chromatography	   (DCM/MeOH,	   100%	   to	   95:5;	  Rf	   =	   0.52)	   to	   give	   a	   light	   yellow	  solid	  (332	  mg,	  79%).	  1H	  NMR	  (CDCl3,	  700	  MHz)	  δ	  1.45	  (9H,	  s,	  C(CH3)3),	  1.46	  (9H,	  s,	   C(CH3)3,	   2.57	   (2H,	   t,	   J	   =	   7,	   CH2CH2CO2tBu),	   3.93	   (2H,	   app.	   q,	   J	   =	   7,	  CH2CH2CO2tBu),	  7.85	   (1H,	  br.	   s,	  NH),	  8.90	   (1H,	  br.	   s,	  NH).	   13C	  NMR	  (CDCl3,	  176	  MHz)	   δ	   28.0,	   28.1	   (C(CH3)3),	   36.9,	   39.9	   ((CH2)2),	   81.7,	   83.9	   (C(CH3)3),	   152.0	  (C=CNHBoc),	  160.1	  (C=CNHCH2),	  170.4,	  171.6,	  182.3,	  187.0	  (CO).	  MS	  (ES+)	  m/z	  =	  363.3	  [M+Na]+;	  C16H24N2O6Na	  requires	  363.1548;	  found	  363.1532.	  M.Pt	  >250	  °C.	  	  	  
tert-­Butyl	   2-­((2-­((tert-­butoxycarbonyl)amino)-­3,4-­dioxocyclobut-­1-­en-­1-­
yl)(2-­methoxy-­2-­oxoethyl)amino)propanoate,	  7	  	  
	  	  To	   a	   solution	   of	   tert-­‐butyl	   2-­‐((2-­‐((tert-­‐butoxycarbonyl)amino)-­‐3,4-­‐dioxocyclobut-­‐1-­‐en-­‐1-­‐yl)amino)propanoate	   (330	  mg,	   0.97	  mmol)	   and	   NaH	   (28	  mg,	  1.16	  mmol)	  in	  anhydrous	  DMF	  (8	  mL)	  was	  added	  methylbromoacetate	  (110	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(CDCl3,	  176	  MHz)	  δ	  27.8,	  28.1	  (C(CH3)3),	  36.8,	  39.8	  (CH2CH2),	  47.6	  (CH2CO2Me),	  52.6	  (CH3),	  81.7,	  85.4	  (C(CH3)3),	  151.5	  (C=CNHBoc),	  160.9	  (C=CN(CH2)2),	  169.0,	  170.6,	   171.2,	   182.3,	   188.0	   (CO).	  MS	   (ES+)	  m/z	   =	   435.7	   [M+Na]+;	   C19H28N2O8Na	  requires	  435.1743;	  found	  435.1548.	  	  
2-­((3-­(tert-­Butoxy)-­3-­oxopropyl)(2-­((tert-­butoxycarbonyl)amino)-­3,4-­
dioxocyclobut-­1-­en-­1-­yl)amino)acetic	  acid,	  8	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Diethyl	  (3-­(1,3-­diocoisoindolin-­2-­yl)propyl)	  phosphonate,	  92	  	  
	  	  To	   the	   solution	  of	   potassium	  phthalamide	   (2.89	   g,	   15.61	  mmol)	   and	  NaH	   (374	  mg,	  15.6	  mmol)	   in	   anhydrous	  DMF	   (25	  mL)	  was	  added	  diethyl-­‐3-­‐bromopropyl	  phosphonate	  (2.0	  mL,	  10.41	  mmol)	  and	  the	  resulting	  mixture	  heated	  to	  100	  °C	  for	  20	  hours.	  After	   this	   time,	   the	  mixture	  was	  cooled	  to	  room	  temperature	  and	  the	  precipitate	  filtered.	  The	  filtrate	  was	  concentrated	  under	  reduced	  pressure	  to	  give	   a	   light	   green	   residue,	   which	   was	   taken	   up	   into	   CHCl3	   (30	   mL).	   The	  chloroform	   was	   washed	   with	   H2O	   (3	   x	   10	   mL)	   and	   dried	   over	   MgSO4.	   After	  filtration,	  the	  solvent	  was	  removed	  under	  reduced	  pressure	  to	  give	  a	  light	  green	  oil	   (1.16	  g,	  34%).	   1H	  NMR	  (CDCl3,	  400	  MHz)	  δ	  1.30	  (6H,	   t,	   J	  =	  7,	  P(OCH2CH3)2),	  1.73-­‐2.03	  (4H,	  m,	  PCH2CH2),	  3.75	  (2H,	  t,	  J	  =	  7,	  P(CH2)2CH2),	  4.07	  (4H,	  qd,	  3JH-­‐H	  =	  7,	  3JH-­‐P	   =	   	   3,	   P(OCH2CH3)2),	   7.70-­‐7.73	   (2H,	  m,	   Ar-­‐H),	   7.83-­‐7.86	   (2H,	  m,	   Ar-­‐H).	   13C	  NMR	   (CDCl3,	   101	   MHz)	   δ	   16.6	   (d,	   3J	   =	   6,	   P(OCH2CH3)2),	   22.1	   (d,	   2J	   =	   5,	  PCH2CH2CH2),	  23.6	  (d,	  1J	  =	  143,	  PCH2(CH2)2),	  38.4	  (d,	  3J	  =	  20,	  P(CH2)2CH2),	  61.8	  (d,	  2J	  =	  7,	  P(OCH2CH3)2),	  123.4	  ,	  133.1,	  134.2	  (Ar-­‐C),	  168.4	  (CO).	  31P	  NMR	  (CDCl3,	  162	  MHz)	  δ	  29.85.	  MS	  (ES+)	  m/z	  326.2	  [M+H]+;	  C15H21NO5P	  requires	  326.1157;	  found	  326.1160.	  	  
Diethyl	  (3-­aminopropyl)	  phosphonate,	  102	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removed	  under	  reduced	  pressure	  and	  the	  white	  residue	  that	  remained	  was	  taken	  up	   into	   DCM	   (15	   mL).	   After	   sonication,	   the	   precipitate	   was	   filtered	   and	   the	  filtrate	  concentrated.	  To	  this	  was	  added	  CHCl3	  (10	  mL),	  which	  yielded	  a	  second	  batch	  of	  precipitate	  that	  was	  again	  filtered.	  The	  filtrate	  was	  concentrated	  under	  reduced	  pressure	  to	  yield	  a	  green	  oil	  (639	  mg,	  92%).	  1H	  NMR	  (CDCl3,	  400	  MHz)	  δ	  1.29	  (6H,	   t,	   J	  =	  7,	  P(OCH2CH3)2),	  1.68-­‐1.86	  (4H,	  m,	  PCH2CH2),	  2.78	  (2H,	   t,	   J	  =	  7,	  P(CH2)2CH2N),	   3.33	   (2H,	   br.	   s,	   NH2),	   3.99-­‐4.13	   (4H,	   qd,	   3JH-­‐H	   =	   7,	   3JH-­‐P	   =	   	   3,	  P(OCH2CH3)2).	  13C	  NMR	  (CDCl3,	  101	  MHz)	  δ	  16.6	  (d,	  3J	  =	  6,	  P(OCH2CH3)2),	  22.1	  (d,	  1J	  =	  142,	  PCH2(CH2)2),	  26.1	  (d,	  2J	  =	  5,	  (PCH2CH2CH2),	  42.4	  (d,	  3J	  =	  17,	  P(CH2)2CH2),	  61.6	  (d,	  2J	  =	  7,	  P(OCH2CH3)2).	  31P	  NMR	  (CDCl3,	  162	  MHz)	  δ	  31.24.	  MS	  (ES+)	  m/z	  196.6	  [M+H]+;	  C7H19NO3P	  requires	  196.1103;	  found	  196.1120.	  	  
tert-­Butyl	   (2-­((diethoxyphosphoryl)ethyl)amino)-­3,4-­dioxocyclobut-­1-­en-­
1-­yl)carbamate,	  11	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2-­((2-­((Tert-­butoxycarbonyl)amino)-­3,4-­dioxocyclobut-­1-­en-­1-­yl)(2-­
(diethoxyphosphoryl)ethyl)amino)acetic	  acid,	  13	  
	  
	  	  Methyl	   2-­‐((tert-­‐butoxycarbonyl)amino)-­‐3,4-­‐dioxocyclobut-­‐1-­‐en-­‐1-­‐yl)(2-­‐(diethoxyphosphoryl)ethyl)amino)acetate	  (185	  mg,	  0.41	  mmol)	  was	  dissolved	  in	  MeOD	  (3	  mL),	  to	  which	  KOD	  (39	  mg,	  0.68	  mmol)	  was	  added	  as	  a	  solution	  in	  D2O	  (4	   mL).	   The	   resulting	   mixture	   was	   stirred	   at	   room	   temperature	   and	   reaction	  profile	  monitored	  by	  TLC,	  1H	  (loss	  of	  methyl	  singlet	  at	  3.76	  ppm)	  and	  31P	  NMR	  spectroscopy	  (no	  shift	   in	   31P	  signal).	  After	  1	  h,	   complete	  conversion	  of	   starting	  material	   was	   achieved	   and	   the	   solvent	   removed	   under	   reduced	   pressure.	   The	  solid	  residue	  was	  taken	  up	  in	  purite	  H2O	  (5	  mL)	  and	  the	  pH	  adjusted	  to	  about	  7	  using	  HCl	  (0.1	  M).	  The	  resulting	  solution	  was	  lyophilized	  to	  give	  the	  product	  as	  a	  light	   green	   solid	   which	   was	   used	   directly	   in	   the	   next	   step	   without	   further	  purification.	   1H	  NMR	   (D2O,	   400	  MHz)	   δ	   1.27-­‐1.35	   (6H,	  m,	   P(OCH2CH3)2),	   1.37-­‐1.42	  (9H,	  s,	  C(CH3)3),	   	  2.17-­‐2.31	  (2H,	  m,	  PCH2CH2),	  3.53-­‐3.75	  (2H,	  m,	  PCH2CH2),	  4.05-­‐4.20	  (4H,	  m,	  P(OCH2CH3)2),	  4.88	  (2H,	  CH2CO2H).	  31P	  NMR	  (D2O,	  162	  MHz)	  δ	  30.59.	  MS	  (ES+)	  m/z	  =	  475.2	  [M+K]+.	  	  
tert-­Butyl	   (2-­((diethoxyphosphoryl)propyl)amino)-­3,4-­dioxocyclobut-­1-­
en-­1-­yl)carbamate,	  14	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diisopropylethylamine	  (283	  µL,	  1.62	  mmol)	  in	  anhydrous	  ethanol	  (4	  mL)	  over	  a	  one	  hour	  period.	  The	  resulting	  mixture	  was	  allowed	  to	  stir	  at	  room	  temperature	  for	   48	  hours.	  After	   this	   time,	   ethanol	  was	   removed	  under	   reduced	  pressure	   to	  give	   an	   orange	   residue	   which	   was	   then	   purified	   by	   column	   chromatography	  (DCM/MeOH,	  100%	  to	  95:5	  using	  0.5%	  increments;	  Rf	  =	  0.35)	  to	  give	  a	  yellow	  oil	  (266	  mg,	  42%).	  1H	  NMR	  (CDCl3,	  700	  MHz)	  δ	  1.33	  (6H,	  t,	  J	  =	  7,	  P(OCH2CH3)2),	  1.51	  (9H,	  s,	  C(CH3)3),	  1.79-­‐1.83	  (2H,	  m,	  PCH2(CH2)2),	  1.93-­‐1.99	  (2H,	  m,	  PCH2CH2CH2),	  3.79	   (2H,	  m,	  P(CH2)2CH2),	  4.06-­‐4.15	   (4H,	  qd,	   3JH-­‐H	  =	  7,	   3JH-­‐P	  =	   	  3,	  P(OCH2CH3)2),	  7.51	  (1H,	  br.	  s,	  NH),	  7.96	  (1H,	  br.	  s,	  NH).	  13C	  NMR	  (CDCl3,	  176	  MHz)	  δ	  16.6	  (d,	  3J	  =	  5,	  P(OCH2CH3)2),	  22.7	  (d,	  1J	  =	  143,	  NH(CH2)2CH2P),	  24.6	  (d,	  2J	  =	  5,	  PCH2CH2CH2),	  28.1	   (C(CH3)3),	   44.4	   (d,	   3J	   =	   18,	   NHCH2(CH2)2P),	   61.9	   (d,	   2J	   =	   7,	   P(OCH2CH3)2),	  84.5	  (C(CH3)3),	  151.8,	  159.4	  (C=C),	  171.6,	  182.1,	  187.1	  (CO).	  31P	  NMR	  (CDCl3,	  283	  MHz)	   δ	   30.70.	  MS	   (ES+)	  m/z	   =	   391.3	   [M+H]+;	   C16H28N2O7P	   requires	   391.1634;	  found	  391.1639.	  	  
Methyl	   2-­((tert-­butoxycarbonyl)amino)-­3,4-­dioxocyclobut-­1-­en-­1-­yl)(2-­
(diethoxyphosphoryl)propyl)amino)acetate,	  15	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reduced	  pressure	  to	  give	  the	  crude	  residue,	  which	  was	  then	  purified	  by	  column	  chromatography	  (DCM/MeOH,	  100%	  to	  95:5	  using	  0.2%	  increments;	  Rf	  =	  0.43)	  to	  give	  a	  viscous	  yellow	  oil	  (126	  mg,	  63%).	  1H	  NMR	  (CDCl3,	  400	  MHz)	  δ	  1.31	  (6H,	  t,	  J	  =	  8,	  P(OCH2CH3)2),	  1.47	  (9H,	  s,	  C(CH3)3),	  1.75-­‐1.84	  (2H,	  m,	  PCH2(CH2)2),	  1.89-­‐1.99	  (2H,	  m,	  PCH2CH2CH2),	  3.76	  (3H,	  s,	  CH3),	  3.80	  (2H,	  m,	  P(CH2)2CH2),	  4.02-­‐4.16	  (4H,	  qd,	  3JH-­‐H	  =	  7,	  3JH-­‐P	  =	  	  3,	  P(OCH2CH3)2),	  4.82	  (2H,	  s,	  CH2CO2Me),	  7.66	  (1H,	  s,	  br,	  NH).	  13C	  NMR	  (CDCl3,	  101	  MHz)	  δ	  16.6	  (d,	  3J	  =	  6,	  P(OCH2CH3)2),	  22.7	  (d,	  1J	  =	  143,	  N(CH2)2CH2P),	   24.6	   (d,	   2J	   =	   5,	   PCH2CH2CH2),	   27.9	   (C(CH3)3),	   44.2	   (d,	   3J	   =	   17,	  NCH2(CH2)2P),	  47.6	  (CH2CO2Me),	  52.6	  (CH3),	  61.9	  (d,	   2J	  =	  7,	  P(OCH2CH3)2),	  85.6	  (C(CH3)3),	  151.6,	  160.9	   (C=C),	  168.9,	  171.5,	  182.3,	  187.9	   (CO).	   31P	  NMR	  (CDCl3,	  162	   MHz)	   δ	   29.89.	   MS	   (ES+)	  m/z	   	   =	   485.2	   [M+Na]+;	   C19H31N2O9PNa	   requires	  485.1665;	  found	  485.1647.	  	  
2-­((2-­((tert-­Butoxycarbonyl)amino)-­3,4-­dioxocyclobut-­1-­en-­1-­yl)(3-­
(diethoxyphosphoryl)propyl)amino)acetic	  acid,	  16	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1.40-­‐1.44	   (9H,	   s,	   C(CH3)3),	   	   1.78-­‐2.06	   (4H,	  m,	   (CH2)2),	   3.36-­‐3.57	   (2H,	  m,	   CH2),	  4.07-­‐4.32	  (4H,	  m,	  P(OCH2CH3)2),	  4.81	  (2H,	  m,	  CH2).	   31P	  NMR	  (D2O,	  162	  MHz)	  δ	  34.24.	  MS	  (ES+)	  m/z	  490.3	  [M+K]+.	  	  
(S)-­2-­Bromo-­6-­(2-­phenylcarbamate)hexanoic	  acid,	  173	  
	  
	  	  To	  a	  stirred	  solution	  of	  H-­‐Lys(Z)-­‐OH	  (5.0	  g,	  17.8	  mmol),	  NaBr	  (5.1	  g,	  49.0	  mmol)	  and	   1M	   HBr	   (106	  mL)	   at	   –5	   °C,	   was	   added	   a	   solution	   of	   NaNO2	   (2.3	   g,	   33.87	  mmol)	  in	  H2O	  (21	  mL)	  over	  a	  period	  of	  40	  minutes.	  The	  resulting	  yellow	  solution	  was	   stirred	   at	   room	   temperature	   overnight.	   After	   this	   period,	   H2SO4	   (1.5	  mL)	  was	  added	  to	  the	  reaction	  mixture,	  which	  was	  extracted	  with	  diethyl	  ether	  (3	  x	  100	  mL).	  The	  organic	  phase	  was	  washed	  with	  brine	  (1	  x	  100	  mL)	  and	  dried	  over	  MgSO4.	   Filtration	   and	   removal	   of	   the	   solvent	   under	   reduced	   pressure	   yielded	  viscous	   yellow	   oil,	   which	   was	   used	   directly	   in	   the	   next	   step	   without	   further	  purification.	  	  	  (S)-­tert-­Butyl	  2-­bromo-­6-­(2-­phenylcarbamate)hexanoate,	  183	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=	  0.42)	  to	  give	  a	  viscous	  yellow	  oil	  (2.50g,	  44%	  over	  two	  steps).	  1H	  NMR	  (CDCl3,	  700	  MHz)	  δ	  1.46	  (9H,	  s,	  C(CH3)3),	  1.49-­‐1.55	  (4H,	  m,	  br,	  CH2CH2CH2NH),	  1.90-­‐2.03	  (2H,	  m,	  br,	  CHCH2),	  3.19	  (2H,	  dd,	  J	  =	  7,	  3,	  CH2CH2CH2NH),	  4.08	  (1H,	  t,	  J	  =	  7,	  CHBr),	  4.88	   (1H,	   s,	   br,	  NH)	  5.08	   (2H,	   s,	  OCH2Ph),	  7.34	   (5H,	  m,	  Ar-­‐H).	   13C	  NMR	  (CDCl3,	  176	   MHz)	   δ	   24.5	   (CH2CH2CH2NH),	   27.8	   (C(CH3)3),	   29.3	   (CH2CH2CH2NH),	   34.5	  (CHCH2),	  40.8	  (CH2CH2CH2NH),	  47.6	  (CBr),	  66.7	  (OCH2Ph),	  82.5	  (C(CH3)3),	  128.2,	  128.6,	   128.6,	   136.7	   (Ar-­‐C),	   156.5,	   168.8	   (CO).	   MS	   (ES+)	   m/z	   422.2	   [M+Na]+;	  C18H26NO4BrNa	  requires	  422.0943;	  found	  422.0945.	  
	  
4,7-­Bis-­tert-­butoxycarbonylmethyl-­1,4,7,10-­tetraaza-­cyclododec-­1-­
yl)acetic	  acid	  tert-­butyl	  Ester,	  194	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  4,7-­‐Bis-­‐tert-­‐butoxycarbonylmethyl-­‐1,4,7,10-­‐tetraaza-­‐cyclododec-­‐1-­‐yl)acetic	   acid	  
tert-­‐butyl	   ester	   (1.57	   g,	   3.05	   mmol),	   (S)-­‐tert-­‐butyl	   2-­‐bromo-­‐6-­‐(2-­‐phenylcarbamate)hexanoate	  (1.41	  g,	  3.70	  mmol)	  and	  K2CO3	  (843	  mg,	  6.1	  mmol)	  were	   dissolved	   in	   anhydrous	   acetonitrile	   (15	   mL)	   and	   the	   reaction	   mixture	  stirred	  at	  80	  °C	  for	  16	  hours.	  Upon	  completion,	  the	  reaction	  mixture	  was	  cooled	  to	   room	   temperature	   and	   the	   potassium	   salts	   filtered.	   The	   filterate	   was	  evapourated	  under	  reduced	  pressure	  and	   the	  resulting	  orange	  residue	  purified	  by	  column	  chromatography	  (DCM/MeOH,	  100%	  to	  90:10	  using	  1%	  increments;	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(R)–tri-­tert-­Butyl	   2,2’,2’’-­(10-­(6-­amino-­1-­(tert-­butoxy)-­1-­oxohexan-­2-­yl)-­
1,4,7,10-­tetraazacyclododecane-­1,4,7-­triyl)triacetate,	  21	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[Conjugate	  1],	  22	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151.7,	  151.8	  (C=C),	  160.4,	  160.6,	  166.2,	  167.6,	  170.4,	  172.7,	  172.7,	   	  172.8	  (CO).	  MS	  (ES+)	  m/z	  =	  1066.7	  [M+H]+;	  C53H92N7O15	  requires	  1066.665;	  found	  1066.670.	  	  
[Conjugate	  2],	  23	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CH2),	  2.98-­‐3.78	  (11H,	  m,	  CH2	  +	  CH),	  4.16-­‐4.35	  (2H,	  m,	  CH2),	  7.54-­‐7.86	  (2H,	  br.	  m,	  NH).	   13C	  NMR	  (CDCl3,	  151	  MHz)	  δ	   24.4,	  27.9	   (CH2),	  27.9,	  28.0,	  28.0,	  28.1,	  28.1,	  28.1	   (C(CH3)3),	   34.6,	   39.2,	   47.4,	   48.2,	   48.6,	   52.6,	   52.6,	   53.5,	   55.6	   (CH2CO2tBu),	  55.9	  (CH2),	  61.4	  (CH),	  81.9,	  82.1,	  82.8,	  82.9,	  83.3	  (C(CH3)3),	  151.9,	  152.0	  (C=C),	  160.6,	   160.8,	   166.4,	   167.8,	   170.6,	   172.9,	   172.9,	   173.0	   (CO).	   MS	   (ES+)	   m/z	   =	  1080.7	  [M+H]+;	  C54H94N7O15	  requires	  1080.681;	  found	  1080.677.	  	  
[Conjugate	  3],	  24	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using	   1%	   increments;	   Rf	   =	   0.24)	   to	   yield	   a	   viscous	   yellow-­‐brown	   oil	   (89	   mg,	  19%).	   1H	   NMR	   (CDCl3,	   700	  MHz)	   δ	   1.23-­‐1.27	   (2H,	   m,	   CH2),	   1.29	   (3H,	   t,	   J	   =	   7,	  P(OCH2CH3)2),	  1.32	  (3H,	  t,	  3J	  =	  7,	  P(OCH2CH3)2),	  1.40,	  1.41,	  1.42,	  1.42,	  	  1.42	  (45H,	  s,	   C(CH3)3),	   1.51-­‐1.68	   (6H,	   m,	   CH2),	   2.06-­‐2.15	   (4H,	   m,	   CH2),	   2.25-­‐2.39	   (4H,	   m,	  CH2),	   2.41-­‐2.61	   (4H,	  m,	   CH2),	   2.70-­‐2.87	   (5H,	  m,	   CH2	   +	   CH),	   3.07-­‐3.43	   (10H,	  m,	  CH2),	   3.65-­‐3.86	   (2H,	   m,	   CH2CH2P),	   3.99-­‐4.16	   (4H,	   m,	   P(OCH2CH3)2),	   7.54-­‐7.86	  (2H,	  br.	  m,	  NH).	  13C	  NMR	  (CDCl3,	  176	  MHz)	  δ	  16.52	  (d,	  3J	  =	  7,	  P(OCH2CH3)2),	  24.6	  (CH2),	   27.7(d,	   1J	   =	   141,	   NCH2CH2P),	   27.8	   (C(CH3)3),	   27.8	   (CH2),	   27.8	   27.9,	  (C(CH3)3),	  28.1	  (CH2),	  29.2	  (C(CH3)3),	  39.1	  (CH2),	  45.2	  (d,	  2J	  =	  6,	  NCH2CH2P),	  47.3,	  48.1,	  48.5,	  52.5,	  52.6	   ,	  55.5,	  55.7	  (CH2),	  61.9	  (CH),	  62.1	  (d,	  2J	  =	  7,	  P(OCH2CH3)2),	  81.9,	   82.0,	   82.1,	   82.7	   (C(CH3)3),	   151.8,	   151.9	   (C=C),	   160.5,	   160.7,	   165.2,	   172.8,	  172.8,	   172.9,	   174.9	   (CO).	   31P	   NMR	   (CDCl3,	   283	  MHz)	   δ	   27.28.	  MS	   (ES+)	  m/z	   =	  1139.9	  [M+Na]+;	  C53H96N7O16P	  requires	  1117.665;	  found	  1117.663.	  	  
[Conjugate	  4],	  25	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(3-­Amino-­2-­hydroxypropyl)carbamic	  Acid	  1,1-­dimethylethyl	  ester,	  265	  
	  
	  	  A	   solution	   of	   1,3-­‐diamino-­‐2-­‐hydroxypropane	   (5.0	   g,	   55.5	   mmol)	   in	   anhydrous	  acetonitrile	   (50	  mL)	  was	  maintained	   at	   room	   temperature	   and	   treated	  with	   a	  solution	   of	   di-­‐tert-­‐butyl	   dicarbonate	   (4.04	   g,	   18.5	   mmol)	   in	   anhydrous	  acetonitrile	   (20	  mL)	  over	  a	  2	  hour	  period	  with	  vigorous	   stirring.	  The	  resulting	  suspension	  was	   left	   to	   stir	   overnight.	   After	   a	   period	   of	   18	   hours,	   the	   reaction	  mixture	  was	  concentrated	  and	  the	  residue	  re-­‐dissolved	  in	  brine	  (50	  mL).	  	  The	  pH	  was	   adjusted	   to	   5	   by	   treatment	  with	  HCl	   (1	  N),	   the	  mixture	  was	  washed	  with	  dichloromethane	  (3	  x	  50	  mL)	  and	  made	  basic	  (pH	  12)	  by	  the	  addition	  of	  NaOH	  solution	  (2.5	  M).	  The	  product	  was	  extracted	  using	  CHCl3	  (5	  x	  100	  mL),	  and	  the	  combined	  organic	   layers	  dried	  over	  MgSO4,	   filtered	  and	  concentrated	  to	  yield	  a	  white	   solid	   (1.23	   g,	   34%).	   	   1H	  NMR	   (400	  MHz,	   CDCl3)	   δ	   1.43	   (9H,	   s,	   C(CH3)3),	  2.42-­‐2.72	  (3H,	  m),	  2.78-­‐2.92	  (2H,	  m),	  3.01-­‐3.15	  (1H,	  m),	  3.20-­‐3.35	  (1H,	  m),	  3.56-­‐3.72	  (1H,	  m),	  5.05	  (1H,	  br,	  s).	  13C	  NMR	  (125	  MHz,	  CDCl3)	  δ	  28.4	  (C(CH3)3),	  44.1,	  44.5	  (CH2),	  71.0	  (COH),	  79.5	  (C(CH3)3),	  156.7	  (CO).	  MS	  (ES+)	  m/z	  191.1	  [M	  +	  H]+;	  C8H19N2O3	  requires	  191.1396;	  found	  191.1392.	  M.	  Pt.	  78-­‐80	  °C	  [Lit.	  77-­‐79	  °C].	  
	  
(3-­((2-­(Diethoxyphosphinyl)ethyl)amino)-­2-­hydroxypropyl)carbamic	   acid	  
1,1-­dimethylethyl	  ester,	  276	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TLC.	   The	   mixture	   was	   concentrated	   under	   reduced	   pressure	   before	   being	  partitioned	  between	  DCM/H2O	  (1:1,	  30	  mL).	  The	  organic	  portion	  was	  separated	  and	   the	   aqueous	   layer	   was	   extracted	   with	   DCM	   (3	   x	   25	   mL).	   The	   combined	  organic	  fractions	  were	  dried	  over	  MgSO4,	  filtered	  and	  concentrated,	  allowing	  the	  crude	  residue	  to	  be	  purified	  by	  column	  chromatography	  (DCM/MeOH,	  100%	  to	  90:10	  using	  1%	  increments;	  Rf	  =	  0.42)	  to	  give	  a	  colourless	  oil	  (975	  mg,	  44%).	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  1.31	  (6H,	  t,	   J	  =	  7,	  P(OCH2CH3)2),	  1.42	  (9H,	  s,	  C(CH3)3),	  2.08	  (2H,	  dt,	  2JH-­‐P	  =	  18,	  3JH-­‐H	  	  =	  7,	  PCH2CH2),	  2.63	  (1H,	  dd,	  J	  =	  12,	  8),	  2.78	  (1H,	  dd,	  J	  =	  12,	  3),	  2.91-­‐3.05	  (2H,	  m,	  PCH2CH2),	  3.05-­‐3.14	  (1H,	  m),	  3.32-­‐3.34	  (1H,	  m),	  3.68	  (3H,	   br,	   s),	   3.79-­‐3.86	   (1H,	   m,	   CH),	   4.03-­‐4.16	   (4H,	   qd,	   3JH-­‐H	   =	   7,	   3JH-­‐P	   =	   3,	  P(OCH2CH3)2).	  13C	  NMR	  (101	  MHz,	  CDCl3)	  δ	  16.6	  (d,	  3J	  =	  6,	  P(OCH2CH3)2),	  25.7	  (d,	  1J	   =	  140,	  NHCH2CH2P),	   28.5	   (C(CH3)3),	   43.2	   (d,	   2J	   =	  5,	  NHCH2CH2P),	   44.3,	   	   51.9	  (CH2),	  62.1	  (d,	  2J	  =	  7,	  P(OCH2CH3)2),	  68.5	  (COH),	  79.6	  (C(CH3)3),	  156.8	  (CO).	  31P	  NMR	   (CDCl3,	   162	   MHz)	   δ	   30.73.	   MS	   (ES+)	  m/z	   355.2	   [M	   +	   H]+;	   C14H32N2O6P	  requires	  355.1998;	  found	  355.2001.	  	  
(3-­((2-­(Diethoxyphosphinyl)ethyl)(2-­ethoxy-­3,4-­dioxo-­1-­cyclobuten-­1-­
yl)amino)-­2-­hydroxypropyl)carbamic	  acid	  1,1-­Dimethylethyl	  Ester,	  286	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purified	   by	   column	   chromatography	   (DCM/MeOH,	   100%	   to	   90:10	   using	   1%	  increments;	  Rf	  =	  0.28)	  to	  give	  a	  colourless	  viscous	  oil	  as	  a	  pair	  of	  rotamers	  (777	  mg,	  65%).	   1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  1.21	   (6H,	   t,	   J	  =	  7,	   (P(OCH2CH3)2),	  1.27-­‐1.36	  (12H,	  m,	  C(CH3)3	  +	  OCH2CH3),	  1.98-­‐2.17	  (2H,	  m,	  PCH2CH2),	  2.89-­‐3.91	  (8H,	  m,	  CH2	  +	  CH	  +	  OH),	  3.94-­‐4.04	   (4H,	  m,	  P(OCH2CH3)2),	  4.58-­‐4.67	   (2H,	  m,	  OCH2CH3),	  5.42	  (1H,	  br,	  NH).	   13C	  NMR	  (101	  MHz,	  CDCl3)	  δ	  15.7	  (OCH2CH3),	  16.3	  (d,	  3J	  =	  6,	  P(OCH2CH3)2),	   25.6	   (d,	   1J	   =	   140,	   NCH2CH2P),	   28.2	   (C(CH3)3),	   44.0	   (NCH2CH2P),	  45.2,	  53.5	  (CH2),	  62.0	  (d,	  2J	  =	  7,	  P(OCH2CH3)2),	  69.5	  (COH),	  69.7	  (OCH2CH3),	  79.4	  (C(CH3)3),	   156.7	   (CO),	   172.5,	   176.6	   (C=C),	   182.6,	   188.4	   (CO).	   31P	   NMR	   (CDCl3,	  162	  MHz)	  δ	  26.28.	  MS	  (ES+)	  m/z	  479.1	  [M+H]+;	  C20H36N2O9P	  requires	  479.2158;	  found	  479.2156.	  	  
(2-­(4-­Hydroxy-­8,9-­dioxo-­2,6-­diazabicyclo[5.2.0]non-­1(7)-­en-­2-­
yl)ethyl)phosphonic	  Acid	  diethyl	  ester,	  296	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residue	  was	   purified	   by	   column	   chromatography	   (DCM/MeOH,	   100%	   to	   90:10	  using	  1%	   increments;	  Rf	   =	  0.40)	   to	   give	   a	  white	   solid	   (488	  mg,	  90%).	   1H	  NMR	  (400	   MHz,	   CDCl3)	   δ	   1.32	   (6H,	   2	   x	   t,	   J	   =	   7,	   (P(OCH2CH3)2),	   2.11-­‐2.31	   (2H,	   m,	  PCH2CH2),	  3.39	  (1H,	  d,	  J	  =	  14,	  CH),	  3.55	  (1H,	  d,	  J	  =	  14,	  CH),	  3.61-­‐3.77	  (5H,	  m,	  CH2	  +	  PCH2CH2	  +	  OH),	  4.04-­‐4.14	  (4H,	  m,	  P(OCH2CH3)2),	  4.16-­‐4.19	  (1H,	  m,	  CH),	  4.29-­‐4.42	  (1H,	  m,	  PCH2CH2),	  7.58	  (1H,	  s,	  NH).	  13C	  NMR	  (101	  MHz,	  CDCl3)	  δ	  16.5	  (d,	  3J	  =	  6,	  P(OCH2CH3)2),	  25.8	  (d,	  1J	  =	  140,	  NCH2CH2P),	  45.3	  (d,	  2J	  =	  5,	  NCH2CH2P),	  53.7,	  57.6	  (CH2),	  62.3	  (d,	  2J	  =	  7,	  P(OCH2CH3)2),	  68.2	  (COH),	  168.4,	  168.5	  (C=C),	  180.8,	  182.1	   (CO).	   31P	   NMR	   (CDCl3,	   162	   MHz)	   δ	   27.4.	   MS	   (ES+)	  m/z	   333.1	   [M+H]+;	  C13H22N2O6P	  requires	  333.1216;	  found	  333.1209.	  M.	  Pt.	  167-­‐169	  °C.	  	  
Benzyl	  tert-­butyl(2-­hydroxypropane-­1,3-­diyl)dicarbamate,	  30	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11,11-­Dimethyl-­3,9-­dioxo-­1-­phenyl-­2,	   10-­dioxa-­4,8-­diazadodecan-­6-­yl	  
methylsulfonate	  
	  	  Benzyl	  tert-­‐butyl(2-­‐hydroxypropane-­‐1,3-­‐diyl)dicarbamate	  (907	  mg,	  2.80	  mmol)	  was	   dissolved	   in	   anhydrous	   dicholormethane	   (16	  mL),	   to	  which	   triethylamine	  (430	  µL,	   3.08	  mmol)	   and	  methanesulfonyl	   chloride	   (238	  µL,	   3.08	  mmol)	  were	  added	   at	   0	   °C.	   The	   resulting	   solution	   was	   stirred	   at	   this	   temperature	   for	   5	  minutes	   before	   being	  warmed	   to	   room	   temperature	   for	   a	   further	   1	   hour	   until	  complete	   conversion	   of	   the	   starting	   material	   was	   observed	   by	   ESI-­‐MS.	   The	  solvent	  was	   removed	  under	   reduced	  pressure	  and	   the	   residue	  was	  partitioned	  between	  brine	  and	  DCM	  (30	  mL,	  1:1).	  The	  organic	  portion	  was	  separated	  and	  the	  aqueous	   layer	  was	  extracted	  with	  dichloromethane	  (3	  x	  30	  mL).	  The	  combined	  organic	   portions	   were	   dried	   over	   MgSO4,	   filtered	   and	   reduced	   to	   give	   a	  colourless	  oil	  (1.20	  g,	  100%).	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  1.43	  (9H,	  s,	  C(CH3)3),	  3.04	  (3H,	  s,	  SO2CH3),	  3.22-­‐3.59	  (4H,	  m,	  2	  x	  NHCH2),	  4.68	  (1H,	  br,	  NH),	  5.10	  (2H,	  s,	  CH2Ph),	  5.13	   (1H,	  m,	  CH),	  5.55	   (1H,	  br,	  NH),	  7.31-­‐7.38	   (5H,	  m,	  Ar-­‐H).	  MS	  (ES+)	  
m/z	  403.1	  [M+H]+.	  	  
Benzyl	  tert-­butyl	  (2-­azidopropane-­1,3-­diyl)dicarbamate,	  31	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EtOAc/H2O	  (40	  mL,	  1:1)	  and	  the	  organic	  portion	  was	  retained.	  The	  aqueous	  was	  extracted	  with	  EtOAc	  (3	  x	  40	  mL)	  and	  the	  combined	  organic	  portions	  were	  dried	  over	  MgSO4,	  filtered,	  concentrated	  to	  give	  the	  crude	  residue	  which	  was	  purified	  by	   column	   chromatography	   (hexane/EtOAc,	   90:10	   to	   70:30	   using	   5%	  increments;	  Rf	  =	  0.51)	  to	  give	  a	  colourless	  oil	  (605	  mg,	  59%).	  1H	  NMR	  (400	  MHz,	  CDCl3)	   δ	   1.44	   (9H,	   s,	   C(CH3)3),	   3.07-­‐3.28	   (2H,	  m,	   CH2),	   3.31-­‐3.49	   (2H,	  m,	   CH2),	  3.66	   (1H,	  quin,	   J	   =	  6,	  CH),	   5.04	   (1H,	  br,	  NH),	   5.11	   (2H,	   s,	   CH2Ph),	   5.46	   (1H,	  br,	  NH),	  7.28-­‐7.39	  (5H,	  m,	  Ar-­‐H).	  13C	  NMR	  (101	  MHz,	  CDCl3)	  δ	  28.4	  (C(CH3)3),	  40.9,	  41.3	   (CH2),	  60.9	   (CN3),	  67.2	   (CH2Ph),	  80.2	   (C(CH3)3),	  128.2,	  128.4,	  128.7,	  136.4	  (C-­‐Ar),	  156.4,	  156.9	   (CO).	  MS	  (ES+)	  m/z	  372.1	   [M+Na]+;	  C16H23N5O4Na	  requires	  372.1648;	  found	  372.1626.	  	  
tert-­Butyl	  (3-­amino-­2-­azidopropyl)carbamate,	  32	  
	  







Experimental	   	   Chapter	  8	  
	   207	  
















Experimental	   	   Chapter	  8	  




















Experimental	   	   Chapter	  8	  
	   209	  
Diethyl	   (2-­(4-­azido-­8,9-­dioxo-­2,6-­diazabicyclo[5.2.0]non-­1(7)-­en-­2-­
yl)ethyl)phosphonate,	  35	  	  	  	  	  	  To	  a	   solution	  of	   tert-­‐butyl	   (2-­‐azido-­‐3-­‐((2-­‐(diethoxyphosphoryl)ethyl)(2-­‐ethoxy-­‐3,4-­‐dioxocyclobut-­‐1-­‐en-­‐1-­‐yl)amino)propyl)carbamate	   (133	   mg,	   0.26	   mmol)	   in	  anhydrous	   dichloromethane	   (1	  mL)	  was	   added	   TFA	   (1	  mL),	   and	   the	   resulting	  solution	   stirred	   at	   room	   temperature	   for	   1	   hour.	   Reaction	  was	   observed	   to	   be	  complete	  after	  this	  period,	  as	  indicated	  by	  TLC,	  and	  the	  solvents	  were	  removed	  under	  reduced	  pressure.	  The	  residue	  was	  re-­‐dissolved	   in	  dichloromethane	  and	  evaporated	   to	   dryness.	   This	   process	  was	   repeated	   5	   times	   to	   ensure	   complete	  removal	  of	  excess	  TFA.	  The	  TFA	  salt	  was	  dissolved	  in	  anhydrous	  ethanol	  (3	  mL)	  to	  which	  a	  solution	  of	  triethylamine	  (145	  µL,	  1.04	  mmol)	   in	  anhydrous	  ethanol	  (2	  mL)	  was	  added	  over	  a	  20	  minute	  period.	  The	  resulting	  solution	  was	  heated	  to	  reflux	  for	  18	  hours,	  until	  no	  further	  reaction	  was	  observed	  by	  TLC.	  At	  this	  point,	  the	  solvent	  was	  removed	  under	  reduced	  pressure	  and	  the	  crude	  residue	  purified	  by	  column	  chromatography	  (DCM/MeOH,	  100%	  to	  90:10	  using	  1%	  increments;	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Diethyl	   (2-­(4-­amino-­8,9-­dioxo-­2,6-­diazabicyclo[5.2.0]non-­1(7)-­en-­2-­
yl)ethyl)phosphonate,	  36	  
	  	  To	   a	   solution	   of	   diethyl	   (2-­‐(4-­‐azido-­‐8,9-­‐dioxo-­‐2,6-­‐diazabicyclo[5.2.0]non-­‐1(7)-­‐en-­‐2-­‐yl)ethyl)phosphonate	   (71	   mg,	   0.2	   mmol)	   in	   anhydrous	   THF	   (4	   mL)	   was	  added	  H2O	   (100	  µL)	   and	  PPh3	   (78	  mg,	   0.3	  mmol).	   The	   suspension	  was	   stirred	  under	  argon	  at	  60	  °C	  and	  over	  time,	  became	  a	  clear	  solution.	  After	  stirring	  for	  16	  hours,	   the	  solvent	  was	  removed	  under	  reduced	  pressure	  and	  the	  crude	  residue	  partitioned	   between	   DCM	   and	   H2O	   (10	   mL,	   1:1).	   The	   aqueous	   layer	   was	  separated	  and	  washed	  twice	  with	  DCM	  (10	  mL),	  before	   lyophilisation	  yielded	  a	  white	   solid	   (65	   mg,	   99%).	   1H	   NMR	   (400	   MHz,	   MeOD)	   δ	   1.34	   (6H,	   t,	   J	   =	   7	  P(OCH2CH3)2),	  2.31	  (2H,	  dt,	  JH-­‐P	  =	  18,	  JH-­‐H	  =	  7,	  PCH2CH2),	  3.48-­‐3.66	  (5H,	  m,	  CH	  +	  CH2),	   3.98-­‐4.07	   (2H,	   m,	   NCH2CH2P),	   4.09-­‐4.19	   (4H,	   qd,	   3JH-­‐H	   =	   7,	   3JH-­‐P	   =	   3,	  P(OCH2CH3)2).	   13C	  NMR	  (101	  MHz,	  MeOD)	  δ	  16.7	  (d,	   3J	  =	  6,	  P(OCH2CH3)2),	  25.5	  (d,	  1J	  =	  140,	  NCH2CH2P),	  46.4	  (NCH2CH2P),	  51.1	  (CH),	  52.3	  (CH2),	  58.0	  (CH2),	  63.6	  (d,	   2J	   =	   7,	   P(OCH2CH3)2),	   169.2,	   169.6	   (C=C),	   182.7,	   182.9	   (CO).	   31P	  NMR	   (162	  MHz,	   MeOD)	   δ	   30.97.	   MS	   (ES+)	   m/z	   332.1	   [M+H]+;	   C13H23N3O5P	   requires	  332.1375;	  found	  332.1362.	  M.	  Pt	  >	  250	  °C.	  
	  
Methyl	  2-­((azido-­3-­((tert-­butoxycarbonyl)amino)propyl)amino)acetate,	  37	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CH2),	  3.50-­‐3.70	  (1H,	  m,	  CH2),	  3.77	  (3H,	  s,	  CH3),	  3.79-­‐3.91	  (1H,	  m,	  CH),	  4.14-­‐4.28	  (1H,	  m,	  CH2),	  4.44-­‐4.56	  (1H,	  m,	  CH2),	  4.73	  (2H,	  q,	  J	  =	  7,	  OCH2CH3),	  5.13	  (1H,	  br,	  NH).	   13C	   NMR	   (101	  MHz,	   CDCl3)	   δ	   15.8	   (OCH2CH3),	   28.4	   (C(CH3)3),	   42.0,	   51.9,	  52.0	   (CH2),	  52.9	   (CH3),	  61.2	   (CN3),	  70.3	   (OCH2CH3),	  80.1	   (C(CH3)3),	  155.9	   (CO),	  168.8	   (C=C)	   ,	   173.2	   (CO),	   177.8	   (C=C),	   183.2,	   188.3	   (CO).	  MS	   (ES+)	  m/z	  434.0	  [M+Na]+;	  C17H25N5O7Na	  requires	  434.1652;	  found	  434.1649.	  [The	  ethyl	  ester	  was	  also	  present	  C18H27N5O4Na	  requires	  448.1;	  found	  448.1].	  
	  
Methyl	   2-­(4-­azido-­8,9-­dioxo-­2,6-­diazabicyclo[5.2.0]non-­1(7)-­en-­2-­
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  A	  solution	  of	  tert-­‐butyl	  (3-­‐amino-­‐2-­‐azidopropyl)carbamate	  (200	  mg,	  0.93	  mmol),	  diisopropylethylamine	  (243	  µL,	  1.4	  mmol)	  and	  methyl-­‐3-­‐bromopropionate	  (102	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Methyl	   3-­(4-­azido-­8,9-­dioxo-­2,6-­diazabicyclo[5.2.0]non-­1(7)-­en-­2-­
yl)propanoate,	  43	  
	  	  To	   a	   solution	   of	   methyl	   3-­‐((2-­‐azido-­‐3-­‐((tert-­‐butoxycarbonyl)amino)propyl)(2-­‐ethoxy-­‐3,4-­‐dioxocyclobut-­‐1-­‐en-­‐1-­‐yl)amino)propanoate	   (78	   mg,	   0.18	   mmol)	   in	  anhydrous	   dichloromethane	   (1	  mL)	  was	   added	   TFA	   (1	  mL),	   and	   the	   resulting	  solution	   stirred	   at	   room	   temperature	   for	   1	   hour.	   Reaction	  was	   complete	   after	  this	  period,	  as	  indicated	  by	  TLC,	  and	  the	  solvents	  were	  removed	  under	  reduced	  pressure.	   The	   residue	   was	   re-­‐dissolved	   in	   dichloromethane	   and	   again	  concentrated	   under	   reduced	   pressure.	   This	   process	   was	   repeated	   5	   times	   to	  ensure	   complete	   removal	   of	   excess	   TFA.	   The	   TFA	   salt	   was	   dissolved	   in	  anhydrous	   ethanol	   (2	  mL)	   to	  which	   a	   solution	  of	   triethylamine	   (102	  µL,	   0.736	  mmol)	   in	  anhydrous	  ethanol	  (1.5	  mL)	  was	  added	  over	  a	  20	  minute	  period.	  The	  resulting	  solution	  was	  heated	  to	  reflux	  for	  18	  hours,	  until	  no	  further	  reaction	  was	  observed	  by	  TLC.	  At	  this	  point,	  the	  solvent	  was	  removed	  and	  the	  crude	  residue	  purified	   by	   column	   chromatography	   (DCM/MeOH,	   100%	   to	   90:10	   using	   1%	  increments;	  Rf	  =	  0.52)	  to	  give	  a	  colourless	  oil	  (42	  mg,	  82%).	  1H	  NMR	  (700	  MHz,	  DMSO-­‐d6)	  δ	  2.69	  (2H,	  overlapping	  dt,	  J	  =	  14,	  7,	  CH2CO2Me),	  3.40	  (1H,	  dd,	  J	  =	  14,	  7,	  
Ha(eq)),	  3.55	  (1H,	  ddd,	  J	  =	  14,	  7,	  4,	  Ha(axial)),	  3.57-­‐3.59	  (2H,	  br,	  m,	  Hc	  (ax/eq)),	  3.60	  (3H,	  s,	  CH3),	  3.86	  (1H,	  dt,	   J	  =	  14,	  7,	  CH2CH2CO2Me),	  3.94	  (1H,	  dt,	   J	  =	  14,	  7,	  CH2CH2CO2Me),	  4.31	  (1H,	  m,	  CH),	  8.53	  (1H,	  br,	  NH).	  13C	  NMR	  (176	  MHz,	  DMSO-­‐
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Methyl	   3-­(4-­amino-­8,9-­dioxo-­2,6-­diazabicyclo[5.2.0]non-­1(7)-­en-­2-­
yl)propanoate,	  44	  
	  	  To	  a	  solution	  of	  methyl	  3-­‐(4-­‐azido-­‐8,9-­‐dioxo-­‐2,6-­‐diazabicyclo[5.2.0]non-­‐1(7)-­‐en-­‐2-­‐yl)propanoate	  (38	  mg,	  0.14	  mmol)	   in	  anhydrous	  THF	  (3	  mL)	  was	  added	  H2O	  (100	  µL)	  and	  PPh3	  (54	  mg,	  0.20	  mmol).	  The	  suspension	  was	  stirred	  under	  argon	  at	  60	  °C	  and	  over	  time,	  became	  a	  clear	  solution.	  After	  stirring	  for	  16	  hours,	   the	  solvent	  was	  removed	  under	  reduced	  pressure	  and	  the	  crude	  residue	  partitioned	  between	   DCM	   and	   H2O	   (10	   mL,	   1:1).	   The	   aqueous	   layer	   was	   separated	   and	  washed	  twice	  with	  DCM	  (10	  mL),	  before	  lyophilisation	  yielded	  a	  white	  solid	  (34	  mg,	   99%).	   1H	   NMR	   (700	   MHz,	   DMSO-­‐d6)	   δ	   1.78-­‐2.18	   (2H,	   br,	   NH2),	   2.69	   (2H,	  overlapping	  dt,	   J	   =	   14,	   7,	   CH2CO2Me),	   3.11	   (2H,	  m,	  Ha),	   3.21	   (1H,	   dd,	   J	   =	   14,	   7,	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phosphonate	  (560	  µL,	  2.91	  mmol)	  in	  anhydrous	  ethanol	  (8	  mL)	  was	  boiled	  under	  reflux	  for	  16	  hours	  until	  no	  further	  reaction	  was	  observed	  by	  TLC.	  The	  mixture	  was	   concentrated	   under	   reduced	   pressure	   before	   being	   partitioned	   between	  DCM/H2O	   (1:1,	   30	   mL).	   The	   organic	   portion	   was	   separated	   and	   the	   aqueous	  extracted	   with	   dicholormethane	   (3	   x	   25	  mL).	   The	   combined	   organic	   fractions	  were	  dried	  over	  MgSO4,	  filtered	  and	  concentrated,	  allowing	  the	  crude	  residue	  to	  be	   purified	   by	   column	   chromatography	   (DCM/MeOH,	   100%	   to	   92:8	   using	   1%	  increments;	  Rf	  =	  0.35)	  to	  give	  a	  colourless	  oil	  (396	  mg,	  55%).	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  1.31	  (6H,	  t,	  J	  =	  7,	  P(OCH2CH3)2),	  1.43	  (9H,	  s,	  C(CH3)3),	  1.71-­‐1.86	  (5H,	  m,	  PCH2CH2CH2	  +	  NH),	  2.66	  (1H,	  dd,	  J	  =	  12,	  7,	  CHH),	  2.69	  (2H,	  m,	  PCH2CH2CH2),	  2.71	  (1H,	  dd,	  J	  =	  12,	  5,	  CHH),	  3.17	  (1H,	  dt,	  J	  =	  14,	  7,	  CHH),	  3.33	  (1H,	  dt,	  J	  =	  14,	  5,	  CHH),	  3.63-­‐3.72	  (1H,	  m,	  CH),	  4.02-­‐4.15	  (4H,	  qd,	  3JH-­‐H	  =	  7,	  3JH-­‐P	  =	  3,	  P(OCH2CH3)2),	  5.01	  (1H,	  br,	  NH).	  13C	  NMR	  (101	  MHz,	  CDCl3)	  δ	  16.6	  (d,	  3J	  =	  6,	  P(OCH2CH3)2),	  23.0	  (d,	  J	  =	  5,	  NCH2CH2CH2P),	  23.4	   (d,	   1J	  =	  143,	  NHCH2CH2P),	  28.5	   (C(CH3)3),	  42.6	   (CH2),	  50.0	   (d,	   2J	   =	  18,	  NCH2CH2CH2P),	  50.8	   (CH2),	  61.7	   (d,	   2J	   =	  7,	  P(OCH2CH3)2),	   61.9	  (CN3),	  79.9	  (C(CH3)3),	  156.1	  (CO).	  31P	  NMR	  (CDCl3,	  162	  MHz)	  δ	  32.01.	  MS	  (ES+)	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2J	  =	  5,	  NCH2CH2CH2P),	  21.5	  (d,	  1J	  =	  143,	  NCH2CH2CH2P),	  47.9,	  50.3	  (CH),	  	  50.7	  (d,	  3J	   =	   18,	  NCH2CH2CH2P),	   54.8	   (CH2),	   61.0	   (d,	   2J	   =	   7,	   P(OCH2CH3)2),	   167.9,	   168.4	  (C=C),	   181.2,	   181.4	   (CO).	   31P	  NMR	   (162	  MHz,	  DMSO-­‐d6)	   δ	  31.27.	  MS	   (ES+)	  m/z	  346.1	  [M+H]+;	  C14H25N3O5P	  requires	  346.1532;	  found	  346.1550.	  M.	  Pt	  >	  250	  °C.	  	  
(S)-­2-­Bromo-­pentanedioic	  acid	  5-­benzyl	  Ester,	  497	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(S)-­2-­Bromo-­pentanedioic	  acid	  5-­benzyl	  ester	  1-­tert-­butyl	  ester,	  507	  	  
	  	  A	  solution	  of	  (S)-­‐2-­‐bromo-­‐pentanedioic	  acid	  5-­‐benzyl	  ester	  (2.00	  g,	  6.85	  mmol)	  in	  tert-­‐butyl	  acetate	  (25	  ml)	  and	  HClO4	  in	  H2O	  (70	  %,	  0.34	  mmol)	  was	  stirred	  at	  rt,	   for	   16	   h.	   H2O	   (35	  ml)	   was	   added	   to	   the	   reaction	  mixture,	   and	   the	   organic	  phase	  separated.	  The	  organic	  phase	  was	  washed	  with	  H2O	  (25	  ml),	  followed	  by	  5	  %	  Na2CO3	  (25	  ml).	  The	  solvent	  was	  removed	  under	  reduced	  pressure	  to	  yield	  a	  yellow	   coloured	   oil	   (2.15	   g,	   88	   %).	   1H	   NMR	   (700	   MHz,	   CDCl3)	   δ	   1.47	   (9H,	   s,	  C(CH3)3),	  2.25-­‐2.30	  (1H,	  m,	  CH2CHBr),	  2.36-­‐2.42	  (1H,	  m,	  CH2CHBr),	  2.55	  (2H,	  m,	  
CH2CH2CHBr),	  4.23	  (1H,	  dd,	  J	  =	  9,	  5,	  CH),	  5.12	  (2H,	  s,	  OCH2Ph),	  7.31-­‐7.36	  (5H,	  m,	  Ar-­‐H).	  13C	  NMR	  (76	  MHz	  CDCl3)	  δ	  27.9	  (C(CH3)3),	  29.9	  (CH2CH),	  31.8	  (CH2CH2),	  46.9	  (CH),	  66.7	  (CH2Ph),	  82.8	  (C(CH3)3),	  128.4,	  128.5,	  128.6,	  128.7,	  128.8,	  136.0	  (Ar-­‐C),	   168.5,	   172.2	   (CO).	   MS	   (ES+):	   m/z	   379.0	   [M+Na]+;	   C16H21O1079BrNa	  requires	  379.0521;	  found	  379.0517.	  
	  
(R)-­5-­Benzyl	   1-­tert-­butyl	   2-­[4,7,10-­tris(2-­tert-­butoxy-­2-­oxoethyl)-­1,4,7,10-­
tetraazacyclododecan-­1-­yl]pentanedioate,	  518	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30	  min.	  (S)-­‐5-­‐Benzyl	  1-­‐tert-­‐butyl	  2-­‐bromopentanedioate	  (1.66	  g,	  4.67	  mmol)	  was	  added	   in	   one	   aliquot	   and	   the	   reaction	  mixture	  was	   heated	   at	   reflux	   overnight.	  The	  completion	  of	  reaction	  was	  verified	  by	  TLC,	  at	  which	  point	  the	  solution	  was	  filtered,	   concentrated	   under	   reduced	   pressure,	   re-­‐dissolved	   in	   CH2Cl2	   (80	   ml)	  and	  washed	  with	  water	   (3	   x	   50	  ml).	   The	   organic	   layer	  was	   evaporated	   under	  reduced	   pressure	   and	   the	   residue	   purified	   by	   column	   chromatography	   (100%	  DCM,	  to	  90:10	  DCM/MeOH;	  Rf	  =	  0.30)	  to	  give	  an	  off-­‐white	  hygroscopic	  solid	  (1.6	  g,	  52%).	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  1.43	  (9H,	  s,	  C(CH3)3),	  1.46	  (18H,	  s,	  C(CH3)3),	  1.47	   (9H,	   s,	   C(CH3)3),	   1.99-­‐2.97	   (20H,	   br.	   m,	   CH2),	   3.12-­‐3.54	   (7H,	   m,	   COCH	   +	  COCH2),	   5.10	   (2H,	   s,	   OCH2Ph),	   7.23-­‐7.41	   (5H,	   m,	   Ar-­‐H).	   13C	   NMR	   (101	   MHz,	  CDCl3)	  δ	  26.4,	  28.1,	  28.9	  (C(CH3)3),	  30.4,	  53.6,	  54.3,	  56.2,	  56.6,	  57.9,	  58.0	  (CH2),	  66.5	   (OCH2Ph),	  69.3	   (CH),	  78.1,	  78.2,	  83.3	   (C(CH3)3),	  128.3,	  128.4,	  128.6,	  135.7	  (Ar-­‐C),	  171.7,	  171.8,	  173.8,	  174.9	  (CO).	  MS	  (ES+):	  m/z	  791.5	  [M+H]+;	  C42H70N4O10	  requires	  791.5170;	  found	  791.5165.	  	  
(R)-­5-­tert-­Butoxy-­5-­oxo-­4-­[4,7,10-­tris(2-­tert-­butoxy-­2-­oxoethyl)-­1,4,7,10-­
tetraazacyclododecan-­1-­yl]pentanoic	  acid,	  528	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3.27-­‐3.35	   (1H,	  m,	   COCH),	   3.67	   (1H,	   s,	   OH).	   13C	   NMR	   (101	  MHz,	   CDCl3)	   δ	   27.6,	  27.7,	  27.9,	  28.0	  (C(CH3)3),	  33.7,	  49.7,	  52.5,	  55.3,	  55.6,	  56.0,	  60.1	  (CH2),	  69.6	  (CH),	  81.7,	  82.0,	  82.5	  (C(CH3)3),	  171.2,	  172.6,	  175.2,	  176.0	  (CO).	  MS	  (ES+):	  m/z	  701.1	  [M+H]+;	  C35H65N4O10	  requires	  701.4701;	  found	  701.4704.	  	  
(R)-­4-­((6-­tert-­Butoxy)-­6-­oxo-­5-­(4,7,10-­tris(2-­(tert-­butoxy)-­2-­oxoethyl)-­
1,4,7,10-­tetraazacyclododecan-­1-­yl)hexyl)amino)-­4-­oxobutanoic	  acid,	  53	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[Conjugate	  5],	  54	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172.8,	   172.9,	   173.6,	   	   175.3,	   182.3,	   182.3	   (CO).	   MS	   (ES+)	   m/z	   922.4	   [M+H]+;	  C45H76N7O13	   requires	   922.5501;	   found	   922.5526.	   [The	   ethyl	   ester	   was	   also	  present	  C46H78N7O13	  requires	  936.5658;	  found	  936.5686].	  
	  
[Conjugate	  6],	  55	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(4H,	  m),	   2.60-­‐2.70	   (5H,	  m,	   CH2e	   +	   CH2),	   2.71-­‐2.78	   (2H,	  m),	   2.78-­‐2.85	   (2H,	  m),	  2.89-­‐2.99	   (3H,	  m),	   	   3.29-­‐3.38	   (2H,	  m),	   3.40-­‐3.52	   (4H,	  m,	  Ha	   +	  CH),	   3.64	   (3H,	   s,	  CH3),	  3.77-­‐3.87	  (2H,	  m,	  Hc),	  3.94	  (1H,	  dt,	  J	  =	  14,	  7,	  CH2d),	  4.03	  (1H,	  dt,	  J	  =	  14,	  7,	  CH2d’),	  4.13-­‐4.19	  (1H,	  m,	  CHNH),	  7.72	  (1H,	  br,	  NH),	  8.70	  (1H,	  br,	  NH).	   13C	  NMR	  (151	  MHz,	  CDCl3)	  δ	  27.9,	  28.0	   (overlapping	  C(CH3)3),	  33.8	   (Ce),	  35.3,	  45.6,	  47.2	  (Cd),	  48.2,	  48.7,	  49.8,	  50.2	  (CHNH),	  51.2	  (CH3),	  52.8,	  55.6,	  55.9,	  56.4,	  60.8	  (CH),	  82.0,	   82.1,	   82.1,	   82.2	   (C(CH3)3),	   167.7,	   167.9	   (C=C),	   171.4,	   172.6,	   172.8,	   172.9,	  173.5,	   	   175.3,	   181.2,	   182.0	   (CO).	   MS	   (ES+)	   m/z	   936.6	   [M+H]+;	   C46H78N7O13	  requires	  936.5658;	  found	  936.5672.	  
	  
[Conjugate	  7],	  56	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portions	  were	  dried	  over	  MgSO4,	  filtered	  and	  the	  solvent	  removed	  under	  reduced	  pressure.	   The	   crude	   residue	   was	   purified	   by	   column	   chromatography	  (DCM/MeOH,	   100%	   to	   90:10	   in	   1%	   increments;	   Rf	   =0.41)	   to	   yield	   a	   brown	  viscous	  oil.	  This	  product	  was	  characterised	  as	  a	  pair	  of	  diastereoisomers	  (42	  mg,	  21%).	   1H	  NMR	  (600	  MHz,	  CDCl3)	  δ	  1.28	   (6H,	   t,	   J	  =	  7,	  P(OCH2CH3)2),	  1.39,	  1.40,	  1.41,	  1.42	  (36H,	  s,	  C(CH3)3),	  1.77-­‐2.08	  (5H,	  m),	  2.12-­‐2.14	  (2H,	  m,	  PCH2CH2),	  2.16-­‐2.25	  (3H,	  m),	  2.35	  (1H,	  m),	  2.45-­‐2.56	  (4H,	  m),	  2.57-­‐2.66	  (3H,	  m),	  2.66-­‐2.87	  (6H,	  m),	   2.90-­‐2.99	   (2H,	  m),	   3.28-­‐3.34	   (2H,	  m),	   3.39-­‐3.50	   (4H,	  m,	  Hc,	  Ha	   ,	   CHCO2tBu)	  3.71-­‐3.78	   (1H,	   m,	   Hc),	   3.81-­‐3.89	   (2H,	   m,	   PCH2CH2),	   4.01-­‐4.12	   (4H,	   m,	  P(OCH2CH3)2),	   4.14-­‐4.20	   (1H,	  m,	  Hb),	   7.64	   (1H,	   br,	   NH),	   7.84	   (1H,	   br,	   NH).	   13C	  NMR	   (151	   MHz,	   CDCl3)	   δ	   16.5	   (d,	   3J	   =	   6,	   P(OCH2CH3)2),	   25.6	   (d,	   1J	   =	   140,	  NCH2CH2P),	  27.9,	  28.0	   (overlapping	  C(CH3)3),	  35.1,	  44.5,	  47.1,	  48.1,	  48.6	   (CH2),	  49.7	   (Cb),	  50.0	   (d,	   J	  =	  16,	  PCH2CH2),	  52.6,	  52.7,	  52.8,	  55.6	   (CH2),	  55.8	   (Ca),	  56.3	  (Cc),	   60.7	   (CH),	   62.0	   (d,	   2J	   =	   7,	   P(OCH2CH3)2),	   81.9,	   82.0,	   82.1,	   82.6	   (C(CH3)3),	  167.6,	  167.8	  (C=C),	  172.6,	  172.8,	  172.9,	  173.4,	  175.3,	  181.3,	  182.0	  (CO).	  31P	  NMR	  (162	  MHz,	  CDCl3)	  δ	  26.78.	  MS	  (ES+)	  m/z	  1014.1	  [M+H]+;	  C48H85N7O14P	  requires	  1014.589;	  found	  1014.593.	  	  
[Conjugate	  8],	  57	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[Conjugate	  9],	  58	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3.30	  (1H,	  d,	  J	  =	  14,	  Hc/a	  (eq)),	  3.35	  (2H,	  dd,	  J	  =	  14,	  7,	  Hc	  (axial)),	  3.42-­‐3.48	  (2H,	  m),	  3.74	  (1H,	  ddd,	  J	  =	  14,	  7,	  4,	  Ha	  (axial)),	  3.78-­‐3.82	  (1H,	  m,	  Hc/a	  (eq)),	  3.86-­‐3.94	  (2H,	  m,	  PCH2CH2),	  4.04-­‐4.14	   (4H,	  m,	  P(OCH2CH3)2),	  4.15-­‐4.19	   (1H,	  m,	  Hb),	  7.46	   (1H,	  br,	  NH),	  7.96	  (1H,	  br,	  NH),	  8.67	  (1H,	  br,	  NH).	  13C	  NMR	  (176	  MHz,	  CDCl3)	  δ	  16.5	  (d,	  3J	  =	  6,	  P(OCH2CH3)2),	  25.0	  (CH2),	  25.5	  (d,	  1J	  =	  140,	  NCH2CH2P),	  26.7	  (CH2),	  27.9,	  28.0,	  28.0	  (overlapping	  C(CH3)3),	  29.4,	  33.0,	  38.8,	  44.7,	  45.7,	  47.3	  (CH2),	  48.2	  (d,	  J	  =	  16,	  PCH2CH2),	  48.5	  (CH2),	  49.5	  (Cb),	  50.2,	  52.7,	  52.8,	  55.7	  (CH2),	  55.9	  (Ca),	  56.2	  (Cc),	   61.3	   (CH),	   62.1	   (d,	   2J	   =	   7,	   P(OCH2CH3)2),	   82.0,	   82.0,	   82.0,	   82.1,	   82.1,	   82.1	  (C(CH3)3),	   167.8,	   167.9	   (C=C),	   172.7,	   172.9,	   173.0,	   173.3,	   173.3,	   175.6,	   181.5,	  182.0	   (CO).	   31P	  NMR	   (283	  MHz,	   CDCl3)	   δ	   27.02.	  MS	   (ES+)	  m/z	  1113.0	   [M+H]+;	  C53H94N8O15P	  requires	  1113.658;	  found	  1113.653.	  	  
[Conjugate	  10],	  59	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[Gd.L5]	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56	  (10	  mg,	  9	   µmol)	  was	  dissolved	  in	  DCM	  (1	  mL)	  with	  stirring.	  To	  this	  solution	  was	  added	  trifluoroacetic	  acid	  (1	  mL)	  and	  the	  resulting	  solution	  stirred	  at	  room	  temperature	   for	  overnight.	  Removal	  of	   the	   tert-­‐butyl	   ester	  groups	  was	  verified	  by	   ESI-­‐MS,	   at	   which	   point	   the	   excess	   solvent	   was	   removed	   under	   reduced	  pressure.	   The	   residue	   was	   repeatedly	   re-­‐dissolved	   in	   DCM	   (2	   mL)	   and	   the	  solvent	   removed	   under	   reduced	   pressure	   to	   remove	   excess	   TFA.	   This	   process	  yielded	   the	   phosphonate	   ethyl	   ester	   as	   a	   light-­‐brown	   solid.	   This	   residue	   was	  dissolved	  in	  DMF	  (1	  mL)	  to	  which	  bromotrimethylsilane	  (13	  µL,	  0.08	  mmol)	  was	  added	   dropwise.	   The	   resulting	   mixture	   was	   heated	   to	   60	   °C	   overnight	   until	  complete	   deprotection	   had	   occurred,	   as	   indicated	   by	   ESI-­‐MS.	   The	   solvent	   was	  removed	  under	  reduced	  pressure,	  before	  the	  residue	  redissolved	  in	  H2O.	  The	  pH	  was	   adjusted	   to	   6	   and	   the	   aqueous	   phase	   washed	   with	   DCM	   (3	   x	   3	   mL)	   and	  diethyl	   ether	   (3	   x	   3	   mL).	   The	   aqueous	   solvent	   was	   then	   removed	   by	  lyophilisation	   to	  give	   the	  protonated	  salt	  of	  L7	   as	  a	   light	  brown	  solid.	  MS	  (ES+)	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gadolinium	   was	   removed	   by	   the	   addition	   of	   Chelex-­‐100	   with	   stirring.	   The	  Chelex	  trap	  was	  filtered	  and	  the	  complex	  eluted	  with	  excess	  H2O.	  Removal	  of	  the	  water	  by	   lyophilisation	  gave	   the	   complex	  as	  a	  white	   solid	   that	  was	  purified	  by	  RP-­‐HPLC.	   HR-­‐MS	   (ES+)	   C28H42157GdN7O14P	   requires	   888.1767	   [M+2H]+;	   found	  888.1763.	   r1p	   =	   5.8	   mM-­‐1s-­‐1	   (60	   MHz,	   310K).	   RP-­‐HPLC:	   tR	   =	   7.3	   mins	   [2-­‐30%	  MeOH	  in	  H2O	  over	  10	  mins].	  	  
[Gd.L8]	  
	  	  
57	   (17	   mg,	   0.02	   mmol)	   was	   dissolved	   in	   DCM	   (1	   mL)	   with	   stirring.	   To	   this	  solution	  was	  added	  trifluoroacetic	  acid	  (1	  mL)	  and	  the	  resulting	  solution	  stirred	  at	  room	  temperature	   for	  overnight.	  Removal	  of	   the	   tert-­‐butyl	  ester	  groups	  was	  verified	   by	   ESI-­‐MS,	   at	   which	   point	   the	   excess	   solvent	   was	   removed	   under	  reduced	  pressure.	  The	  residue	  was	  repeatedly	  re-­‐dissolved	   in	  DCM	  (2	  mL)	  and	  the	  solvent	  removed	  under	  reduced	  pressure	  to	  remove	  excess	  TFA.	  This	  process	  yielded	   the	   phosphonate	   ethyl	   ester	   as	   a	   light-­‐brown	   solid.	   This	   residue	   was	  dissolved	  in	  DMF	  (1	  mL)	  to	  which	  bromotrimethylsilane	  (18	  µL,	  0.13	  mmol)	  was	  added	   dropwise.	   The	   resulting	   mixture	   was	   heated	   to	   60	   °C	   overnight	   until	  complete	   deprotection	   had	   occurred,	   as	   indicated	   by	   ESI-­‐MS.	   The	   solvent	   was	  removed	  under	  reduced	  pressure,	  before	  the	  residue	  re-­‐dissolved	  in	  H2O.	  The	  pH	  was	   adjusted	   to	   6	   and	   the	   aqueous	   phase	   washed	   with	   DCM	   (3	   x	   3	   mL)	   and	  diethyl	   ether	   (3	   x	   3	   mL).	   The	   aqueous	   solvent	   was	   then	   removed	   by	  lyophilisation	   to	  give	   the	  protonated	  salt	  of	  L8	   as	  a	   light	  brown	  solid.	  MS	  (ES+)	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mL)	   and	   diethyl	   ether	   (3	   x	   3	  mL).	   The	   aqueous	   solvent	  was	   then	   removed	   by	  lyophilisation	   to	  give	   the	  protonated	  salt	  of	  L9	   as	  a	   light	  brown	  solid.	  MS	  (ES+)	  
m/z	   833.7	   [M+H]+.	  The	   salt	   of	  L9	   (10.8	  mg,	  0.013	  mmol)	  was	  dissolved	   in	  H2O	  (1.0	   mL)	   and	   the	   pH	   adjusted	   to	   6.0.	   GdCl3.6H2O	   (5.79	   mg,	   0.016	   mmol)	   was	  added	   as	   a	   solution	   in	  H2O	   (0.5	  mL)	   and	   the	   reaction	  mixture	   stirred	   at	   60	   °C	  overnight.	   The	   pH	   of	   the	   solution	   was	   periodically	   checked	   and	   maintained	  between	   5	   and	   6	   by	   the	   addition	   of	   NaOH/HCl	   (0.1	   M).	   Upon	   completion	   of	  complexation,	  excess	  gadolinium	  was	  removed	  by	   the	  addition	  of	  Chelex-­‐100	  with	   stirring.	  The	  Chelex	   trap	  was	   filtered	  and	   the	   complex	   eluted	  with	   excess	  H2O.	  Removal	  of	   the	  water	  by	   lyophilisation	  gave	   the	   complex	  as	   a	  white	   solid	  that	   was	   purified	   by	   RP-­‐HPLC.	   HR-­‐MS	   (ES+)	   C33H51154GdN8O15P	   requires	  984.2420	  [M+2H]+;	  found	  984.2433.	  r1p	  =	  5.0	  mM-­‐1	  s-­‐1	  (60	  MHz,	  310K).	  RP-­‐HPLC:	  

























Experimental	   	   Chapter	  8	  
	   239	  
added	   dropwise.	   The	   resulting	   mixture	   was	   heated	   to	   60	   °C	   overnight	   until	  complete	  deprotection	  was	  indicated	  by	  ESI-­‐MS.	  The	  solvent	  was	  removed	  under	  reduced	  pressure,	  before	  the	  residue	  re-­‐dissolved	   in	  H2O.	  The	  pH	  was	  adjusted	  to	  6	  and	  the	  aqueous	  phase	  washed	  with	  DCM	  (3	  x	  3	  mL)	  and	  diethyl	  ether	  (3	  x	  3	  mL).	   The	   aqueous	   solvent	   was	   then	   removed	   by	   lyophilisation	   to	   give	   the	  protonated	  salt	  of	  L10	  as	  a	  light	  brown	  solid.	  MS	  (ES+)	  m/z	  847.8	  [M+H]+.	  The	  salt	  of	  L10	  (7.6	  mg,	  0.01	  mmol)	  was	  dissolved	  in	  H2O	  (1	  mL)	  and	  the	  pH	  adjusted	  to	  6.	  GdCl3.6H2O	  (4.0	  mg,	  0.011	  mmol)	  was	  added	  as	  a	  solution	   in	  H2O	  (0.5	  mL)	  and	  the	   reaction	   mixture	   stirred	   at	   60	   °C	   overnight.	   The	   pH	   of	   the	   solution	   was	  periodically	   checked	   and	   maintained	   between	   5	   and	   6	   by	   the	   addition	   of	  NaOH/HCl	   (0.1	   M).	   Upon	   completion	   of	   complexation,	   excess	   gadolinium	   was	  removed	   by	   the	   addition	   of	   Chelex-­‐100	   with	   stirring.	   The	   Chelex	   trap	   was	  filtered	   and	   the	   complex	   eluted	   with	   excess	   H2O.	   Removal	   of	   the	   water	   by	  lyophilisation	  gave	   the	  complex	  as	  a	  white	  solid	   that	  was	  purified	  by	  RP-­‐HPLC.	  HR-­‐MS	  (ES+)	  C34H53158GdN8O15P	  requires	  1002.261	  [M+2H]+;	  found	  1002.267.	  r1p	  =	  5.2	  mM-­‐1	  s-­‐1	  (60	  MHz,	  310K).	  RP-­‐HPLC:	  tR	  =	  7.8	  mins	  [2-­‐30%	  MeOH	  in	  H2O	  over	  10	  mins].	  	  
[Eu-­DOTAGlu]	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times	  in	  order	  to	  ensure	  complete	  removal	  of	  excess	  TFA.	  Confirmation	  of	  ester	  deprotection	  was	  gained	  through	  1H	  NMR	  analysis	  before	  the	  residue	  dissolved	  in	   H2O	   (3	  mL).	   The	   pH	  was	   adjusted	   to	   6.5	   and	   EuCl3	   (15.7	  mg,	   0.043	  mmol)	  added.	  The	  reaction	  was	  heated	  to	  60	  °C	  for	  the	  progress	  monitored	  by	  ESI-­‐MS.	  Upon	  completion	  after	  4	  hours,	  excess	  europium	  was	  removed	  through	  chelation	  to	  Chelex-­‐100™	  resin.	  The	  Chelex	  trap	  was	  filtered	  and	  the	  complex	  eluted	  with	  excess	  H2O.	  Removal	  of	  the	  water	  by	  lyophilisation	  gave	  the	  complex	  as	  a	  white	  solid	  (15.7	  mg,	  70%).	  HR-­‐MS	  (ES+)	  C19H29153EuN4O10	  requires	  626.1096	  [M+H]+;	  found	  626.1102.	  	  
1,4,7,10-­Tetraazacyclododecane-­1,7-­dicarboxylic	  acid	  dibenzyl	  ester,	  607	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128.3,	  128.7,	  128.9,	  129.1,	  136.1	  (Ar-­‐C),	  156.3,	  156.4	  (CO).	  MS	  (ES+)	  m/z	  441.5	  [M+H]+;	  C24H33N4O4	  requires	  441.2502;	  found	  441.2514.	  M.pt.	  115-­‐117	  °C.	  	  
	  
4,10-­Bis-­tert-­butoxycarbonylmethyl-­1,4,7,10-­tetraazacyclododecane-­1,7-­
dicarboxylic	  acid	  dibenzyl	  ester,	  617	  
	  	  1,4,7,10-­‐Tetraazacyclododecane-­‐1,7-­‐dicarboxylic	  acid	  dibenzyl	  ester	  (2.6	  g,	  5.83	  mmol)	   and	   tert-­‐butyl	   bromoacetate	   (1.93	   mL,	   13.1	   mmol)	   were	   dissolved	   in	  anhydrous	  CH3CN	  (25	  mL)	  followed	  by	  the	  addition	  of	  Cs2CO3	  (5.7	  g,	  17.5	  mmol).	  The	   mixture	   was	   stirred	   under	   reflux	   for	   18	   hours.	   The	   cesium	   salts	   were	  filtered,	   and	   the	   solvent	   removed	   under	   reduced	   pressure.	   The	   resulting	   dark	  yellow	  oil	  was	  purified	  by	  column	  chromatography	  (DCM/MeOH,	  100%	  to	  98:2;	  
Rf	  =	  0.58)	  to	  yield	  a	  light	  yellow	  oil	  (2.81	  g,	  69	  %).	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  1.42	  (18H,	  s,	  C(CH3)3),	  2.76-­‐	  2.96	  (8H,	  br.	  s,	  CH2),	  3.14-­‐	  3.49	  (12H,	  CH2	  +	  CH2CO),	  5.12	   (4H,	   s,	   OCH2Ph),	   7.27-­‐	   7.37	   (10H,	  m,	   Ar-­‐H).	   13C	  NMR	   (CDCl3,	   176	  MHz)	   δ	  28.0	  (C(CH3)3),	  46.7-­‐	  46.9	  (br.,	  CH2	  ring),	  54.2-­‐	  54.5	  (br.,	  CH2	  ring),	  55.9	  (CH2CO),	  66.8	   (OCH2Ph),	   80.7	   (C(CH3)3),	   127.7,	   127.8,	   128.0,	   128.3,	   128.5,	   136.8	   (Ar-­‐C),	  156.3,	   170.4	   (CO);	  MS	   (ES+)	  m/z	  669.7	   [M+H]+;	   C36H53N4O8	   requires	   669.3858;	  found	  669.3860.	  	  
(7-­tert-­Butoxycarbonylmethyl-­1,4,7,10-­tetraazacyclododec-­1-­yl)-­acetic	  
acid	  tert-­butyl	  ester,	  627	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ethanol	   (20	   mL)	   to	   which	   Pd(OH)2/C	   (10%)	   was	   added.	   The	   mixture	   was	  agitated	  in	  a	  Parr	  hydrogenation	  apparatus	  (40	  psi)	  for	  3	  days.	  The	  catalyst	  was	  filtered	   and	   the	   ethanol	   removed	   under	   reduced	   pressure	   to	   yield	   a	   viscous	  yellow	  oil	  (1.67	  g,	  99	  %).	  1H	  NMR	  (500	  MHz,	  CDCl3)	  δ	  1.45	  (18H,	  s,	  C(CH3)3),	  2.71	  (8H,	   br.	   s,	   CH2),	   2.82	   (8H,	   br.	   s,	   CH2),	   3.31	   (4H,	   s,	   CH2CO).	   13C	  NMR	   (125MHz,	  CDCl3)	   δ	   27.3	   (C(CH3)3),	   51.8,	   53.4	   (CH2),	   82.7	   (C(CH3)3),	   171.9	   (CO).	  MS	   (ES+)	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(R)-­4-­(7-­((R)-­6-­(((benzyloxy)carbonyl)amino)-­1-­(tert-­butoxy)-­1-­oxohexan-­
2-­yl)-­4,10-­bis(2-­(tert-­butoxy)-­2-­oxoethyl)-­1,4,7,10-­tetraazacyclododecan-­
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tert-­Butyl	   (2-­(5-­((3aS,	   4S,	   6aR)-­2-­oxohexahydro-­1H-­thieno[3,4-­d]imidazol-­
4-­yl)pentanamido)ethyl)carbamate,	  6611	  
	  
	  	  A	   suspension	   of	  D-­‐biotin	   (300	  mg,	   1.23	  mmol),	  N-­‐Boc-­‐1,2-­‐diaminoethane	   (236	  mg,	  1.48	  mmol)	  and	  EDC	  (307	  mg,	  1.60	  mmol)	  in	  a	  solution	  of	  anhydrous	  MeOH	  (3	   mL)	   and	   anhydrous	   acetonitrile	   (9	   mL),	   was	   stirred	   for	   5	   hour	   at	   room	  temperature.	   Upon	   no	   further	   reaction,	   as	   verified	   by	   TLC,	   the	   mixture	   was	  concentrated	  under	  reduced	  pressure.	  The	  crude	  residue	  was	  then	  re-­‐suspended	  in	   MeOH	   (25	   mL)	   and	   filtered.	   The	   filtrate	   was	   concentrated	   and	   the	   crude	  product	  was	  purified	  by	  column	  chromatography	  (DCM/MeOH,	  100%	  to	  90:10;	  
Rf	  =	  0.64)	  to	  give	  a	  white	  solid	  (170	  mg,	  36%).	  1H	  NMR	  (400	  MHz,	  MeOD)	  δ	  1.27-­‐1.29	  (2H,	  m,	  CH2),	  1.34	  (9H,	  s,	  C(CH3)3),	  1.46-­‐1.69	  (4H,	  m,	  CH2),	  2.11	  (2H,	  t,	  J	  =	  7,	  CH2CO),	  2.61	  (1H,	  d,	  J	  =	  12,	  SCHH),	  2.83	  (1H,	  dd,	  J	  =	  12,	  5,	  SCH’H),	  3.05	  (2H,	  m,	  NHCH2CH2NHBOC),	  3.09-­‐3.18	  (3H,	  m,	  NHCH2CH2NHBOC	  +	  SCH),	  4.21	  (1H,	  dd,	  J	  =	  8,	  4,	  CH),	  4.41	  (1H,	  dd,	  J	  =	  8,	  4,	  CH).	  13C	  NMR	  (400	  MHz,	  MeOD)	  δ	  26.8,	  28.8,	  29.5	  (CH2),	   29.8	   (C(CH3)3),	   36.8	   (CH2CO),	   37.4,	   40.5	   (NHCH2),	   41.0	   (CH2),	   57.0	   (CH-­‐biotin	  chain),	  61.6,	  63.3	  (CH),	  80.2	  (C(CH3)3),	  158.5,	  166.1,	  176.4	  (CO).	  MS	  (ES+)	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2.78-­‐2.92	  (6H,	  m,	  CH2),	  3.04-­‐3.23	  (9H,	  m,	  CH2),	  3.23-­‐3.41	  (5H,	  m,	  CH2),	  4.27	  (1H,	  dd,	  J	  =	  8,	  5,	  NHCHCH2S),	  4.45	  (1H,	  dd,	  J	  =	  8,	  5,	  NHCHCH2S),	  5.06	  (2H,	  s,	  OCH2Ph),	  5.89	  (1H,	  br.	  s,	  NH),	  6.51	  (1H,	  br.	  s,	  NH),	  7.28-­‐7.35	  (5H,	  m,	  Ar-­‐H).	  13C	  NMR	  (151	  MHz,	   CDCl3)	   δ	   23.6,	   25.6,	   27.9,	   28.0	   (CH/CH2),	   28.2,	   28.3,	   28.4	   (C(CH3)3),	   29.7,	  29.9,	  33.3,	  35.9,	  39.4,	  40.6,	  41.0,	  49.5,	  50.0,	  50.7,	  53.0,	  53.2,	  55.7,	  56.7	  (CH/CH2),	  60.3,	   61.8	   (CH2CO2tBu),	   63.5,	   64.5	   (CHCO2tBu),	   66.6	   (OCH2Ph),	   80.9,	   81.0,	   81.1	  (C(CH3)3),	   128.1,	   128.2,	   128.5,	   136.8	   (Ar-­‐C),	   156.6,	   164.1,	   171.3,	   172.5,	   173.0,	  173.9,	   175.4	   (CO).	   MS	   (ES+)	   m/z	   =	   1174.7	   [M+H]+;	   C59H100N9O13S	   requires	  1174.716;	  found	  1174.719.	  	  
[Conjugate	  11],	  69	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pre-­‐stirred	  solution	  of	  2-­‐((2-­‐((tert-­‐Butoxycarbonyl)amino)-­‐3,4-­‐dioxocyclobut-­‐1-­‐en-­‐1-­‐yl)(3-­‐(diethoxyphosphoryl)propyl)amino)acetic	   acid	   (28	   mg,	   0.06	   mmol),	  EDC	   (14	  mg,	   0.07	  mmol)	   and	  HOBt	   (10	  mg,	   0.07	  mmol)	   in	   anhydrous	  DMF	   (1	  mL).	  The	  resulting	  mixture	  was	  stirred	  at	  room	  temperature	  overnight,	  before	  a	  second	  addition	  of	  the	  coupling	  reagents	  (EDC	  14	  mg,	  0.07	  mmol;	  HOBt	  10	  mg,	  0.07	   mmol).	   The	   reaction	   mixture	   was	   again	   stirred	   overnight	   at	   room	  temperature.	  Upon	  no	  further	  reaction	  by	  ESI-­‐MS,	  the	  DMF	  was	  removed	  under	  reduced	   pressure	   and	   the	   residue	   taken	   up	   into	   EtOAc	   (20	   mL).	   The	   organic	  phase	   was	   washed	   with	   saturated	   NaHCO3	   solution	   (20	  mL)	   and	   the	   aqueous	  repeatedly	   extracted	   with	   EtOAc	   (3	   x	   20	   mL).	   The	   combined	   organics	   were	  washed	  with	  saturated	  brine	  (30	  mL),	  dried	  over	  MgSO4,	  filtered	  and	  evaporated.	  The	  crude	  residue	  was	  then	  purified	  by	  RP-­‐HPLC	  to	  give	  the	  desired	  compound	  as	   a	   brown	   film	   (5	  mg,	   6%).	   1H	  NMR	   (700	  MHz,	   CDCl3)	   δ	   1.22-­‐1.54	   (53H,	   br.),	  1.62-­‐2.48	   (35H,	   br.),	   2.70-­‐3.51	   (22H,	   br.),	   4.10	   (4H,	   br.).	   31P	   NMR	   (283	   MHz,	  CDCl3)	   δ	   30.49.	   MS	   (ES+)	   m/z	   =	   736.3	   [M+2H]2+;	   C69H121N11O19SP	   requires	  736.422;	  found	  736.420.	  	  
[Gd.L11]	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esters	  was	  verified	  by	  ESI-­‐MS	  ([M+2K]2+;	  m/z	  =	  745.5).	  The	  free	  phosphonic	  acid	  was	  then	  partially	  dissolved	  in	  DCM	  (1	  mL)	  to	  which	  TFA	  (1	  mL)	  was	  added.	  The	  resulting	   yellow	   solution	   was	   stirred	   at	   room	   temperature	   overnight	   before	  removal	   of	   the	   solvent	   under	   reduced	   pressure.	   The	   crude	   product	   was	   re-­‐dissolved	   in	  DCM	  and	   concentrated	   under	   reduced	  pressure.	   This	   process	  was	  repeated	   3	   times	   to	   yield	   L11	   ([M+2H]2+	   m/z	   =	   545.1).	   The	   residue	   was	   then	  dissolved	   in	   H2O	   (1	  mL)	   and	   the	   pH	   adjusted	   to	   5.5	   by	   the	   addition	   of	   NaOH	  (0.1M).	  GdCl3.6H2O	  (2	  mg,	  5.4	  µmol)	  was	  added	  as	  a	  solution	  in	  H2O	  (0.2	  mL)	  and	  the	   reaction	   mixture	   stirred	   at	   60	   °C	   overnight.	   The	   pH	   of	   the	   solution	   was	  periodically	   checked	  and	  adjusted	   to	  5.5	  by	   the	  addition	  of	  NaOH/HCl	   (0.1	  M).	  Upon	   completion,	   excess	   gadolinium	   ions	   were	   removed	   by	   the	   addition	   of	  chelex-­‐100	  with	  stirring.	  The	  Chelex	  trap	  was	  filtered	  and	  the	  complex	  eluted	  with	  excess	  H2O.	  Removal	  of	   the	  water	  by	   lyophilisation	  gave	   the	  complex	  as	  a	  light	   yellow	   solid	   that	   was	   purified	   by	   RP-­‐HPLC.	   HR-­‐MS	   (ES+)	  C44H69157GdN11O17PSK2	   requires	   440.672	   [M+H+2K]3+;	   found	   440.671.	   r1p	   =	   7.2	  mM-­‐1s-­‐1	  (60	  MHz,	  310K).	  RP-­‐HPLC:	  tR	  =	  15.9	  mins	  [2-­‐30%	  MeOH	  in	  H2O	  over	  10	  mins].	  	  
(S)-­2-­Bromo-­pentanedioic	  acid	  5-­methyl	  ester,	  70	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CDCl3)	   δ	   2.27-­‐2.32	   (1H,	   m,	   CH2CHBr),	   2.38-­‐2.43	   (1H,	   m,	   CH2CHBr),	   2.57-­‐2.65	  (2H,	  m,	  CH2CH2CHBr),	  3.69	  (3H,	  s,	  CH3),	  4.41	  (1H,	  dd,	  J	  =	  9,	  5,	  CH).	  13C	  NMR	  (176	  MHz,	  CDCl3)	  δ	  29.7	  (CH2CH2CHBr),	  31.6	  (CH2CHBr),	  44.2	  (CH),	  52.0	  (CH3),	  172.1,	  173.4	  (CO).	  MS	  (ES+)	  m/z	  246.8	  [M	  +	  Na]+.	  	  
(S)-­2-­Bromo-­pentanedioic	  acid	  5-­methyl	  ester	  1-­tert-­butyl	  ester,	  71	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  (R)-­‐di-­‐tert-­‐butyl	   2,2’-­‐(4-­‐(6-­‐(((benzyloxy)carbonyl)amino)-­‐1-­‐(tert-­‐butoxy)-­‐1-­‐oxohexan-­‐2-­‐yl)1,4,7,10-­‐tetraazacyclododecane-­‐1,7-­‐diyl)diacetate	   (1.35	   g,	   1.87	  mmol),	  K2CO3	  (310	  mg,	  2.24	  mmol)	  and	  (S)-­‐2-­‐bromo-­‐pentanedioic	  acid	  5-­‐methyl	  ester	   1-­‐tert-­‐butyl	   ester	   (631	   mg,	   2.24	   mmol)	   were	   stirred	   as	   a	   solution	   in	  acetonitrile	  (20	  mL)	  at	  60	  °C	  for	  48	  hours.	  Completion	  of	  reaction	  was	  verified	  by	  ESI-­‐MS,	  at	  which	  point	  the	  mixture	  was	  cooled	  to	  room	  temperature,	  filtered	  and	  the	  filtrate	  concentrated	  under	  reduced	  pressure.	  The	  crude	  orange	  residue	  was	  then	   purified	   by	   column	   chromatography	   (DCM/MeOH,	   100%	   DCM	   to	   93:7	  utilising	  1%	  increments;	  Rf	  =	  0.41)	  to	  give	  a	  dark	  yellow	  oil	   (571	  mg,	  33%).	  1H	  NMR	  (700	  MHz,	  CDCl3)	  δ	  1.36	  (9H,	  s,	  C(CH3)3),	  1.37	  (18H,	  s,	  C(CH3)3),	  1.38	  (9H,	  s,	  C(CH3)3),	  1.43–1.50	  (4H,	  m,	  CH2),	  1.54–1.63	  (2H,	  m,	  CH2,),	  1.64-­‐1.78	  (2H,	  m,	  CH2),	  1.84-­‐1.93	   (2H,	  m,	  CH2),	  2.38-­‐2.52	   (2H,	  br.	  m,	  CH2),	  2.52-­‐2.61	   (4H,	  br.	  m),	  2.62-­‐2.86	   (12H,	  m,	  CH2),	   3.06-­‐3.19	   (6H,	  m),	   3.57	   (3H,	   s,	   CH3),	   5.00	   (2H,	   s,	  OCH2Ph),	  5.17	  (1H,	  s,	  NH),	  7.21–7.31	  (5H,	  m,	  Ar-­‐H).	  13C	  NMR	  (176	  MHz,	  CDCl3)	  δ	  27.7,	  27.8	  (CH2),	  28.2,	  28.3,	  28.3	  (C(CH3)3),	  30.4,	  32.1,	  40.5,	  40.7,	  44.1,	  44.5,	  47.1,	  47.2,	  48.7,	  48.8	  (CH2),	  51.4	  (CH2),	  52.9	  (CH3),	  55.8,	  56.0,	  59.7	  (CH2	  ring),	  61.1	  (CH2CO2tBu),	  63.2,	   63.4	   (CHCO2tBu),	   66.3	   (OCH2Ph),	   81.8,	   81.9,	   82.0,	   82.5	   (C(CH3)3),	   127.8,	  127.9,	  128.0,	  128.4	  (Ar-­‐C),	  172.8,	  172.9,	  173.3,	  174.0,	  174.6,	  175.1	  (CO).	  MS	  (ES+)	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4-­(((R)-­5-­(4,10-­Bis(2-­(tert-­butoxy)-­2-­oxoethyl)-­7-­((R)-­1-­(tert-­butoxy)-­5-­
methoxy-­1,5-­dioxopentan-­2-­yl)-­1,4,7,10-­tetraazacyclododecan-­1-­yl)-­6-­
(tert-­butoxy)-­6-­oxohexyl)amino)-­4-­oxobutanoic	  acid,	  73	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P(OCH2CH3)2),	  1.43	  (36H,	  s,	  C(CH3)3),	  1.44-­‐1.46	  (4H,	  m),	  1.56-­‐1.66	  (2H,	  m),	  1.75-­‐1.84	  (2H,	  m),	  1.90-­‐1.98	  (2H,	  m),	  2.12-­‐2.19	  (2H,	  m,	  PCH2CH2),	  2.42-­‐2.51	  (2H,	  m),	  2.54-­‐2.65	  (7H,	  m),	  2.66-­‐2.74	  (5H,	  m),	  1.76-­‐2.87	  (8H,	  m),	  3.10-­‐3.13	  (1H,	  m),	  3.15-­‐3.19	  (3H,	  m),	  3.21-­‐3.24	  (3H,	  m),	  3.33	  (1H,	  d,	  J	  =	  14,	  Hc/a	  (eq)),	  3.50	  (1H,	  d,	  J	  =	  14,	  
Hc	  (axial)),	  3.64	  (3H,	  s,	  CH3),	  3.69-­‐3.79	  (2H,	  m,	  PCH2CH2),	  3.90	  (1H,	  dd,	  J	  =	  14,	  7,	  
Ha	  (axial)),	  4.05-­‐4.14	  (4H,	  m,	  P(OCH2CH3)2),	  4.25-­‐4.29	  (1H,	  m,	  Hb).	  13C	  NMR	  (176	  MHz,	   CDCl3)	   δ	   16.5	   (d,	   3J	   =	   6,	   P(OCH2CH3)2),	   24.0	   (CH2),	   25.0	   (d,	   1J	   =	   140,	  NCH2CH2P),	  25.2,	  27.9,	  27.9,	  28.3	   (CH2),	  28.3,	  28.4,	  28.5	   (overlapping	  C(CH3)3),	  30.6,	  31.0,	  31.4,	  31.8,	  39.5,	  45.2,	  48.7	  (CH2),	  49.7	  (d,	  J	  =	  16,	  PCH2CH2),	  51.5	  (Cb),	  52.9,	  53.1,	  53.1(CH2),	  55.5	  (Ca),	  56.1	  (Cc),	  62.2	  (d,	  2J	  =	  7,	  P(OCH2CH3)2),	  62.5	  (CH),	  63.2	  (CH2CO2tBu),	  64.5	  (CH),	  80.8,	  80.8,	  80.8,	  81.0	  (C(CH3)3),	  168.0,	  168.2	  (C=C),	  171.1,	  172.2,	  172.5,	  173.0,	  173.5,	  174.4,	  177.2,	  181.2,	  182.2	  (CO).	  31P	  NMR	  (283	  MHz,	   CDCl3)	   δ	   27.26.	   MS	   (ES+)	   m/z	   1199.4	   [M+H]+;	   C57H100N8O17P	   requires	  1199.694;	  found	  1199.693.	  	  
[Conjugate	  12],	  75	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temperature	  and	  progress	  of	  the	  reaction	  monitored	  by	  ESI-­‐MS.	  Upon	  complete	  hydrolysis	   of	   the	   methyl	   ester	   after	   1	   hour,	   the	   solvent	   was	   removed	   under	  reduced	   pressure	   to	   give	   a	   pale	   yellow	   solid,	   which	  was	   dried	   fully	   on	   a	   high	  vacuum	  line.	  This	  yielded	  the	  carboxylic	  acid	  (49	  mg,	  0.042),	  to	  which	  EDC	  (9.6	  mg,	  0.050	  mmol)	  and	  HOBt	  (6.8	  mg,	  0.050	  mmol)	  were	  added	  and	  dissolved	   in	  anhydrous	  DMF	  (1	  mL).	  The	  mixture	  was	  stirred	  at	  room	  temperature	  under	  an	  atmosphere	  of	  argon	  for	  20	  minutes.	  After	  this	  period,	  a	  pre-­‐stirred	  solution	  of	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RP-­‐HPLC.	  HR-­‐MS	   (ES+)	  C48H75154GdN12O18PS	   requires	  1324.399	   [M+2H]+;	   found	  1324.399.	   r1p	   =	   7.2	  mM-­‐1	   s-­‐1	   (60	  MHz,	   310K).	  RP-­‐HPLC:	   tR	   =	  16.7	  mins	   [2-­‐30%	  MeOH	  in	  H2O	  over	  10	  mins].	  	  
[2-­(4-­Hydroxy-­8,9-­dioxo-­2,6-­diazabicyclo[5.2.0]non-­1(7)-­en-­2-­
yl)ethyl]phosphonic	  acid,	  766	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orange	  oil	   that	   remained	  was	   taken	   into	  aqueous	  NaOH	  solution	   (10	  mL,	  4	  M),	  the	  solvent	  removed	  and	  the	  residue	  redissolved	  in	  MeOH	  (20	  mL).	  The	  solution	  was	  filtered	  and	  the	  filtrate	  added	  to	  DCM	  (70	  mL)	  and	  passed	  through	  a	  pad	  of	  celite.	   The	   filtrate	  was	   evapourated	   to	   give	   a	   yellow	   oil	   (3.9	   g,	   75%).	   1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  1.30-­‐1.46	  (10H,	  m,	  NH2	  +	  H4	  +	  H5),	  1.85	  (2H,	  m,	  H3),	  2.68	  (2H,	  t,	   J	  =	  6,	  H6),	  2.80	  (2H,	  t,	   J	  =	  6,	  H8),	  3.28	  (2H,	  q,	   J	  =	  6,	  H7),	  3.32-­‐3.35	  (1H,	  m,	  H2),	  7.57	  (1H,	  br.	  s,	  NH).	  13C	  NMR	  (101	  MHz,	  CDCl3)	  δ	  23.2,	  33.5,	  35.0	  (C3	  +	  C4	  +	  C5),	  41.5,	   41.7,	   41.9	   (C6	   +	  C7	   +	  C8),	   55.2	   (C2),	   188.6	   (CO).	  MS	   (ES+)	  m/z	   211.3	   [M	  +	  Na]+;	  C8H20N4ONa	  requires	  211.1535;	  found	  211.1535.	  	  
(5S)-­3-­Azanonane-­1,5,9-­triamine,	  7812	  
	  
	  	  (2S)-­‐N-­‐(2-­‐Aminoethyl)-­‐(2,6-­‐diaminohexanamide)	   (3.9	   g,	   21	   mmol)	   was	   boiled	  under	   reflux	   (70	   °C)	   in	   BH3-­‐THF	   (100	  mL,	   100	  mmol)	   for	   24	   hours.	   After	   this	  time,	  the	  reaction	  was	  quenched	  by	  the	  slow	  addition	  of	  methanol	  (100	  mL)	  at	  0	  
°C	  and	   the	   solvent	   removed	  under	   reduced	  pressure.	  Reaction	   completion	  was	  confirmed	  by	  IR	  spectroscopy	  (disappearance	  of	  amide	  carbonyl).	  The	  resulting	  white	  solid	  was	  boiled	  under	  reflux	  overnight	  in	  HCl	  (50	  mL,	  2	  M),	  at	  which	  point	  evaporation	   of	   the	   solvent	   under	   reduced	   pressure	   revealed	   the	   tetra-­‐hydrochloride	   salt	   as	   a	  white	   gum	   (6.67	   g,	   100%).	   1H	  NMR	   (400	  MHz,	   D2O)	   δ	  1.38-­‐1.73	  (6H,	  m,	  H3	  +	  H4	  +	  H5),	  2.93	  (2H,	  t,	  J	  =	  8,	  H6),	  3.30-­‐3.38	  (6H,	  m,	  H1	  +	  H7	  +	  
H8),	  3.58-­‐3.64	  (1H,	  m,	  H2).	  13C	  NMR	  (101	  MHz,	  D2O)	  δ	  21.5,	  26.5,	  30.0	  (C3	  +	  C4	  +	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(5S)-­N-­(5,9-­Diamino-­7-­azanonyl)benzamide,	  7912	  	  
	  	  The	   tetrahydrochloride	   salt	   of	   (5S)-­‐3-­‐azanonane-­‐1,5,9-­‐triamine	   was	   converted	  to	  the	  free	  amine	  by	  the	  addition	  of	  KOH	  (to	  pH	  7).	  The	  free	  amine	  (1.49	  g,	  8.52	  mmol)	  was	  dissolved	   in	  H2O	  (25	  mL)	  and	  Cu(CO3)Cu(OH)2	  (1.04	  g,	  4.68	  mmol)	  was	  added	  to	  give	  an	  intense	  blue	  colour.	  The	  mixture	  was	  heated	  to	  50	  °C	  for	  45	  mins	  before	  cooling	  to	  0	  °C.	  Benzoyl	  chloride	  (1.29	  mL,	  11.08	  mmol)	  was	  added	  dropwise	  to	  the	  cooled	  solution,	  whilst	   the	  pH	  was	  maintained	  between	  8-­‐9	  by	  the	   addition	   of	   KOH.	   The	   reaction	  was	   allowed	   to	  warm	   to	   room	   temperature	  and	  the	  stirring	  continued	   for	  1	  hour.	  The	  solution	  was	   filtered	  and	  the	   filtrate	  treated	   with	   H2S	   for	   5	   minutes	   to	   precipitate	   a	   brown	   solid.	   This	   solid	   was	  filtered	  and	  pale	  yellow	  solution	  was	  washed	  with	  DCM.	  The	  aqueous	  layer	  was	  reduced	   to	  50%	  original	  volume	  and	   the	  pH	  was	   increased	   to	  12.	  The	  aqueous	  solution	  was	  repeatedly	  extracted	  with	  DCM	  and	  CHCl3,	  with	  evaporation	  of	  the	  organic	  giving	  a	  colourless	  oil	  (1.02	  g,	  43%).	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  1.53-­‐1.67	  (11H,	  m,	  NH2	  +	  H2	  +	  H3	  +	  H4),	  2.38-­‐2.42	  (1H,	  m,	  H5),	  2.66-­‐2.72	  (6H,	  m,	  H6	  +	  
H8	  +	  H9),	  2.82	  (2H,	  t,	  J	  =	  4,	  H1),	  6.33	  (1H,	  br.s,	  NH),	  7.43-­‐7.80	  (5H,	  Ar-­‐H).	  13C	  NMR	  (101	  MHz,	  CDCl3)	  δ	  22.5,	  23.7,	  28.7	  (C2	  +	  C3	  +	  C4),	  38.7	  (C1),	  40.8,	  50.0,	  51.6	  (C6	  +	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(5S)-­N-­(5,9-­Bistoluene-­p-­sulphonamido-­7-­toluene-­p-­sulphonyl-­7-­
azanonyl)benzamide,	  8012	  





















Experimental	   	   Chapter	  8	  
	   262	  
(S)-­2-­(4-­Benzamidobutyl)-­1,4,7-­tris-­(toluene-­p-­sulphonyl)-­1,4,7-­
triazacyclononane,	  8112	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(S)-­4-­(1,4,7-­Triazonan-­2-­yl)butan-­1-­amine,	  8212	  
	  	  Ammonia	  (excess)	  was	  condensed	  into	  a	  solution	  of	  the	  tritosylamide	  (692	  mg,	  0.92	  mmol)	   in	   a	  mixture	  of	   anhydrous	  THF	   (30	  mL)	   and	   anhydrous	  EtOH	   (2.3	  mL)	  whilst	  stirring	  under	  argon	  at	  –78	  °C.	  Lithium	  (400	  mg,	  excess)	  was	  added	  in	  small	  portions	  to	  the	  solution	  and	  a	  strong	  blue	  colour	  developed.	  The	  solution	  was	   slowly	   warmed	   to	   room	   temperature	   overnight;	   during	   this	   period	   the	  solution	   turned	   colourless	   and	   the	   ammonia	   gas	   was	   allowed	   to	   evaporate	  through	  an	  anti-­‐suck	  back	  apparatus.	  Water	  (20	  mL)	  was	  added	  to	  the	  solution	  and	  the	  solvent	  was	  removed.	  The	  residue	  that	  remained	  was	  dissolved	  directly	  in	  HCl	   solution	   (7.5	  mL,	   6	  M)	   and	   the	  mixture	   heated	   to	   100	   °C	   for	   72	   hours.	  Upon	   completion,	   the	   reaction	  was	   diluted	  with	  H2O	   (5	  mL)	   and	  washed	  with	  diethyl	   ether	   (3	   x	   15	   mL).	   The	   aqueous	   layer	   was	   concentrated	   to	   give	   the	  tetrahydrochloride	   salt	   (162	  mg,	   100%).	   1H	   NMR	   (400	  MHz,	   D2O)	   δ	   1.37-­‐1.64	  (6H,	  m,	  H10	  +	  H11	  +	  H12),	  2.87-­‐3.96	  (3H,	  m,	  H2	  +	  H13),	  3.13-­‐3.42	  (10H,	  m,	  H3	  +	  H5	  +	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(S)-­tert-­Butyl	  (4-­(1,4,7-­triazonan-­2-­yl)butyl)carbamate,	  8313	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Methyl	  2-­(4-­ethynylphenoxy)acetate,	  8414	  
	  
	  	  The	   trimethylsilane-­‐protected	   alkyne	   (134	   mg,	   0.511	   mmol)	   was	   dissolved	   in	  anhydrous	   THF	   (2	   mL)	   and	   triethylammonium	   dihydrofluoride	   (833	   µL,	   5.11	  mmol)	  was	  added.	  The	  mixture	  was	  stirred	  under	  argon	  for	  24	  hours	  at	  35	  °C,	  at	  which	   point	   the	   solvent	   was	   removed	   under	   reduced	   pressure.	   The	   crude	  residue	   that	   remained	  was	  purified	  by	   column	  chromatography	   (DCM/Hexane,	  70:30;	  Rf	  =	  0.25)	  to	  give	  a	  colourless	  oil	  (70	  mg,	  72%).	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  3.00	  (1H,	  s,	  H1),	  3.80	  (3H,	  s,	  CH3),	  4.64	  (2H,	  s,	  CH2),	  6.85	  (2H,	  d,	  J	  =	  9,	  H5),	  7.43	  (2H,	  d,	  J	  =	  9,	  H4).	  13C	  NMR	  (101	  MHz,	  CDCl3)	  δ	  52.5	  (C9),	  65.3	  (C7),	  76.3	  (C1),	  83.4	  (C2),	   114.7	   (C5),	   115.6	   (C3),	   133.8	   (C4),	   158.2	   (C6),	   169.1	   (CO).	   MS	   (ES+)	  m/z	  191.9	  [M	  +	  H]+;	  C11H11O3	  requires	  191.0708;	  found	  191.0712.	  	  
Methyl	  2-­(4-­((2-­(ethoxy(methyl)phosphoryl)-­6-­(hydroxymethyl)pyridin-­4-­
yl)ethynyl)phenoxy)acetate,	  8514	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triethylamine	  (214	  µL,	  1.535	  mmol),	  and	  the	  solution	  was	  degassed	  (freeze-­‐thaw	  cycle)	   three	   times.	   [1,1-­‐Bis(diphenylphosphino)ferrocene]dichloropalladium(II)	  (26	  mg,	  0.031	  mmol)	  and	  CuI	  (6	  mg,	  0.031	  mmol)	  were	  added	  and	  the	  resulting	  brown	   solution	   was	   stirred	   at	   65	   °C	   under	   argon	   for	   18	   h.	   The	   solvent	   was	  removed	  under	  reduced	  pressure	  and	  the	  brown	  residue	  was	  purified	  by	  column	  chromatography	  (DCM/MeOH,	  100%	  to	  97:3	  using	  0.5%	  increments;	  Rf	  =	  0.15)	  to	  give	  a	  yellow	  oil	  (68	  mg,	  55%).	  1H	  NMR	  (600	  MHz,	  CDCl3)	  δ	  1.26	  (3H,	  t,	  J	  =	  7,	  OCH2CH3),	   1.76	   (3H,	   d,	   1JH-­‐P	   =	   15,	   PCH3),	   3.79	   (3H,	   s,	   CH3),	   3.85-­‐3.87	   (1H,	   m,	  OCH2CH3),	  3.99	  (1H,	  br.s,	  OH),	  4.07-­‐4.09	  (1H,	  m,	  OCH2CH3),	  4.65	  (2H,	  s,	  OCH2CO),	  4.80	  (2H,	  s,	  CH2OH),	  6.88	  (2H,	  d,	  J	  =	  9,	  H15),	  7.45	  (2H,	  d,	  J	  =	  9,	  H14),	  7.50	  (1H,	  br.s,	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methanesulfonyl	  chloride	  (16	  μL,	  0.208	  mmol)	  were	  added	  and	  the	  mixture	  was	  stirred	  under	  argon	  for	  90	  min.	  The	  progress	  of	  the	  reaction	  was	  monitored	  by	  TLC	   [DCM/CH3OH	  95:5	  v/v,	  Rf(product)	   =	  0.23,	  Rf(reactant)	   =	  0.11].	  The	   solvent	  was	  removed	  under	  reduced	  pressure	  and	  the	  residue	  was	  dissolved	  in	  DCM	  (30	  mL)	  and	  washed	  with	  saturated	  aqueous	  brine	  solution	  (30	  mL).	  The	  aqueous	   layer	  was	   extracted	   with	   DCM	   (3	   ×	   30	   mL)	   and	   the	   combined	   organic	   layers	   were	  dried	  over	  MgSO4,	  and	  concentrated	  under	  reduced	  pressure	  to	  give	  a	  yellow	  oil	  (66	  mg,	  100%.).	   1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  1.26	  (3H,	   t,	   J	  =	  7,	  OCH2CH3),	  1.76	  (3H,	  d,	  1JH-­‐P	  =	  15,	  PCH3),	  3.79	  (3H,	  s,	  CH3),	  3.85-­‐3.87	  (1H,	  m,	  OCH2CH3),	  4.07-­‐4.09	  (1H,	  m,	  OCH2CH3),	  4.65	  (2H,	  s,	  OCH2CO),	  5.33	  (2H,	  s,	  CH2OMs),	  6.88	  (2H,	  d,	  J	  =	  9,	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4-­((8,9-­Dioxo-­2-­(2-­phosphonoethyl)-­2,6-­diazabicyclo[5.2.0]non-­1(7)-­en-­4-­
yl)amino)-­4-­oxobutanoic	  acid,	  90	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[Eu.L13]	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[Eu.L14]	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Potassium-­2,3,3-­trimethyl-­3H-­indole-­5-­sulfonate,	  9115	  
	  
	  	  Hydrazinobenzene	   sulfonic	   acid	   (15.0	   g,	   79.5	  mmol)	   and	   3-­‐methyl-­‐2-­‐butanone	  (25.2	   mL,	   240	   mmol)	   were	   dissolved	   in	   acetic	   acid	   (45	   mL)	   and	   the	   mixture	  heated	   to	   reflux	   for	   3	   h.	   After	   this	   time,	   the	   acetic	   acid	   was	   removed	   under	  reduced	  pressure	  and	  the	  crude	  residue	  obtained	  dissolved	  in	  MeOH.	   	  This	  was	  stirred	   with	   a	   saturated	   solution	   of	   potassium	   hydroxide	   in	   propan-­‐2-­‐ol.	   The	  alkaline	   solution	   turned	   yellow	   and	   the	   potassium	   salt	   of	   the	   sulfoindole	  precipitated	  as	  a	  pale	  yellow	  solid	  (16.5	  g,	  75%).	  1H	  NMR	  (400	  MHz,	  DMSO-­‐d6)	  δ	  1.24	  (6H,	  s,	  (CH3)2),	  2.21	  (3H,	  s,	  CH3),	  7.33	  (1H,	  d,	  J	  =	  8,	  H7),	  7.54	  (1H,	  dd,	  J	  =	  8,	  2,	  	  
H6),	  7.62	  (1H,	  d,	  J	  =	  2,	  H4).	  13C	  NMR	  (101	  MHz,	  DMSO-­‐d6)	  δ	  15.2,	  22.51	  (CH3),	  53.2	  (C(CH3)2),	  118.1,	  119.2,	  125.1,	  145.1,	  145.2,	  153.6	  (Ar-­‐C),	  188.8	  (C=N).	  MS	  (ES+)	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(2H,	  t,	  J	  =	  7,	  CH2CH2SO3),	  7.93	  (1H,	  d,	  J	  =	  8,	  H7),	  8.05	  (1H,	  dd,	  J	  =	  8,	  2,	   	  H6),	  8.14	  (1H,	  d,	   J	  =	  2,	  H4).	   13C	  NMR	  (101	  MHz,	  D2O)	  δ	  21.4,	  21.5	  (CH3),	  25.8	  (NCH2CH2),	  47.8	  (CH2CH2SO3),	  50.0	  (NCH2CH2),	  55.0	  (CH2CH2SO3),	  115.9,	  120.9,	  126.9,	  142.6,	  142.8,	   144.1	   (Ar-­‐C),	   199.3	   (C=N).	   MS	   (ES+)	   m/z	   376.2	   [M+H]+;	   C15H22NO6S2	  requires	  376.0889;	  found	  376.0884.	  M.Pt	  >	  250	  °C.	  	  
(E)-­2-­Chloro-­3-­(hydroxymethylene)cyclohex-­1-­enecarbaldehyde,	  9317	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4-­(2-­((E)-­2-­((E)-­2-­(4-­carboxyphenoxy)-­3-­((E)-­2-­(3,3-­dimethyl-­5-­sulfo-­1-­(4-­
sulfobutyl)indolin-­2-­ylidene)ethylidene)cyclohex-­1-­en-­1-­yl)vinyl)-­3,3-­
dimethyl-­5-­sulfo-­3H-­indol-­1-­ium-­1-­yl)butane-­1-­sulfonate,	  95	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1-­(4-­(Benzyloxy)phenyl)-­2-­bromopropan-­1-­one,	  9619	  	  
	  	  Bromine	   (512	   µL,	   10.00	   mmol)	   was	   added	   to	   a	   solution	   of	   1-­‐(4-­‐(benzyloxy)phenyl)propan-­‐1-­‐one	  (2.40	  g,	  10.00	  mmol)	  in	  diethyl	  ether	  (25	  mL).	  The	   mixture	   was	   stirred	   at	   room	   temperature	   for	   30	   minutes	   when	   a	   colour	  change	   from	   red	   to	   yellow	   was	   observed.	   At	   this	   point,	   the	   reaction	   was	  quenched	  by	  the	  addition	  of	  H2O	  (10	  mL)	  and	  the	  mixture	  was	  diluted	  with	  Et2O	  (25	  mL).	  The	  organic	   layer	  was	   separated	   and	  washed	  with	   saturated	  NaHCO3	  solution	  (30	  mL),	  saturated	  Na2S2O3	  (30	  mL)	  and	  saturated	  brine	  (30	  mL),	  before	  drying	   over	   MgSO4.	   Filtration	   and	   evaporation	   of	   the	   solvent	   gave	   the	   crude	  product,	  which	  was	  purified	  by	  column	  chromatography	  (DCM/Hexane,	  50:50;	  Rf	  =	  0.33)	  to	  give	  an	  orange	  solid	  (2.61	  g,	  82%).	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  1.89	  (3H,	  d,	  J	  =	  7,	  CH3),	  5.15	  (2H,	  s,	  OCH2Ph),	  5.26	  (2H,	  q,	  J	  =	  7,	  CHBr),	  7.03	  (2H,	  d,	  J	  =	  9,	  H5),	  7.33-­‐7.46	  (5H,	  m,	  Ar-­‐H),	  8.02	  (2H,	  d,	  J	  =	  9,	  H6).	  13C	  NMR	  (101	  MHz,	  CDCl3)	  δ	   20.4,	   (CH3)	   41.6	   (CHBr),	   70.4	   (OCH2Ph),	   114.9	   (C6),	   127.2	   (C10),	   127.6	   (C12),	  128.4	   (C11),	  128.8	   (C5),	  131.5	   (C4),	  136.1	   (C9),	  163.2	   (C7),	  192.1	   (CO).	  MS	   (ES+)	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1-­(4-­(Benzyloxy)phenyl)-­2-­(4-­benzylpiperidin-­1-­yl)propan-­1-­one,	  9720	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(1R,2R)-­1-­(4-­(Benzyloxy)phenyl)-­2-­(4-­benzylpiperidin-­1-­yl)propan-­1-­ol,	  
9820	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tert-­Butyl	  (6-­(((1R,2R)-­1-­(4-­(benzyloxy)phenyl)-­2-­(4-­benzylpiperidin-­1-­
yl)propyl)amino)hexyl)carbamate,	  9921	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38.6	  (C15),	  40.7(C26),	  43.5	  (CH2Ph),	  44.5,	  47.1	  (C13),	  52.9(C21),	  63.8	  (CHCH3),	  65.7	  (CHNH),	  70.2	  (OCH2Ph),	  79.2	  (C(CH3)3),	  114.7	  (C6),	  125.9	  (C20),	  127.7	  (C10),	  128.1	  (C12),	   128.3	   (C5),	   128.7	   (C18),	   129.2	   (C19),	   129.6	   (C11),	   133.9	   (C4),	   137.3	   (C9),	  140.9	   (C17),	   156.1	   (CO),	   158.2	   (C7).	   MS	   (ES+)	   m/z	   614.0	   [M+H]+;	   C39H56N3O3	  requires	  614.4322;	  found	  614.4327.	  M.	  Pt.	  97-­‐99	  °C.	  	  
N1-­((1R,2R)-­1-­(4-­(Benzyloxy)phenyl)-­2-­(4-­benzylpiperidin-­1-­
yl)propyl)hexane-­1,6-­diamine,	  10021	  	  
	  	  To	   a	   solution	   of	   tert-­‐butyl	   (6-­‐(((1R,2R)-­‐1-­‐(4-­‐(benzyloxy)phenyl)-­‐2-­‐(4-­‐benzylpiperidin-­‐1-­‐yl)propyl)amino)hexyl)carbamate	   (109	   mg,	   0.180	   mmol)	   in	  acetic	   acid	   (3.3	   mL),	   was	   added	   HBr	   (47%	   in	   H2O,	   0.3	   mL)	   and	   the	   solution	  heated	   to	  100	  °C	  overnight.	  After	   cooling	   to	   room	  temperature,	  aqueous	  NaOH	  (3M)	  was	  added	  until	  pH	  12.	  The	  aqueous	  layer	  was	  extracted	  with	  CHCl3	  (3	  x	  20	  mL)	   and	   the	   organic	   dried	   over	   MgSO4,	   filtered	   and	   concentrated.	   The	   crude	  residue	   was	   then	   purified	   by	   column	   chromatography	   (DCM/MeOH,	   100	   to	  85:15;	  Rf	   =	  0.12)	   to	  give	  a	  pale	  yellow	  solid	   (24	  mg,	  32%).	   1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  0.59	  (3H,	  d,	  J	  =	  7,	  CH3),	  1.22-­‐1.70	  (13H,	  m,	  H9	  +	  H10	  +	  H17	  +	  H18	  +	  H19	  +	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N-­‐Boc-­‐6-­‐aminohexanoic	  acid	  (52	  mg,	  0.22	  mmol),	  EDC	  (51	  mg,	  0.264	  mmol)	  and	  HOBt	  (36	  mg,	  0.264	  mmol)	  were	  dissolved	  in	  anhydrous	  DMF	  (2	  mL)	  and	  stirred	  at	   room	   temperature	  under	   an	   atmosphere	  of	   argon	   for	  20	  minutes.	  After	   this	  period,	   a	   pre-­‐stirred	   solution	   of	   diethyl	   (2-­‐(4-­‐amino-­‐8,9-­‐dioxo-­‐2,6-­‐diazabicyclo[5.2.0]non-­‐1(7)-­‐en-­‐2-­‐yl)ethyl)phosphonate	  (74	  mg,	  0.22	  mmol)	  and	  NMM	  (48	  µL,	  0.44	  mmol)	  in	  anhydrous	  DMF	  (1.5	  mL)	  was	  added	  drop	  wise	  and	  the	  resulting	  solution	  stirred	  at	  room	  temperature	  until	  complete	  consumption	  of	   the	  starting	  materials	  by	  ESI-­‐MS.	  After	   this	  period,	   the	  solvent	  was	  removed	  under	  reduced	  pressure	  and	  the	  crude	  oil	  taken	  up	  into	  EtOAc	  (15	  mL).	  NaHCO3	  (15	  mL)	  was	  added,	  the	  layers	  separated	  and	  the	  aqueous	  fraction	  washed	  with	  EtOAc	   (3	   x	   20	   mL).	   The	   combined	   organic	   portions	   were	   dried	   over	   MgSO4,	  filtered	  and	  the	  solvent	  removed	  under	  reduced	  pressure.	  The	  crude	  residue	  was	  purified	   by	   column	   chromatography	   (DCM/MeOH,	   100%	   to	   90:10	   in	   1%	  increments;	   Rf	   =0.25)	   to	   give	   a	   yellow	   oil	   (52	   mg,	   43%).	   1H	   NMR	   (700	   MHz,	  CDCl3)	  δ	  1.23-­‐1.29	  (2H,	  m,	  H3),	  1.31	  (6H,	  2	  x	  t,	   J	  =	  7,	  P(OCH2CH3)2),	  1.40	  (9H,	  s,	  C(CH3)3),	   1.42-­‐1.44	   (2H,	   m,	   H4),	   1.56-­‐1.63	   (2H,	   m,	   H2),	   2.09-­‐2.24	   (2H,	   m,	  PCH2CH2),	   2.25-­‐2.34	   (2H,	   m,	   H5),	   3.00-­‐3.14	   (2H,	   m,	   H1),	   3.20-­‐3.38	   (1H,	   m,	  





















Experimental	   	   Chapter	  8	  
	   284	  
(1H,	  br.	  NH).	  13C	  NMR	  (176	  MHz,	  CDCl3)	  δ	  16.5	  (2	  x	  d,	  3J	  =	  6,	  P(OCH2CH3)2),	  24.7	  (d,	  1J	  =	  140,	  PCH2CH2),	  25.4	  (C3),	  26.4	  (C4),	  28.6	  (C(CH3)3),	  29.8	  (C2),	  35.7	  (C5),	  40.5	   (C1),	   48.6	   (Cc),	   49.4,	   (d,	   2J	   =	   16,	   PCH2CH2),	   55.3	   (Ca),	   62.1	   (d,	   2J	   =	   7,	  P(OCH2CH3)2),	  62.6	  (CH),	  79.1	  (C(CH3)3),	  156.2	  (CO),	  167.6,	  168.6	  (C=C),	  174.6,	  180.6,	   182.2	   (CO).	   31P	   NMR	   (162	   MHZ,	   CDCl3)	   δ	   27.24.	   MS	   (ES+)	   m/z	   545.0	  [M+H]+;	  C24H42N4O8P	  requires	  545.2740;	  found	  545.2745.	  The	  Boc-­‐group	  was	   subsequently	  hydrolysed	   in	   a	   solution	  of	  DCM/TFA	   (1:1,	   2	  mL)	  to	  give	  the	  TFA-­‐salt	  of	  the	  amine	  (101.TFA),	  which	  was	  used	  directly	  in	  the	  coupling	  step	  without	  further	  purification.	  MS	  (ES+)	  m/z	  446.0	  [M+H]+.	  
	  
[NIR-­1]	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and	  coupling	   reagent	  were	  added	  and	   stirring	   continued	   for	  a	   further	  5	  hours.	  After	  no	   further	  reaction	  was	  observed	  by	  analytical	  RP-­‐HPLC,	   the	  solvent	  was	  removed	  under	  reduced	  pressure	  and	  the	  crude	  residue	  purified	  by	  preparative	  RP-­‐HPLC	  to	  give	  a	  light	  green	  solid	  (1.5	  mg,	  16%).	  MS	  (ES-­‐)	  m/z	  1392.5	  [M-­‐H]-­‐;	  C72H90N5O15S4	  requires	  1392.532;	  found	  1392.529.	  	  λmax	  (H2O)	  776	  nm.	  RP-­‐HPLC:	  
tR	  =	  18.3	  mins	  [2-­‐40%	  MeCN	  in	  triethylammonium	  acetate	  buffer	  (25	  mM)	  over	  20	  mins].	  	  
[NIR-­2]	  
 	  4-­‐(2-­‐((E)-­‐2-­‐((E)-­‐2-­‐(4-­‐carboxyphenoxy)-­‐3-­‐((E)-­‐2-­‐(3,3-­‐dimethyl-­‐5-­‐sulfo-­‐1-­‐(4-­‐sulfobutyl)indolin-­‐2-­‐ylidene)ethylidene)cyclohex-­‐1-­‐en-­‐1-­‐yl)vinyl)-­‐3,3-­‐dimethyl-­‐5-­‐sulfo-­‐3H-­‐indol-­‐1-­‐ium-­‐1-­‐yl)butane-­‐1-­‐sulfonate	   (8.2	   mg,	   0.0083	   mmol)	   and	  HATU	   (4.1	   mg,	   0.011	  mmol)	   were	   dissolved	   in	   anhydrous	   DMF	   (600	   µL)	   and	  stirred	  under	  argon	  at	  room	  temperature	  for	  10	  mins.	  The	  TFA	  salt	  of	  the	  amine,	  
















Experimental	   	   Chapter	  8	  
	   286	  
purified	  by	  preparative	  RP-­‐HPLC	   to	  give	   the	  phosphonate	  ethyl	  ester	  as	  a	   light	  green	  solid.	  The	  phosphonate	  ethyl	  ester	  (1.7	  mg,	  0.0012	  mmol)	  was	  dissolved	  in	  anhydrous	  DMF	  (300	  µL)	   to	  which	  bromotrimethylsilane	   (1.2	  µL,	  0.009	  mmol)	  was	   added.	   The	   resulting	   solution	   was	   stirred	   under	   argon	   at	   60	   °C	   and	   the	  reaction	  monitored	  by	   analytical	  RP-­‐HPLC.	  Upon	   completion	   after	  5	  hours,	   the	  solvent	  was	  removed	  under	  reduced	  pressure	  and	  the	  crude	  residue	  purified	  by	  preparative	  RP-­‐HPLC	  to	  give	  a	  green	  powder	  (0.65	  mg,	  6%	  over	  two	  steps).	  MS	  (ES-­‐)	  m/z	   1357.3	   [M-­‐H]-­‐;	   C60H74N6O20S4P	   requires	   1357.359;	   found	   1357.358.	  
λmax	  (H2O)	  776	  nm.	  RP-­‐HPLC:	  tR	  =	  17.4	  mins	  [2-­‐40%	  MeCN	  in	  triethylammonium	  acetate	  buffer	  (25	  mM)	  over	  20	  mins].	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Appendix.	  List	  of	  Key	  Compounds	  	  
1. NMDA	  Receptor-­Targeted	  MR	  Contrast	  Agents	  	  	  
	  	  	  	  	  	  	  	  


















[Gd.L1]   R = CH2CO2H              
[Gd.L2]          CH2CH2CO2H         
[Gd.L3]         CH2CH2PO3H2          
















[Gd.L5]   R = CH2CO2H              
[Gd.L6]          CH2CH2CO2H         
[Gd.L7]         CH2CH2PO3H2          



















[Gd.L9]   R = CH2CH2PO3H2              
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3.	  NMDA	  Receptor-­Targeted	  Photoacoustic	  Imaging	  Agents	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